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The European Hematology Association (EHA) Roadmap forEuropean Hematology Research highlights major achievementsin diagnosis and treatment of blood disorders and identifies the
greatest unmet clinical and scientific needs in those areas to enable bet-
ter funded, more focused European hematology research. Initiated by
the EHA, around 300 experts contributed to the consensus document,
which will help European policy makers, research funders, research
organizations, researchers, and patient groups make better informed
decisions on hematology research. It also aims to raise public awareness
of the burden of blood disorders on European society, which purely in
economic terms is estimated at €23 billion per year, a level of cost that
is not matched in current European hematology research funding.
In recent decades, hematology research has improved our fundamental
understanding of the biology of blood disorders, and has improved diag-
nostics and treatments, sometimes in revolutionary ways. This progress
highlights the potential of focused basic research programs such as this
EHA Roadmap.
The EHA Roadmap identifies nine ‘sections’ in hematology: normal
hematopoiesis, malignant lymphoid and myeloid diseases, anemias and
related diseases, platelet disorders, blood coagulation and hemostatic
disorders, transfusion medicine, infections in hematology, and
hematopoietic stem cell transplantation. These sections span 60 smaller
groups of diseases or disorders.
The EHA Roadmap identifies priorities and needs across the field of
hematology, including those to develop targeted therapies based on
genomic profiling and chemical biology, to eradicate minimal residual
malignant disease, and to develop cellular immunotherapies, combina-
tion treatments, gene therapies, hematopoietic stem cell treatments, and
treatments that are better tolerated by elderly patients. 
ABSTRACT
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Introduction 
Blood can be described as one of the human body’s
largest organs. It is essentially a liquid tissue containing
many different types of specialized cells needed for the
normal functioning of the human body. When one or
more of these cell types do not perform well, a wide vari-
ety of blood disorders can result, ranging from blood can-
cers and coagulation and platelet disorders to very com-
mon diseases such as anemia.
Hematology is the medical discipline concerned with
diagnosing and treating all of these diseases.
In the European Union (EU) alone, an estimated 80 mil-
lion people are currently affected with blood disorders. 
Various types of anemia affect more than 50 million
children and adults in the World Health Organization’s
European region.1 Blood cancers, some of which mainly
affect young people, contribute strongly to premature can-
cer-related mortality and lost productivity in Europe.2
Among cancers, blood cancers [leukemia, Hodgkin and
non-Hodgkin lymphomas (HLs and NHLs), and multiple
myeloma] together rank third after lung cancer and col-
orectal cancer in terms of age-adjusted mortality in the
European Economic Area.3
Inherited blood diseases, such as thalassemia, sickle cell
disease, and glucose-6-phosphate dehydrogenase deficien-
cy, also affect millions of people and cause substantial
morbidity and mortality. Rarer forms of congenital blood
disorders represent an immense burden on those affected.
Many infectious diseases affect various types of blood or
blood-forming cells, causing widespread diseases such as
malaria and HIV/AIDS. 
In recent decades, enormous progress has been made in
terms of diagnosis and treatment of these diseases.
Unfortunately, many blood disorders remain incurable.
Approximately 115,000 patients die each year.4
Blood disorders have immense economic consequences
as well. The combined societal cost of hematologic dis-
eases for the EU, Norway, Iceland, and Switzerland has
been estimated at €23 billion per year.
At a European level, current public spending on hema-
tology research does not match this vast medical need. Of
the €6.1 billion that the European Union allocated to
health research under its 7th Framework Programme
(2007-2013), only 2.2% (€137 million) was granted to
hematology research. That amounts to less than 0.1% of
the societal cost of blood disorders in Europe over that
same period.
Milestones in hematology and the contribution
from Europe
Research in hematology has fundamentally improved
our understanding of the biology of hematologic diseases
and resulted in many innovative discoveries. Many of
these discoveries are powerful examples of how carefully
designed basic research can lead to new approaches that
block or interact with key pathways in diseased cells,
resulting in very impressive anti-tumor effects. European
hematologists have pioneered important inventions and
played leading roles in developing, for example, curative
approaches for patients with malignant diseases, such as
lymphomas and leukemias,5,6 which often affect young
patients.
Key milestones included the characterization of hemo-
globin (Hb),7 induced pluripotent stem cells (iPSCs),8 and
somatic driver mutations.9 The discovery of the
Philadelphia chromosome and the subsequent identifica-
tion of the BCR-ABL1 tyrosine kinase and its role in chron-
ic myeloid leukemia (CML)10 led to the successful develop-
ment of potentially curative targeted treatment in this
form of blood cancer.11 This was an unprecedented rate of
success and it occurred in a malignancy that previously
could only be treated by allogeneic transplant in a very
select number of patients. Acute promyelocytic leukemia
became one of the first malignancies that could be cured
without conventional chemotherapy.12
Another key development in hematology was that of a
wide range of monoclonal antibodies following the original
invention by Köhler and Milstein in the UK.13 Humanized
or fully human monoclonal antibodies are now used in
hematology for both diagnostic and therapeutic purposes.
The clinical breakthrough was a humanized monoclonal
antibody targeting the CD20 antigen on B-cell lymphoma.14
Today, monoclonal antibodies or antibody-based conju-
gates are used successfully in most malignant lymphomas
and leukemias. They can, however, also be effective in non-
malignant blood disorders such as paroxysmal nocturnal
hemoglobinuria (PNH), a rare acquired clonal stem cell
defect leading to increased fragility of hematopoietic cells
and hemolytic anemia (HA), thrombosis, and bone marrow
failure (BMF). Prognosis of patients with severe PNH used
to be less than five years, but changed radically with the
advent of an anti-complement monoclonal antibody that
counteracts membrane fragility.15 Today, PNH patients
treated with this antibody have a normal life expectancy.
Severe hemophilia represents another story of unprece-
dented success. Patients used to be confined to wheel-
chairs or face the specter of death because of untreatable
hemorrhage or blood-born infections such as HIV/AIDS.
Today, new recombinant substitutive therapy is complete-
ly safe and effective in long-term prophylaxis.
Hematology expects to further improve in this area, with
innovative factor VIII or IX molecules that have increased
activity and prolonged half-life.
Gene therapy is becoming a reality for more and more
blood diseases, while treatment of malignant and non-
malignant hematologic diseases is impossible without
blood transfusions and blood-derived medicinal products.
“Haemovigilance”, a European initiative that provides a
surveillance registry of serious unwanted transfusion
effects, is now up and running in most EU member states.
European research policy
Governments, politicians and other policy makers carry
the responsibility for making well informed decisions on
regulation and funding priorities for health research and
medicinal product development. The research community
has a responsibility in providing policy makers with the
kind of information and evidence that they need to make
those informed decisions.
With respect to research funding, the authors feel that
hematology was underfunded in the EU’s 7th Framework
Programme. The current Framework Programme (Horizon
2020) was spared major budget cuts, but raising the rela-
tive level of funding for hematology research needs to be
improved.
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With respect to regulation, a key issue on the table is the
EU’s new regulation on clinical trials on medicinal prod-
ucts for human use, which will come into effect in 2016.
Over the past years, the number of clinical trials in Europe
has decreased. These trials are key to medical research.
European research groups have been instrumental in set-
ting up multicenter clinical trials to test important new
products. However, the new regulation has the potential
of making future trials in Europe too expensive and too
complex to carry out, especially in terms of academic
research, and, therefore, may lead to a further decrease in
clinical trials. A drop in the number of trials and the num-
ber of participants would harm the interests of European
patients and damage Europe’s knowledge infrastructure
and future economy.
The European Hematology Association
Roadmap
In 2014, at its 19th Annual Congress in Milan, Italy, the
European Hematology Association (EHA), Europe’s largest
non-profit membership organization in the field of hema-
tology, decided to launch a Roadmap project. One of its
goals was to better inform European policy makers and
other stakeholders about the urgent needs and priorities of
patients with blood diseases and the field of hematology.
Another goal was to help the European hematology
research community in harnessing resources by bringing
basic researchers, clinical trial networks and patient advo-
cates together in comprehensive study groups. A
European consensus on medical and research priorities
will also promote excellence and collaboration between
academics and the pharmaceutical industry.
The EHA Roadmap Task Force included EHA board
members and other top experts from all fields of hematol-
ogy. Hundreds of hematologists, clinical trial groups, drug
makers, national hematology societies, patient representa-
tives and others were invited to provide input and advice.
Many contributed to the drafting of the document and the
various stages of review.
This Roadmap is the outcome of this project. It identi-
fies the greatest unmet needs in hematology research and
clinical science, describing: 1) state-of-the-art hematologic
research; 2) the most urgent research priorities; and 3) the
anticipated impact this research could have.
The EHA Roadmap Task Force identified nine major ‘sec-
tions’ in hematology: normal hematopoiesis, malignant
lymphoid and myeloid diseases, anemias and related dis-
eases, platelet disorders, blood coagulation and hemostatic
disorders, transfusion medicine, infections in hematology,
and hematopoietic stem cell transplantation (HSCT). For
each section, the Roadmap Task Force appointed one or
two editors. Together, the Roadmap Task Force and section
editors drafted and reviewed a more detailed framework of
60 ‘subsections’ of groups of diseases and conditions.
Section editors selected experts from their various fields to
contribute as subsection editors or authors. Each section
and subsection adapted the same basic format.
Draft texts and figures were discussed by the Roadmap
Task Force and section editors during three meetings
between October 2014 and March 2015. Sections were
then reviewed by the Roadmap Task Force, the EHA
board, and a selection of experts. The final draft was sent
for consultation to stakeholders such as national hematol-
ogy societies, patients' organizations, hematology trial
groups, and other European organizations in, for example,
overlapping disease areas. All comments were discussed
and integrated before submission of the manuscript to
Haematologica.
In all, around 300 European hematologists and top
experts helped to create the Roadmap.
At the request of the EHA board, the University of
Oxford simultaneously carried out a study into the socie-
tal burden and cost of blood disorders in Europe.
Outcomes from their analysis also informed various parts
of this Roadmap.
Some dominating topics and unmet needs can be recog-
nized in nearly all of the nine EHA Roadmap sections.
They include:
1. developing novel targeted therapies based on genomic
profiling and chemical biology;
2. unleashing the power of cellular immunotherapy;
3. eradicating minimal residual disease (MRD) in hema-
tologic malignancies;
4. creating smarter combination treatments;
5. developing better tolerated treatments for blood disor-
ders with a special emphasis on elderly patients;
6. using gene therapy to tackle blood disorders;
7. maximizing the clinical application of hematopoietic
stem cells (HSCs) for transfusion, immunomodulation,
and repair.
Taken together, this EHA Roadmap highlights major
past achievements in the diagnostics and treatment of
blood disorders, identifies unmet clinical and scientific
needs in those same areas, and will enable better funded
and more focused European hematology research.
The EHA will pro-actively bring this Roadmap to the
attention of all stakeholders involved in hematology, and
calls upon those stakeholders to do the same. 
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Hematopoiesis, the formation of blood, is initiated in
our bone marrow by hematopoietic stem cells (HSCs),
first identified by Till and McCulloch in the 1960s. After
cell division, these HSCs can generate progenitor cells
that gradually differentiate into all the erythroid,
myeloid, and lymphoid lineages that reconstitute our
blood. Via a process termed self-renewal, they are also
able to generate new stem cells to ensure a lifelong reser-
voir of HSCs. In the past decades, excellent in vitro and in
vivo model systems have been generated that have
allowed us to obtain a thorough understanding of
hematopoiesis at the molecular and cell biological level.
HSCs were also the first stem cells that were used in a
clinical setting through bone marrow transplantation
(BMT). It is, therefore, not surprising that the hematopoi-
Section 1. Normal hematopoiesis
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etic system has served as a paradigm for the study of
many other stem cell types as well.
We have learned much about growth factors and
cytokines that regulate the fate of HSCs and their proge-
nies. With the availability of genome-wide multiomics
technologies, transcription factor (TF) networks and epige-
netic landscapes of cells within the hematopoietic hierar-
chy are currently being characterized at a rapid pace. Step
by step, we are now beginning to understand how these
are interlinked and how they control the transcriptomes
and proteomes of hematopoietic cells. We have learned a
lot about the microenvironment within the bone marrow
that keeps HSCs in their quiescent state and regulates their
self-renewal. We have learned about how and where
HSCs are formed during embryogenesis, and we are also
beginning to better understand how HSCs age.
Fundamental translational research has been critically
important in getting us where we are today. But still many
questions remain. Among many others, these include the
question as to how (epi)genetic aberrations cause hemato-
logic malignancies, and how we can use these insights to
develop better therapeutic strategies. It is now being real-
ized that there is a clonal heterogeneity in many hemato-
logic cancers, and possibly even within the normal HSC
compartment. But how does this affect disease develop-
ment and current treatment options? In contrast to adult
life, HSCs are rapidly expanding during embryogenesis.
So can we unravel those mechanisms and apply them to in
vitro HSC expansion protocols for clinical use? A thorough
understanding of embryonic versus adult hematopoiesis
might also help us to better understand the differences
between childhood and adult hematologic malignancies.
Reprogramming now allows patient-specific induced
pluripotent stem cells (iPSCs) to be generated, but the gen-
eration of fully functional HSCs from these is still rather
challenging. Can this be improved? We live in a continu-
ously aging society, but how does HSC aging actually
affect health and disease? Within the first section, we have
brought together leading scientists and clinicians in the
field of hematopoiesis. They provide an overview of the
current status of the field and an outlook on where future
research should be directed (Figure 1). We firmly believe
that combining fundamental and translational research
will result in not only a better understanding of the
hematopoietic system, but also in the development of bet-
ter therapeutic approaches for hematologic malignancies,
many of which are still difficult to treat.
1.1. Erythropoiesis
Sjaak Philipsen (Erasmus MC, Rotterdam, the
Netherlands), Joan-Lluis Vives Corrons (Universitat de
Barcelona, Barcelona, Spain), Lucia de Franceschi
(Università degli Studi di Verona, Verona, Italy), Olivier
Hermine (Université Paris Descartes, Paris, France),
Douglas Higgs (University of Oxford, Oxford, United
Kingdom), Marina Kleanthous (Cyprus School of
Molecular Medicine, Nicosia, Cyprus).
Introduction
The major cell type in our blood is the red blood cell
(RBC) or erythrocyte. RBCs transport oxygen from the
lungs to other parts of the body, and from there they carry
carbon dioxide back to the lungs. An adult has approxi-
mately 5 liters of blood, containing 25x1012 RBCs. Because
the lifespan of an RBC is approximately 120 days, a healthy
person needs to produce 2.4x106 RBCs per second to main-
tain a constant number of RBC.16 The oxygen carrier hemo-
globin (Hb), composed of two a-like and two b-like globin
proteins, makes up approximately 90% of soluble protein
in RBCs. RBCs and Hb form during a process called erythro-
poiesis, which includes the initial specification of HSCs
from mesoderm during embryogenesis, the decision of
these cells to self-renew or differentiate, the process of pro-
liferation and erythroid specification, and, finally, their ter-
minal differentiation and post-mitotic maturation.
Terminally differentiating erythroid cells extrude their
nucleus and shed their endoplasmic reticulum and mito-
chondria. The new cells enter the circulation as reticulo-
cytes, which are still engaged in protein translation. Finally,
the population of mature, biconcave RBCs with diameters
of only 6-8 micrometers creates a large surface area for gas
exchange, which, through RBC membrane deformability,
extends from major blood vessels into the microcirculation.
Abnormally low Hb levels cause anemia. Approximately
one-third of the world’s population has some form of ane-
mia, making this diverse group of disorders by far the most
common clinical problem worldwide. Perturbation of ery-
thropoiesis might be acquired and related to iron deficiency
or to different systemic disorders associated with chronic
inflammation (e.g. autoimmune diseases and cancers) or
myelodysplasia. A multitude of different inherited anemias
affect erythropoiesis by diverse mechanisms, such as tha-
lassemias (by reduced or absent functional Hb), sickle cell
disease (SCD) (by a pathological Hb variant), HAs (by
defects in membrane proteins, metabolic enzymes, or
pathological Hbs), Diamond Blackfan anemia (DBA) (by
impaired ribosome biogenesis), Fanconi anemia (FA) (by
DNA repair defects), and congenital dyserythropoietic ane-
mia (CDA) (e.g. CDA type II by defects in protein traffick-
ing). Polycythemia vera (PV), although not limited to ery-
thropoiesis and also seen in myeloproliferative neoplasms
(MPNs), is caused by activating JAK2 kinase mutations. The
physiological and molecular mechanisms underlying these
disorders are still not completely understood, while ery-
throid defects are also associated with many other, and
often still unknown, genetic defects. Elucidation of normal
erythropoiesis is, therefore, essential to develop new strate-
gies for treating the wide variety of conditions affecting the
erythroid system.
European research contributions 
Historically, research of the hematopoietic system has
driven novel biological concepts and methods, owing to
the accessibility and ready purification of hematopoietic
progenitor cells (HPCs) for molecular and functional analy-
ses. Early European contributions included the Nobel Prize
winning discovery of the structure of Hb7 and understand-
ing the etiology and epidemiology of inherited anemias,
leading to implementation of pre-natal diagnostic pro-
grams.17 Other European contributions include determin-
ing the origin of hematopoietic stem cells (HSCs), the tran-
scriptional circuitry underlying erythropoiesis, the molec-
ular control of differentiation versus apoptosis, the role of
iron metabolism, and DNA sequences driving high-level
expression of Hb, which are now applied in gene therapy
vectors. Other discoveries, such as the roles of serotonin
and transferrin receptors, also heralded significant
progress in our understanding of normal erythropoiesis.
Recently, purified cells have been characterized using
“omics” techniques to determine their transcriptional pro-
files, epigenetic programs, and responses to cell signaling.
A database dedicated to erythroid disorders has been
established18 aiming to integrate data from fundamental
and translational research with data from routine clinical
care. Translational research has resulted in optimized
BMT protocols, magnetic resonance imaging (MRI) moni-
toring of iron overload, improved iron chelation therapies,
and targeted inhibition of signaling pathways mutated in
(pre)leukemic conditions.19
Proposed research for the Roadmap
Previous research has laid the foundation on which a
comprehensive framework for understanding erythro-
poiesis can be built. Next generation sequencing (NGS)
technologies have opened up exciting new avenues for
qualitative and quantitative biology, with unprecedented
sensitivity and specificity. For instance, mutation detec-
tion in single cells is now possible, and quantitative gene
expression profiles can be generated from hundreds of
individual cells in a single experiment. For the first time,
this allows hierarchical relationships between cells of a
single lineage to be determined and the impact of cell-cell
interactions and signaling cascades on erythroid develop-
ment to be unraveled. Although pioneering research will
rely on the use of cellular and animal model systems, the
protocols developed will be quickly translated to the study
of erythropoiesis in human subjects, taking full advantage
of single-cell omics analyses. Our goal is to apply this
deeper understanding of erythropoiesis to improve diag-
nosis, prognosis, and treatment algorithms for patients
with conditions affecting the erythroid system.
Anticipated impact of the research
Understanding the basic physiological and molecular
mechanisms of normal erythropoiesis will have a direct and
long-lasting impact on the medical care of patients with
hereditary and acquired anemias. Firstly, improved diagno-
EHA Roadmap for European Hematology Research
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Figure 1. An overview of the current ‘normal' hematopoiesis field and an outlook on
where future research should be directed.
sis will enable clinicians to predict disease progression for
individual patients much more accurately, leading to better-
informed decisions on disease management by transfusion,
iron chelation, cytokines or cytokine inhibitors, and
splenectomy. Secondly, fundamental knowledge of normal
erythropoiesis will likewise guide the development of safer
and more effective curative treatments, such as those
involving gene correction or gene therapy, and identifica-
tion of new therapeutic targets to be exploited in public-pri-
vate partnerships for the development of new treatments
for erythroid disorders. Thirdly, an increased understanding
of the microenvironment and cell signaling mechanisms
will enable the development of clinical algorithms for man-
agement of patients with anemias. Fourthly, in vitro genera-
tion of fully functional human erythrocytes will ultimately
bring completely defined and guaranteed disease-free
human blood units to the clinic, with a major impact on
transfusion medicine. Finally, the erythroid system repre-
sents a fascinating and tightly regulated process of prolifer-
ation, survival, and differentiation and has always served as
a paradigm for other biological systems. New fundamental
insights into erythropoiesis will, therefore, likely continue
to facilitate discoveries in all fields of medicine, leading to
an improved understanding of disease mechanisms and bet-
ter clinical care for patients.
1.2. Myelopoiesis
Kim Theilgaard-Mönch (Københavns Universitet,
Copenhagen, Denmark), Niels Borregaard (Københavns
Universitet, Copenhagen, Denmark), Jörg Cammenga
(Linköpings Universitet, Linköping, Sweden), Ruud Delwel
(Erasmus MC, Rotterdam, the Netherlands), Henk
Stunnenberg (Radboud Universiteit, Nijmegen, the
Netherlands), Ivo Touw (Erasmus MC, Rotterdam, the
Netherlands).
Introduction
Myeloid cells, including granulocytes, monocytes/
macrophages, and dendritic cells, are key effector cells of
the innate immune defense against invading micro-organ-
isms.20 Myeloid cells are continuously generated from
hematopoietic stem cells (HSCs) in the bone marrow
through a tightly regulated process referred to as myeloid
differentiation or myelopoiesis. This complex process is
regulated in part by growth factors and epigenetic and tran-
scriptional regulators that in concert orchestrate cell sur-
vival, proliferation, and, most importantly, instruction of
lineage-restricted differentiation of HSCs via a series of
hematopoietic progenitor cells (HPCs) into all types of fully
mature myeloid cells. For the past two decades, a plethora
of studies have demonstrated the pathognomonic link of
genetic aberrations in myeloid key regulators with several
hematologic disease entities, such as acute myeloid
leukemias (AMLs), myeloproliferative neoplasms (MPNs),
and severe congenital, as well as cyclic neutropenia. Hence,
characterization of myeloid regulators and their function
during steady-state hematopoiesis at both the molecular
and systems level is important to understand: 1) the biology
of myeloid differentiation and innate immune defense; and
2) how genetic aberrations of myeloid regulators affect nor-
mal myeloid differentiation and cause myeloid disease.
European research contributions 
Lineage priming is an idea that was brought forward
by scientists in Europe. The concept of lineage priming,
which postulates that lineage-specific transcription fac-
tors (TFs) are already present in uncommitted HSCs, is
now widely accepted. European scientists have also
made substantial contributions to the understanding of
TF networks in hematopoiesis, as well as identification
of the earliest cells in the hematopoietic hierarchy that
can give rise to myeloid cells. Moreover, research groups
in Germany and the Netherlands have identified muta-
tions in the granulocyte colony-stimulating factor recep-
tor as the cause of severe congenital neutropenia, and
have shown that treatment with granulocyte colony-
stimulating factor can improve survival but also lead to
AML.21
Later, HAX1 and JAGN1 mutations were identified by a
German research group as another genetic cause for severe
congenital neutropenia. Other European researchers have
pioneered our understanding of neutrophil differentiation
and antimicrobial granule proteins of neutrophils.22
The role of the TF CEBPA as a key regulator in normal
and malignant myeloid differentiation was pioneered by
European research groups. Specifically, these groups
applied genetic models to uncover the important role of
CEBPA for granulocytic lineage commitment and differen-
tiation, as well as the causative role for mutant CEBPA in
AML, thereby dissecting the complexity of how biallelic
CEBPA mutations contribute to leukemogenesis.23,24
Proposed research for the Roadmap
The advent of novel comprehensive omics technologies,
such as RNA-seq/microarray analyses, miRNA array
analysis, ChIP-seq analyses of transcriptional and epige-
netic regulators, metabolomics, and finally proteomics and
phosphoproteomics, allow us to define phenotypes of cel-
lular states at the systems level. The current proposal is to
apply a comprehensive omics strategy to improve our
understanding of normal myeloid differentiation and
innate immune defense at a systemic level and how genet-
ic aberrations cause perturbations of normal cellular activ-
ities, resulting in myeloid disease phenotypes.
Given this, the proposal will combine omics technolo-
gies and comprehensive cell sorting to generate a state-of-
the art reference omics data set of prospectively purified
human bone marrow populations representing successive
stages of myeloid differentiation (i.e. HSCs, myeloid pro-
genitors, and mature myeloid cells) in healthy subjects.
The resultant data set will improve our understanding of
how dynamic regulatory networks control cell fate and
function during normal myeloid differentiation and
immune defense. Moreover, the research community will
be able to match the resultant normal reference omics data
set with omics data sets of sorted bone marrow popula-
tions from patients with myeloid diseases harboring
defined genetic aberrations. This strategy will allow a
standardized omics data set comparison of normal and
disease states, which will unravel how specific genetic
aberrations in patients promote aberrant cellular activities
(e.g. signaling, proliferation, metabolism, apoptosis, etc.)
underlying the phenotype of specific myeloid diseases.
Significantly, comprehensive data mining of the normal
“reference” and patient omics data sets will allow us to
identify novel diagnostic markers, as well as targets for
therapeutic interventions, and ultimately improve treat-
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ment and clinical outcome of patients suffering from
AML, MPNs, and other myeloid diseases.
A co-ordinated European effort involving basic
researchers, clinical researchers, and bioinformatic techni-
cians is required to achieve the following aims of the pro-
posal.
1. Establishment of a European expert group that will dis-
cuss and define a standard for cell sorting of myeloid
cells, applied omics technology platforms, and the
development of bioinformatic methodologies for inte-
grated omics and clinical data analysis.
2. Establishment of core facilities/hospitals for standard-
ized collection and biobanking of human bone mar-
row samples from healthy subjects for the project.
3. Establishment of core facilities/research teams for sorting
of bone marrow populations according to the standard
sorting strategy defined by the expert group (see point 1).
4. Establishment/identification of core facilities/research
teams for omics analysis of sorted bone marrow pop-
ulations according to the consensus omics standard
platform defined by the expert group (see point 1).
5. Establishment of a European core bioinformatics group
for concerted processing and analysis of omics data in
order to generate a “reference” omics data set of nor-
mal myeloid differentiation.
Ideally, the bioinformatics group will also assist
European clinicians with standardized comparison of the
obtained reference omics data set and omics data sets of
patients enrolled in clinical trials. In addition, the bioinfor-
matics group will develop an open-access web-based plat-
form allowing researchers worldwide to download and
match omics data from patients with myeloid diseases for
comparison with the reference omics data set.
Anticipated impact of the research
The proposed research program relies on a concerted
multidisciplinary European effort to generate a compre-
hensive omics reference data set of myeloid differentia-
tion. The resultant data set represents an extremely pow-
erful tool for the research community, as it can be used in
part as a reference of how expression and activity of
genes, proteins, or signaling pathways change during nor-
mal myeloid differentiation and are perturbed by genetic
aberrations in myeloid diseases. Significantly, the latter is
important for pre-clinical and clinical research programs
aiming at identifying: 1) novel diagnostic markers for
improved prognostication; and 2) novel therapeutic targets
for the development of more effective treatment modali-
ties improving survival of patients with AML, MPNs, and
other rare myeloid diseases.
1.3. Megakaryopoiesis
William Vainchenker (Institut Gustave Roussy, Villejuif,
France), Alessandra Balduini (Università degli Studi di
Pavia, Pavia, Italy), Cedric Ghevaert (University of
Cambridge, Cambridge, United Kingdom).
Introduction
Megakaryopoiesis is the differentiation process that
leads to platelet production. This is a unique cell biology
system, because platelets arise from the fragmentation
in the blood shear of their marrow precursors, namely
the megakaryocytes. A large part of the platelet produc-
tion is regulated by the megakaryocyte size through
polyploidization. The regulation of megakaryopoiesis is
dependent on a cytokine/hormone called thrombopoi-
etin (THPO), which signals through the MPL receptor.
However, THPO is not directly involved in the last dif-
ferentiation steps directly responsible for platelet pro-
duction. In terms of development, megakaryopoiesis is
extremely close to erythropoiesis, and the regulation of
megakaryopoiesis and HSCs unexpectedly share many
common features concerning gene transcription and reg-
ulation by THPO with the presence of megakaryocyte-
biased hematopoietic stem cells (HSCs).
Megakaryopoiesis is affected by numerous acquired and
hereditary disorders. Most of them target the
THPO/MPL signaling or the actin and tubulin cytoskele-
tons, which play a central role in late stages of megakary-
opoiesis.25-28
Platelet transfusion is the most common way to treat
profound thrombocytopenia, but this increasing need in
platelet transfusion is limited by a donor deficit, and thus,
there is now a place for alternative approaches, including
ex vivo platelet production and small molecules stimulating
platelet production in vivo. All of these approaches require
major progress to be made in basic research.
European research contributions 
Researchers from Europe have played a central role in
understanding the regulation of megakaryopoiesis. 
1. They have been pioneers in the identification of the
MPL/THPO axis and the main transcription factors
(TFs) (GATA1, FLI1, TAL1, and LYL1). 
2. They have largely contributed to the mechanisms of
polyploidization and proplatelet formation. 
3. They have developed new investigational techniques,
such as 2-D and 3-D cultures, videomicroscopy, and
use of shear to produce platelets.29
Proposed research for the Roadmap
The major topics that require intense research resources
and efforts are listed here.
Mechanisms of megakaryocyte commitment and differentia-
tion from HSCs: defining these different cellular steps in
terms of transcription factors, epigenetic regulators, and
growth factors involved in this cellular process will be
important to: 1) increase platelet production in vivo; 2)
develop in vitro techniques for somatic cell reprogram-
ming toward the megakaryocyte lineage; and 3) increas-
ing the megakaryocyte potential of induced pluripotent
stem cells (iPSCs).
Further characterization of the THPO/MPL functions: MPL
plays a central role in regulating megakaryopoiesis
through direct signaling, as well as by clearing THPO.
Studies of THPO synthesis, the precise MPL signaling
pathways, including their consequences on gene regula-
tion and MPL cell trafficking will be important for under-
standing the mechanisms of thrombocytopenia or throm-
bocytosis and for developing new molecules capable of
positively or negatively regulating MPL.
Determination of the precise mechanisms of polyploidization:
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the processes of endomitosis and its regulation by both
extrinsic and intrinsic mechanisms, including ontogene-
sis processes, are poorly known. A complete under-
standing will be important for developing in vitro cell
systems able to produce highly polyploid megakary-
ocytes. In addition, this topic might be relevant to
understanding the processes of polyploidization in
malignant tumors.
Regulation of platelet formation: in order to discover disease
mechanisms and new therapeutic targets, it is fundamen-
tal to understand how megakaryocytes differentiate and
form platelets. These mechanisms include all the bone
marrow environment molecules that participate in the reg-
ulation of TFs and biochemical signaling through activa-
tion of specific receptors. New cellular techniques, includ-
ing single-cell assays, should be developed, generating
candidate regulators of this crucial step of platelet produc-
tion. Intrinsic cellular determinants, such as the actin and
tubulin cytoskeletons and their regulation, will have to be
studied. It will be important to determine the precise
mechanism of platelet abscission and the role of the shear.
These approaches may also provide candidate molecules
implicated in proplatelet formation and the migration of
megakaryocytes in the marrow. The endothelium partici-
pates in the regulation of megakaryocyte function, and
megakaryocytes have to remodel the basement mem-
brane of the sinusoids in order to extend proplatelets
through the vascular wall of the bone marrow sinusoids.
It will be important to understand how proplatelets inter-
act with the endothelium to reach the blood flow and be
released, and how megakaryocytes and endothelial cells
mutually regulate their behavior. New processes to be
considered also include the role of calcium in megakary-
ocyte development and the importance of autophagy in
megakaryocyte development within the bone marrow
environment.
Mutual regulation of megakaryocyte and bone marrow envi-
ronment: it is known that megakaryocytes are able to
express and release different molecules that may regulate
bone marrow homeostasis in both steady-state, post-
injury conditions, and in malignant and inflammatory dis-
orders. Alteration of these processes may lead to patholog-
ical conditions or support diseases. On this basis, it is
important to understand which molecules megakary-
ocytes actively express and release, and their role in the
bone marrow regulation.
Anticipated impact of the research
In recent decades, much progress has been made in our
knowledge of megakaryopoiesis, but better understanding
its regulation and the function of the increasing number of
genes found to be mutated in pathology will require sig-
nificant effort. The precise understanding of endomitosis
and platelet formation may have important clinical conse-
quences, particularly for developing new technologies for
large platelet production in vitro and also new molecules
capable of modifying platelet production in vivo. Europe
has played a leading role in studies of megakaryopoiesis,
but research has remained fragmented. Integrated
European programs will provide the critical mass of
resources and expertise needed to develop the large ambi-
tious programs required to proceed from basic to clinical
research.
1.4. Lymphopoiesis
Isabelle Andre-Schmutz (Université Paris Descartes,
Paris, France), Jean-Christophe Andrau (Institut de
Génétique Moléculaire de Montpellier, Montpellier,
France), Sophie Ezine (Université Paris Descartes, Paris,
France), Francoise Pflumio (Institut de recherche en radio-
biologie cellulaire et moléculaire (IRCM), Paris, France),
João Pedro Taborda Barata (Universidade de Lisboa,
Lisbon, Portugal), Tom Taghon (Universiteit Gent, Ghent,
Belgium).
Introduction
The immune system constitutes the body’s defense sys-
tem against disease and foreign cells/micro-organisms.
Immune cells are diverse, conventionally divided into
innate and adaptive subsets. B and T lymphocytes are the
main protagonists in adaptive immunity and are generat-
ed by a complex process referred to as lymphopoiesis,
which involves numerous finely regulated steps, includ-
ing the lymphoid-specific somatic rearrangement of genes
encoding the immunoglobulins and T-cell receptors for
antigens. Lymphocytes are generated within defined
microenvironments that provide the growth factors and
signals necessary for their commitment, survival, expan-
sion, and education to self-/non-self-discrimination. A
deep understanding of the steps that allow the production
and amplification of lymphoid precursors and mature
cells is crucial in order to obtain an efficient immune sys-
tem, which is important for lymphoid-based therapies in
humans.
European research contributions 
European groups have a strong research record in the
field of lymphopoiesis and achieved the first successful
gene therapy protocols for human genetic defects affect-
ing lymphopoiesis.30 They contributed to the develop-
ment of in vitro assays, allowing studies on T- and B-cell
differentiation using bone marrow-derived stromal
cell/progenitor and organotypic thymic cultures further
complemented by humanized murine models in which
the generation of human T and B cells could be studied.31
Such tools helped identify murine and human lymphoid
progenitors, as well as thymus-seeding progenitors.
Moreover, lymphoid progenitor expansion conditions for
cell therapy purposes have been recently described.
Pioneering European studies also characterized the
thymic microenvironment, crosstalks between the
epithelium and developing T cells, and the role of the
Notch pathway and regulators in the molecular regula-
tion of T-cell differentiation.32 Other groups focused on
the early steps of B-cell development in mice and identi-
fied progenitor B-cell regulators that modulate patholog-
ical immune responses. Studies on human B-cell deficien-
cies emphasized species differences between mice and
humans, underlining the need for the establishment of
novel research strategies that help us understand species-
specific peculiarities and the common features of B- and
T-cell development. Several pathologies involving lym-
phoid deficiencies were found to be caused by defects in
various steps of V(D)J recombination, implicating general
and specific mechanisms of DNA repair in lym-
phopoiesis and telomere maintenance.33 Finally, innate
lymphoid cell and natural killer (NK)-cell development
were described,34 bringing robust cell role-players to
develop new therapies.
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Proposed research for the Roadmap
Mature lymphocytes and their subsets concomitantly
arise from very infrequent progenitor subsets that are not
well characterized. These processes take place in complex
“niches,” the settings of which are only just being unrav-
eled. Dissecting the role of various non-hematopoietic and
hematopoietic cell subsets of the bone marrow and thy-
mus involved in lymphoid development/progenitor main-
tenance will favor identification of the major players in
steady-state conditions and new molecular targets for
anti-cancer and anti-viral immunotherapies. This knowl-
edge will be important for modeling normal T/B/NK-cell
development within their specific niches, using scaffolds
as surrogate thymic and bone marrow niches to help
uncover side effects and resistance mechanisms observed
in chemotherapies. A precise description of the migratory
pattern of developing T and B cells will be necessary to
efficiently transplant newly generated, ex vivo lymphoid
progenitors from different HSC sources, including induced
pluripotent stem cells (iPSCs) and embryonic stem cells
(ESCs). Identification of drugs able to mobilize lymphoid
progenitors for cell/gene therapy also needs to be investi-
gated. Further studies are required to assess the impact of
these and other drugs/small molecules on normal develop-
mental processes, such as hematopoiesis. Such experi-
ments will support the design of new assays for human
lymphoid development. They should also stimulate drug
research for acute lymphoblastic leukemias (ALLs). For
realistic lymphoid-based therapies to become “routine” in
the near future, one should learn from previous experi-
ences with the successes achieved in gene therapy. These
experiences emphasize the continuous need for modifica-
tion of existing viral vectors to improve transduction of
lymphoid progenitors, as well as the development of lym-
phoid-specific protocols of gene therapy.
Improved modeling of human disease and cellular ther-
apy of immune deficiencies is also essential and is required
to support the development and expansion of lymphoid
cells from iPSCs or ESCs, as well as to generate lymphoid
progenitors ex vivo from isolated hematopoietic cell popu-
lations. Identification of human HSCs biased toward T-
and B-cell production will facilitate understanding of the
origin of lymphoid cells and their potent expansion prior
to transplant into patients.
At the molecular level, epigenetic changes and major
regulatory signals (microRNA, long non-coding RNA, and
chromatin modifications) need to be explored by develop-
ing robust genome-wide protocols on small cell subsets.
This may help to: 1) define an “epigenetic and transcrip-
tomic ID card” of aforementioned progenitors and B- and
T-subsets in normal and pathological development; and 2)
evaluate the consequences of infections, inflammations,
irradiations, and hypoxia in this development. A major
factor that compromises the immune system is aging, and
future studies should be aimed at maintaining a fit, long-
lived lymphopoietic compartment.
Anticipated impact of the research
The primary goals of such studies are lymphoid-based
therapies, the maintenance of a healthy immune system in
the elderly, and the engineering of personalized treatment.
The tools developed should enable clinicians to reconsti-
tute the lymphopoiesis of patients carrying invading
pathogens and neutralize autoimmunity and response to
tumor cell growth. Additional knowledge about normal
lymphopoiesis will undoubtedly benefit new drug discov-
ery for leukemia/lymphoma/myeloma therapies.
1.5. Hematopoietic stem cells
Gerald de Haan (Universitair Medisch Centrum
Groningen, Groningen, the Netherlands), Dominique
Bonnet (The Francis Crick Institute, London, United
Kingdom), Hartmut Geiger (Universitätsklinikum Ulm,
Ulm, Germany), Gerwin Huls (Universitair Medisch
Centrum Groningen, Groningen, the Netherlands).
Introduction
Hematopoietic stem cells (HSCs) were the first adult stem
cells to find their way into the clinic. Indeed, each year
more than 50,000 patients receive HSCs for various (benign
and malignant) diseases. Therefore, HSCs are frequently
regarded as a role model in adult stem cell biology.
Notwithstanding their very successful and beneficial clinical
applicability, many aspects of basic HSC biology remain
unresolved, precluding additional rational approaches to
further expand their use, or that of their more mature cellu-
lar derivatives, in the clinic. In this subsection, we will
briefly discuss research topics that will need to be addressed
to further expand and maximize the impact of the use of
HSCs (and/or their progenies) in the clinic.
Proposed research for the Roadmap and anticipated impact of
the research
HSC heterogeneity and clonal diversity: it is still not known
how many stem cells contribute to blood cell develop-
ment in normal individuals, nor whether all contributing
HSCs in fact contribute equally.35 Multiple hypotheses
have been put forward over the past decades, yet we do
not know how many HSCs there are in the human body,
how many of these cells contribute to blood cell produc-
tion, how long individual stem cells remain active,
whether active stem cells can become dormant and
whether this process is reversible, and to what extent
active stem cells differ individually in their contribution to
the various blood cell types.
HSC aging and rejuvenation:most patients who develop a
hematologic disease (including anemia, immune senes-
cence, lymphoma, myelodysplasia, and chronic and acute
leukemias) are older, typically 65 years and over. It has
become apparent that aged HSCs suffer from multiple
functional defects: they show reduced self-renewal, over-
all produce fewer mature cells per stem cell, and are
impaired in terms of generating lymphocytes. The molec-
ular causes of these defects have not been defined, but
may involve DNA damage, telomere attrition, erosion of
epigenetic marks, replication stress, or loss of cell polarity,
or, indeed, may result from microenvironmental perturba-
tions.36 Elucidation of the molecular cause(s) of stem cell
aging will be required to assess whether, and how, it may
be possible to reverse it. Reversion or prevention of stem
cell aging will contribute to delaying age-related
hematopoietic deficiencies.
Generation of HSCs from non-stem cells: in the post-
Yamanaka era, many labs are attempting to generate bona
fide HSCs from induced pluripotent stem cells (iPSCs), or
indeed to embark on direct conversion of non-HSCs to
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transplantable stem cells. Whereas these attempts initially
proved to be very cumbersome, substantial progress has
recently been made in this field. It has been proved possi-
ble, using an array of transcription factors (TFs), to induce
hematopoietic (stem) cell activity, while the molecular
mechanisms are still unknown.37 The generation of func-
tional HSCs from non-stem cells will greatly expand the
clinical use of stem cells and their differentiated progenies.
HSC expansion, transplantation, and homing: HSCs are
very rare cells, and many attempts have been made to
amplify them in order to improve engraftment kinetics
after transplant and to allow manipulation of these cells
prior to transplantation. In the light of very significant clin-
ical progress in the field of (hematopoietic) gene therapy,
the ability to maintain, grow, and expand HSCs during
gene transduction protocols becomes more important
than ever. Classical protocols that used cytokines have not
been successful in expanding stem cells. More recently,
however, small molecule-based approaches have suggest-
ed that the massive expansion that occurs in vivo when
few stem cells are transplanted to conditioned recipients
can be recapitulated in vitro. Efforts to explore such expan-
sion protocols are highly warranted and should include
studies aimed at increasing the homing efficiency of trans-
planted stem cells to their proper niche in the bone mar-
row. Novel imaging tools have been developed to record,
in real time, the lodging of transplanted cells to specific
preferred sites.38 Such tools and the insight they provide
are essential for developing methods to improve homing
and to identify the microenvironmental cells to which nor-
mal and leukemic cells home in transplantation settings.
HSCT will benefit from in vitro manipulation of the graft
to expand more desired cells and decrease the number of
less desired cells in certain conditions (i.e. facilitate the
development of “designer grafts”).
HSC transformation, cell of origin, and pre-leukemia: it has
become clear that the identity of the hematopoietic stem
or progenitor cell in which a leukemic event first arises
plays a crucial role in the biology of the disease. It seems
plausible that the epigenetic context in which a
(pre)leukemic lesion first arises plays an important role in
establishment and progression of the disease. Pre-
leukemic lesions have been identified that appear to con-
fer a proliferative advantage to not yet transformed prim-
itive cells, the progenies of which then continue to accu-
mulate additional mutations.39 Cataloging these pre-
leukemic events and identification of the primitive cells in
which they first arise will be crucial in order to embark on
approaches that allow very early detection of aberrant
hematopoiesis. Understanding the value of these pre-
leukemic events in the predisposition of developing a full-
blown leukemia will allow us to screen mutations in eld-
erly patients’ blood and decrease the risk of leukemia
development. In addition, despite our knowledge of the
mutation landscape present in leukemic stem cells (LSCs),
the importance of the order in which a mutation or muta-
tions occurred might provide us with a better understand-
ing of the co-operative effect of different mutations.
Furthermore, understanding the biology of stem cells will
provide insight into how leukemic (stem) cells hijack spe-
cific biological processes exploited by stem cells to remain
undifferentiated. Consequently, this insight should result
in better treatment strategies.
1.6. Developmental aspects of hematopoiesis
Elaine Dzierzak (University of Edinburgh, Edinburgh,
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Oxford, Oxford, United Kingdom), Irene Roberts
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Introduction
Throughout adult life, the hematopoietic system is a
highly dynamic, self-renewing hierarchy of cells founded
by robust hematopoietic stem cells (HSCs) that produce
billions of mature blood cells daily. How these self-renew-
ing HSCs in the bone marrow are first generated during
embryonic life is only beginning to be understood.
Already, the clinical use of umbilical cord stem cells sug-
gests that ontogenetically early cells have a therapeutic
advantage. Research into the mechanisms of hematopoi-
etic fate determination, expansion, and homing during
embryogenesis and in successive ontogenetic microenvi-
ronments will be instrumental to the production and
amplification of HSCs from pluripotent stem cells (PSCs),
two current issues in regenerative medicine, and this
knowledge will have relevance in understanding/treating
hematologic disease and childhood leukemias. Europe has
been, and continues to be, the major leader in the field of
developmental hematopoiesis.
Among the key challenges are:
1. HSC generation: currently limited to the embryo and
occurs through the transdifferentiation of endothelial
cells;
2. extrinsic microenvironmental and cell-intrinsic factors
that govern the HSC generative program;
3. by understanding and harnessing the program of
hematopoietic cell ontogeny, it may be possible to
reprogram  somatic cells and  produce HSCs for regen-
erative therapies and leukemic treatments.
European research contributions 
European developmental biologists spearheaded the
search for the embryonic origins of the adult hematopoi-
etic system.40,41 As demonstrated in chick and frog
embryos, the adult blood system originates in an intraem-
bryonic site encompassing the dorsal aorta, whereas the
yolk sac contributes to transient embryonic
hematopoiesis. Extensive analyses in these models and in
the mouse and human intraembryonic aorta-gonad-
mesonephros region clearly demonstrate that the first
adult-type HSCs are generated in that region in a process
called endothelial-to-hematopoietic transition. This sur-
prising natural cell transdifferentiation event was revealed
by real-time imaging of the developing aorta in mouse and
zebrafish embryos. The late embryonic development of
these potent HSCs has raised the question of why there
are many earlier, less potent hematopoietic progenitors in
the embryonic hematopoietic tissues, such as the yolk sac,
placenta, and fetal liver.40,41 Early hematopoietic cells
(primitive erythrocytes, macrophages, etc.) support the
growth of the embryo, may influence the generation of
HSCs, and prepare the developing hematopoietic
microenvironments to receive the cells of the adult
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hematopoietic system. The unique complexity of HSCs
arises through several maturational steps orchestrated by
molecular regulators. Mouse deficiencies for hematopoiet-
ic transcription factors (TFs) (many of them involved in
leukemic chromosomal translocations) and in vitro
hematopoietic differentiation of embryonic stem cells
(ESCs) have facilitated the identification of pivotal regula-
tors.
Proposed research for the Roadmap
The key factors initiating HSC generation and the adult
hematopoietic stem cell program will be found by com-
paring gene expression profiles obtained from embryonic
endothelial/HSC precursor cells and the first HSCs gener-
ated in the aorta.42 Computational methods and the com-
parative analysis of the transcriptomes of HSC subsets
across different vertebrate models will also further define
the molecular signature of HSCs through the identification
of TF complexes and epigenetic regulators that each play
a role in modulating the hematopoietic program during
ontogeny. Mouse models and systems biology approaches
are beginning to provide insight into the molecular differ-
ences between embryonic, fetal, and adult hematopoietic
cells and their specific developmental
microenvironments.43 Considerable advances have been
made regarding the cellular complexity of the bone mar-
row HSC niche, but very little is known about specific cel-
lular components and the molecular signatures of the cells
within the HSC supportive niches of the developing
embryo.
Examination and comparison of the gene regulatory net-
works active in the aorta-gonad-mesonephros, placenta,
and fetal liver hematopoietic supportive microenviron-
ments will be instrumental for identifying the molecular
pathways involved in specific processes, such as the emer-
gence, amplification, and differentiation of hematopoietic
progenitors and stem cells. This knowledge can then be
interpreted in the context of childhood leukemias that
resolve at later developmental stages. For example, Down
syndrome trisomy 21 impacts fetal, neonatal, and child-
hood hematopoiesis, and expands HSCs and megakary-
ocyte-erythroid progenitors.44 Acquired GATA1 mutations
in these cells lead to abnormal myelopoiesis. These initiat-
ing events are occurring in utero during embryonic and fetal
stages when hematopoietic progenitors represent a major
part of the hematopoietic system. The transient nature of
these progenitors prevents their lifelong persistence and
acquisition of additional mutations leading to leukemia.
Understanding the cellular targets of particular leukemias
during the different developmental stages and in the dif-
ferent microenvironmental compartments presents an
important challenge for ongoing and future research.
Induced pluripotent stem cells (iPSCs) from patients and
animal models in which leukemia can be induced during
development are among the options for such studies.
The ex vivo expansion of HSCs for clinical transplanta-
tion has continued to be a major challenge in the field
despite many years of research. Our knowledge of the TFs
and other regulators that play a role in endothelial-to-
hematopoietic transition, together with the molecular pro-
grams of HSCs and their surrounding microenvironments,
hold promise for unlimited production of such cells for
therapeutic purposes. These data will also have an impact
on how to generate HSCs from PSCs. Yamanaka-style
reprogramming may allow the de novo production of HSCs
via gene transduction/factor stimulation of endothelial
cells or other somatic cell types. In Europe, some success
is currently being seen in the production of blood and
platelet production from iPSCs. 
Anticipated impact of the research
Taken together, by understanding all the hematopoietic
cell types, progenitors, and stem cells produced in embry-
onic, fetal, and neonatal stages, we will begin to establish
how the hematopoietic microenvironment is shaped,
what mechanisms co-operate in regulating the emergence
and amplification of HSCs, how this relates to changes in
HSC heterogeneity during ontogeny, and how leukemia is
initiated at developmentally early stages. These findings
are sure to have an impact on treatment regimens, espe-
cially during postnatal periods. Moreover, once we are
able to directly establish HSCs by reprogramming somatic
cells from the patient, graft rejection issues will become a
thing of the past and will allow all patients to receive
transplants in cases of hematopoietic malignancy and fail-
ure.
1.7. Mesenchymal and other stromal cells
Simón Méndez-Ferrer (Centro Nacional de
Investigaciones Cardiovasculares, Madrid, Spain), Rosa
Bernardi (IRCCS San Raffaele Scientific Institute, Milan,
Italy), Cristina Lo Celso (Imperial College London,
London, United Kingdom), Pierre Charbord (Université
Pierre et Marie Curie, Paris, France), Willem Fibbe (Leids
Universitair Medisch Centrum, Leiden, the Netherlands),
Daniela Krause (Georg Speyer Haus - Institute for
Tumorbiology and Experimental Therapy, Frankfurt,
Germany), Robert Oostendorp (Technische Universität
München, Munich, Germany), Marc Raaijmakers
(Erasmus MC, Rotterdam, the Netherlands).
Introduction
Hemopoiesis is critically regulated by non-hematopoiet-
ic cells that are capable of controlling the production of
blood and immune cells according to the demands of the
organism. These stromal cells make up the so-called
hematopoietic microenvironment. It is becoming increas-
ingly clear that different stromal populations regulate dis-
tinct subsets of hematopoietic cells, and vice versa. The
complexity of these networks is further increased by the
recognition of heterogeneity among bone marrow stem
cells and their progenies. Recent technological develop-
ments will allow this complexity to be addressed experi-
mentally. This will be critical in fulfilling the enormous
potential of stromal cells in immune modulation, tissue
regeneration, and cancer treatment.
European research contributions 
Soon after Till and McCulloch demonstrated the exis-
tence of hematopoietic stem cells (HSCs), European
researchers contributed to characterizing the hematopoi-
etic microenvironment and extrapolating this knowledge
to the clinical and technological arenas. Simultaneously
with the discovery of mesenchymal stem cells (MSCs) in
the bone marrow, Owen and Friedenstein dissected skele-
tal turnover at the cellular level and demonstrated the
capacity of osteoprogenitor cells to give rise to both skele-
tal-forming and hematopoietic-supporting stroma. Dexter
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devised protocols to maintain blood cell production in
long-term culture and Schofield hypothesized that a spe-
cific niche in the bone marrow is essential to maintaining
HSCs. The stem cell niche concept was later extrapolated
to other organs. Remarkably, at variance from niches
made of fully differentiated cells (e.g. Drosophila ovariole
and mammalian intestine), some of the cells belonging to
the niche are the immediate progenies of the MSCs, or the
MSCs themselves.
Proposed research for the Roadmap
Unraveling the physiology of mesenchymal-hematopoietic net-
works: HSCs and their microenvironment probably repre-
sent the best-characterized hierarchical stem cell system in
vertebrates, paving the path to understanding how other
organs function. Dissecting the regulation of HSCs and
their progenies by their microenvironment, and vice versa,
will be key to optimizing the use of HSCs and therapeuti-
cally applying the emerging role of the HSC microenviron-
ment in hematologic disorders. Ongoing research by
European groups has identified MSCs in vivo and charac-
terized their functions in the HSC niche. Detailed charac-
terization of the properties of MSCs will rely on the devel-
opment of markers to isolate relevant subsets of human
MSCs and understand their HSC-supporting and regulato-
ry properties at the anatomical and functional levels.43
Understanding the role of mesenchymal elements in human
disease: future work will uncover the complexity of HSC-
stroma reciprocal regulation in normal and pathological
settings. Recent intravital microscopy studies showed
altered physical interaction between HSCs and stroma
during infection.45 Mesenchymal elements have recently
been experimentally implicated in the initiation, progres-
sion, and drug resistance of a variety of hematopoietic
neoplasms. Osteoblastic cells are altered in chronic
myeloid leukemia (CML) and effectively support leukemic
stem cells (LSC) maintenance while hampering normal
hematopoiesis. Parathyroid hormone stimulation of
osteoblastic cells attenuates CML progression, but
enhances acute myeloid leukemia (AML).46 Another type
of myeloproliferative neoplasms (MPN), polycythemia
vera (PV), reduces nestin+ MSCs, and their rescue is asso-
ciated with disease blockade.47 In parallel to a concept in
which (pre)malignant hematopoietic elements alter their
niche to promote disease progression, emerging research
is showing that primary (genetic) abnormalities in mes-
enchymal cells can initiate malignant transformation in
hematopoietic cells.48 Finally, stromal cells might promote
leukemic cell survival and/or protect them from
chemotherapy. A better understanding of the molecular
mechanisms driving these pivotal contributions of mes-
enchymal cells to disease pathogenesis opens the way to
not only more effective treatments, but also to novel
strategies to prevent malignant evolution and the associat-
ed socio-economic burden.
Mesenchymal cells in regeneration, immune modulation and
systemic disease: bone marrow stromal cells do not only
regulate HSCs, they are also instrumental in the (re)gener-
ation of other bone marrow cell types, including bone
cells. Characterizing the mechanisms by which stromal
cells maintain and regulate hematopoiesis and osteogene-
sis will be essential for optimizing recovery following
injury or bone marrow transplantation (BMT), as well as
increasing the number of patients that can benefit from
cell therapies. In addition, stromal cells also have a pro-
found impact on different immune cells, having therapeu-
tic benefits in sepsis, autoimmune disorders, and graft-ver-
sus-host disease (GvHD). More mature stromal cells, or
cells isolated from other sources (e.g. adipose tissues), also
seem to display some of these immunomodulatory prop-
erties. Bone marrow stromal cells are also responsive to
factors mediating diabetes, obesity, and aging, which are
likely to increase in Europe in the next ten years.
Understanding how the hematopoietic niches respond to
these physical conditions and how these changes affect
the blood cell system will be essential. Research in this
area holds promise for correcting some of the debilitating
effects associated with these conditions.
Anticipated impact of the research
An increase research in the hematopoietic microenvi-
ronment will, scientifically, feed into other (hierarchical)
stem cell systems and, clinically, provide new ways to
modulate and treat hematopoietic diseases, immune
responses, and regenerative processes. Both pharmacolog-
ical modulation and cellular therapy are expected to
emanate from further efforts. As a result of the productive
research, the European Union is already the world region
with the second highest number of registered clinical trials
using mesenchymal stem/stromal cells.
1.8. Transcriptional/epigenetic networks
Berthold Gottgens (University of Cambridge,
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Universiteit, Nijmegen, the Netherlands), Carsten Müller-
Tidow (Universitätsklinikum Halle, Halle, Germany),
Henk Stunnenberg (Radboud Universiteit, Nijmegen, the
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Introduction
Maintaining a balanced output of mature hematopoietic
cell lineages is critically dependent on exquisite control of
cell fate choices at the stem and progenitor level within
the hematopoietic hierarchy.49-53 These cell fate choices are
executed through the interplay of extracellular signaling
pathways with the intracellular decision-making machin-
ery. The latter is driven by networks of transcriptional reg-
ulators that interact in a combinatorial fashion and can
form larger protein complexes with different functions
dependent on composition and cellular context. These
establish cell type-specific transcriptional programs and
also mediate developmental transitions when cells differ-
entiate down a particular hematopoietic lineage.
Within these transcriptional regulatory networks, tran-
scription factor (TF) proteins bind to specific DNA
sequences, and therefore represent the primary stage of
decoding regulatory information present in lineage-specif-
ic gene regulatory elements. Once bound, TF proteins
recruit a number of accessory proteins with enzymatic
activity, which cause either modifications to the DNA
(e.g. DNA methylation) or covalent modification of his-
tone proteins (e.g. histone methylation, acetylation, phos-
phorylation). These so-called epigenetic modifications in
turn influence the accessibility of the DNA template for
subsequent binding of further TFs, and therefore serve a
critical function in the establishment of stable transcrip-
tional programs. The epigenetic status of the chromatin
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template can also influence additional aspects of transcrip-
tional control, such as the assembly of RNA polymerase
complexes on the promoter, and also the rate of transcrip-
tional elongation. In addition, these TF-regulated net-
works are related to higher-order structure organization
and nuclear localization of DNA elements.
European research contributions 
European researchers have contributed significantly to
the identification and characterization of TFs involved in
normal and aberrant hematopoiesis. In addition, they have
extended many of these analyses toward genome-wide
mapping of normal as well as mutated TFs in primary
hematopoietic cells from healthy and diseased individuals,
thereby revealing multiple unanticipated functions of
these proteins.
European researchers have been working at the fore-
front of epigenetic research, a prime research interest of
the European Union, which has supported a multitude of
projects on this subject in the past decade (e.g.
Epigenome NoE, HEROIC, EPITRON, and Epigenesys).
Recently, these interests specifically focused on the
hematopoietic lineage with the support of BLUEPRINT,
a project that set out to generate epigenomic data of
more than 100 blood cell types from healthy individuals
and patients suffering from blood diseases. This project
has already provided many new insights into the inter-
play of TFs with chromatin to establish epigenetic pat-
terns that define cell type functionality, but also led to
the realization that much can still be learned about how
blood cell types develop and how we could modulate
their activities to prevent or counteract disease. This will
require a concerted effort to better understand regulatory
networks in both normal hematopoiesis and disease, and
will only be accomplished through close collaboration
between experimentalists, computational biologists, stat-
isticians, and clinicians.
Proposed research for the Roadmap
Mutations in transcriptional and epigenetic regulators
are some of the most common mutations in hematologic
malignancies. Given that these proteins function as regu-
latory network components, it will be important to gain
an understanding of the malignant state as a perturbation
of wider regulatory networks. Research on the concerted
actions as well as post-transcriptional regulation of TFs,
and on how these regulate the local and global epigenetic
environment, should be intensified.
Although the main TFs involved in disease development
have been identified, many components that drive the
functional fine-tuning of the blood cell types are still not
known. These are likely controlled by the niche in which
the cells reside, the availability of metabolites, both
endogenous (amino acids, sugars, and vitamins) and
exogenous (drugs, food additives, and toxins), and other
environmental factors. In addition, it has become clear
that not only the adaptive immune system confers mem-
ory potential, but that also cells of the innate immune sys-
tem can be trained and are functionally dependent on past
and present behavior, offering another starting point to
utilize cells of the hematopoietic system in disease pre-
vention and control.
Apart from creating additional comprehensive data sets
on genomics, epigenomics, and metabolomics, integrative
analysis of data is mandatory. Computational, conditional
dependency models need to be established, for example
by creating Bayesian networks, to formulate the relation-
ship between the cell niche, environmental factors, TF
binding, epigenetic alterations, and the presence of various
hematologic disorders.
Anticipated impact of the research
Intensifying the research on normal blood development
provides an opportunity to better understand the intrinsic
molecular systems that regulate normal hematopoiesis and
provide knowledge of how these mechanisms can be shaped
and regulated to the benefit of the individual. It will provide
a framework to which similar analysis on hematologic dis-
eases can be compared, allowing the identification of the pri-
mary mechanisms that are disrupted and providing starting
points for the development of targeted interventions. Finally,
the depth to which these networks can be studied in vitro and
in vivo will be of great importance to deciphering transcrip-
tional and epigenetic networks, not only in blood cell forma-
tion, but in multiple other organ systems as well.
1.9. Reprogramming/induced pluripotent stem
cells/embryonic stem cells
Valerie Kouskoff  (University of Manchester, Manchester,
United Kingdom), Lesley Forrester (University of
Edinburgh, Edinburgh, United Kingdom), Thomas Graf
(Center for Genomic Regulation, Barcelona, Spain), Hannes
Klump (Universitätsklinikum Essen, Essen, Germany),
Georges Lacaud (University of Manchester, Manchester,
United Kingdom), Pablo Menendez (Universitat de
Barcelona, Barcelona, Spain), Joanne Mountford (University
of Glasgow, Glasgow, United Kingdom).
Introduction
Pluripotent stem cells (PSCs), including embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs), rep-
resent a limitless source of cells for investigations ranging
from developmental processes to drug discovery. Dissecting
the molecular and cellular mechanisms underlying the in
vitro differentiation of PSCs to blood progenitors has been
instrumental in furthering our knowledge of the early steps
of hematopoietic development. The use of human ESCs has
proved particularly useful given the difficult and restricted
access to human embryos. Furthermore, dissecting the in
vitro differentiation of iPSCs derived from cells of patients
with hematologic diseases is starting to provide invaluable
insights into these pathological conditions. But one of the
greatest promises of the stem cell field remains the in vitro
derivation of cell populations that can be used in the clinic
for therapeutic purposes. PSC-derived cells could be used to
regenerate a damaged hematopoietic system or to modu-
late the repair of other tissues (e.g. macrophage in fibrosis)
or the immune response [e.g. chimeric antigen receptor
(CAR)-expressing T cells]. Finally, the fast-expanding field
of direct reprogramming in which one somatic lineage is
directly converted into another clinically useful cell type is
gaining momentum and may complement the derivation of
cell populations from PSCs.
European research contributions 
In the past two decades, European researchers have
contributed significantly to the field of embryonic
hematopoiesis, using PSCs as a model system to decipher
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the early steps of mesoderm specification and blood com-
mitment. These efforts have led to the identification of the
hemogenic endothelium as a cornerstone in the in vitro gen-
eration of blood progenitors.54,55 Studies by several European
laboratories have provided insights into the role of key tran-
scription factors (TFs) (e.g. RUNX1, ETV2, TAL1, HOXB4,
and HOXA9) and Notch signaling (e.g. DLL4 and CDCA7)
in promoting hematopoiesis. Innovative studies exploring
the derivation of in vivo engrafting blood progenitors from
ESCs56 and investigations on the instructive role of leuke-
mogenic fusion genes (e.g. MLL-AF4) in human ESC–
derived blood cells have also been undertaken in European
laboratories. Furthermore, the use of disease-specific iPSCs
to unravel inherited hematologic disorders, such as Fanconi
anemia (FA), chronic granulomatous disease, and pyruvate
kinase deficiency, provided unique clues to understanding
the mechanisms underlying these diseases.
On the translational front, European teams have made
seminal progress toward establishing protocols for the in
vitro generation of platelets, macrophages, dendritic cells,
and red blood cells (RBCs) and their manufacturing for use
in the clinic.57 Alternative methods for the derivation of
hematopoietic populations are now starting to emerge
with direct reprogramming as a forerunner in this fast
expanding area of research. Although still in its infancy,
direct reprogramming explores the instructive conversion
of one somatic lineage into another mediated by the
ectopic expression of TFs. Pioneering work was per-
formed in Europe to decipher the reprogramming of com-
mitted immune cells into macrophages mediated by
CEBPA.58 More recently, the reprogramming of fibroblasts
to hematopoietic progenitors was achieved upon ectopic
expression of specific TFs.
Proposed research for the Roadmap
Fundamental research focusing on developmental
processes of the hematopoietic specification of PSCs
needs to be maintained, because this area of investiga-
tion holds the key to establishing robust and efficient
protocols for the production of clinically applicable blood
and immune cells. These protocols would benefit from
the reproducible derivation of long-term repopulating
hematopoietic stem cells (HSCs) with adult characteris-
tics. Deriving therapeutic cells from PSCs by modulating
the differentiating conditions is a priority, but other
approaches should be followed in parallel. One of the
new avenues to be pursued is the direct reprogramming
of human non-hematopoietic cells to blood cells/progen-
itors for therapeutic purposes. There is still much to be
understood about the fundamental aspects of somatic
cell reprogramming, and funding opportunities should be
provided for European groups to intensify their efforts in
this groundbreaking field. Both basic and translational
areas need to be explored in order to remain competitive
at an international level. Another important area that
European research should focus on is further developing
the use of iPSCs as a model system for hematologic dis-
ease in both fundamental and applied studies. This
approach represents a unique opportunity to: 1) deter-
mine the contribution of the epigenome to disease initi-
ation and maintenance; and 2) understand the develop-
mental impact of leukemia-specific mutations and chro-
mosomal translocations in blood specification and cell
fate decisions.
Anticipated impact of the research
Ultimately, harnessing the power of PSCs for regenera-
tive medicine and the production of blood derivatives will
profoundly benefit patients, families, and European socie-
ty as a whole. To reach that goal, however, we will need
to gain a deeper understanding of the differentiation
processes leading to the generation of the desired
hematopoietic subsets. We will also need to implement
robust protocols for the large-scale production of desired
blood products. iPSCs as model systems to understand
mechanisms of disease emergence and maintenance will
be instrumental in identifying and developing novel treat-
ment options for the relevant disorders.
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Malignant lymphoid diseases represent the most fre-
quent hematologic malignancies, with an age-adjusted
estimated incidence of 24.5 per 100,000 inhabitants in
Europe,59 and are associated with significant mortality60
and morbidity. This disease group is highly heterogeneous
in terms of frequency, epidemiology, biology, genetic
abnormalities, and outcome. While in a way all individual
lymphoma subtypes could be seen as rare diseases, some
of them are relatively common, e.g. multiple myeloma,
chronic lymphocytic leukemia (CLL), diffuse large B-cell
lymphomas (DLBCLs), follicular lymphomas (FLs), and
Hodgkin lymphomas (HLs). Others are less common e.g.
mantle cell lymphoma (MCL), acute lymphoblastic
leukemia (ALL), T-cell lymphoma, and mucosa-associated
lymphoid tissue (MALT) lymphoma, or even very rare,
e.g. some subsets of marginal zone lymphomas (MZLs)
and HIV-associated lymphoma. After the progress made in
the morphological classification of these tumors in the
1990s, the advent of large-scale genomic approaches
enabled identification of multiple molecular subsets,
which may further subdivide the different entities in mul-
tiple rare diseases.61-63 These achievements justify the need
for European-based epidemiological studies and contribu-
tions to the InterLymph consortium64 to investigate the
role of environmental and lifestyle factors, which, in the
context of inherited genetic background, may favor the
development of these malignancies.
Significant progress was also made in unraveling key
biological features of these diseases, including: 1) the more
precise delineation of intrinsic genetic defects in tumor
cells, delineation still ongoing with NGS approaches;63,65,66
2) the growing understanding of the complex interplays
between malignant cells and their microenvironment,
which is especially critical in these diseases arising in lym-
phoid organs;67 and 3) the emerging identification of con-
stitutional genetic traits associated with an increased sus-
ceptibility to develop these malignancies.68,69 Finally, sever-
al recent developments have pointed toward the existence
of “lymphoid cancer stem cells,” which may represent
highly desirable targets to achieve a definitive cure in
these malignancies.70-72 Although several European groups
have already made outstanding contributions to this field,
in part within large international consortia, further
Section 2. Malignant lymphoid diseases
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achievements will only be possible if major investments
can be realized. These should particularly focus on estab-
lishing new cellular and animal models (critically rare in
the field of mature lymphoid malignancies) to better
understand how these diseases develop and for pre-clini-
cal assessment of new therapeutic agents.
Despite important advances in the past few years,73 the
survival of patients with lymphoid malignancies remains
unsatisfactory. This is true for the most aggressive malig-
nancies (e.g. ALLs, T-cell lymphomas, and some forms of
DLBCL), which still are frequently fatal. In addition, the
lack of cure in patients with multiple myeloma or indolent
lymphoma is equally challenging. Furthermore, short- or
long-term morbidities such as infertility, secondary malig-
nancies, as well as cardiac, pulmonary, renal, or neurolog-
ical dysfunction are associated with intensive treatment in
HL or DLBCL. Chronic exposure to therapeutic agents
such as in indolent lymphoma and CLL also represents a
health burden for patients, as well as an increasingly rele-
vant economic burden for the European Union.2,74
Attention to malignancies occurring in elderly patients
should also be considered in this regard given the fact that
life expectancies continue to grow.
European co-operative groups have been leading clinical
research in lymphoid malignancies in the past decades.
Progress is being made in investigating the role of targeted
agents in well-characterized molecular subsets. The num-
ber of new therapeutic agents under development in this
field demands further academic research collaboration. For
example, analyzing the medico-economic impacts of
patient management should clarify costs and benefits of
new therapeutic strategies, including those related to pub-
lic health economics. These groups also need further sup-
port in their translational research activities, especially in
their efforts to constitute and analyze large biobanks with
high-quality clinical annotations. Efforts should also aim
to eliminate the differences in outcome observed in differ-
ent parts of Europe and to improve patients’ survival and
quality of life.
2.1. Hodgkin lymphoma
Marc André (Université Catholique de Louvain, Yvoir,
Belgium), Anke van den Berg (Universitair Medisch
Centrum Groningen, Groningen, the Netherlands), Peter
Borchmann (University Hospital Cologne International,
Cologne, Germany), Massimo Federico (Università degli
studi di Modena e Reggio Emilia, Modena, Italy), Judith
Landman-Parker (Hôpital Armand Trousseau, Paris,
France), Stephan Mathas (Charité Universitätsmedizin
Berlin, Berlin, Germany), John Radford (University of
Manchester, Manchester, United Kingdom).
Introduction
Classical Hodgkin lymphoma (HL) is a highly curable
disease and is considered one of the most successful sto-
ries in hematology. For both localized and advanced-stage
disease, more than 90% of patients are alive five years
after diagnosis, and the progression-free survival (PFS) is
85%-93% for localized disease and 70%-89% for patients
with advanced disease. After a first relapse, the disease
remains curable in nearly half of the cases when high-dose
chemotherapy with autologous stem cell transplantation
(ASCT) is feasible. As HL is one of the most common
malignancies in young adults, most patients will have a
very long survival. During their follow up, however, a sig-
nificant proportion of patients experience serious long-
term toxicities, such as second malignancies, cardiovascu-
lar diseases, and infertility. Most of these late toxicities
have been related to the treatments for HL. To reduce
long-term, treatment-related toxicities, optimization of
the balance between the risks and benefits of the different
treatment strategies is still the subject of controversy and
the main goal of most clinical trials.
European research contributions 
Two European risk models (proposed by the German
Hodgkin Study Group and the European Organisation for
Research and Treatment of Cancer/the Lymphoma Study
Association) are commonly used and were established to
separate HL into three different risk categories: early favor-
able, early unfavorable or intermediate, and advanced dis-
ease. Using these prognostic categories, European lym-
phoma groups have been major contributors in clinical trials
that established ABVD (doxorubicin, bleomycin, vinblas-
tine, and dacarbazine) as a reference chemotherapy for HL.
Alteration of ABVD by omitting any drug including
bleomycin was also recently reported as inferior in terms of
disease control.75 However, as approximately 30% of
patients with advanced disease relapse after ABVD,  a more
intensified chemotherapy, BEACOPPesc (bleomycin,
etoposide, doxorubicin, cyclophosphamide, vincristine,
procarbazine, and prednisone) was developed for these
patients. It showed a better progression-free survival (PFS),
although it is also associated with more toxicity.76 Since the
late 1980s, children and adolescents with HL have been
treated with chemotherapy designed to limit cumulative
doses of anthracycline, alkylating agents, and bleomycin to
limit long-term toxicity. Recently, OEPA (vincristine, etopo-
side, prednisone, and doxorubicin) associated with COP-
DAC (cyclophosphamide, vincristine, prednisone, and
dacarbazine) was commonly used in European studies and
demonstrated global efficacy comparable to treatment with
regimens containing procarbazine with, therefore, an
expected lower rate of impaired fertility in both men and
women.
Radiotherapy is a major contributor to the late toxicities,
such as secondary cancers and cardiovascular diseases.
European trials provided an important contribution to the
reduction of radiotherapy for HL treatment. Indeed, sever-
al trials have shown that when given in combination with
chemotherapy, the radiotherapy fields can be reduced
from extended to involved. In recent years, even more
restricted radiotherapy modalities, such as involved node
and involved site radiotherapy, have also been proposed
and evaluated in randomized clinical trials. Moreover,
these trials have also demonstrated that the dose of radio-
therapy can be safely reduced without compromising
treatment efficacy. The dose of radiotherapy in the more
favorable group of localized patients has been reduced to
20 Gy. In the vast majority of cases, radiotherapy in chil-
dren and adolescents is delivered at 20 Gy and restricted
to the involved site in order to limit growth abnormalities,
and long-term vascular and heart toxicity. More recently,
European trials in pediatric, adolescent, and adult patients
have also tested the possibility of omitting radiotherapy in
select patients. As it has been shown that patients with a
fluorodeoxyglucose positron-emission tomography (PET)
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negativity after two cycles of ABVD have an excellent out-
come, it was suggested that those PET-negative patients
could receive less intense therapy without any radiothera-
py.77 This PET-driven treatment adaptation is still restrict-
ed to clinical trials and whether this select population of
patients can be safely treated without radiotherapy
remains controversial and a matter of debate. Importantly,
HL trials led by several European co-operative groups
allowed nuclear medicine physicians to establish criteria
for a good and reproducible interpretation of PET-CT
scans in lymphoma patients. This 5-point scale, referred as
the Deauville scale, is now commonly adopted by the
international community to properly evaluate interim and
end-of-treatment PET-CT scan results in the field of lym-
phoma.78
Apart from these clinical achievements, various
European groups have a long history of research on HL
pathogenesis, beginning with the identification of HL as a
B-cell-derived malignancy. Most of the currently known
molecular defects considered to be key alterations of HL
were identified by European groups, including the dereg-
ulated NF-κB activity and genomic defects of components
of the NF-κB and JAK/STAT signaling pathway.
Proposed research for the Roadmap
Research should be pursued into the etiology and epi-
demiology of HL with attention to genetic, immune-based
and infectious (e.g. Epstein-Barr virus) determinants. Most
patients with HL will ultimately be cured from their dis-
ease and experience long-term survival. We are now in a
situation of trying to better identify patients who will be
more readily cured from those who will need more inten-
sified therapy (e.g. radiotherapy for localized patients and
BEACOPPesc for advanced patients). This will allow us to
meet the urgent need of avoiding unnecessary toxicities
for the vast majority of patients who can be cured with
less aggressive treatments. Special efforts towards opti-
mizing treatment for elderly patients should also be made. 
PET-CT and biomarker-driven strategies are currently
being explored with the hope of individualizing treatment
decisions. However, pre-treatment prognostic markers
(e.g. circulating biomarkers), genomic markers, or molecu-
lar markers have to be identified to stratify patients before
starting treatment or early thereafter. To develop such
tools, coupling international clinical trials with the estab-
lishment of a biobank including tumor tissue and blood
samples is essential. Moreover, as the pathogenesis of HL
is still largely unknown, establishment of a comprehensive
picture of the role of the microenvironment, genetic alter-
ations, and molecular pathways driving pathogenesis of
the disease is required. This may also lead to the identifi-
cation of novel targets for treatment that could potentially
cause fewer undesired side effects.
Interestingly, for the first time since the 1970s and the
introduction of doxorubicin, new drugs are now becoming
available in the field of HL and are suggested as treatments
with a safe toxicity profile. A CD30 antibody-drug conju-
gate was recently approved for the treatment of relapses
after high-dose chemotherapy with ASCT and for patients
failing two previous lines of chemotherapy but ineligible
for high-dose chemotherapy. This drug induced durable
remissions and favorable long-term survival in patients
with relapsed/refractory HL.79 More recently, when given
as a consolidation therapy after ASCT, this drug was also
shown to improve PFS of patients treated with high-dose
chemotherapy for a first relapse. Finally, this drug is now
being tested for both first- and second-line therapy. More
recently, as pre-clinical studies suggested that
Hodgkin/Reed-Sternberg cells exploit the programmed
death-1 (PD-1) pathway to evade the immune system, PD-
1–blocking antibodies were evaluated in ASCT and CD30
antibody-drug conjugate refractory patients and showed
substantial therapeutic activity with an acceptable safety
profile. The place of these new drugs and possible associ-
ations with the currently available treatment modalities
need to be further refined, especially with the aim of lim-
iting long-term toxicities.
As late toxicities and complications are a major concern
in this situation, continuous and rigorous evaluation of
long-term survivors also remains a major topic of interest
for clinical research.
Anticipated impact of the research
As HL is a disease of the third and fourth decade of life,
and one of the most common cancers in young adults,
cured patients are potential long-term survivors. Reducing
their risk of late toxicities, while keeping their high cure
rate, is of utmost importance for increasing their individ-
ual chances of becoming active members of society in the
long term. The recent successful implementation of target-
ed treatment strategies shows the importance and clinical
relevance of unraveling the pathogenesis of HL. Moreover,
knowledge about disease relapse is lacking and intensive
research is needed into this. This will only be possible
within large European clinical trials combined with exten-
sive biobanking and the development of tools that allow
analysis of the scarce tumor cell population characteristic
of HL. In addition, these clinical trials provide a solid basis
to identify, if possible, pre-treatment prognostic biomark-
ers to select patients who will benefit from the respective
treatment regimen. Finally, the definition of the place of
already-developed new drugs in our armamentarium and
individualized therapy strategies is one of the main goals
of the next generation of clinical trials. Special attention
should be given to disseminate knowledge and innovation
to vulnerable populations in Europe and elsewhere.
2.2. Diffuse large B-cell lymphoma and Burkitt
lymphoma in adults and children
Hervé Tilly (Université de Rouen, Rouen, France), Igor
Aurer (University of Zagreb, Zagreb, Croatia), Peter
Johnson (University of Southampton, Southampton,
United Kingdom), Georg Lenz (Universitätsklinikum
Münster, Münster, Germany), Véronique Minard (Institut
Gustave Roussy, Villejuif, France), Vincent Ribrag (Institut
Gustave Roussy, Villejuif, France), Andreas Rosenwald
(Universität Würzburg, Würzburg, Germany), Umberto
Vitolo (Università degli Studi di Torino, Turin, Italy).
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most
common mature B-cell neoplasm, with an estimated inci-
dence of 3.8 per 100,000. This indicates that approximate-
ly 30,000 cases occur in Europe each year, with some vari-
ations in geographic distribution.59 The median age at
diagnosis is 60 years. The standard method of diagnosis is
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a surgical excision biopsy with morphology and immuno-
histochemistry study. Gene expression profiling has iden-
tified three major subtypes of DLBCL according to the cell
of origin of the malignant cells: germinal center B-cell, acti-
vated B cell-like, and primary mediastinal B-cell lym-
phoma. A large majority of DLBCL in adolescents belongs
to the germinal center B-cell subtype, and the proportion
of the activated B cell-like subtype increases with age.
Next generation sequencing (NGS) studies demonstrated
very heterogeneous genomic alterations among these sub-
types, which could be related to a variable outcome and
could indicate putative targets for therapeutic interven-
tions. The combination of the anti-CD20 antibody ritux-
imab with chemotherapy resulted in an important
improvement in survival over the past decades.73,80 A pro-
portion of 50%-90% of patients can be cured by
immunochemotherapy depending on age and other clini-
cal prognostic factors gathered in the International
Prognostic Index.81 As salvage treatment is often disap-
pointing, a successful first-line treatment is the key to
longer survival.
Burkitt lymphoma (BL) is an aggressive B-cell lym-
phoma characterized by the presence of a translocation
that activates the oncogene MYC. The sporadic form
found in Europe mostly affects children and young adults
with a crude incidence of 0.22 per 100,000, accounting for
80% of B-cell lymphomas in these age groups. It is associ-
ated with immunosuppression, especially HIV infection,
mostly among older patients. Intensive chemotherapy and
supportive care can cure most young patients in high-
income countries, but outcome is less favorable for other
populations.
MYC translocations can also occur in lymphoma with
features intermediate between DLBCL and BL. This B-cell
lymphoma unclassifiable has a more aggressive behavior
and potentially needs a specific therapeutic approach.
European research contributions 
Large randomized studies conducted by European co-
operative study groups have contributed to the establish-
ment of a worldwide standard treatment. Fifteen years
ago, the advantages of the combination of rituximab and
standard chemotherapy CHOP (cyclophosphamide, dox-
orubicin, vincristine, and prednisone) over chemotherapy
alone were demonstrated by these study groups in young
and older patients.80 Further studies have proposed opti-
mal combinations varying according to prognostic factors,
the exploration of salvage treatment, the evaluation of
treatment by functional imaging, and the description of
biological characteristics correlated to clinical outcome in
patients treated with immunochemotherapy. Efforts in
children and adolescents consisted of intensive
chemotherapies to increase a high-rate cure, sometimes
accompanied with immediate toxicity, but with the aim of
reducing long-term toxicity.
European hematologists have contributed to an interna-
tional collaborative project aiming at defining the molecu-
lar definition of lymphoid malignancies. This consortium
was at the origin of the identification of molecular sub-
types of DLBCL and the distinction between BL and
DLBCL with MYC translocations.82 These investigators
explored the genomic and transcriptional mechanisms
implicated in lymphomagenesis and identified genetic
alterations modifying major cellular pathways, influencing
clinical outcome of patients with DLBCL and representing
possible therapeutic targets.
Proposed research for the Roadmap
An effort to further characterize the genomic, transcrip-
tional, epigenetic, proteomic, and metabolomic landscape
of each DLBCL subtype is a common goal in research into
hematologic malignancies. Development of new cell lines
and animal models representative of these subtypes are
certainly needed to improve our understanding of the
important biological mechanisms of the lymphoma cell,
the interaction with the tumor microenvironment, and to
explore the efficacy of new drugs.
The most important challenge in DLBCL is to improve
survival of those patients who have refractory disease or
who relapse early in the course of the lymphoma.
Molecular heterogeneity is, at least in part, responsible for
this outcome. If whole-exome sequencing has redefined the
genetic landscape of the disease, identification and charac-
terization of genetic alterations in this population requires a
large number of samples, important clinical data, and access
to extensive sequencing and analysis possibilities. This
approach should overcome the inherent complexity of
these alterations, the low frequency of some of them, the
tumor heterogeneity, and the mechanisms of resistance.
New tools for children and adolescents will be devel-
oped to assess risk stratification, early response, and mon-
itoring of the disease in order to tailor chemotherapy and
strike a balance between acute toxicity and the risk of
long-term toxicity. This will require further international
collaboration, along with partnerships with adult lym-
phoma groups.
Early access to targeted drugs will be conditional on the
ability of the European centers to collect the tumor sam-
ples and establish a viable network of platforms to
exchange data, define common protocols, and share qual-
ity-control processes. A large number of new agents tar-
geting driver mutations involved in lymphomagenesis are
awaiting clinical application. The selection of patients
who are likely to respond to a single agent should be
based on the identification of subtypes, the exploration of
pathways, or the presence of genetic abnormalities. In this
view, targeting MYC would be a highly desirable goal in
both BL and DLBCL.
Combining targeted drugs with standard first-line
immunochemotherapy in order to increase its efficacy and
decrease its toxicity will certainly be the major therapeutic
path to be explored in the coming years. The next step
could then be the advent of chemotherapy-free regimens
containing a combination of targeted molecules or a com-
bination of these molecules with monoclonal antibodies
or other immune therapies. Access to platforms and devel-
opment of these novel combinations will be of critical
importance in elderly patients who represent the fastest-
growing group and the frailest population.
New biomarkers of response and survival need to be
explored. Functional imaging has been shown to be a use-
ful tool for evaluating early response and correlating it to
clinical outcome. Efforts to develop new markers of spe-
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cific pathways or new evaluation modalities could help
guide treatment. Circulating DNA could also be a power-
ful tool to help diagnosis, evaluate response to treatment,
and predict relapse.
Anticipated impact of the research
All of these research directions aim at a better under-
standing of the biology of DLBCL and BL. Future manage-
ment of patients with these diseases will have to change
from empiric administration of chemotherapy to a combi-
nation of precision therapy, thus leading to more person-
alized treatment approaches. This change will have a
major impact on increasing treatment efficacy, decreasing
the rate of treatment complications, and ultimately pro-
longing survival. A close collaboration between patients,
academic laboratories, pharmaceutical and biotech com-
panies, and co-operative study groups must work towards
ensuring this translation in adults and children. Finally, a
reduction of hospital costs and optimization of treatment
strategies will allow this policy to be adopted in all parts
of Europe.
2.3. Mantle cell lymphoma
Marek Trneny (Univerzita Karlova, Prague, Czech
Republic), Elias Campo (Universitat de Barcelona,
Barcelona, Spain), Martin Dreyling (Ludwig-Maximilians-
Universität München, Munich, Germany), Steven
LeGouill (Université de Nantes, Nantes, France), Simon
Rule (Derriford Hospital, Plymouth, United Kingdom).
Introduction
Mantle cell lymphoma (MCL) represents approximately
7% of all non-Hodgkin lymphomas (NHLs) and is geneti-
cally characterized by the translocation t(11;14)(q13;q32)
and the overexpression of CCND1. Most cases have an
aggressive course and require intensive treatment. The
standard approach is based on immunochemotherapy,
which consists of rituximab and CHOP-like and/or high-
dose, Ara-C–containing regimens followed by high-dose
treatment (HDT) with autologous stem cell transplantation
(ASCT). Elderly patients are usually treated with rituximab
and CHOP (R-CHOP) or R-bendamustine chemotherapy,
and rituximab maintenance is used for responding patients.
The MCL International Prognostic Index (MIPI) can identi-
fy patients with a high risk, who still have a very poor out-
come in spite of intensive treatment. Proliferation index
evaluated by Ki-67 has been established as an important
prognostic marker. There is growing evidence that patients
who achieve minimal residual disease (MRD) negativity
have a significantly better outcome than patients who
remain MRD-positive.83 Patients who relapsed have a very
poor outcome with median overall survival of approxi-
mately 18 months. A small subset of MCL biologically
characterized by IGHV hypermutation and SOX11 nega-
tivity has a favorable outcome and usually does not require
immediate treatment after diagnosis.
European research contributions 
The effort in Europe has been focused on several differ-
ent priorities: 1) description of a clinically relevant prognos-
tic index with the use of some biological parameters; 2)
development of treatment strategies for the young as well
as the elderly population; and 3) response criteria. The
German Low Grade Lymphoma Study Group established
an MIPI that consists of age, lactate dehydrogenase level,
white blood cell count, and performance status.84 This
index has been accepted worldwide as a tool to discrimi-
nate between different outcomes. Evaluation of prolifera-
tion index by Ki-67 adds important prognostic informa-
tion; the most common threshold used is 30% positive
cells.84 High-dose chemotherapy (HDCT) and ASCT is
regarded the standard of care for young MCL patients. The
addition of rituximab and high-dose Ara-C has been
explored by the Nordic Lymphoma Study Group and the
Lymphoma Study Association.85 The European Mantle Cell
Lymphoma Network showed that incorporating DHAP
(dexamethasone, high-dose Ara-C, and cisplatin) led to a
better outcome in these patients. Whether the improve-
ment is due to high-dose Ara-C only or if combination
high-dose Ara-C with platinum is important has not been
tested; there is, however, some hint that combination
(DHAP) can be better than high-dose Ara-C monotherapy.
The issue of total body irradiation (TBI) as part of HDT
has not been resolved; it might well be that the incorpora-
tion of TBI results in better outcomes. Maintenance treat-
ment after stem cell transplant has been evaluated by the
Lymphoma Study Association. Although significant
improvements have been achieved, young patients with a
high MIPI score still have a poor outcome.85 However, the
majority of MCL patients are ineligible for intensive treat-
ment with HDCT and ASCT. The treatment with R-
CHOP or R-bendamustin has been accepted as standard,
and the European Mantle Cell Lymphoma Network study
demonstrated that rituximab maintenance for two years
after R-CHOP significantly prolongs progression-free sur-
vival (PFS).86 Although there is significant improvement in
terms of survival, the majority of patients suffer from poor
outcomes. This led to collaborative trials with new drugs
including temsirolimus, lenalidomide, ibrutinib, borte-
zomib, and others.87 It has been clearly demonstrated that
outcome depends on response. Several groups have
worked to define the impact of MRD negativity. Pooled
data from different trials under the umbrella of the
European Mantle Cell Lymphoma Network demonstrated
that MRD negativity is a more important prognostic factor
than classical staging.
Proposed research for the Roadmap
The general outcome of MCL patients has improved but
is still worse than that of other lymphoma subtypes. The
growing understanding of MCL biology and improvements
in therapeutic strategies have led to a situation in which the
MCL patient population is considered more heterogeneous
than it was 15 years ago. Heterogeneity regarding MCL epi-
demiology in different parts of Europe should be investigat-
ed. On one side, there is a subgroup of MCL patients with
an indolent course; these patients can be followed until
treatment is required. There is, however, the need for a bet-
ter biological description of this subgroup. For the other
MCL patients, MIPI or Ki-67 is not yet used for treatment
tailoring. All young patients outside clinical trials are treated
similarly with HDCT and ASCT as standard management.
There is, however, a significant survival difference accord-
ing to prognostic subgroups and there is a need for individ-
ualized treatment. Patients with more aggressive MCL
(blastoid variants, high Ki-67, p53 mutations or deletion,
mutations in some related genes, such as NOTCH1 or
NOTCH2, several chromatin modifiers, such as WHSK1,
and others) still have a very poor outcome.
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On the other hand, a description of patients with good
prognosis, who could be treated without HDT, is also
needed. Targeted therapy at relapse seems to improve
outcome, but the median survival is still only approxi-
mately two years. Due to the low incidence of MCL,
prospective trials based on international collaboration are
warranted. These trials should test new classes of drugs
combined with established immunochemotherapy, and
translational research should be included. The important
issue is to collect biological samples of patients who fail
the treatment in order to understand the mechanism of
resistance.
Another task is to define how to use the information on
MRD. Should it become a standard response criterion?
Until now, this information has been used without affect-
ing therapeutic decisions. The question of whether there
is room for treatment intensification in MRD-positive
patients or treatment reduction in MRD-negative patients
should be answered in prospective clinical studies.
It has been accepted that post-induction treatment with
rituximab improves outcome in MCL. The question that
should be explored is whether targeted treatments, such
as ibrutinib, lenalidomide, or others, should be used as a
maintenance approach in first-line treatment.
Anticipated impact of the research
Mantle cell lymphoma is a rare lymphoma subtype
with a genetically well-defined primary event and many
secondary events. This disease has a very poor prognosis
with some recent improvements but results are still far
from satisfactory. The European collaborative effort could
provide a fresh insight into the impact of different sec-
ondary genetic events in MCL and identify subgroups for
individualized therapeutic approaches. The important
issue is establishing tissue bank samples, not only from
the time of diagnosis but also at the time of relapse. This
can only be achieved through large international efforts,
such as those initiated under the umbrella of the
European Mantle Cell Lymphoma Network.
Collaborative efforts should aim at further improvements
in the outcome of this disease. Although MCL is a rare
disease, it represents a paradigm for the exploration of
innovative, targeted therapies. 
2.4. Follicular lymphoma
John Gribben (Queen Mary University, London, United
Kingdom), Christian Buske (Universitätsklinikum Ulm,
Ulm, Germany), Jude Fitzgibbon (Queen Mary University
of London, London, United Kingdom), Peter Hoskin
(Mount Vernon Hospital, Northwood, United Kingdom),
Armando Lopez-Guillermo (Hospital Clínic de Barcelona,
Barcelona, Spain), Bertrand Nadel (Université de la
Méditerranée, Marseille, France).
Introduction
Follicular lymphoma (FL) is the second most common
lymphoma, comprising approximately 20% of all non-
Hodgkin lymphomas (NHLs), with an incidence in
Europe of approximately 2.18 cases per 100,000 people
per year. FL typically presents in middle age and in the
elderly, and the median age at diagnosis is 60 years. FL
arises from germinal center B cells and maintains the gene
expression profile of this stage of B-cell differentiation.
Morphologically, the disease is composed of a mixture of
centrocytes and centroblasts; an increased percentage of
centroblasts is predictive of a poor outcome. A hallmark of
the disease is the chromosomal translocation t(14.18), con-
tributing to overexpression of the antiapoptotic protein
BCL2. In addition, next generation sequencing (NGS)
studies have identified several recurring mutational events
targeting genes, highlighting the importance of epigenetic
dysregulation in the pathogenesis of the disease and
tumor microenvironment modulation through NF-κB and
B-cell receptor signaling pathways, as well as defects in
DNA repair and apoptosis, challenging the notion that
t(14;18) is sufficient for tumor initiation and demonstrat-
ing the genetic heterogeneity of the disease.88 Guidelines
for the diagnosis of indolent lymphomas were outlined by
the European Society for Medical Oncology. The majority
of affected individuals exhibit a characteristic indolent dis-
ease course with multiple relapses requiring repeated
courses of treatment; others develop aggressive disease
and histological transformation with shortened overall
survival. The disease remains incurable in most cases.
European research contributions 
In the past decades, European scientists have made
major contributions to the understanding of the molecular
basis of the disease and the relationship between the
tumor cells and their microenvironment. The conduct of
large controlled randomized trials within highly organized
lymphoma co-operative groups has changed the treatment
of FL and improved outcome. In particular, European-led
trials have paved the way to demonstrating the benefit of
immunochemotherapy over chemotherapy and the
advantage of maintenance anti-CD20 monoclonal anti-
body in first and subsequent remission, and have defined
new approaches to optimize first-line treatment.89
Proposed research for the Roadmap
Despite major progress in the management of FL, the
biological basis is not fully understood, and there is cur-
rently no cure. To find an effective treatment, we need to
be able to determine the molecular basis of the disease so
that more targeted treatment approaches can be adopted.
Because there does not appear to be a single target that can
be applied to all cases, a combination of novel biomarkers
(based on genomic, proteomic, transcriptomic, and
metabolomic analyses of biopsies) will be required. It will
be important to identify those molecular events involved
in early development of the disease90,91 and those involved
in progression and transformation.88 The prognosis and
clinical course of FL appears to be highly dependent on the
tumor microenvironment, and immunohistochemical
methods are being assessed to address this.92 The valida-
tion of these techniques will require the integration of lon-
gitudinal standardized data, as well as uniform criteria for
diagnosis and outcome that can be applied in the clinical
setting. Better integration of basic and clinical research will
also be crucial. Salient features of that integration should
include the following:
1. Where possible, consent should be obtained for the
procurement and storage of use of excess tissue from
lymph node biopsies and normal tissue at the time of
presentation and at each subsequent disease relapse for
research purposes in order to investigate the molecular
biology of these diseases.
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2. A biobank of biopsies linked to the clinical database
should be available, with protocols for standardized
sampling and storage procedures adapted to genomics
and functional assays (including live cells), which
would form the basis of correlative and biomarker
studies. Of particular importance would be the bank-
ing of longitudinal samples from patients at diagnosis
and at subsequent relapses and transformation to the
nature of relapsing disease.
3. A database (a co-ordinated pan-European registry) that
can be accessed by all research partners, containing the
biological and clinical information collected for each
participating patient, should be made available.
4. Uncovering the molecular mechanisms involved in FL,
especially in its early stages90-92 and the processes
involved in transformation, should be a common
goal.88 A key issue would be performing both genetic
and microenvironment analyses on longitudinal
and/or paired FL biopsies to obtain an integrated view
on bidirectional dependency.
5. Robust biomarkers (both prognostic and predictive)
should be developed, reflecting the molecular biology
of the disease and the impact of the immune microen-
vironment for disease development and treatment out-
come.92
6. Novel animal models that recapitulate disease features
and allow pre-clinical investigation could also be devel-
oped. No good animal models of this disease are cur-
rently available, limiting research and drug develop-
ment.
7. Academic clinical research should also address issues
related to the costs and benefits of different therapeutic
options and optimal strategies in the elderly population.
Anticipated impact of the research
The current lack of understanding of the molecular basis
of the disease, the nature of the lymphoma “stem cell”, and
the events involved in progression and transformation limit
our ability to cure this disease. The research plans above
hold the key to understanding the molecular pathogenesis
of disease and identifying key targets for optimal therapeu-
tic intervention. The characterization of the genetic,
genomic, proteomic, transcriptomic, and metabolomic pro-
file of individual patients and patient cohorts will allow the
most appropriate treatment to be selected within clinical tri-
als investigating novel targeted therapeutic agents. This will
also allow identification of robust biomarkers for monitor-
ing response to treatment in order to allow a precision ther-
apeutic strategy to be applied to improve the survival and
quality of life of patients with FL.
2.5. Marginal zone lymphoma: extranodal, nodal, and
splenic forms
Andrés Ferreri (IRCCS San Raffaele Scientific Institute,
Milan, Italy), Ming-Qing Du (University of Cambridge,
Cambridge, United Kindom), Carlos Montalbán (MD
Anderson Cancer Center Madrid, Madrid, Spain), Kostas
Stamatopoulos (Institute of Applied Biosciences,
Thessaloniki, Greece), Alexandra Traverse-Glehen (Centre
Hospitalier Lyon Sud, Lyon, France).
Introduction
Marginal zone lymphomas (MZLs) are a diverse group
of clinic-pathological entities, comprising extranodal (also
called MALT lymphoma), nodal, and splenic forms. The
ontogeny of these lymphomas is in most cases related to
autoimmune disorders and chronic infections. Indeed,
Sjögren syndrome, systemic lupus erythematosus,
rheumatoid arthritis, and Hashimoto thyroiditis, among
the former, and hepatitis C virus, Helicobacter pylori, and
Chlamydia psittaci, among the latter, have been linked to
MZL development. Persistent (auto)antigenic stimulation
by chronic infections or autoimmune disorders leads to
lymphoid proliferation, susceptible to malignant transfor-
mation; the acquisition of genetic aberrations culminates
in the activation of intracellular survival pathways and
clonal outgrowth due to proliferation and resistance to
apoptosis. However, the interactions between cell-extrin-
sic (environmental factors) and cell-intrinsic (genetic,
molecular, and immunological abnormalities) factors that
underlie disease pathogenesis are still not completely
understood.
From a clinical standpoint, MZLs are indolent disorders,
often manageable with a “watch and wait” strategy, and
exhibiting excellent survival when treated with conven-
tional immunochemotherapy or radiotherapy. However,
such approaches result in overtreatment of many patients
affected by these indolent lymphomas. Accordingly, sev-
eral investigators are exploring new active and less toxic
therapies. In particular, monoclonal antibodies, immu -
nomodulators, antibiotics, and other targeted therapies
have been tested, sometimes with promising results.
Nevertheless, efficacy rates are still lagging behind those
achieved with conventional treatments.
European research contributions 
In the past 20 years, European researchers have made
great progress in basic, translational, and clinical research
into MZL. In particular, the establishment of pathogenic
links with microorganisms has boosted understanding of
the mechanisms underlying MALT lymphomagenesis and
advanced therapeutic concepts.93 A seminal finding was
that t(1;14)(p22;q32)/BCL10-IGH, t(14;18)(q32;21)/IGH-
MALT1, and t(11;18)(q21;q21)/API2-MALT1, recurrently
seen in MALT lymphomas, activate the nuclear factor NF-
κB pathway. More recently, high-throughput studies have
identified several genetic changes that are useful as bio-
markers for disease diagnosis and refined classification
(e.g. BRAF, MYD88, NOTCH2, and KLF2 and NOTCH2
mutations), and new targets to be translated into thera-
peutic interventions (e.g. BCR, TLR, Notch, NF-κB, and
MAPK signaling pathways), especially in splenic MZL.
Splenic MZL was also shown to display a remarkably
skewed immunoglobulin gene repertoire because up to
one-third of cases express clonotypic B-cell receptor
immunoglobulin utilizing the IGHV1-2*04 gene, support-
ing antigen selection in splenic MZL ontogeny.
The precise diagnosis of MZL remains challenging, but
real progress has been achieved. The contribution of
European researchers though the Splenic Lymphoma
Working Group has been important, especially for the
establishment of guidelines for the diagnosis, treatment,
and monitoring of splenic MZL. Their studies have been
instrumental in the characterization of a broad category of
variably well-defined provisional entities, involving pri-
marily the spleen, that do not fall into any of the other dis-
tinct types of splenic B-cell neoplasms (splenic B-cell lym-
phoma/leukemia unclassifiable), especially splenic diffuse
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red pulp lymphoma and hairy cell leukemia variant, and
their precise ontogenetic relationship with splenic MZL.
Furthermore, positive diagnostic markers (e.g. MNDA and
FCRL4) have been established, and gene expression stud-
ies have identified a specific gene expression profile that
separates nodal MZL from other lymphoma types.
The Splenic Lymphoma Working Group has also formu-
lated standard criteria to initiate treatment and a simple
but effective prognostic score for splenic MZL.94 Such
advancements have complemented the therapeutic
progress in MZLs achieved thanks to European trials,
often performed within the International Extranodal
Lymphoma Study Group. An International Extranodal
Lymphoma Study Group trial and a nationwide Spanish
trial have established a standard of care with
immunochemotherapy for extranodal MZL.95,96 Moreover,
the activities of drugs such as rituximab, everolimus,
bortezomib, lenalidomide, and clarithromycin, among
others, in MZLs have been addressed in European trials.
Importantly, studies of the association between infectious
agents and MZL resulted in the development of safe, cost-
benefit, and effective therapeutic strategies,93 as exempli-
fied by the efficacy of antiviral therapy for hepatitis C
virus-related MZL.97
Proposed research for the Roadmap
A concerted use of high-throughput platforms available
in several European research centers will significantly
advance our knowledge of these lymphomas. The main
objectives of future studies should be the following.
1. Characterize genetic aberrations and molecular mech-
anisms involved in the natural history of MZL, map
recurrent mutations to molecular pathways, and inves-
tigate their correlation with gene expression signature
and potential oncogenic co-operation among the
altered molecular pathways.
2. Unravel the ontogenetic mechanisms of splenic MZL
and other lymphomas of MZ origin, through genome
(e.g. whole-exome sequencing), transcriptome (e.g.
RNA-seq), epigenome (e.g. DNA methylome), and
immunoglobulin repertoire analysis and comparison to
normal B-cell subsets from human spleen and lymph
nodes.
3. Analyze multi-stage lymphomagenesis and clonal evo-
lution, including transformation, applying deep
sequencing to longitudinal samples from different
phases of the disease.
4. Define functional immune profiles of disease sub-
groups with particular clinical and/or biological fea-
tures.
5. Identify other micro-organisms that could play a path-
ogenic role and serve as target for more specific thera-
pies.
6. Identify and characterize the antigens and immune
pathways that drive lymphoma development, thus
paving the way for tailored treatment strategies appli-
cable to each major immunogenetic subgroup.
7. Investigate the precise mechanisms associated with
chronic inflammation involved in the development
and evolution of nodal MZL arising in patients with
autoimmunity.
8. Address the complex interactions between the neo-
plastic B cells and the surrounding microenvironment,
including both cellular and humoral components.
9. Develop prospective clinical trials on risk-adapted
treatments that result in improved efficacy and
reduced toxicity.
Anticipated impact of the research
Advances in unraveling the molecular abnormalities and
mechanisms of antigenic triggering combined with progress
in genetic profiling will likely result in the identification of
subjects with an increased risk of MZL and, consequently,
the potential to implement prevention strategies.
Knowledge of involved antigens, pathogenic mechanisms,
altered molecular pathways, and the crosstalk between
tumor cells and the microenvironment will promote per-
sonalized therapies, thus maximizing benefits while mini-
mizing unnecessary toxicities and costs.
Given the recent refinement of some entities and their rel-
ative rarity, pan-European co-operation is a prerequisite for
real progress. This is especially important given the emerg-
ing trend of designing clinical trials for highly select sub-
groups of MZL patients, which is a challenge considering the
rarity of these lymphomas. Patient selection will always be
based on clinical criteria, but biological and molecular
parameters will be progressively incorporated as selection
criteria in important trials. This is necessary for testing new
compounds, as well as for guiding patient choice among the
armamentarium of personalized therapies.
2.6. T-cell and NK-cell lymphoma
Philippe Gaulard (Hôpital Henri-Mondor, Creteil,
France), Bertrand Coiffier (Université Claude Bernard,
Lyon, France).
Introduction
T-cell and natural killer (NK)-cell lymphomas are rather
heterogeneous and uncommon malignancies. They repre-
sent less than 15% of all non-Hodgkin lymphomas (NHLs)
worldwide but their epidemiology shows important geo-
graphic variations, partly overlapping with the prevalence
of certain viral infections [e.g. Epstein-Barr virus (EBV) and
human T-cell leukemia virus type 1] and linked to the het-
erogeneous distribution of genetic backgrounds. The cur-
rent WHO classification recognizes more than 20 entities
grouped according to their predominant nodal, extranodal,
cutaneous, or leukemic presentation; some of them indo-
lent, but most of them aggressive or very aggressive.98
With some exceptions, such as ALK-positive anaplastic
large cell lymphoma, survival is usually short. The long-
term overall survival for all entities is less than 30%.
Unfortunately, there is no real standard treatment for most
T-cell/NK-cell lymphoma, except for NK/T-cell nasal type
lymphoma where the role of L-asparaginase (alone or in
combination) has been well demonstrated.99 Prognostic
biomarkers are not well characterized for most groups or
entities. In addition, most entities lack pre-clinical models.
Leading researchers in the field feel that substantial and
continuous efforts should be made while appreciating the
challenges represented by the rarity of these lymphomas.
European research contributions 
In recent years, a better understanding of most entities of
the different T-cell and NK-cell proliferations has been
established.100,101 The different identities have become better
defined, primarily through pathological classification.
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Several European groups have long-lasting research activity
and experience in the pathogenesis of T-cell lymphoma. In
larger cohorts, genome-wide molecular profiling of avail-
able tumor material has provided new insights into the
pathobiology of these diseases. This subsequently led to the
identification of new markers with diagnostic, prognostic,
and/or therapeutic implications. The identification of the
follicular helper T-cell subset as the cell of origin of angioim-
munoblastic T-cell lymphoma and a proportion of peripher-
al T-cell lymphoma (PTCL) represented an important step
in defining markers with diagnostic and therapeutic impli-
cations. European groups described the currently known
molecular signatures of most T-cell lymphomas. These
findings also contributed to the discovery of several genetic
aberrations and deregulated pathways, such as the involve-
ment of mutations in epigenetic modifiers and dysregula-
tion in important signaling pathways, including JAK-/STAT,
PDGFRA, and NF-κB. Now there is a good chance that at
least some of these pathways may serve as targets for the
development of novel therapies.
New drugs such as romidepsin, pralatrexate, and belino-
stat have shown clinical responses in up to 30%-35% of
relapsing patients but the question as to their role in daily
patient management remains unanswered. Promising
advances include a targeted immunoconjugate against
CD30-positive T-cell lymphoma (expressed on anaplastic
lymphoma, but also on some others T-cell subtypes) and
small molecules against the activity of the ALK kinase (e.g.
crizotinib). However, no substantial improvement has been
made in defining the best first-line treatment or the role of
high-dose chemotherapy and transplant for these patients.
Several phase III clinical trials have been launched that eval-
uate therapeutic options such as transplants in first remis-
sion and the addition of new drugs to CHOP, but results are
still pending.
Proposed research for the Roadmap
Insights into the molecular basis of T-cell and NK-cell
lymphomas will probably help define future risk stratifica-
tion, predict treatment response, and provide the basis for
novel drug design. The emphasis is put on defining the best
combination for first-line patients. They represent the best
opportunity for finding curative treatments, as salvage
treatments for these lymphomas clearly remain insufficient.
Given the modest efficacy of most agents, improving out-
come will likely rely on drug combinations with comple-
mentary mechanisms of action. Furthermore, we need to
better identify patients who will respond to therapies, with
correlative studies performed in parallel.
Despite some improvement in recent years, there is a
need to characterize the genomic, transcriptional, epigenet-
ic, and metabolomic landscape of each PTCL subtype.
Development of new cell lines and animal models represen-
tative of these subtypes are also needed to explore the effi-
cacy of new drugs, and to improve our understanding of the
important biological mechanisms of the lymphoma cell and
the interaction with tumor microenvironment.
The most important challenge in PTCL is to develop alter-
native therapies to the conventional CHOP or CHOP-like
chemotherapy regimens in order to improve survival.
Biologically oriented strategies with drugs targeting altered
genes, pathways or surface molecules expressed in specific
PTCL entities need to be developed. Despite recent whole-
exome sequencing studies, the genetic landscape and
potential driver alterations remain poorly characterized. A
European effort to collect clinical and biological data of
PTCL patients enrolled within clinical trials or registries is
critical. It should aim to perform whole-exome and whole-
genome sequencing analysis on a large number of clinically
well-annotated PTCL samples of each entity to identify
driver alterations and novel candidates for therapy.
Early access to targeted drugs will be needed for
European groups in order to collect tumor samples and
establish a viable network of platforms to exchange data,
define common protocols, and share quality-control
processes. A number of novel compounds targeting driver
mutations (e.g. demethylating agents and IDH2 inhibitors
in PTCLs with mutations in epigenetic modifiers) are await-
ing clinical application. The selection of patients who are
likely to respond to a single agent should be based on the
identification of the alterations, the exploration of path-
ways, or the presence of genetic abnormalities. Evaluation
of targeted drug combinations should also be undertaken.
Access to platforms and development of these novel com-
binations will be of critical importance in PTCL patients, a
group of patients with a very poor outcome.
In parallel, new response and outcome biomarkers need
to be explored. Functional imaging has been shown to be a
useful tool for evaluating early response and correlating it to
clinical outcome. Within the populations of patients collect-
ed in Europe, in view of the rarity of the diseases, efforts to
develop new markers of specific pathways or new evalua-
tion modalities could help guide treatment. Circulating
DNA could also be a powerful tool to help diagnosis, eval-
uate response to treatment, and predict relapse.
Anticipated impact of the research
All of these projects will help describe well-defined enti-
ties with their specific genetic modifications and will
enable new targets for innovative drugs to be evaluated;
these could provide more efficient and personalized treat-
ment approaches for PTCL patients and prolong their sur-
vival. PTCLs are certainly the best example of lymphomas
for which there is still a need for biologically oriented
novel strategies. Randomized studies will help set new
standards and enable better entity-specific treatment regi-
mens to be tested. Close collaboration between patients,
academic laboratories, pharmaceutical and biotech com-
panies, and European co-operative lymphoma study
groups with a long-standing tradition of working together
offers the possibility of a rapid translation of biological
studies into the clinic. Finally, reduction of hospital costs
and optimization of treatment strategies will allow this
policy to be adopted in all parts of Europe.
2.7. Lymphoma and immune deficiency (including AIDS,
post-transplant, and drug-induced immunodeficiency)
José Maria Ribera (Institut Catala d'Oncologia,
Barcelona, Spain), Antonino Carbone (Centro di
Riferimento Oncologico, Aviano, Italy), Jose-Tomas
Navarro (Institut Catala d'Oncologia, Barcelona, Spain),
Ralf Trappe (Charité-Universitätsmedizin Berlin, Berlin,
Germany).
Introduction
The incidence of Hodgkin lymphoma (HL), and espe-
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cially non-Hodgkin lymphoma (NHL), in patients with
immune deficiencies is higher than in the normal popula-
tion. Although particularly evident in patients with HIV
infection, this also occurs in other situations, such as after
solid organ and hematopoietic transplants, and in patients
receiving immunosuppressive therapies or with autoim-
mune diseases. Characteristically these lymphomas have
high-grade malignancy and are in advanced stage, with
frequent extranodal involvement.
Since the introduction of combination antiretroviral
therapy (cART), there have been a number of changes in
the spectrum of cancer affecting HIV-infected individuals.
Although the incidence and proportion of deaths related
to non-AIDS–defining malignancies are increasing, lym-
phoma is still the most frequent neoplastic cause of death
among HIV-infected individuals. The incidence of NHL
initially fell in the cART era but has now stabilized. On
the other hand, the incidence of diffuse large B-cell lym-
phoma (DLBCL) and primary central nervous system lym-
phomas has decreased, whereas that of Burkitt's lym-
phoma (BL) and HL has increased.
Post-transplant lymphoproliferative disorders (PTLDs)
include a range of diseases ranging from benign prolifera-
tions to malignant lymphomas. Risk factors for developing
PTLD include Epstein-Barr virus (EBV) infection, recipient
age, transplanted organs, type of immunosuppression, and
genetics. Uncontrolled proliferation of EBV-infected B cells
is implicated in EBV-positive PTLD, whereas the patho-
genesis of EBV-negative PTLD may be similar to that of
NHL arising in the general population.
The management of lymphomas in immunosuppressed
patients differs according to the cause of the immunosup-
pression. In HIV-infected patients, the extensive use of
cART has allowed these patients to be treated with iden-
tical schedules of immunochemotherapy as those used in
the general population (together with cART and adequate
prophylaxis of opportunistic infections). In PTLD, the first
step is the removal of immunosuppressive therapy, fol-
lowed by anti-CD20 immunotherapy, moving quickly to
standard immunochemotherapy schedules if response is
not rapidly achieved. Sequential therapy using rituximab
followed by chemotherapy has demonstrated promising
results and may establish a standard of care. The remain-
ing immunosuppression-associated lymphomas are man-
aged like those arising in the normal population.102-106
European research contributions 
Most of the achievements made through collaborative
efforts in Europe have been in HIV-related lymphomas.
Several national groups from European Union countries
have conducted phase II trials showing similar results of
the treatment of HIV-related lymphomas in the cART era.
The most frequent schedules used for DLBCLs are R-
CHOP, R-CDE (rituximab, cyclophosphamide, doxoru-
bicin, and etoposide) and R-EPOCH (rituximab, etoposide,
prednisone, vincristine, cyclophosphamide, and doxoru-
bicin); for BLs the most frequent schedules are R-
CODOX-M/IVAC (rituximab, cyclophosphamide, vin-
cristine, doxorubicin, and methotrexate/ifosfamide,
etoposide, and cytarabine), LMB, NHL2002, Burkimab,
and dose-adjusted R-EPOCH, among others. A general
consensus has been reached on the improvement in out-
come with the addition of rituximab to the different
chemotherapy schedules in patients not severely immuno-
suppressed. A new prognostic score for HIV-related lym-
phomas in the rituximab era (AIDS-Related Lymphoma
International Prognostic Index) has been developed, com-
bining patients from Europe and the United States includ-
ed in phase II or phase III trials of immunochemotherapy.
This score includes the age-adjusted International
Prognostic Index (IPI), the number of extranodal sites, and
the HIV-score (composed of CD4 count, viral load, and
prior history of AIDS). Twenty-eight percent of patients
were defined as low risk by the AIDS-Related Lymphoma
International Prognostic Index and had an estimated 5-
year overall survival of 78%, 52% as intermediate risk (5-
year overall survival of 60%), and 20% as high risk (5-year
overall survival of 50%). Another European-US study has
shown that the outcome of patients with AIDS-related
lymphomas has improved in the past two decades, and
effective HIV-directed therapies have reduced the impact
of HIV-related prognostic factors on outcome, allowing
curative anti-lymphoma therapy to be used in most
patients with aggressive NHL. As far as HL is concerned,
the results of chemotherapy schedules used in different
European countries, such as BEACOPP (Germany) and
VEBEP (Italy), have been comparable to those obtained
with the classical ABVD regimen (Spain and other coun-
tries). Similarly to NHL, an international effort (Europe,
the US, and South America) has been made to define the
prognostic factors of HL patients treated with ABVD and
cART, showing the negative impact of low CD4 lympho-
cyte counts on overall and progression-free survival.
A comparative analysis of HIV-related lymphoma and a
matched cohort of HIV-negative lymphoma patients from
several European countries was conducted by the
European Group for Blood and Marrow Transplantation
(EBMT). Comparable survival between HIV-positive and
HIV-negative NHL and HL patients undergoing autolo-
gous peripheral blood stem cell transplantation was
observed, leading to the conclusion that, in the cART era,
HIV-infected patients with lymphoma should be consid-
ered for autologous peripheral blood stem cell transplanta-
tion according to the same criteria adopted for HIV-nega-
tive lymphoma patients. Finally, a co-operative study from
the European Group of AIDS and Tumors analyzed the
autologous peripheral blood stem cell mobilization poli-
cies used in HIV-associated lymphomas, evaluated the fail-
ure rate, and identified factors influencing mobilization
results.
In summary, most of the co-operative European studies
on lymphomas associated with immunosuppression have
been focused on therapeutic strategies and the identifica-
tion of prognostic factors. Pan-European trials have also
established treatment standards for the management of
post-transplant B-cell lymphomas, using sequential
administration of rituximab followed by rituximab-
chemotherapy. However, rare post-transplant lymphoma
entities remain challenging.
Proposed research for the Roadmap
Basic aspects
1. To improve the knowledge of the mechanisms of lym-
phomagenesis in immunosuppression-related lym-
phomas, especially EBV-driven lymphomagenesis and
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the relation with other viruses (e.g. other gammaher-
pesviruses, HIV, and hepatitis viruses).
2. To evaluate the potential value of plasma load of
gammaherpesviruses as a surrogate marker of residual
disease in lymphomas in immunosuppressed patients.
3. To develop early biological predictors of development
of lymphomas in immunosuppressed patients (e.g.
EBV viral load and serum-free light chains).
4. To study the dynamics of the T-cell and natural killer
(NK)-cell repertoire in immunosuppressed patients and
its relation with the development of lymphomas.
Clinical aspects
The key clinical research goals are as follows.
1. To develop pan-European clinical trials with new
drugs, especially in the setting of relapsed/refractory
patients with HL and NHL, since immunosuppressed
patients (especially those who are HIV-infected) are
usually excluded from current clinical trials. Given
their low frequency, specific trials for these patients are
required in a multicenter setting.
2. To compare the strategies based on R-CHOP with
those based on infusional dose-adjusted chemotherapy
(e.g. dose-adjusted-R-EPOCH) in the treatment of
immunosuppression-related NHL.
3. To develop a joint effort to conduct specific clinical tri-
als for the treatment of infrequent subtypes of lym-
phoma arising in immunosuppressed patients (e.g.
plasmablastic, peripheral T-cell, and primary effusion
lymphomas).
4. To conduct joint trials with therapies including antivi-
ral agents, adoptive immunotherapy (e.g. genetically
modified EBV-specific cytotoxic T cells), and mono-
clonal antibodies targeting cytokines for the preven-
tion and treatment of PTLD.
Anticipated impact of the research
With the extensive use of immunologically-based thera-
pies to treat cancer and immunological diseases, the
increased frequency of solid organ and stem cell trans-
plants, and the increased life expectancy of patients with
HIV infection, the number of lymphomas arising in
immunosuppressed patients is expected to increase in the
coming years. However, the frequency of these lym-
phomas is still lower than that of those involving the non-
immunosuppressed population, making it essential to ini-
tiate co-operative efforts in order to improve the knowl-
edge of the mechanisms of lymphomagenesis and to
develop more effective therapies. As the first-line therapy
of HL and aggressive NHL in these patients has been rea-
sonably well standardized in Europe, efforts must mainly
be focused on relapse and refractory patients, for whom
promising new drugs and immunologically-based thera-
pies are in development. Progress in the knowledge of the
mechanisms of lymphoma development in these patients
will contribute to improving the treatment results, and
will hopefully help in the prevention of these lymphomas.
2.8. Chronic lymphocytic leukemia and other chronic
lymphoproliferative disorders
Stephan Stilgenbauer (Universitätsklinikum Ulm, Ulm,
Germany), Frederic Davi (Université Pierre et Marie Curie,
Paris, France), Dimitar Efremov (International Centre for
Genetic Engineering and Biotechnology, Trieste, Italy),
Peter Hillmen (University of Leeds, Leeds, United
Kingdom), Emili Montserrat (Hospital Clínic de Barcelona,
Barcelona, Spain), Tadeusz Robak (Uniwersitet Medyczny
W Lodzi, Lodz, Poland).
Introduction
Chronic lymphocytic leukemia (CLL) is the most com-
mon leukemia among adults in Europe. The disease is
characterized by a complex pathogenesis due to the inter-
play between genetic and microenvironmental factors and
a variable clinical course, making it a paradigm for the
understanding of other malignancies. Recent discoveries
in biology, therapy, and the relationship between these
two have led to groundbreaking advances, and underline
the impact of this “translational” approach for cancer
research in general.
European research contributions 
Research in Europe has been at the forefront regarding
CLL biology and therapy. This goes back to the defining of
the Binet staging system, the discovery of pathogenic
mechanisms and prognostic parameters, the development
of the current standard of care, and the latest innovations
regarding novel therapies and resistance mechanisms.
Details of each of these are outlined in the priorities of the
proposal in the following section.
Proposed research for the Roadmap
The cellular origin of CLL has been difficult to identify.
The finding that the clinical behavior of CLL differs dra-
matically depending on the mutational load and rearrange-
ments of their immunoglobulin genes has opened new
perspectives. Although it was initially postulated that CLL
with mutated IGHV corresponded to memory B cells
while CLL with unmutated IGHV corresponded to naive
B-lymphocytes, the current consensus is that both repre-
sent clonal expansions of antigen-experienced cells. Based
on similar patterns of antigen recognition, both have been
thought to derive either from marginal zone B cells or
putative human B1 cells. Recent studies coupling gene
expression profiling and IGHV repertoire analysis have led
to the conclusion that both IGHV subtypes derive from
subsets of CD5+ B lymphocytes. Surprisingly, recent data
from xenotransplantation experiments and next genera-
tion sequencing (NGS) suggest that the disease may, in
fact, originate within hematopoietic progenitor (CD34+)
cells. Thus, although progress has been made, the precise
cellular origin still needs to be elucidated.
As indicated by the importance of the immunoglobulin
genes and rearrangements and the clinical success of BCR
pathway inhibitors (see below), the BCR and its down-
stream signaling elements play a crucial role in the patho-
genesis of CLL. However, as BCR pathway inhibitors can-
not cure the disease and the functional pathogenic mech-
anisms of BCR stimulation remain elusive, further
research in this area is needed. Specific topics that need to
be addressed in order to allow selective therapeutic target-
ing of disease subsets are related to the characterization of
the stimuli and interactions that activate the BCR path-
way and determine their impact and the downstream sig-
naling molecules activated by different types of BCR inter-
actions.107 Furthermore, it will be extremely important to:
1) develop rational therapeutic strategies with curative
potential by combining BCR pathway inhibitors with
drugs that target other essential pathways, such as apop-
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tosis regulation; and 2) decipher mechanisms underlying
treatment resistance.
Genomic aberrations and gene mutations have been
identified as major factors determining resistance to ther-
apy and poor survival. 17p deletion and/or TP53 muta-
tion remain the strongest prognostic markers in multi-
variable analyses despite the improvement in treatment
with immunochemotherapy (see below), and NOTCH1
mutation may be a predictive marker indicating a
decrease in benefit from the addition of CD20 antibody.
Mutations of specific target structures, such as BTK, and
downstream signaling molecules, such as PLCG2, have
been identified as resistance mechanisms against target-
ed therapies, such as ibrutinib.108 Questions remain, how-
ever; for example, those related to resistance mecha-
nisms and their impact on treatment decisions for novel
treatments such as PI3K and BCL2 inhibitors and novel
antibodies. Furthermore, the outcome of some disease
subgroups (e.g. 17p-CLL) still appears inferior to other
subgroups, and the transformation of CLL to more
aggressive lymphoma (Richter transformation) is a fre-
quent phenomenon of unclear etiology, leading to new
and urgent research questions.
The standard conventional treatment approach in CLL is
now immunochemotherapy with FCR (fludarabine,
cyclophosphamide, and rituximab) for young/fit patients109
and chlorambucil plus anti-CD20 antibodies (rituximab,
obinutuzumab or ofatumumab) for elderly/unfit patients.110
Despite the dramatic improvements in efficacy with these
regimens, a number of critical issues remain. The first
regards when to initiate therapy in the light of novel devel-
opments; also important are the therapeutic objectives
[symptom control/palliation vs. minimal residual disease
(MRD) eradication/cure]. Moreover, there is a relentless pat-
tern of relapse despite the often initially deep remissions,
making cure unlikely with these regimens. Therefore, pre-
dictive factors allowing informed treatment choice (i.e. is
any one treatment superior to another in a particular
patient?) represent an urgent need for individualized treat-
ment (“precision medicine”).
The improved understanding of disease biology in CLL
has led to the identification of targeted therapeutic
approaches against BTK (e.g. ibrutinib), PI3K (e.g. idelalis-
ib), BCL2 (e.g. venetoclax), and CD20 (e.g. obinutuzumab
and ofatumumab). These agents have provided com-
pelling evidence not only for dramatic efficacy but also for
outstanding tolerability.111 Nevertheless, a number of criti-
cal questions have emerged, in particular, related to the
choice and handling of these agents. With some novel
agents, “benign” disease persistence (lymphocytosis) is a
frequent phenomenon, whereas there is rapid disease
eradication with other agents (e.g. immunochemotherapy,
BCL2 antagonists), and the principles guiding treatment
aims between disease control and eradication remain to be
determined. New, rare adverse events (e.g. bleeding, atrial
fibrillation, and colitis) have been identified in spite of the
generally outstanding treatment tolerability, and the long-
term (side) effects of novel treatments are unclear. Given
that combination treatments have been beneficial on the
one hand, whereas on the other hand the novel com-
pounds have already shown great single agent activity,
will the concept of a combination approach or a sequential
use of the novel agents lead to better long-term results? As
differences are seen, on the one hand, between patients'
and their disease characteristics and, on the other hand,
between the specific features of each compound, will all
patients be treated with the same approach, or how can
subgroups be identified for the greatest individual benefit?
Lastly, given the cost of indefinite treatment duration with
the currently licensed novel agents, and the worldwide
demand for efficacious cancer therapy, how will the issue
of cost and equal access to these treatments be handled?
Anticipated impact of the research
As is often the case with breakthroughs, the answers from
the biological and clinical studies mentioned above open up
new questions, and it appears that the magnitude of these
questions is at least as great as the advances made through a
new understanding of CLL biology and treatment. Clearly,
to move beyond the understanding and success witnessed
already, more well-designed clinical trials are needed with
the ultimate goal of cure. Of equal importance, and under-
lined by the development of these targeted agents in CLL, is
the advance of laboratory science. Taken together, CLL can
serve as a valid model system for cancer in general by high-
lighting the dramatic progress that can be made within a
short time frame when linking biology to therapy in a truly
translational approach.
2.9. Acute lymphoblastic leukemia
Monique den Boer (Erasmus MC, Rotterdam, the
Netherlands), André Baruchel (Hôpital Universitaire
Robert-Debré, Paris, France), Andrea Biondi (Università
degli Studi di Milano-Bicocca, Monza, Italy), Nicola
Gökbuget (Universitätsklinikum Frankfurt, Frankfurt,
Germany), Elizabeth MacIntyre (Université Paris
Descartes, Paris, France), Anita Rijneveld (Erasmus MC,
Rotterdam, the Netherlands).
Introduction
Acute lymphoblastic leukemia (ALL) is a life-threatening
disease if not treated immediately. ALL occurs most fre-
quently in children under 15 years of age and accounts for
25% of pediatric cancers and less than 1% of adult cancers.
ALL arises from hematopoietic stem cells (HSCs) in the
bone marrow that have acquired genomic lesions that result
in the survival and a proliferative capacity of immature,
non-functional malignant cells at the expense of normal,
functionally differentiated white blood cells. This results in
an impaired immune response against pathogens, resulting
in fever or infections, anemia, and decreased wound healing
capacity or bleeding. The type of genomic lesions differs
somewhat between children and adults; for example,
KMT2A gene fusions are predominantly found in infants (<
1 year of age), and the ETV6-RUNX1 gene fusion is mainly
found in children, whereas the BCR-ABL1 gene fusion is
most frequently found in adults. Treatment mainly consists
of combination chemotherapy and allogeneic hematopoiet-
ic stem cell transplantation (HSCT), mainly limited to high-
risk categories of ALL. Due to risk-stratified treatment,
more optimized treatment protocols, and improved sup-
portive care, the 5-year event-free survival on contempo-
rary treatment protocols is more than 80% for children and
is approaching 50% for adults.112 The short- and long-term
side effects of therapy are considerable, however, particu-
larly with respect to the quality of life (QoL) in at least some
of the adult survivors of childhood cancer.
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European research contributions 
The treatment of ALL is relatively well structured in
Europe by the assembly of national and international
study groups, such as the International-Berlin-Frankfurt-
Munster study group for childhood ALL and the European
Working Group for adult ALL (EWALL). New prognostic
subtypes of ALL were identified by screening large patient
cohorts, facilitating structured diagnosis and treatment of
ALL. The European collaborative studies under the
umbrella of EuroMRD have been key in standardizing and
developing monitoring minimal residual disease (MRD)
and in building risk-adapted therapies that benefit ALL
patient outcomes. The prognosis of adolescents and
young adults has been significantly improved by pediatric
protocols. In addition, pediatric-like therapies, including
the use of L-asparaginase, have significantly improved
outcome for adults with ALL.
In addition to disease monitoring, major achievements
have been obtained in molecularly redefining ALL.
Initially, chromosomal lesions were identified, such as
those affecting chromosomal copy number (e.g. high
hyperdiploidy with more than 50 chromosomes, as well
as good prognosis) and those leading to aberrant chromo-
somes [e.g. the Philadelphia chromosome t(9;22), which
gives rise to the BCR-ABL1 gene fusion and is predictive of
an unfavorable outcome]. The development of the molec-
ular toolbox, mainly driven by the deciphering of the
human genome in 2001, has accelerated the oncoge-
nomics field in the past decade. Together with their US
colleagues, European researchers have significantly con-
tributed to the molecular characterization of ALL. Gene
expression profiling has identified new subtypes of B-cell
precursor and T-cell lineage ALL, and deepened our
knowledge of mechanisms of resistance to frequently-
used chemotherapeutic drugs, such as prednisone and L-
asparaginase.114 The BCR-ABL1–like ALL subtype, which
was originally identified in children, has also been identi-
fied in adults with ALL, representing a relatively large new
unfavorable prognostic subtype. Genomic screens and
next generation sequencing (NGS) have revealed many
new fusion genes, including more than 10 ABL1-class and
more than 10 JAK-class fusion genes, which result in con-
stitutively-activated gene products that can be targeted
with precision medicines, such as ABL1 inhibitors like
imatinib and JAK inhibitors like ruxolitinib. In addition to
gene fusions, smaller genetic mutations have been identi-
fied, which often affect the survival and proliferative
capacity of leukemic cells. 
Proposed research for the Roadmap
The molecular deciphering of ALL revealed the com-
plexity of this disease; the heterogeneity among ALL
patients, and between children and adults, is further
complicated by the identification of mutated subclones,
which can resist chemotherapy or be acquired during
treatment, and which can give rise to (late) relapse.115 In
addition, our knowledge about the supportive (and pro-
tective) role of the bone marrow microenvironment in
the progression and treatment response of leukemia is
still limited. Research will improve our knowledge of the
pathobiology of ALL and its interaction with the
microenvironment, which presumably also plays a role
in the spread of ALL to extramedullary sites, such as the
central nervous system, liver, and testicles, associated
with an adverse clinical outcome. Many new
genomic/molecular lesions have been identified in past
years, of which a few are prognostic. It is a huge mistake
to only foster research dedicated to identifying and
unraveling prognostic lesions because the improvements
in clinical outcome will also limit the number of new
prognostic lesions that can be identified, whereas the
side effects of treatment will remain considerable.
Research should increasingly focus on functional studies
addressing the tumor dependency of new lesions (includ-
ing those found in subclones) in relevant leukemia mod-
els. Last but not least, studies need to address how new
precision medicines should be combined with (reduced)
up-front chemotherapy to minimalize side effects with-
out jeopardizing clinical outcome. Attention should also
be paid to age-related differences in pharmacokinetics of
novel and old drugs in order to individualize dosing and
accelerate the implementation of new drugs in children.
Support by regulatory authorities, such as the European
Medicines Agency (EMA), the development of European
laws to facilitate drug development in children (Pediatric
Regulation, 2001/20/EC), and early access to new poten-
tial drugs for ex vivo (patients’ leukemic cells) and in vivo
(ALL animal models) studies are essential for accomplish-
ing better therapies with reduced side effects.116
Furthermore, harmonizing the backbone of chemothera-
peutic protocols of different study groups will be highly
beneficial for performing clinical trials with new drugs in
rare subsets of patients and will accelerate early drug
development programs together with pharmaceutical
companies. Recently developed monoclonal antibodies
(bispecific antibodies and immunoconjugates) in ALL
need to be further evaluated and eventually integrated in
the standard management of some patients, particularly
in adult ALL. Early results using cellular therapy (adop-
tive modified T cells, such as CAR-T cells) are promising
and point towards alternative innovative strategies that
might be effective in ALL. Leukemias have always repre-
sented proof-of-concept cancers for solid tumors, where-
by their understanding permeates to less easily accessible
tumors in both adults and children. Reinforced funding
for acute leukemia will, therefore, have an impact well
beyond the small percentage of cancers they represent.
Anticipated impact of the research
The treatment will change from disease-type to molec-
ular target-type, and from risk-stratified treatment sched-
ules to more personalized therapies with precision medi-
cines. In addition, individualized drug dosing may prevent
underdosing and hence may reduce the risk of relapse,
while therapeutic drug monitoring may also prevent over-
dosing and associated toxic side effects. More specific
therapies and new immunotherapy-based approaches are
of the utmost importance, not only for improving the
prognosis of high-risk patients but also for significantly
reducing treatment-related morbidity for patients of all
ages, and especially for long-term survivors of childhood
cancer.
2.10. Multiple myeloma and other plasma cell
neoplasms
Meletios Dimopoulos (National and Kapodistrian
University of Athens, Athens, Greece), Hervé Avet-Loiseau
(Centre Hospitalier Universitaire de Toulouse, Toulouse,
France), Monika Engelhardt (Universitätsklinikum Freiburg,
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Freiburg, Germany), Hartmut Goldschmidt
(Universitätsklinikum Heidelberg, Heidelberg, Germany),
Antonio Palumbo (Università degli Studi di Torino, Turin,
Italy), Evangelos Terpos (National and Kapodistrian
University of Athens, Athens, Greece).
Introduction
Plasma cell disorders are common hematologic malig-
nancies; multiple myeloma, the most common of these
disorders, accounts for about 2% of all neoplasms and is
the second most common hematologic malignancy. The
median survival of patients with myeloma is 3-7 years;
however, there is significant heterogeneity depending on
the characteristics of the disease, of the patient and the
therapy. The prevalence of the precursor monoclonal gam-
mopathy of undetermined significance (MGUS) increases
with age, and it is estimated that approximately 3%-5%
of individuals over 65 years of age may have a MGUS.
The risk of developing myeloma or other lymphoprolifer-
ative disorders with underlying MGUS is approximately
1% per year and remains lifelong.
Myeloma is a disease of the elderly with a median age
at diagnosis of around 65-70 years. In the past two
decades, there has been a major increase in the number of
patients over 75 years of age who are diagnosed and
receive therapy for myeloma, and this has been largely
attributed to the major demographic changes that have
occurred in Europe. Thus, more patients of advanced age
will require therapy, presenting a major challenge in terms
of management and health care costs. Despite the recent
improvements in the survival of patients with myeloma,
there is a significant minority of patients who have a very
poor prognosis even with the use of the most intensive
therapies, including transplantation. This group includes
patients who are refractory to both proteasome inhibitors
and immunomodulatory drugs, as well as patients with
high-risk cytogenetics [del17p, t(4;14), and add1q], plasma
cell leukemia, extramedullary relapses, or myeloma of the
central nervous system. New therapies and innovative
strategies are urgently needed for the treatment of these
patients.
The recent advances made with the introduction of new
drugs are also a challenge for the health care system due
to the high cost of these therapies. Furthermore, these
therapies are moving forward to front-line/early applica-
tions, they are combined very intensively, and many of
them are given continuously until disease progression,
resulting in substantial additional costs. Therefore, there
must be a prudent allocation of health care resources in
order to provide the best therapy for patients within a sus-
tainable health care system.117-121
European research contributions 
The European Myeloma Network (EMN) was estab-
lished in 2003 by integrating 27 research institutions and
14 trial groups with the intent of supporting development
of novel diagnostics and therapies for multiple myeloma.
Now, the EMN is a legal entity and has initiated co-oper-
ative clinical trials and laboratory research in different
research fields in plasma cell dyscrasias. The close rela-
tionship between these research areas facilitated the
exchange of information and experience, and has created
a spirit of co-operation within the European area, pro-
moting clinical and laboratory research in myeloma and
related disorders.
Different groups have initiated research programs and
projects within the EMN and most of the researchers in
Europe have been involved. As a result, several clinical
trials have been conducted in myeloma, both multicenter
phase III and phase I and II. The results of these clinical
studies have framed the contemporary management of
the disease in Europe. Importantly, through the collabo-
rative network of the EMN it has been possible to con-
duct large clinical trials in rare diseases, such as
Waldenström macroglobulinemia and light chain sys-
temic amyloidosis, which represent major advances in
the field. Through the EMN, a network of laboratories is
working on several projects and participates in European
Framework Programmes. As a result, the EMN has regu-
larly published recommendations and guidelines on the
management and other aspects of myeloma and related
disorders, and these provide guidance to European and
other physicians who care for myeloma patients, thus
advancing the quality of care of patients with plasma cell
malignancies.
Proposed research for the Roadmap
Genetic studies have revealed the complex nature of
myeloma and other plasma cell disorders. Large-scale
genetic studies will provide new insights into the patho-
genesis of plasma cell malignancies but, importantly, will
uncover mechanisms of development, resistance, and
relapse. Biobanking will be crucial for collecting sufficient
high-quality samples. Genetic studies require the develop-
ment of additional tools for interpretation and application
of the results of the genetic mapping. The EMN has set up
a network for biobanking, and for providing guidance and
facilities.
Asymptomatic myeloma and MGUS are models for
progression of the disease, and the integration of advanced
genomics will provide the required knowledge of the evo-
lution of plasma cell malignancies. Myeloma is character-
ized by inherent genomic instability and evolution of clon-
al disease has been shown for different pathways. Studies
on disease evolution and genetic instability, integrating
next generation technology and the detailed and prospec-
tive evaluation of the genetic evolution of the disease, will
provide a framework for understanding mechanisms of
resistance and escape.
The role of the microenvironment is crucial in the devel-
opment and evolution of the disease, and genetic and
functional studies that will address the role of other cells
in the microenvironment of the plasma cell can delineate
the pathobiology of myeloma and provide new rational
targets for therapy. Although mechanisms of resistance
are crucial in order to build new therapies and combina-
tions of existing drugs, it is also important to develop tech-
nologies and in vitro/ex vivo systems that can provide rea-
sonable sensitivity and specificity and predictive tools for
responses to various therapies in order to avoid toxicity
and reduce health care costs. In particular, valid and repro-
ducible animal models are needed in multiple myeloma.
These require advanced technologies in order to become
widely available and usable.
In view of the deep responses that are now attained by a
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significant fraction of patients with myeloma, the prognos-
tic importance and the characteristics of minimal residual
disease (MRD) are issues of intensive investigation. MRD
may be considered a surrogate for cure or survival in clinical
trial settings, but the different aspects of MRD need to be
thoroughly and prospectively assessed. Technologies that
involve multicolor flow cytometry, next generation
sequencing (NGS), and single cell analysis will provide the
data needed to build new regimens and modify therapeutic
targets. In this setting, it will not be sufficient to monitor the
disease by the traditional serum and urine electrophoresis,
and new markers of disease for both diagnostic and moni-
toring procedures need to be developed and validated.
Imaging of the disease is another area of intensive
research, which may provide crucial information on the
extent, prognosis, and response of the disease. New tech-
nologies (PET/CT, PET/MRI, DWI-MRI) and advanced
imaging software can identify disease foci with high sen-
sitivity. Over the next few years, these advances will
change the landscape of disease imaging and it is expected
that evaluation of response will imply imaging criteria.
Survival outcome (usually progression-free survival
and, less often, overall survival) is the main end point of
most clinical studies that aim to improve disease out-
come. However, the availability of new therapies with
different toxicity profiles and the changing demographics
of the disease require an appraisal of quality of life (QoL)
as a critical end point of clinical studies. Redefining out-
come based not only on metrics of survival end points,
but also on QoL, is an area of intense study, with major
social and economic impact, which will become impor-
tant for the choice of therapy, as well as for the approval
and financial compensation of new drugs. Furthermore,
well-designed clinical trials, including more investigator-
initiated efforts, are needed. Appropriate treatment
options need to be harmonized within corporate groups
to explore and answer questions such as: 1) when should
treatment be initiated? 2) for how long should a regimen
be given? 3) is cure rather than long-term disease control
attainable, and in which patient cohort? and (4) what
exactly benefits ultra-high-risk patients (i.e. patients with
poor cytogenetics, RISS-3, plasma cell leukemia or
extramedullary disease)?
Anticipated impact of the research
The intensification of research in the field of plasma cell
dyscrasias and related disorders is expected to improve
outcome, according to all end points. This has been
proved in the past decades where a major survival
improvement has changed the landscape of these diseases
as a result of new therapies, advanced technologies, and
improved criteria for definition, diagnosis, and treatment
initiation. These improvements reflect the major advances
in our understanding of the disease biology, which have
led to the improvement of therapies in terms not only of
the availability of new drugs, but also by improving treat-
ment strategies and delivery of therapy. It is also crucial
that several aspects of this research result in the develop-
ment and establishment of new technologies in genetics,
single cell analysis, ex vivo predictive systems, and imag-
ing. In addition, a better understanding of the disease and
patients’ needs will allow a rational allocation of health
care resources, with significant social impact.
The EHA Roadmap for European Hematology
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The malignant myeloid diseases that are discussed in
this section are disorders of hematopoietic progenitor cells
(HPCs) characterized by varying degrees of cell matura-
tion defects and/or uncontrolled proliferation. These dis-
orders commonly affect older patients and will, therefore,
constitute an increasing burden for caregivers in an aging
society.
In recent years, European scientists have made major
contributions to the understanding of the molecular basis
of these disorders. Key disease-associated gene mutations
have been discovered in myelodysplastic syndromes
(MDSs), acute myeloid leukemias (AMLs), and myelopro-
liferative neoplasms (MPNs).9,122,123
The conduct of large controlled randomized trials with-
in highly organized leukemia co-operative groups, in con-
junction with the implementation of correlative science
programs on well-annotated patient samples, has been
one of the great assets of the European hematology com-
munity. The introduction of 1st- and 2nd-generation ABL1
TKIs in chronic myeloid leukemia (CML), characterized
by the BCR-ABL1 gene fusion, has been the paradigm for
the successful development of precision medicine in can-
cer. New strategies are now being studied that aim at
curing this previously fatal disease. The discovery of the
JAK2 mutation has been instrumental in rapidly bringing
the first JAK1/JAK2 inhibitor into the clinic for the treat-
ment of patients with MPNs.124,125 European investigators
have also played a leading role in the development of
hypomethylating agents for the treatment of MDS and
AML.126,127 European co-operative groups have shown that
around 95% of patients with acute promyelocytic
leukemia can be cured by a chemotherapy-free combina-
tion therapy with the vitamin A derivative all-trans-
retinoic acid and arsenic trioxide.128 For the great majority
of patients with MDS and AML, however, progress has
been very modest, and a high unmet medical need
remains.
The European research groups, under the umbrella of
the European Hematology Association (EHA) and the
European LeukemiaNet (ELN),129 and in collaboration with
international investigators, have been instrumental in pro-
viding fundamental information to the scientific commu-
nity by publishing recommendations and guidelines for
clinical and laboratory practice of all the malignant
myeloid diseases discussed here.130-133
Nevertheless, major challenges remain, as outlined in
the following subsections. To further advance precision
medicine for these disorders, a complete understanding of
the disease biology will be needed. With the advent of
novel technologies, comprehensive analyses of the
genomes, epigenomes, transcriptomes, and metabolomes
of these heterogeneous disorders will become possible.
Robust bioinformatics tools need to be developed that are
capable of processing such complex data and that can be
applied on a clinical scale. Due to the demographic devel-
Section 3. Malignant myeloid disease
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opment in Western countries, particular attention should
be paid to the study of older patients in order to improve
their outcome and, importantly, also their quality of life
(QOL).
A joint effort of clinicians and scientists, research con-
sortia, and leukemia co-operative groups on an interna-
tional level, in close collaboration with the biotech and
pharmaceutical industry, will be essential for more rapid
scientific achievements.
3.1. Myelodysplastic syndromes and
myelodysplastic/myeloproliferative neoplasms
Mario Cazzola (Università degli Studi di Pavia, Pavia,
Italy), Pierre Fenaux (Hôpital Saint Louis, Paris, France),
Ulrich Germing (Universitätsklinikum Düsseldorf,
Düsseldorf, Germany), Eva Hellström-Lindberg (Karolinska
Institutet, Stockholm, Sweden).
Introduction
Myelodysplasia is a term used to describe morphologi-
cal abnormalities in one or more of the major myeloid cell
lineages of hematopoiesis and is a typical feature of
myelodysplastic syndromes (MDSs). MDSs are clonal dis-
orders of hematopoiesis with a propensity to evolve into
acute myeloid leukemia (AML), caused by somatic muta-
tions that occur in hematopoietic stem cells (HSCs). These
disorders include primary conditions as well as secondary
and therapy-related forms. Primary MDSs occur mainly in
older people as a result of stem cell aging, and their crude
incidence rate is 4 per 100,000 people per year, indicating
that more than 30,000 new cases are expected in Europe
each year. Myelodysplasia is also found in other myeloid
malignancies, in particular in the so-called myelodysplas-
tic/myeloproliferative neoplasms (MPNs), which include
chronic myelomonocytic leukemia and atypical chronic
myeloid leukemia (CML). MDS and MDS/MPNs show
marked clinical heterogeneity, ranging from conditions
with an indolent clinical course and a near-normal stan-
dardized mortality ratio to entities with very poor progno-
sis. A risk-adapted treatment strategy is, therefore, manda-
tory for these disorders. Several treatments have been pro-
posed for MDS, but only a few have met evidence-based
criteria of efficacy. At present, the only treatment with a
potentially curative effect is allogeneic hematopoietic
stem cell transplantation (HSCT), but less than 20% of all
MDS patients are eligible for such treatment and have a
donor. Azacitidine can prolong survival in patients with
high-risk MDS, while erythropoiesis-stimulating agents
and lenalidomide improve anemia in patients with low-
risk MDS and the MDS associated with deletion 5q,
respectively. Red cell transfusion remains the mainstay of
therapy for many patients with MDS.
European research contributions 
In the past few years, the genetic basis of MDS has been
revealed by means of massive parallel DNA sequencing,
and seminal studies have been performed in Europe.134,135
Approximately 90% of MDS patients carry one or more
oncogenic mutations, and two-thirds of them are found in
individuals with a normal karyotype. Driver mutations
have been identified in genes involved in RNA splicing,
DNA methylation, chromatin modification, transcription
regulation, DNA repair, and signal transduction. Only six
genes are consistently mutated in 10% or more MDS
patients, while a long tail of more than 50 genes are mutat-
ed less frequently. Seminal contributions have also been
made in pediatric hematology, for example, in elucidating
the genetic predisposition to juvenile myelomonocytic
leukemia.136 European hematologists have provided piv-
otal contributions to developing effective treatments for
MDS, including erythropoietin and azacitidine.126,137
Recommendations for treatment of the individual patient
with MDS have also been developed.130
Proposed research for the Roadmap
Myeloid malignancies appear to be propagated by rare
self-renewing mutant HSCs. However, the cellular and
molecular mechanisms that regulate development, propa-
gation, and therapy resistance of these myelodysplastic
stem cells remain unknown. Studies are needed to: 1)
delineate the stem and progenitor cell hierarchy in order to
identify the cancer-propagating cells in MDS and
MDS/MPN patients; 2) characterize the cellular and
molecular mechanisms underlying disease development,
progression, and therapy resistance; and 3) identify thera-
peutic targets suitable for efficient elimination of the
MDS-propagating cells.
In order to decipher the genetic complexity of MDSs,
prospective studies of comprehensive mutational profiling
of acquired gene mutations should be performed in large
patient populations, ideally within clinical trials. The com-
bined analysis of the genome and transcriptome may iden-
tify the impact of recurrent molecular abnormalities on
gene expression. Particular focus should be given to
spliceosome mutations, which occur in about half of all
patients with MDS and are highly specific for this myeloid
malignancy, suggesting an important role in disease patho-
genesis.
Gender and age significantly influence prognosis of MDS
patients; in particular, age is an independent adverse prog-
nostic factor. One or more comorbidities are found in more
than half the patients at the time of diagnosis, and they
have a significant impact on survival. Studies that analyze
the relationships between genotypes, gender, age, and
comorbidities are needed. The findings of these studies
should be used to develop prognostic/predictive models.
Outcome improvements in MDS patients remain mod-
est. Identifying drugs that may further improve survival of
patients with high-risk MDS and drugs that may inhibit
ineffective erythropoiesis and improve anemia in those
with low-risk MDS represents a priority. The importance
of spliceosome and epigenetic mutations in MDS suggests
that novel drugs targeting these pathways should be
specifically investigated. Patient inclusion in clinical trials
should be encouraged. The relationship between the
genetic basis of MDS and the outcome of allogeneic HSCT
should be explored, and more effective transplantation
procedures should be developed.
Anticipated impact of the research
The current lack of understanding of the molecular
mechanisms that regulate MDS stem cell development
and their escape from therapeutic targeting is limiting our
ability to efficiently eliminate the cells required for MDS
propagation. The research lines described above have the
potential to decipher these mechanisms.
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The current diagnostic approach to MDS and
MDS/MPNs includes a complete blood count, peripheral
blood and bone marrow morphology, and cytogenetics.
Mutational profiling of peripheral blood has the potential
to dramatically improve our approach to the diagnosis of
myeloid malignancies, leading to a clinically relevant
molecular classification of these disorders.
The characterization of genomic and transcriptomic
profiles of each individual patient with MDS or
MDS/MPNs will allow the most appropriate treatment to
be selected, patients to be enrolled in ad hoc clinical trials
investigating new targeted therapeutic agents, and molec-
ular biomarkers for monitoring response to treatment to
be identified. This will eventually lead to precision medi-
cine strategies.
3.2. Acute myeloid leukemia
Gert Ossenkoppele (VU University Medical Center,
Amsterdam, the Netherlands), Lars Bullinger
(Universitätsklinik Ulm, Ulm, Germany), Robin Foà
(Università degli Studi di Roma ‘La Sapienza’, Rome,
Italy), Ralf Rambach (Deutsche Leukämie- und
Lymphomhilfe (DLH), Bonn, Germany), Tadeusz Robak
(Uniwersitet Medyczny W Lodzi, Lodz, Poland), Jorge
Sierra (Hospital de la Santa Creu i de Sant Pau, Barcelona,
Spain).
Introduction
Acute myeloid leukemia (AML) is a clonal disorder aris-
ing from hematopoietic progenitor cells (HPCs) character-
ized by defects in their maturation program and by
uncontrolled proliferation.138 AML is the most common
form of acute leukemia with an estimated incidence of 3
per 100,000 individuals, resulting in 15,000 newly diag-
nosed patients each year in Europe. AML most common-
ly affects the elderly population, males more commonly
than females, with a median age that has reached 70
years. The incidence of the disease will rapidly rise due to
the proportional increase of the aging population. A fur-
ther increase is expected from the rising incidence of ther-
apy-related AML (i.e. myeloid neoplasms occurring in
cancer survivors after successful treatment of a primary
cancer). A particularly significant unmet medical need lies
in the management of older patients with AML. Whereas
in younger patients cure rates of 40%-50% can now be
achieved, the outcome of older patients has remained
very poor, in particular for those patients who are consid-
ered unsuitable for intensive chemotherapy. The back-
bone of treatment for AML, the combination of an
anthracycline and cytarabine, has not changed in decades.
This demonstrates the urgent need for the development
of new agents, the mechanisms of action of which are
based on a better understanding of the disease biology.
Using novel genomics technologies, such as next genera-
tion sequencing (NGS) techniques, major progress has
been made in deciphering the heterogeneity of the dis-
ease; however, translating this knowledge into clinical
practice is lagging behind.
European research contributions 
In Europe there is a long-standing tradition of con-
trolled randomized trials within well-organized leukemia
co-operative groups and this has largely contributed to
the scientific achievements of European hematology. The
European LeukemiaNet (ELN) has facilitated the interna-
tionally embraced ELN recommendations on the diagno-
sis and management of AML as well as the consensus
statement on allogeneic hematopoietic cell transplanta-
tion (HCT).131,139 European hematologists have played a
leading role in the improved management of a particular
form of AML, acute promyelocytic leukemia, by showing
superiority of the chemotherapy-free combination of the
vitamin A derivative all-trans-retinoic acid and arsenic tri-
oxide over conventional treatment, with cure rates of
approximately 95%, a first highly successful step toward
precision medicine in AML.128
European investigators have made major contributions
to our understanding of the molecular basis of AML, as
exemplified by the discovery of the mutation in the
nucleophosmin 1 gene (NPM1), one of the most impor-
tant biomarkers currently used in the clinic.140 The identi-
fication of new biomarkers was paralleled by the intro-
duction of the concept of minimal residual disease (MRD)
detection either by quantitative polymerase chain reac-
tion (PCR) or by flow cytometry, which is now imple-
mented in many treatment algorithms. Recently, investi-
gators have shown that clonal hematopoiesis with somat-
ic mutations previously implicated in hematologic cancer
(DNMT3A, ASXL1, and TET2) is increasingly common as
people age, and it is associated with an increased risk of
hematologic cancer. The data from this study are instru-
mental for the further understanding of the biology of
AML in the aging population, one of the main challenges
that we are now facing.141
Proposed research for the Roadmap
Concerted efforts from basic, translational, and clinical
hematologists will be required to make major advances in
the forthcoming years.
One important prerequisite to advance the field is the
further understanding of the disease pathogenesis. This
includes the identification and characterization of pre-
leukemic cells and leukemic stem cells (LSCs), the analy-
sis of the clonal architecture of genomic lesions, and
their clonal evolution during the disease course, as well
as the analysis of primary and acquired resistance mech-
anisms. To capture the entire complexity of leukemia
biology, it will be instrumental to also analyze the tran-
scriptional and epigenetic landscape of the leukemic
cells. Integrated analysis of these complex omics data
sets will require the parallel development of appropriate
bioinformatics tools. These studies should be performed
on well-annotated biosamples from patients treated in
controlled clinical trials.
A particular focus should be on the study of older
patients, who in the past have been largely under-repre-
sented in both clinical trials and correlative science stud-
ies. Instruments need to be developed to better define
patients who are considered fit for intensive therapy ver-
sus those who a priori should be considered for investiga-
tional treatment.
A large number of new drugs targeting leukemic drivers
or a multitude of deregulated pathways are awaiting clin-
ical application. Careful pre-treatment selection by exten-
sive molecular profiling will pave the way to a successful
A. Engert et al.
144 haematologica | 2016; 101(2)
outcome. Examples for targeting of defined subgroups
are: AML with IDH1/IDH2 mutations (using small mole-
cule IDH inhibitors), AML with FLT3 mutations [tyrosine
kinase inhibitors (TKIs)], AML with KMT2A rearrange-
ment (DOT1L or CDK6 inhibitors), and AML with
DNMT3A mutations (hypomethylating agents).
Another promising route of investigation is offered by
the new avenues of immunotherapy, beyond the further
development of the concept of allogeneic hematopoietic
cell transplantation that will remain a mainstay in the
management of AML patients. New immunotherapy
approaches, such as vaccination, CAR T cells, natural
killer (NK) cells, bispecific T-cell engagers, novel mono-
clonal antibodies, and immunoconjugates, hold great
promise for treatment of bulk disease or for targeting
residual LSCs.
Finally, harmonization and standardization of complex
diagnostic procedures, such as gene panel diagnostics and
monitoring of MRD, need to be realized on an interna-
tional level, because results from these diagnostic tests are
expected to have a major impact on informing patient
management.
Anticipated impact of the research
The program aims at further understanding the com-
plex molecular heterogeneity of the disease. Deciphering
this enormous complexity will be essential for the devel-
opment of personalized approaches to AML treatment.
Given the current knowledge of the clonal architecture
of the disease, no single drug is expected to cure it; rather,
the combination of established therapies with novel
agents that target disease-associated molecular lesions
will be needed. Special attention must also be paid to the
better management of older patients, given the more
unfavorable biology and the still dismal outcome of the
disease in these patients.
Dissecting the molecular trajectories of the disease
using well-annotated biosamples from patients treated in
innovative clinical trials will be instrumental to achieve
these goals. These research programs are expected to
make a major contribution to improving outcome in
patients with this fatal disease.
3.3. Chronic myeloid leukemia
Andreas Hochhaus (Universitätsklinikum Jena, Jena,
Germany), Francisco Cervantes (Universitat de Barcelona,
Barcelona, Spain), Jan Geissler (CML Advocates Network,
Bern, Switzerland), Francois Guilhot (Université de
Poitiers, Poitiers, France), Guiseppe Saglio (Università di
Torino, Turin, Italy).
Introduction
Chronic myeloid leukemia (CML) is a malignant neo-
plastic disease of the hematopoietic stem cells (HSC).
CML is typically linked with the Philadelphia chromo-
some, a shortened chromosome 22 as the result of a recip-
rocal translocation of chromosomes 9 and 22 leading to
fusion of BCR and ABL1 genes. CML constitutes approxi-
mately 15% of all leukemia and occurs with an incidence
of approximately 1.2 per 100,000 people. CML was
almost always fatal until 15 years ago, but the excellent
results of BCR-ABL1 TKI treatment are raising the expec-
tation that a considerable proportion of patients will
achieve a treatment-free remission. The use of  interferon
(IFN) a in parallel with or after tyrosine kinase inhibitor
(TKI) therapy is associated with the induction of an
immune response against the leukemic clone with further
improvement of the remission rate. An essential part of
the management of CML patients is rigorous use of cyto-
genetic and molecular follow up with standardized meth-
ods to regularly assess the residual disease status.132
Prevalence of patients with CML treated with TKIs is
expected to increase by approximately 10% per year so
that CML is a challenge for health care systems world-
wide. With average treatment costs in Europe of between
€40,000 and €70,000 per patient per year, the challenge
is how to maximize patient benefit with an affordable
allocation of resources.
European research contributions 
European co-operative CML study groups were estab-
lished 30-40 years ago and have continued to contribute
to the optimization of management. The impact of inter-
feron (IFN) has been investigated in a series of large stud-
ies. IFN as an immunomodulatory agent has activity in
CML and has resulted in sustained cytogenetic remissions
in an important minority of patients. Meta-analyses of
conflicting studies revealed new prognostic factors for
IFN response. In 1998, the EUROscore was presented to
better discriminate patients with a favorable, intermedi-
ate, and unfavorable outcome. The place of stem cell
transplantation in disease management had been gradual-
ly evolving, having been displaced as first-line treatment
by 2002, and then moving to a 3rd-line option after the
licensing of the 2nd-generation TKI in 2006. From 2001 on,
European investigators have participated in the clinical
development of five TKIs. National and supranational
[the European LeukemiaNet (ELN)] networks of European
CML investigators and clinicians have provided funda-
mental knowledge for clinical practice. National and
multinational studies with imatinib, IFN a, Ara-C, nilo-
tinib, and dasatinib have contributed to understanding
the biology of TKI response, the impact and potential
problems of combination therapies, and base-line and
time-dependent prognostic factors. As a result of a study
of the ELN involving more than 2000 patients, a new
score predicting the chance of a complete cytogenetic
response on imatinib therapy has been presented.142 The
predictive value of early molecular response, deep molec-
ular response, and the velocity of response has been
established in Europe.143 ELN expert recommendations for
CML management were published in 2006, 2009, and
2013, and have become a key reference for CML treat-
ment worldwide.132
In basic and translational research, European investiga-
tors significantly contributed to the understanding of the
mechanisms of TKI resistance and how to prevent and
overcome it. Molecular monitoring of CML has been
developed, optimized, and standardized in Europe, allow-
ing accurate quantification of residual disease in a dynam-
ic range of six orders of magnitude.144 Such contributions
permitted the successful attempt to discontinue treatment
after deep molecular response.145 Currently, the mecha-
nisms that allow persistence of BCR-ABL1–positive stem
cells are a major focus of research. Other research direc-
tions are the origin of CML, the clonal molecular evolu-
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tion, and the characterization of the BCR-ABL1–negative
hematopoiesis. Still, challenges remain, in particular in
those patients who develop resistance mechanisms and
eventually fail current treatment options.
Proposed research for the Roadmap
Tyrosine kinase inhibitors have substantially improved
survival of CML patients. There is reasonable expectancy
to cure the disease in a significant proportion of patients.
The main objective is to integrate the leading European
national trial groups in CML to form a co-operative net-
work for advancements in CML-related research and
health care. A clinical trials platform was created to pro-
mote the performance of clinical trials with new drugs
and/or treatment strategies. Standardization of diagnostic
and therapeutic procedures allows outcome to be com-
pared across Europe. The formation of an exemplary
“European platform to cure CML” is proposed to consoli-
date and lead international efforts to improve CML thera-
py with harmonized methods of molecular monitoring,
definition of prognostic factors, and assessment of quality
of life (QOL), as well as to reveal the biology of CML stem
cells in order to induce immune response or to target spe-
cific features. We aim to improve: 1) the rate of deep
molecular response; and 2) the rate of patients in durable
remission after stopping TKIs. New induction therapies,
combination with immunotherapies or stem cell active
drugs, and new approaches of stem cell transplantation
after treatment failure are methods to improve treatment
responses. Patients in durable deep molecular remission
after withdrawal of TKIs are considered cured of the dis-
ease. The complexity of CML blast crisis pathophysiology,
the failure of TKIs to eradicate CML at the stem cell level,
and the observation of molecularly defined BCR-ABL1-
negative clones demand further research despite major
improvements in the standard of care for CML. A better
understanding of the events governing LSC behavior might
lead to the biological cure of CML and effective treatment
of blast crisis. Translational studies will contribute to early
outcome prediction and treatment surveillance.
Biostatisticians and patient advocacy groups co-operate
with the study groups and with a European clinical trials
platform that will support the co-ordination of the studies.
Anticipated impact of the research
In-depth molecular and cellular characterization of
CML patients will facilitate personalized medicine with
regard to diagnosis, prognostication, and therapeutic
decisions. Overall, this will have a major impact on low-
ering the disease burden, reducing the rate of complica-
tions, and, prospectively, prolonging survival. The cost of
novel technologies and treatments might be balanced by
their more specific application as well as a favorable
impact on patients’ QoL and the lessening of the burden
for caregivers; this will translate to a more general favor-
able impact for society by reducing use of resources and
improving individual work capabilities. Standardization
of diagnostics and therapeutic procedures will further
strengthen integration. The resultant comparability of
outcome will facilitate recognition of interstudy differ-
ences and rare subtypes. Recommendations, network
meetings, training courses, and exchange of researchers
will spread excellence and raise standards of research and
patient care across Europe. The CML network and its
activities provide the critical mass for added value and
European leadership. The impact on the future manage-
ment of CML patients is expected to be considerable,
because a rational advanced treatment design will likely
lead to higher remission rates, longer survival, and a high-
er proportion of patients in whom treatment can be per-
manently discontinued as an indicator of cure.
3.4. Myeloproliferative neoplasms
Alessandro Maria Vannucchi (Università degli Studi di
Firenze, Florence, Italy), Martin Griesshammer
(Mühlenkreiskliniken, Minden, Germany), Claire
Harrison (Guy’s and St Thomas’, London, United
Kingdom), Francesco Passamonti (Ospedale di Circolo e
Fondazione Macchi, Varese, Italy).
Introduction
The chronic Philadelphia chromosome-negative myelo-
proliferative neoplasms (MPNs) are disorders of
hematopoietic stem cells (HSCs) and include poly-
cythemia vera (PV), essential thrombocythemia (ET), and
primary and post-PV/post-ET myelofibrosis. These are
chronic disorders usually affecting individuals in middle
to advanced age; the estimated overall incidence in
Europe is 1-5 people per 100,000 a year. Life expectancy
is close to normal in ET and modestly reduced in PV,
whereas in primary myelofibrosis median survival is 5-6
years. There is no reliable estimate of the prevalence of
MPNs; however, the prevalence is likely rising due to ear-
lier diagnosis and prolonged survival. MPN patients suffer
from major cardiovascular events and, less commonly,
hemorrhages. Patients, and particularly those with
myelofibrosis, may present with disabling constitutional
symptoms, including marked cachexia, and suffer the
consequences of abnormal cell proliferation with massive
splenomegaly, hepatomegaly, and foci of extramedullary
hematopoiesis. MPNs have an intrinsic tendency to trans-
form to acute leukemia.
European research contributions 
European researchers have a long-standing record of
achievements in this field regarding both basic/translation-
al and clinical research. European researchers have discov-
ered the JAK2V617F mutation, JAK2 exon 12 mutations,
and CALRmutations that constitute major diagnostic crite-
ria in the up-dated WHO classification.146-148 The character-
ization of the key pathogenetic role of activated JAK/STAT
signaling has been instrumental to directing pharmaceuti-
cal research that culminated in the approval of the first
JAK1 and JAK2 inhibitor, ruxolitinib. The pivotal COM-
FORT-II study in myelofibrosis patients has been co-ordi-
nated and performed in Europe;124 the international pivotal
RESPONSE study in PV has been co-ordinated and largely
carried out in Europe as well.125 European researchers first
discovered genetic haplotypes predisposing to MPNs and
highlighted the prognostic impact of subclonal mutations
in primary myelofibrosis. National and supranational
[European LeukemiaNet (ELN)] networks of European
investigators and clinicians specifically focusing on MPNs
have produced fundamental knowledge for clinical prac-
tice, including the drawing up of clinical risk scores, defini-
tions of drug intolerance and resistance, treatment
response criteria, and clinical end points for novel drug
studies. Major phase III studies that established standards
of care for MPN patients were performed in Europe, such
as: 1) the ECLAP study, which demonstrated the safety and
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efficacy of low-dose aspirin for thrombosis prophylaxis in
PV; 2) the PT-1 and the ANAHYDRET study, which com-
pared hydroxyurea versus anagrelide for high-risk ET
patients; and 3) the CYTO-PV trial, which established the
optimal hematocrit target in PV. European researchers have
produced the largest prospective experience of stem cell
transplantation in myelofibrosis.
Proposed research for the Roadmap
In spite of the above achievements in molecular charac-
terization of MPNs, additional genomic research is need-
ed to identify novel phenotype driver mutation(s) in the
approximately 20% of patients with ET and primary
myelofibrosis who still lack a molecular marker; reaching
this goal will certainly facilitate earlier and more accurate
diagnosis. However, a more ambitious goal is the discov-
ery of the initiating mutation for MPNs, because the cur-
rently known mutations are certainly required for disease
manifestation but are not essential for its development.
Disease progression to either secondary myelofibrosis or
acute leukemia is a particularly important aspect that is
poorly understood and has not been studied in adequate
depth, notwithstanding its eventual occurrence in more
than 25% of patients with ET and PV whose conditions
are regarded as more indolent. A better understanding of
the molecular framework of MPNs would be important
for improving our ability to subcategorize patients
according to their risk of disease progression and dying.
This would also permit appropriate therapies to be better
selected. For example, stem cell transplantation may be a
curative option, but it carries considerable risk; converse-
ly, the recently developed JAK2 inhibitors must be credit-
ed with an incredible efficacy for symptomatic disease
management, possibly resulting in prolongation of sur-
vival, but are unable to cure the disease. Thus, research is
also needed to better delineate the cell-intrinsic abnor-
malities that determine and/or accompany these diseases;
such insights might enable development of novel and
more efficacious therapeutic strategies. Lastly, better ani-
mal models are required as an integral part of proposed
research plans in order to facilitate a full understanding of
the functional consequences of mutations and to test
novel therapies. Overall, these studies might be greatly
facilitated by supporting and reinforcing the existing net-
works of European scientists and clinicians in order to
share carefully annotated patient samples and take advan-
tage of existing technological platforms and expertise.
Anticipated impact of the research
Detailed molecular and cellular characterization of
MPN patients would facilitate personalized medicine in
the context of diagnosis, prognostication, and therapeutic
decisions. Overall, this would have a major impact on
lowering the disease burden, reducing the rate of compli-
cations, and, prospectively, prolonging survival. The cost
of novel technologies and treatments might be balanced
by their more specific application as well as a favorable
impact on patients’ quality of life and the lessening of the
burden for caregivers; this would translate into a favor-
able outcome for society in general by reducing use of
resources and improving individual work capabilities.
Scientific achievements frequently result in patent devel-
opment, which, by strengthening the relationships
between European academia and the industry, facilitates
public and private investments.
The EHA Roadmap for European Hematology
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Anemia affects 1.6 billion people worldwide1 and has a
huge direct impact on human health and economic well-
being, as well as being associated with worse prognosis
and higher treatment costs because of the numerous
comorbid diseases. Global anemia prevalence is approxi-
mately 47% in children under the age of five years, 42%
in pregnant women, and 30% in non-pregnant fertile
women.1 The consequences of morbidity associated with
chronic anemia extend to loss of productivity due to
impaired work capacity, cognitive impairment, increased
susceptibility to infection, and in the elderly, a huge con-
tribution to comorbidities, which places a substantial eco-
nomic burden on health care systems.149 Nevertheless,
anemia frequently goes unrecognized and untreated,
causing high direct and indirect costs both to the individ-
ual and at a national level.
The globalization of migration flows in recent decades
has increased the multicultural diversity of our societies.
According to the Organisation for Economic Co-operation
and Development, the percentage of foreign-born popula-
tions within the European Union in 2008 ranged from 4%
in Finland to 37% in Luxembourg, with an overall average
of 8%.150
Health care services in these countries have to deal with
increasingly culturally diverse populations. Due to the
movement of immigrants in Europe, there is a new epi-
demiology of acquired and inherited anemias. It is impor-
tant to know the exact distribution of the different forms
of anemia in each country in order to plan healthcare inter-
ventions. To carry this out, it appears mandatory to have
European guidelines for diagnosis and establish a common
and more sustainable therapeutic approach.
Moreover, clinical trials on new drugs and therapeutic
procedures could ameliorate the quality of treatment of
patients affected with these diseases, that are mainly
inherited, enhance their quality of life, and extend their
life expectancy.
Co-ordinated efforts should be made to develop strate-
gies for prevention of acquired and inherited anemias in
individuals at risk in Europe. Detailed epidemiological
studies in all countries, especially in Western Europe, are a
prerequisite for the implementation of effective preven-
tion programs. For a correct diagnosis, it is mandatory to
share a common diagnostic flowchart for each of the main
forms of anemias.
Thus, new tools urgently need to be developed to reli-
ably diagnose anemias and this fits well with the needs of
personalized medicine. We expect that the development
of such diagnostic tools will improve timely diagnosis
throughout Europe, especially in those countries where it
is difficult to gain access to “classical” diagnostic tests.
In the past 15 years, hematology research has made a
big leap forward. The emergence of sophisticated genetic
Section 4. Anemias and related diseases
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and molecular tools [e.g. next generation sequencing
(NGS) techniques] have allowed spectacular progress to be
made in our understanding of the structure and function of
the blood cells in health and disease. Our general aim will
be to solve several hematologic problems using these new
approaches.151,152
Research on rare iron-related genetic diseases that are
informative biological models may contribute to a further
understanding of iron metabolism. Precise diagnosis of
these diseases might help avoid unnecessary and costly
diagnostic tests and possibly harmful treatments.
4.1. New technologies for anemia and related disorders
Stefano Rivella (Weill Medical College, New York, United
States of America), Nicholas Anagnou (University of
Athens School of Medicine Athens, Greece), Celeste Bento
(Centro Hospitalar e Universitário de Coimbra, Coimbra,
Portugal), Achille Iolascon (Università Federico II di Napoli,
Naples, Italy), Mayka Sanchez (Josep Carreras Leukaemia
Research Institute, IJC, Badalana, Barcelona, Spain).
Introduction
The production of the oxygen carrier red blood cells
(RBCs) is called erythropoiesis, a process that begins with
pluripotent hematopoietic stem cells (HSCs) and terminates
with the production of RBCs. Anemia, defined as a
decreased amount of hemoglobin (Hb), can result from
blood loss as well as from decreased synthesis of Hb,
decreased RBC production, or increased RBC destruction.
Examples include hemolytic anemias (HAs), anemia of
inflammation, chronic kidney disease (CKD), some forms of
myelodysplastic syndromes (MDS), and bone marrow fail-
ure (BMF). In Europe, it is estimated that each year there are
8 new cases of MDS per every 100,000 people, 13% of peo-
ple present clinical or biochemical evidence of CKD, and
anemia of inflammation affects approximately 50% of
patients with chronic inflammatory disease. Clinical man-
agement includes administration of anti-inflammatory mol-
ecules in anemia of inflammation, erythropoiesis-stimulat-
ing agents and iron in CKD, and blood transfusions, admin-
istration of hematopoietic growth factors, low-intensity
chemotherapy, and bone marrow transplantation (BMT) in
MDS. Hb disorders, such as b-thalassemia, a-thalassemia,
and sickle cell anemia (SCA), are monogenic disorders char-
acterized by reduced or altered synthesis of the b- or a-glo-
bin chain, components of the oxygen carrier Hb. Causes of
morbidities and mortality associated with hemoglo-
binopathies are extramedullary hematopoiesis, iron over-
load, thrombosis, pain, bone defects, and liver and heart fail-
ure. Hemoglobinopathies represent the most frequent disor-
der worldwide, with at least 300,000 children born with
these disorders every year. Clinical management has been
focusing on supportive therapy, such as blood transfusions,
iron chelation, and management of pain. BMT has also been
utilized as a definitive curative option, although it is not
without risks. Additional anemias are due to dietary limita-
tions, such as folate, vitamin B12, and iron deficiency, while
others are due to infections or exposure to toxic agents.
European research contributions 
Advances have been made in our understanding of mol-
ecules and pathways that could be targeted to improve the
anemia or the secondary manifestations associated with
defective erythropoiesis, such as splenomegaly, bone
abnormalities, iron overload, and pain. B-cell chronic lym-
phocytic leukemia (CLL)/lymphoma 11A (BCL11A) and
Krüppel-like factor 1 (KLF1), which modulate the produc-
tion of fetal hemoglobin, are important modifiers of clinical
severity in b-thalassemia and SCA.153 JAK2 and growth dif-
ferentiation factor 11 (GDF11), modulators of erythro-
poiesis, have been negatively associated with anemia in b-
thalassemia, SCA, and MDS.154 Cell adhesion molecules,
such as E-, L-, and P-selectin, are being investigated for
their potential role in hemolysis, inflammation, pain, and
thrombosis in SCA.155 Hepcidin (HAMP), the main regula-
tor of iron absorption, has been associated with increased
iron absorption in b-thalassemia and iron-restricted anemia
in anemia of inflammation.154 Molecules that control
dietary iron absorption in the gut and HAMP production in
the liver, such as hypoxia-inducible factor 2a, divalent
metal transporter 1, duodenal cytochrome B , ferroportin,
transferrin, erythroferrone, and type II transmembrane ser-
ine protease, have also been investigated for their contribu-
tion to iron overload and anemia in b-thalassemia.154
Despite huge progress, however, there is still no radical
treatment for b-thalassemia and SCA, besides allogeneic
HSCT, which has limitations such as donor histocompati-
bility. Gene therapy and gene editing approaches have
been introduced as realistic alternatives to treat b-tha-
lassemia and SCA. The technology for viral-mediated gene
addition of the b-globin chain gene reached the clinical trial
stage with promising results in two ongoing clinical trials
in the United States.154 This technology allows insertion of
the curative gene by random integration in the genome.
However, this might be associated with genotoxicity (i.e.
undesirable gene disruption or oncogene activation). Gene
editing technologies are focusing on the correction of
mutations in the b-globin gene or in modifying genes that
modulate fetal hemoglobin expression.156 The latter tech-
nology could be intrinsically safer, because it does not
require random integration of a curative transgene.
Proposed research for the Roadmap
All of these new potential targets and technologies may
translate into clinical treatments with a positive impact on
the management of these disorders. For instance, new
agents that target GDF11 are now in phase I clinical trials
for hemoglobinopathies and MDS.154 Drugs that limit iron
absorption and improve anemia are showing very promis-
ing results in pre-clinical studies.154 As some of these drugs
might target additional molecules, however, negative side
effects following long-term treatments have not yet been
excluded. Gene therapy trials for the cure of b-thalassemia
show very promising results, but long-term effects are
unknown. In Europe, there has been significant progress in
generating appropriate gene therapy vectors, but this
needs to be further supported in order to reach the clinic.
Gene editing requires additional studies before it can be
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Table 1. Key priorities in a European Anemia Research Roadmap.
• Epidemiology of anemias in Europe
• Common flowcharts for diagnosis
• Pathogenesis studies of rare inherited anemias to have new therapeutic targets
• Enhancement of clinical trials for new drugs
• Use of new technologies for a personalized diagnosis and therapy
translated into mainstream clinical therapy.156 Genetic vari-
ability will likely influence the efficacy of these new ther-
apeutics or therapies. For this reason, we recommend the
use of next generation (omics) technologies to assess the
role of genetic makeup of the patients, modifiers, and
environment. This will help clinicians develop precision
medicine (i.e. prevention and treatment strategies that
take individual variability into account, leading to person-
alized treatment for each patient).157 Therefore, as many of
these approaches are still under characterization or in an
early phase of development, we propose investing in these
new lines of investigations and technologies in order to
validate their potential and transform them into effective
and safe ways of treatment (Figure 2).
Anticipated impact of the research
The clinical cost and socio-economic impact of these
disorders is tremendous. Children affected by hemoglo-
binopathies require life-long transfusion for survival but,
eventually, much morbidity develops, leading to a
decreased life span. Anemia of inflammation, CKD, and
MDS predominantly impact the adult population, repre-
senting a growing and pressing issue in Europe. Therefore,
efforts to develop new scientific discoveries and therapeu-
tics can have a major impact on the growing and aging
population in Europe at many different levels. This new
source of information and potential novel technologies
might have a profound impact, not only on these disor-
ders, but also on many other diseases that require manage-
ment of RBC production, such as in cancer therapies or
following BMT. Moreover, many additional incurable dis-
orders could benefit from the development of gene thera-
py and gene editing technologies developed for b-tha-
lassemia and SCA.
4.2. Iron-deficiency anemia
Clara Camaschella (San Raffaele Institute, Milan, Italy),
Adlette Inati (Lebanese American University, Beirut,
Lebanon), Mariane de Montalembert (Necker-Enfants
Malades University Hospital, Paris, France), Dorine
Swinkels (Radboud Universitair Medisch Centrum,
Nijmegen, the Netherlands), Sule Unal (Hacettepe
University, Ankara, Turkey).
Introduction
Iron-deficiency anemia (IDA) is the most common
form of anemia worldwide, affecting almost 1 billion
people. There are strong differences in IDA prevalence
between developing and high-income countries, and
even among European countries.158 Individuals at risk are
those with increased iron needs, such as pre-school chil-
dren, adolescents, and young (especially pregnant)
women. Pathological causes of IDA, such as malabsorp-
tion and chronic blood loss, are common and may be
associated with cancer, especially in the elderly. IDA
poses a major burden to society: it has been reported to
cause cognitive defects in children, increased morbidity
and mortality in pregnancy, reduced physical perform-
ance in workers, and is a common comorbidity in the
elderly. Genetic causes of IDA are extremely rare, often
remaining undiagnosed, though relevant in children.
Also challenging is the diagnosis of IDA in the context of
anemia of chronic disease (ACD), a condition frequently
found in the elderly. Diet fortification is an effective pre-
ventive modality of IDA, although there are concerns
that iron may worsen infections, as shown in children
living in malaria-endemic areas.159 Treatment of IDA is
apparently simple, because several (oral and intravenous)
iron preparations are available.
European research contributions 
European researchers have contributed identifying hep-
cidin, the key liver hormone regulating systemic iron
homeostasis, defining its role in genetic iron-related disor-
ders and clarifying how high hepcidin induces iron
sequestration and iron-deficient erythropoiesis in ACD.160
Our advanced understanding of iron metabolism has
allowed the recognition of rare genetic iron-related ane-
mias that are challenging to diagnose. The e-rare JTC
2009 HMA-IRON project has helped raise awareness of
these novel entities in Europe. Orphanet and the
European Network for Rare and Congenital Anaemias
(ENERCA) (www.enerca.org), a European network of
expert centers, offer online tools useful for the diagnosis
of these rare anemias. From genetic iron-refractory IDA,
characterized by high hepcidin levels and iron refractori-
ness, the lesson is that hepcidin levels should be
low/undetectable to allow oral (and pharmacological)
iron absorption and that, when needed, intravenous iron
should be preferentially employed in the presence of
inflammation with high hepcidin. However, analytically
and clinically validated hepcidin tests are available in only
a few European centers.
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Figure 2. A roadmap for research into new technologies in anemias and relat-
ed disorders.
The results of clinical trials comparing the efficacy of
novel intravenous preparations with oral iron drugs are
available or being processed. Intravenous preparations
appear safe even at high doses (up to 1 g) administered in
a single infusion. However, experience is limited, and cri-
teria for using oral or intravenous iron are only partially
defined. Long-term effects and cost-effectiveness also
need to be evaluated.
Proposed research for the Roadmap
Co-ordinated efforts should be made to develop strate-
gies for the following.
1. Prevention and treatment of IDA in individuals at risk
in Europe. From the available data, Eastern European
countries show a higher IDA prevalence than countries
in Western Europe.158 Detailed epidemiological studies
in all countries, especially Western countries, are a pre-
requisite for the implementation of effective preven-
tion programs.
2. A better understanding of the impact of iron-deficien-
cy on physical performance and cognitive and physical
development in children, even independently from
anemia; understanding is now based only on epidemi-
ological evidence, also necessitating molecular and bio-
logical studies. A flowchart should be developed and
shared for differential diagnosis of IDA, IDA in ACD,
and ACD, and for therapeutic criteria.161
3. Clinical trials focused on the new intravenous iron
preparations should be designed to compare their effi-
cacy and side effects. There is a need for evidence-
based strategies for accurate and timely diagnosis and
optimal treatment of genetic iron-related anemias.
4. Clarify the possible genetic propensity to develop iron
deficiency and the relationship of iron with erythro-
poiesis efficiency. We have just started to understand
how erythropoiesis adapts to iron deficiency. It is
unclear why and how iron deficiency induces microcy-
tosis and through which mechanisms it increases
platelet production in severe cases. Iron deficiency is a
positive modifier of ineffective erythropoiesis in pre-
clinical murine models of b-thalassemia,162 but the
mechanisms have not been explored and should be
verified in patients.
5. The iron-related changes in the composition of gut
microbiota, with a prevalence of pathogens over the
beneficial lactobacilli, is an emerging problem in devel-
oping countries that needs to be further explored con-
sidering the relevance of microbiota for human health
and the safety of oral iron supplementation in develop-
ing countries.
Anticipated impact of the research
To correct IDA is simple and usually inexpensive. The
underlying cause in some cases is more relevant than ane-
mia itself. Society will benefit from programs aimed at
controlling iron and Hb levels in all age groups. Research
on rare genetic iron-related diseases that are informative
biological models may contribute to further understanding
iron metabolism and its regulation. Their precise diagnosis
might lead to avoiding unnecessary and costly diagnostic
tests and possibly harmful treatments.
Elucidating the role of iron in ineffective and effective
erythropoiesis would benefit patients with b-thalassemia
and other inherited anemias and may have implications
for acquired disorders of erythropoiesis in myeloprolifera-
tive disorders [e.g. polycythemia vera (PV)] and low-risk
MDSs. The results of clinical trials may indicate when and
how intravenous iron should be safely used. Targeted
therapies are the results of increased knowledge. The dis-
covery of hepcidin is fostering its therapeutic manipula-
tion as a novel approach to control iron levels. Trials with
hepcidin antagonists that aim at making the sequestered
iron in inflammation available for erythropoiesis are ongo-
ing in European centers and beyond. Epidemiological sur-
veys, biological studies, and clinical observations suggest
an important role for iron in common disorders, including
heart failure, obesity, CKD, diabetes, and metabolic syn-
drome. Studies triggered by IDA have the potential to help
establish the optimal levels of iron according to age and
sex in these disorders.
4.3. Dyserythropoietic and hyporegenerative anemias
Hannah Tamary (Schneider Children's Medical Center
of Israel, Petach Tikva, Israel), Wilma Barcellini (Ospedale
Maggiore Policlinico, Milan, Italy), Lydie da Costa
(Hôpital R. Debré, Paris, France), Irma Dianzani
(Università di Torino, Turin, Italy), Roberta Russo
(Università Federico II di Napoli, Naples, Italy).
Introduction
Congenital dyserythropoietic anemias (CDAs) and
Diamond Blackfan anemia (DBA) are rare hereditary ane-
mias caused by abnormal erythropoiesis that is ineffective
in the former and hypo/aregenerative in the latter. The
prevalence of the CDAs in Europe varies according to
European region and is 0.1-3 cases per million live births,
while that of DBA is 4-7 cases per million live births.163
The CDAs are characterized by moderate to severe ane-
mia, distinct morphological features in bone marrow late
erythroblasts, and development of secondary iron over-
load. The morphological classification initially proposed
by Heimpel and Wendt (CDA I, II, and III) is still valid in
clinical practice and is now supported by the identification
of different genes mutated in each type.164 CDA I is caused
mainly by mutations in CDAN1, but also in C15orf41.
CDA II is a result of mutations in SEC23B and CDA III of
KIF23. However, there are families that fulfill the general
definition of the CDAs but do not conform to any of the
three classical types (CDA variants). Moreover, mutations
in erythroid-specific TFs genes GATA1 and KLF1 have
been described in few such patients. The protein encoded
by KIF23 is a mitotic kinesin crucial for cytokinesis; how-
ever, the possible role of the proteins encoded by CDAN1,
C15orf41, and SEC23B in erythropoiesis is still unknown.
Children with DBA classically present with severe
macrocytic anemia in the first year of life. The bone mar-
row discloses a paucity of erythroid precursors.
Approximately 30% of DBA patients also have physical
anomalies (e.g. craniofacial, thumb, and cardiac malforma-
tions). The risk of solid tumors, myelodysplastic syndromes
(MDS), or leukemia is elevated in DBA and was calculated
to be 20% by the age of 46 years.165 Following the first year
of life, the anemia is currently treated with corticosteroids.
Infants in the first year of life or patients who do not
respond to steroids or require high doses with unacceptable
toxicities receive chronic red blood cell (RBC) transfu-
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sions.166 These patients often develop substantial iron over-
load and require careful monitoring to detect this, as well as
iron chelation therapy. Stem cell transplantation is an alter-
native to chronic transfusions. DBA is the first ribosomopa-
thy described resulting in haploinsufficiency of 16 genes
encoding ribosomal proteins, RPS19, RPL5, RPS10, RPL11,
RPL35A, RPS26, RPS24, RPS17, RPS7, RPL26, RPS27,
RPS28, RPS29, RPL15, RPL27, and TRS2. Mutations in ribo-
somal genes account for 60%-70% of DBA cases. The
effect of decreased ribosomal activity in vivo and in a tissue-
specific manner is unknown; p53 activation has been
observed in bone marrow from DBA patients, after deple-
tion of ribosomal proteins. Recently, it has been shown that
rare mutations in the GATA1 gene can cause DBA.
Subsequently, an elegant study suggested that impaired
translation of GATA1 mRNA (as a consequence of riboso-
mal protein haploinsufficiency) is an important factor in
mediating the erythroid defect observed in DBA.
European research contributions 
Almost all the work carried out on CDAs, including the
description of the clinical picture and identification of the
genes involved, was done in Europe. Heimpel made an
important contribution to the field, becoming the first to
diagnose the disorder and to describe its morphological
and clinical features. Iolascon did much of the work on
CDA II, defining the molecular genetics and the genotype-
phenotype correlation of this disease. The genes mutated
were mainly described in Europe. Although the major
gene mutated in CDAI (CDAN1) was identified in Israel,
the second gene causing CDA I was described in the UK.
The CDA II gene identification was an Italian-German
collaboration; that of the CDA III gene was performed in
Sweden.
The main DBA patient registries are kept in France,
Germany, Italy, the UK, and the US. Israel also keeps a reg-
istry of bone marrow failure (BMF) syndromes that
includes Diamond Blackfan anemia (DBA). Collaboration
among European groups led to the identification of the
first DBA gene, RPS19. Subsequently, many collaborative
papers explored several aspects of genotype-phenotype
correlation. A group from Lund has developed many cel-
lular and mice models of DBA, and is involved in gene
therapy and new drug research for the anemia.
Educational activities train young doctors and
researchers in their understanding of these disorders, and
patients have organized themselves into national organi-
zations throughout Europe.
Proposed research for the Roadmap
We suggest programs to improve diagnosis and optimal
clinical care for patients with these rare disorders, as well
as basic research programs to better understand the role of
the proteins encoded by mutated genes in erythropoiesis
(Figure 3).
1. Improve CDA and DBA European registries by harmo-
nization and collaboration among the existing national
registries to create a unique European database.
2. Improve molecular diagnosis and identification of
potential new genes by using next generation sequenc-
ing (NGS) methods. The first step in this proposal is to
employ targeted NGS with a panel of known genes
mutated in CDAs, DBA, and other rare anemias. If no
mutation is identified by targeted NGS, a whole-
exome sequence will be performed to identify new
causative genes.
3. Perform functional studies to define the role of pro-
teins, encoded by known and any new genes in ery-
thropoiesis. The proteins will be studied in relevant
human erythroid progenitors grown in liquid medium
CD34+ cells and also using patients’ induced pluripo-
tent stem cells (iPSCs).
4. Investigate the role of new drugs that modulate ery-
thropoiesis (anti-JAK2 and TGF-b ligand modifiers)
using in vitro models of erythropoiesis. Anti-JAK2 has
the potential to decrease ineffective erythropoiesis and
thus ameliorate anemia in CDAs. TGF-b ligand modi-
fiers correct anemia by promoting late-stage erythro-
poiesis and have recently been shown to decrease
transfusion requirements and serum ferritin level with
favorable safety profile in patients with b-
thalassemia.167 Because of the similarity in pathogene-
sis between thalassemia and CDAs, their study in
CDAs is warranted.
5. Implement studies for CDAs/DBA. Gene therapy has
also been proved to cure diseases that affect
hematopoietic cells, such as severe combined immu -
no deficiency.
Anticipated impact of the research
As CDAs/DBA are rare disorders, there is often misdiag-
nosis or a delay in diagnosis which may result in years of
inappropriate therapy, including iron preparations. Patient
registries and cutting-edge molecular technology will con-
tribute to accurate diagnosis and optimal therapy for most
patients. Defining the role of the proteins encoded by
mutated genes in CDAs and DBA in erythropoiesis may
eventually be exploited therapeutically. Gene therapy
EHA Roadmap for European Hematology Research
haematologica | 2016; 101(2) 151
Figure 3. A roadmap for research into dyserythropoietic and hypogenerative
anemias.
approaches and new drugs that modulate erythropoiesis
have the potential to ameliorate the anemia and iron over-
load, and thus improve patients’ quality of life and sur-
vival.
4.4. Hemolytic anemias, including membrane and
enzyme defects
Alberto Zanella (Ospedale Maggiore Policlinico, Milan,
Italy), Patricia Aguilar Martinez (Hôpital Saint-Eloi,
Montpellier, France), Immacolata Andolfo (Università
Federico II di Napoli, Naples, Italy), Paola Bianchi
(Ospedale Maggiore Policlinico, Milan, Italy), Richard van
Wijk (Universitair Medisch Centrum Utrecht, Utrecht, the
Netherlands).
Introduction
Hemolytic anemias (HAs) are a heterogeneous group of
hereditary and acquired disorders. Among hereditary
forms, the most common are defects of the red cell mem-
brane and enzymopathies that disturb red cell metabo-
lism. Except for glucose-6-phosphate dehydrogenase defi-
ciency, which affects more than 400 million people, the
most frequent congenital hemolytic disease in Europe is
hereditary spherocytosis, a cytoskeletal defect with a
prevalence of 1-5 cases per 10,000 individuals. Other
hereditary HAs are rare or extremely rare (Figure 4).
Hereditary HAs are characterized by anemias of vari-
able degree, from fully compensated hemolysis to severe
and transfusion-dependent anemia. Other manifestations
of clinical significance include jaundice, splenomegaly, and
iron overload. Hydrops fetalis has been reported in rare
cases. In some enzymopathies (those involving genes with
ubiquitous expression) and in rare conditions, non-hema-
tologic symptoms, such as neurological/neuromuscular
impairment, may also be present. Because the pathophys-
iology of around 30% of hereditary HAs is poorly under-
stood, these disorders represent a substantial and hetero-
geneous group of diseases that still lack easy-to-apply
tools for diagnosis, clinical management, and patient strat-
ification. Moreover, epidemiological data in Europe are
generally still incomplete, and the estimated prevalence of
some defects varies widely among countries. This is likely
due to the limited and incomplete availability of diagnos-
tic tools.163
Although the general diagnosis of anemia is part of daily
clinical practice, the differential diagnosis of HAs is often
difficult, requiring specialized analyses available in only a
few expert EU centers. In addition, the conclusive diagno-
sis is often delayed, thus increasing the overall costs of the
health care systems and causing considerable degrees of
distress for patients and their families.
It has been calculated that the cost of diagnosis for one
of these anemias is between €850 and €2500; that can
triplicate or even quadruplicate if a conclusive diagnosis is
not reached.
Although the total number of affected individuals is sub-
stantial, the rarity and heterogeneity of HAs have resulted
in limited interest from the pharmaceutical industry.
European research contributions 
In past 20 years, inherited HAs have been the object of
intensive research by internationally recognized EU
groups, aimed at elucidating the molecular bases of these
diseases, as is the case for hereditary stomatocytosis and
enzymopathies.168,169
A great step forward in the classification of these rare
defects, as well as in the identification of expert centers for
diagnosis, has been made in the past ten years by ENER-
CA. ENERCA is an EU project currently in its fourth phase
(e-ENERCA). An important outcome is the ENERCA
White Book containing the recommendations and the def-
inition of the criteria that Centers of Expertise and local
centers have to fulfill as health care providers.170
Due to the concerted efforts of several EU groups, a new
edition of diagnostic guidelines for hereditary spherocyto-
sis is about to be published.171 However, no specific guide-
lines are currently available for the rarer HAs.
Proposed research for the Roadmap
Create an EU network and registry for rare HAs: through the
work carried out by ENERCA, it has been possible over
the past years to map EU expert centers for the referral of
cases with RBC cytoskeletal membrane disorders, heredi-
tary stomatocytosis, and RBC enzymopathies. This expe-
rience has shown that an officially recognized European
Reference Network (ERN-RA), combining different areas
of expertise and dedicated specialists, is needed to better
define these disorders and share common diagnostic and
therapeutic flowcharts. The creation of European reg-
istries for these rare disorders will also be of great help to
increase knowledge about their prevalence and to collect a
greater number of patients; this will improve clinical diag-
nosis, allow a better definition of complications, and facil-
itate possible therapeutic trials.
Understand the pathophysiological mechanisms and identify
new genes to develop new diagnostic tools: despite detailed,
exhaustive hematologic and molecular investigations,
approximately 10%-15% of HA patients remain undiag-
nosed. Moreover, the wide heterogeneity of their pheno-
typical expression has made it difficult in the past to devel-
op easy-to-apply molecular diagnostic tools. The advent
of next generation sequencing (NGS) technologies make
these new approaches useful tools to investigate the
genetic basis of undiagnosed cases and to identify new
nosological entities. Moreover, the reduction in cost of
these technologies may allow the development of NGS-
based diagnostic tools (i.e. by creation of a panel of known
genes) and their market development.
Develop new therapeutic approaches (e.g. new drugs and gene
therapy models): whereas new drugs and therapeutic
approaches recently became available for acquired HA, no
specific or curative treatments are available for congenital
HAs except for hematopoietic stem cell transplantation
(HSCT). Because most of these defects are monogenic,
gene therapy may represent a therapeutic option. In this
respect, a promising approach concerns the use of gamma-
retroviral vectors that has proved effective in correcting
the disease in a pyruvate kinase-deficient mouse model as
recently developed by EU groups. A therapeutic and clini-
cally applicable lentiviral vector has recently received the
orphan drug designation for the treatment of pyruvate
kinase deficiency by the European Commission
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(EU/3/14/1130). Finally, investigation of new drugs that
could increase specific enzymatic activity and/or activate
isoenzymes could pave the way for attractive therapeutic
approaches to RBC enzyme disorders.
Anticipated impact of the research
A correct diagnosis will have a major impact on patients’
quality of life (QoL) and survival, especially by the early
detection of complications such as iron overload, and will
allow for appropriate genetic counseling of patients and
their families. A more timely diagnosis will also result in a
significant reduction of the overall costs of the health care
systems.
The increased knowledge of pathophysiology of these
disorders and the identification of new nosological entities
will be of great help in improving the diagnosis and will
offer the basis for the development of new therapeutic
approaches for HAs.
Finally, the creation of EU registries for rare HAs will
improve awareness of these rare disorders and their preva-
lence.
4.5. Congenital bone marrow failure, aplastic anemias,
and paroxysmal nocturnal hemoglobinuria
Antonio Risitano (Università Federico II di Napoli,
Naples, Italy), Carlo Dufour (Istituto Giannina Gaslini,
Genoa, Italy), Antonis Kattamis (Athens University,
Athens, Greece ), Regis Peffault de Latour (National
Institutes of Health, Bethesda, MD, United States of
America), Irene Roberts (University of Oxford, Oxford,
United Kingdom).
Introduction
Bone marrow failure (BMF) syndromes are a heteroge-
neous group of diseases characterized by a quantitative
deficiency in one or more blood cell lineages. Inherited
BMFs include different entities, such as Fanconi anemia
(FA) (which is due to impaired DNA repair and cytokine
hypersensitivity),172,173 dyskeratosis congenita, Diamond
Blackfan anemia (DBA), and Shwachman-Diamond syn-
drome (all associated with impaired ribosomal or telomere
function). Inherited BMFs are rare disorders, the most
common of which is FA (1-3 per 500,000 newborns).172
Indeed, the majority of BMFs are acquired forms, mostly
idiopathic; the most typical form, idiopathic aplastic ane-
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Figure 4. Red blood cell membrane disorders.
mia (IAA), has an incidence of 1-5 people per million in
Western countries. Another less common acquired BMF is
paroxysmal nocturnal hemoglobinuria (PNH); here the
underlying bone marrow disorder is associated with the
expansion of an abnormal, non-malignant, blood cell pop-
ulation that is deficient in the expression of glycosylphos-
phatidylinositol-linked proteins due to a somatic PIGA
mutation. As well as BMF, which is seen in only a propor-
tion of PNH patients, the clinical phenotype of PNH is
characterized by anemia due to complement-mediated
intravascular hemolysis secondary to the lack of the glyco-
sylphosphatidylinositol-linked complement regulators
CD55 and CD59, along with an increased frequency of
major thromboembolic events.
European research contributions 
The improved understanding of all BMFs has led to better
patient management in Europe; the Working Party for
Severe Aplastic Anemia (WPSAA) of the EBMT has con-
tributed greatly to improved clinical outcome in this field.
Milestones, where European hematologists have taken the
lead, include the first observations on the use of antithymo-
cyte globulin (ATG) as treatment for IAA and the first use
of hematopoietic stem cell transplantation (HSCT) in
patients with FA. There have also been improvements in
diagnostic strategies in BMF, mostly in the differential diag-
nosis of inherited versus acquired forms of BMF. (The for-
mer are often cryptic and may appear even in adolescents
or adults.) In terms of treatment, the most relevant
improvements include: 1) intensive immunosuppressive
treatment (mainly for acquired IAA); 2) anticomplement
treatment (for hemolytic forms of PNH); 3) HSCT, for inher-
ited BMFs, IAA, and, more rarely, PNH. These improve-
ments are particularly relevant given that they were
achieved in the setting of rare disorders where there are
innate difficulties in making progress. The database of the
WPSAA of the European Group for Blood and Marrow
Transplant (EBMT) contains data on more than 11,000
patients with different subtypes of BMFs, thereby providing
a unique opportunity for investigating many different criti-
cal aspects of these diseases. The WPSAA of the EBMT con-
tinues to run a multinational database to collect data from
all European BMFs; the aim is to combine this retrospective
work with prospective studies to address further improve-
ments in the complex treatment of these disorders.
Proposed research for the Roadmap
Patients suffering from BMFs continue to represent a chal-
lenge for the medical community because of their poor
prognosis when the underlying disease is not controlled.
Additional efforts are needed to offer the most appropriate
treatment to all European patients and improve current
standards of care. The WPSAA of the EBMT is dedicated to
this goal through different research lines.
1. Improvement of non-transplant treatment for acquired IAA:
current immunosuppressive treatment for acquired
IAA is based on the combination of horse ATG and
cyclosporine A. The recent withdrawal of the horse
ATG preparation from the European market has had
detrimental effects on outcome in European IAA
patients, as demonstrated in several studies,174,175 lead-
ing the WPSAA to highlight the need for this ATG
preparation for IAA patients.175,176 In addition, ongoing
efforts are investigating the benefit in randomized,
controlled trials of the addition of newer agents (e.g.
the THPO-mimetic agent eltrombopag) on the “scaf-
fold” of standard immunosuppression (which may be
different according to the severity of IAA).
2. Improvements in HSCT for inherited and acquired forms of
BMF: HSCT remains a key treatment option for all
BMF patients, with the current indication depending
on the phase/severity of the disease and on the avail-
ability of alternative treatments. Possible improve-
ments in HSCT procedures will exploit different (and
possibly combined) strategies: 
a) identification of improved HSCT protocols (includ-
ing pre-transplant conditioning and pre-, peri-, and
post-transplant immunosuppression) to reduce post-
transplant mortality and morbidity (e.g. comparing dif-
ferent immunosuppressive regimens); 
b) development of novel HSCT protocols in the setting
of unrelated donor HSCT, aiming to neutralize the
detrimental effect of a non-related donor, such that
unrelated HSCT could be used earlier in the treatment
algorithm of IAA;
c) investigation of HSCT from alternative donors, such
as human leukocyte antigen (HLA)–haploidentical
donors and cord blood units, aiming to offer a HSCT
option to all candidate patients;
d) identification of novel HSCT procedures tailored to
specific conditions (e.g. for PNH or for FA and other
inherited BMFs)
3. Observational studies on PNH: the treatment of PNH has
been revolutionized in the past decade by the intro-
duction of the anticomplement agent eculizumab. The
WPSAA is currently looking at the actual role (and
most appropriate procedures) of HSCT in PNH in the
eculizumab era, as well as evaluating possible unmet
medical needs that may still remain during this treat-
ment.
4. Observational studies on the natural history of BMFs: these
studies aim to improve the diagnosis, classification,
and definition of response categories of both acquired
and inherited BMFs, with the goal of identifying burn-
ing clinical questions to be investigated by specific
investigations.
Anticipated impact of the research
The management of BMF represents an urgent medical
need not only for individual patients but also for society as
a whole. Many affected patients will become unproduc-
tive and require lifelong, expensive treatments. In the past
four decades, BMFs have changed from inevitably fatal
diseases into curable ones, with an overall survival rate
approaching 70% at ten years. These outcome data can
still be improved. It is only through the design and execu-
tion of stringent and well-focused studies that the scientif-
ic community will learn how to deliver better treatment
options to these patients. Furthermore, improvement of
the management of BMF will lead to a better use of
increasingly restricted resources, which will also have a
positive impact on society, also from a financial point of
view.
4.6. Thalassemia and congenital hemoglobinopathies
Maria Domenica Cappellini (Università degli Studi di
Milano, Milan, Italy), Emanuele Angelucci (Ospedale A.
Businco, Cagliari, Italy), Androulla Eleftheriou
(Thalassaemia International Federation, Strovolos,
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Cyprus), Antonio Piga (Università di Torino, Turin, Italy),
Ali Taher (American University of Beirut Medical Center,
Beirut, Lebanon), Vip Viprakasit (Mahidol University,
Bangkok, Thailand).
Introduction
The thalassemia syndromes are a heterogeneous group
of inherited hemolytic anemias (HAs) characterized by
reduced or absent production of one or more of the globin
chains of hemoglobin (Hb). This leads to imbalanced glo-
bin chain synthesis that is the hallmark of thalassemia
syndromes. In hemoglobinopathies, globin chain synthe-
sis is usually balanced but one chain is abnormal: HbS,
HbC, and HbE are the most common and relevant.
The thalassemias and hemoglobinopathies are the most
common single gene disorders in the world population,
with estimated carrier number of more than 270 million
and an annual birth rate of more than 300,000. They are
most frequent in southern Asian, Middle Eastern, and
Mediterranean countries, and North and Central Africa.
As a result of migration, however, these conditions are
found all over Europe.177
European research contributions 
The natural history of these diseases has changed signif-
icantly in Europe during the past decades due to three
main reasons:
1. carrier screening and prenatal diagnosis;
2. advances in diagnosis and conventional treatment;
3. HSCT.
Carrier screenings and prenatal diagnosis: a couple identi-
fied at risk for a severe form of thalassemia or hemoglo-
binopathy can be offered prenatal diagnosis to avoid the
birth of an affected child. Prenatal diagnosis of thalassemia
was introduced in Europe in the late 1970s, initially per-
formed through globin chain synthesis on cord blood, and
then in the 1980s by DNA analysis. Since then, the birth
rate of children with thalassemia in Cyprus and Italy has
dropped almost to zero. However, the wide variability of
the phenotype of many mutation combinations demands
great experience and counseling. Prenatal diagnosis may
be difficult for religious and cultural reasons in recent
migrants.178
Improvement of conventional treatment: for thalassemias, the
improved understanding of the pathophysiology and the
availability of safe and high-quality blood in Europe has
allowed an optimal suppression of ineffective erythro-
poiesis by appropriate transfusion therapy. Iron chelation
has had a major impact on morbidity and mortality in
Europe. The standard chelation therapy for more than 40
years was deferoxamine, given by continuous subcuta-
neous infusion 5-7 days per week. The long-term efficacy
of deferoxamine has been extensively documented in
large cohorts of patients. Unfortunately, long-term compli-
ance with daily subcutaneous infusions is a serious limit-
ing factor. This has led to identifying safe, effective oral
iron chelators. At present, two oral iron chelators are avail-
able: deferiprone and deferasirox. Deferiprone was regis-
tered in Europe and only recently in the United States and
Canada. Deferiprone may be more effective than deferox-
amine in protecting the heart from the accumulation of
iron. Combined deferoxamine/deferiprone therapy is used
in high-risk patients, such as those with heart iron or car-
diac dysfunction. The more recent oral iron chelator,
deferasirox, has been shown to be effective and safe in
removing excess iron from different organs, including the
heart. While the availability of oral iron chelators has
improved patients’ compliance, the introduction of non-
invasive techniques to quantify tissue iron, especially MRI
T2* to measure myocardial iron, has significantly con-
tributed to optimizing and intensifying iron chelation,
reducing cardiac mobility and mortality.179
HSCT: allogeneic HSCT in thalassemia syndromes has
been increasingly successful during the past three
decades, mainly in b-thalassemia major. Predictors of
transplant outcome established by the Pesaro group cate-
gorized patients into three risk classes. The probability of
thalassemia-free survival for patients under 17 years of
age who receive the allograft from an HLA-identical rela-
tive is above 85% in class 1 or 2 patients and is much
lower in young patients in class 3. The progressive adjust-
ment of conditioning therapy in class 3 patients and in
adults (over 17 years of age) has also significantly
improved outcome in this class. HSCT from unrelated
donors has a higher risk of acute and chronic graft-versus-
host disease (GvHD), particularly in thalassemia. A recent
study from Eurocord reported no mortality and better
outcome in 33 patients with class 1 and 2 thalassemia
who received cord blood HSCTs from HLA-identical sib-
lings, suggesting that related cord blood HSCT is a safe
procedure for thalassemia patients. The European experi-
ence in bone marrow transplantation (BMT) in tha-
lassemia represents a milestone for thalassemia treatment
in the world. HSCT in sickle cell disease (SCD) has also
been developed in Europe, and recent recommendations
have been proposed.180
Proposed research for the Roadmap
Boost transplantation options: HSCT may be considered a
definitive treatment for the major Hb disorders; however,
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Figure 5. Proposed priorities for European research on hereditary hemolytic
anemias.
most patients with thalassemia lack a compatible sibling
donor and thus there is interest is using alternative donors.
In this context, other approaches require further develop-
ment:
1. matched unrelated donor;
2. matched unrelated cord blood;
3. mismatched related or haploidentical donors.
Pharmacological intervention: although there is current-
ly no definitive treatment (with the exception of HSCT),
the potential of correcting the globin chain imbalance
through pharmacological intervention is an approach that
holds tremendous promise and could lead to widespread
therapeutic options for patients. This includes identifica-
tion of new and potent fetal hemoglobin inducers or new
molecules that may potently modulate the ineffective ery-
thropoiesis, such as agents that block the activity of cer-
tain TGF-b–family cytokines, as well as JAK2 kinase
inhibitors.181
Gene therapy: gene therapy is the major investment for
the future for the cure of thalassemias and SCD.
Quality of life (QoL): more research work should be
undertaken to investigate the impact of good social and
psychiatric support in improving the QoL of this group of
patients. Most thalassemia and sickle patients in Europe
are immigrants who, in addition to their lifelong disease,
are exposed to extra stress when they move to a new
country with regulations and a social and cultural life that
are different from that of their country of origin.
Anticipated impact of the research
During the past three decades, the improvement in diag-
nosis and management has enabled patients to live normal
lives but has increased the economic and social burden.
The cure of thalassemias and hemoglobinopathies repre-
sents an urgent medical need, not only for individual
patients, but also for society as a whole.
4.7. Iron overload disorders
Yesim Aydinok (Ege Üniversitesi, Izmir, Turkey),
Barbara Butzeck (European Federation of Associations of
Patients with Haemochromatosis, Croissy sur Seine,
France), Domenico Girelli (Università degli Studi di
Verona, Verona, Italy), Martina Muckenthaler
(Universitätsklinikum Heidelberg, Heidelberg, Germany),
Jecko Thachil (Manchester Royal infirmary, Manchester,
United Kingdom), Sophie Vaulont (Institut Cochin, Paris,
France).
Introduction
Iron overload represents a major health problem world-
wide. Excess iron accumulates in vital organs of the human
body and increases the risk for liver disease (cirrhosis or
cancer), heart failure, diabetes mellitus, metabolic syn-
drome, osteoarthritis, and hypogonadism, and in some
cases it causes premature death. Iron overload can be a
consequence of inherited diseases, such as hereditary
hemochromatosis, the most frequent genetic disorder in
the Caucasian population (carrier frequency of 1:8).
Similarly, patients with “iron-loading anemias” (e.g. with
a-thalassemia) present with elevated iron levels. Iron accu-
mulates dramatically in patients that require regular blood
transfusions. Furthermore, mild to moderate elevation of
tissue iron levels exacerbates the pathologies of common
acquired diseases, such as chronic liver disease, diabetes,
atherosclerosis, and cardiovascular disease. Iron misdistrib-
ution in the brain hallmarks the main neurodegenerative
disorders (i.e. Alzheimer and Parkinson diseases).
European research contributions 
Research into mechanisms that cause iron overload was
fueled by the discovery of mutations in the HFE gene as the
cause of hereditary hemochromatosis. Subsequently,
European researchers identified more aggressive subtypes
of hereditary hemochromatosis,182 as well as novel disease
entities characterized by iron accumulation (e.g. ferroportin
disease).183 The discovery by European researchers of the
iron-regulatory hormone hepcidin and its target receptor
ferroportin improved our understanding of how iron over-
load develops in hereditary hemochromatosis and provided
new insights into mechanisms that underlie iron accumula-
tion in blood diseases caused by insufficient or malfunction-
ing red blood cells (RBCs) [e.g. myelodysplastic disease syn-
dromes (MDS) and thalassemias].160 These anemic patients
frequently require blood transfusions, which exacerbates
iron overload. (One unit of RBCs contains 200-250 mg
iron.) Iron overload causes oxidative stress, and up till now,
use of phlebotomy and chelation therapies has been com-
mon to prevent iron toxicity. European research groups
established disease models for iron overload disorders to
identify mechanisms that control iron balance.184 These
important research findings not only gave an insight into
the classical iron-related disorders, but also significantly
improved our knowledge of how iron accumulates and
contributes to the pathologies of acquired diseases, such as
chronic liver disease, heart failure, and diabetes mellitus.
Importantly, basic research into iron metabolism disorders
was successfully translated into novel therapeutic opportu-
nities. Together with European biotech companies, novel
therapies were defined that are currently being tested in
clinical trials.185 Educational activities train young doctors
and researchers in their understanding of iron-related disor-
ders throughout Europe. Patients have organized them-
selves in the European Federation of Associations of
Patients with Haemochromatosis.
Proposed research for the Roadmap
The past decades provided us with important insights
into cellular and systemic iron metabolism that have
improved understanding of the pathophysiology of iron
overload disorders. Despite that, fundamental questions
remain unanswered.
1. An improved understanding of the etiology and path-
ogenic mechanisms of iron overload in inherited dis-
orders. We need to identify:
a) the signals sent from the erythroid compartment to
regulate systemic iron homeostasis and how these
signals are controlled and sensed by different organs;
b) how iron traffics inside cells;
c) how iron causes toxicity;
d) how different organs handle iron or heme that is
released during hemolysis.
2. An improved understanding of clinical implications of
iron overload in inherited disorders. We need to
understand how iron influences the early stages of
erythropoiesis and how iron overload damages ery-
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thropoiesis in conditions such as b-thalassemia, as
well as how the kidneys handle iron, which under-
goes glomerular filtration and reabsorption with
important physiological and potentially therapeutic
implications. Similarly, the nervous system poses an
enormous challenge. Despite the fact that patients
with high plasma and systemic iron levels are protect-
ed from iron accumulation in the brain, local alter-
ations of iron metabolism contribute to neurodegen-
eration. We need to devise strategies to prevent or
ameliorate its course. We still do not fully understand
the role that iron overload plays in inflamed or infect-
ed tissues and how this affects the immune system.
The link between mild to moderate iron overload and
type 2 diabetes or other highly prevalent insulin-
resistant conditions (e.g. the metabolic syndrome) is
increasingly recognized, but the molecular mecha-
nisms underlying these associations are largely
unknown.
3. An unanswered question remains as to how iron
metabolism differs in the fetal, neonatal, and infant
stages and how this compares with adulthood.
Furthermore, there are uncertainties regarding when
chelation therapy should be started and what the safe
levels of body iron burden are. An improved under-
standing of basic cell biology principles of iron
metabolism will allow further exploration of disease
states and will help devise new therapeutic concepts.
4. Novel diagnostic means to identify patients with iron
overload at risk of clinical progression and develop-
ment of comorbidities. We need to identify modifier
genes that affect the pathological course of iron over-
load disorders and that can be applied as diagnostic
parameters. Epidemiological and prospective cohort
studies are required to substantiate our knowledge of
how perturbations of iron homeostasis are linked to
disease progression and development of comorbid
complications in other acquired disorders, such as
cancer and cardiovascular, liver, kidney, or bone dis-
ease.
5. Clinical trials to evaluate the potential of targeted thera-
pies in reducing systemic iron levels in widespread dis-
eases, including atherosclerosis, diabetes, chronic liver
disease, and neurodegenerative disorders. Integrated
pre-clinical and clinical approaches are needed to contin-
ue the translation of novel targeted approaches that
were designed based on the impressive progress in
unraveling the regulation of hepcidin and ferroportin
expression, in addition to commonly applied therapies,
such as phlebotomy and iron chelation.
Anticipated impact of the research
Continued research into iron metabolism will discover
novel iron-related genes and regulatory mechanisms that
maintain iron homeostasis. This will improve our under-
standing of the etiology, pathogenic mechanisms, and clin-
ical implications of iron overload in inherited disorders, as
well as in those diseases where iron accumulates second-
ary to primary disease pathology (e.g. iron-loading ane-
mias, dysmetabolic iron overload syndrome, atherosclero-
sis, and chronic liver disease). This is expected to have a
major impact on the treatment of hereditary and acquired
iron overload disorders. The identification of “iron signa-
tures” in iron overload diseases will be an important diag-
nostic means of identifying patients with iron overload at
risk of clinical progression and development of comorbidi-
ties or to differentiate true iron overload from other disor-
ders characterized by high hyperferritinemia. Clinical tri-
als will evaluate the potential of targeted therapies in
reducing systemic iron levels in widespread diseases,
including atherosclerosis, diabetes, chronic liver disease,
and neurodegenerative disorders.
4.8. Anemia in the elderly
Reinhard Stauder (Medizinische Universität Innsbruck,
Innsbruck, Austria), Swee Lay Thein (King’s College
London, London, United Kingdom), Joan-Lluis Vives
Corrons (Universitat de Barcelona, Barcelona, Spain),
Giovanna Graziadei (Università degli Studi di Milano,
Milan, Italy), Gerwin Huls (Radboud Universitair Medisch
Centrum, Nijmegen, the Netherlands).
Introduction
Anemia is associated with an increased risk of adverse
outcome in older adults, including hospitalization,
impaired cognitive capacities, diminished quality of life
(QoL), frailty, and higher mortality. Analyses have
revealed a prevalence of anemia (WHO definition: Hb
<130 g/L for men; <120 g/L for women) of 12% in adults
over 65 years of age living in the community, 40% in those
admitted to the hospital, and 47% in nursing home resi-
dents (Table 2). Based on an overall proportion of 17% in
the general population,186,187 approximately 15 million eld-
erly citizens (over 65 years of age) in the European Union
are affected by anemia. Hence, anemia is a frequent con-
dition in the elderly population, exceeding 40% in those
aged 85 years or over.
Anemia has been associated with increased morbidity,
mortality, and hospital stays. Despite this clinical impor-
tance, anemia in the elderly is often neglected, and evi-
dence-based guidelines for diagnostic workups and indi-
vidualized therapeutic algorithms are lacking.
Causes of anemia in the elderly include nutritional defi-
ciency in approximately one-third (primarily iron deficien-
cy), while one-third have chronic inflammation (ACD) or
chronic kidney disease (CKD). While ACD is caused by
cytokine- and hepcidin-mediated processes,188 the underly-
ing mechanisms of anemia in approximately 30% of cases
remain unexplained.189 Moreover, decreased testosterone
levels have been considered as an underlying mechanism.
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Table 2. Late-life anemia is frequent in the elderly. Numbers based on
a cohort of 19,758 university hospital inpatients and outpatients.203
Age group (years)                               Anemia prevalence*
                                                       Men                            Women
64-69                                                          18%                                      13%
70-74                                                          21%                                      16%
75-79                                                          25%                                      20%
80-84                                                          34%                                      25%
85-89                                                          40%                                      29%
>89                                                            47%                                      33%
All                                                             23.4%                                   19.3%
*As defined by WHO (Hb <12 g/dL in women and <13 g/dL in men).
European research contributions 
The rational therapy of anemia is hampered by the diffi-
culty of dissecting the underlying pathological mechanisms
and the lack of evidence-based guidelines. Whereas a $16
million grant supports studies of unexplained anemia in the
United States (Partnership for Anemia: Clinical and
Translational Trials in the Elderly; www.agingportfolio.org/pro-
jects/project/5U01AG034661-02), very few European pro-
grams have addressed issues of anemia in the elderly.
A network for the recognition, epidemiological surveil-
lance, and medical education of rare anemias was estab-
lished in Europe (ENERCA). The aim is to offer an
improved public health service in rare anemias.
Based on clinical studies, several drugs have so far
achieved approval by the European Medicines Agency,
including different iron formulations and erythropoiesis-
stimulating agents. Studies on promising drugs, including
drugs directed at hepcidin,190 TGF-b superfamily ligand
traps, and novel oral iron supplementations, are ongoing.
Proposed research for the Roadmap
We propose to study the epidemiology of anemia in the
elderly and to raise awareness among health care providers.
The most essential objective is to develop and perform evi-
dence-based clinical treatment strategies and health care
interventions, which are based on a refined pathological
algorithm. The innovative combination of new anti-inflam-
matory drugs and novel iron formulations will improve
health care interventions in end-of-life anemia.
Objectives of the research agenda include the following.
1. Study Hb concentrations as well as the epidemiology
and prognostic impact of anemia in distinct cohorts of
elderly patients in select geographical regions through-
out Europe. Structured evaluation of comorbidities and
functional capacities will allow the estimation of the
prevalence and relative contribution of different chron-
ic diseases and frailty on Hb concentrations.
2. Raise awareness of the clinical relevance of a structured
workup, diagnosis, and treatment. A European compe-
tence network on “anemia in the elderly” encompassing
relevant stakeholders, such as physicians, researchers,
health care providers, regulatory institutions, and patient
groups, for the dissemination and utilization of up-to-
date, evidence-based recommendations will be estab-
lished. The network will actively facilitate the diffusion
of evidence-based guidelines among patient organiza-
tions and European anemia study groups.
3. Develop a new pathological classification of anemia,
particularly addressing unexplained anemia, in different
patient groups. This will be based on parameters such as
hepcidin, erythroferrone, cytokine, and hormone levels
in combination with established hematologic parame-
ters such as serum ferritin, reticulocyte count, Hb con-
centration, and soluble transferrin receptors.
4. Infer individualized algorithms based on these refined
laboratory analyses that will assist differential diagno-
sis and rational treatment for the principal therapeutic
interventions in anemia: 
a) supplementation of oral or IV iron; 
b) erythropoiesis-stimulating agents; 
c) antihepcidin strategies; and 
d) new drugs, such as TGF-b superfamily ligand traps.
5. Exclude congenital disorders of erythropoiesis, includ-
ing thalassemias and congenital dyserythropoietic ane-
mias (CDAs), because inherited anemias might repre-
sent an underlying cause of anemia.
6. Evaluate the effect of these tailored health care inter-
ventions on Hb levels, survival, and other health-relat-
ed outcomes. Patient-reported outcomes, including
scores to assess fatigue and quality of life (QoL) and
objective functional parameters (e.g. gait speed), will
be included and analyzed.
Anticipated impact of the research
It is anticipated that a refined definition of the causes and
pathological classification of anemias in the elderly will
widen our understanding and achieve the following goals.
1. Develop and distribute new health care interventions
in anemia:
a) develop and validate simple and evidence-based
guidelines for diagnosis and treatment of anemia in
the elderly, with particular consideration of gender
aspects;
b) improve therapeutic outcome by clinical studies;
c) reduce morbidity and mortality related to anemia in a
group of vulnerable patients through tailored treatment.
2. Develop an algorithm for intervention in cases that
are likely to succeed.
a) exclude inherited anemias;
b) identify early patients in whom specific strategies
are ineffective or even harmful;
c) develop a predictive model to classify patient pop-
ulations with high likelihood of treatment response.
3. Assess and improve clinical outcome of anemia by
generation of new core outcome sets:
a) raise awareness of novel therapeutic options for
anemia;
b) generate clinical evidence even in non-fit elderly
patients displaying comorbidities;
c) comprehensively address patients’ needs and sup-
port treatment algorithms by using parameters that
are relevant to the patient and society, including
patient-reported outcomes, QoL, and functional
capacities;
d) generate new and innovative core outcome sets and
add them to classical parameters;
e) form the basis for cost-effective use of diagnostic
and health care resources for diagnosis and treatment.
4. European competitiveness in the field includes the
following:
a) generate data to form the basis for a rational design
of clinical trials to apply for European Medicines
Agency registration and marketing of novel therapeu-
tic substances;
b) generate a European competence network on “ane-
mia in the elderly.”
4.9. Sickle cell disease
Lucia De Franceschi (Università degli Studi di Verona,
Verona, Italy), Jacques Elion (Université Paris Diderot,
Paris, France), Frederic Galacteros (Hôpitaux
Universitaires Henri Mondor, Créteil, France), Cornelis
Harteveld (Leids Universitair Medisch Centrum, Leiden,
the Netherlands), David Rees (King’s College Hospital,
London, United Kingdom).
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Introduction
Sickle cell disease (SCD) is a rare hereditary red cell dis-
order caused by a point mutation in the b-globin gene that
results in the synthesis of pathological hemoglobin S
(HbS). The term SCD is used to indicate different geno-
types that cause the characteristic clinical syndromes (SS,
SC, bS).
SCD is a chronic and disabling disorder, that is still
associated with a high mortality. In the past two
decades, due to immigration fluxes from areas endemic
for SCD, SCD has spread throughout the European
Union (EU). The prevalence of SCD newborns and SCD
carriers in the EU is approximately 1-5 in 10,000 and one
in 150, respectively. Epidemiological predictions suggest
an increasing global burden of SCD between 2010 and
2050, making SCD an emerging public health problem
with limited therapeutic options. In fact, the years lived
with disability for hemoglobinopathies and SCD is esti-
mated to be 10,197, which is a dramatic observation,
because the years lived with disability for cardiovascular
disorders is 21,985. In the past two decades, the survival
of children with SCD has significantly improved due to
the introduction of hydroxycarbamide therapy and the
comprehensive care provided through pediatric age to
adulthood. However, the shape of survival curves for
SCD has not been affected by these therapeutic
approaches and has been shifted to the second and third
decade of life, showing a mortality rate that remains high
for young adult SCD patients.191-195
European research contributions 
Historically, SCD was first described by James Herrick
in 1910. The identification of the molecular defect and the
characterization of the peculiar biochemical properties of
pathological HbS that polymerize when deoxygenated
have definitely opened a new era of research in the SCD
field. Studies on red cell membrane physiology in SCD
have allowed the identification of the key membrane ion
systems involved in the generation of dense dehydrated
red cells, which play an important role in the pathogenesis
of acute and chronic clinical manifestation of SCD.
Increasing fetal Hb levels was explored as a therapeutic
strategy to delay HbS polymerization. This resulted in the
introduction of hydroxycarbamide treatment for SCD
patients with improvement of patients’ survival and ame-
liorations of clinical outcome, such as pain crisis rate and
chronic complications with some impact also on their
quality of life (QoL). European research contributions
have included: 1) the long-term evaluation of hydroxycar-
bamide in treatment of pediatric and adult patients with
SCD; 2) the development of comprehensive sickle cell cen-
ters for multidisciplinary care of SCD patients; and 3) the
development of hematopoietic stem cell transplantation
(HSCT) programs for pediatric patients with severe forms
of SCD. In addition, EU research has contributed to the
development of the first transgenic mouse model for SCD,
which has improved knowledge of the disease, starting
from identification of new mechanisms of disease to test-
ing new therapeutic targets in SCD. Furthermore, the
availability of animal models for SCD has allowed the
European research community to open new high-risk and
high-innovative therapeutic approaches to SCD through
the development of different strategies for gene therapy in
the disease. This has recently been moved from bench-
side to bedside in an ongoing trial in patients with various
hemoglobinopathies and also SCD. The European scien-
tific community has also contributed to the definition of
the biocomplexity of SCD, which involved chronic
inflammation, vasculopathy, oxidative stress (i.e. free
heme), and cytokine storm, as well as to the clinical defi-
nition and characterization of severe chronic organ com-
plications related to SCD, such as pulmonary hyperten-
sion and cerebrovascular disease. In conclusion, European
research has made an important contribution to state-of-
the-art advances in the field of SCD and to a widening of
knowledge of the disease within the international scientif-
ic community.
Proposed research for the Roadmap
Although significant progress has been made in our
knowledge of SCD, treatment strategies remain unsatis-
factory for both acute and chronic clinical complications.
Thus, future research horizons in the disease should face
up to that SCD biocomplexity which makes it a multior-
gan disease.
The recent development of high-throughput techniques
for both molecular and protein analysis, integrated with a
rigorous phenotype characterization of the large EU SCD
cohort of patients, will allow us to identify new biomark-
ers of disease severity to generate subgroups of patients to
be driven to personalized medicine (secondary outcomes:
SCD EU registry, biobanking).
These will also allow us to select new targets for future
development of new therapeutic options. The presence of
both in vitro and in vivo animal models for SCD within the
EU research teams will ensure the exploitation of new
therapeutic approaches will lead to clinical trials in the
near future. These might involve SCD vasculopathy,
chronic hemolysis, free heme, or novel fetal hemoglobin
inducers.
In addition, the novel imaging techniques developed for
functional studies will help the scientific community learn
more about the disease and the management of SCD with
the generation of new diagnostic approaches to organ
damage to facilitate early treatment. This will have an
impact on the natural history of SCD and improve the sur-
vival of adult patients.
Anticipated impact of the research
Future European research programs on SCD will widen
our knowledge of SCD and will deliver: 1) new therapeu-
tic molecules for clinical management of SCD; 2) new pro-
filing of disease severity for personalized medicine; 3)
optimization of SCD patient care; and 4) clinical trials
addressing basic aspects of clinical care.
These will positively affect: 1) patient health outcome
and QoL; 2) national and European health systems by
reducing hospitalization lengths and care costs; and 3)
national and European welfare spending due to the reduc-
tion in disabilities of SCD patients and in the level of sick
leave from work.
In addition, the novel identified therapeutic molecules
would have an impact on the management of SCD in
other high-income countries, such as the United States, as
well as in low- and middle-income countries, such as
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Africa and India, where SCD is a significant health prob-
lem. These will also stimulate public-private partnerships
for orphan drug development largely based on innovation,
generating new opportunities in the context of interna-
tional competition.
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Knowledge about platelet disorders has greatly expand-
ed in recent years, and this topic has become one of the
most complex in the field of hematology. Many new dis-
eases have been identified, and a better understanding of
old diseases revealed their complexity in terms of etiolo-
gy, pathogenesis, and clinical features.196-200 Moreover, we
are now recognizing that the peculiar genetic background
of each patient may modulate the clinical expression of
both acquired and inherited platelet disorders,201 while
even slight differences in the mutations affecting one
gene may be the origin of quite different clinical pictures
in subjects with inherited thrombocytopenias (ITs).202
Finally, the therapeutic armamentarium has been
enriched with new, targeted drugs interfering specifically
with the pathogenic mechanisms of diseases and promis-
ing to modify their natural history.199,203-205 Thus, platelet
disorders have truly entered the era of personalized med-
icine, and European researchers have played a key role in
achieving this goal.
Despite the remarkable advances made, the increase in
knowledge has not gone forward at the same rate for the
different diseases. For instance, the number of well-
defined inherited forms of thrombocytopenia has
increased from 3 to more than 20 in the past 15 years,196
while that of inherited disorders of platelet function have
changed little, and the majority of affected subjects still
remain without a definite diagnosis because the nature of
their illness has not yet been identified.206 Also, some
forms of acquired platelet disorders (APDs), in spite of
their high prevalence, remain poorly defined; this is the
case of, for example, platelet dysfunction in chronic liver
and kidney diseases, for which we do not have a clear
understanding of clinical relevance, standardized diagnos-
tic methods, or validated therapeutic approaches. Drug-
induced platelet dysfunction is even more important con-
sidering the impact it has on general health, especially
with the increasing number of subjects receiving
antiplatelet drugs for the prevention of thrombosis. In
addition, for patients receiving drugs that interfere with
platelet function, we have no evidence-based guidelines
to help them deal with bleeding or hemostatic challenges.
Another undefined issue of great clinical relevance is the
differentiation between primary and secondary immune
thrombocytopenia (ITP) and other forms of acquired
thrombocytopenia, especially those associated with
infection. Finally, new curative approaches for ITP based
on restoring the immune dysregulation are required.
Major outcomes of new therapeutic studies should be
rooted in bleeding assessment and quality of life (QoL)
more than on platelet count.207 Given the great expertise
being applied to platelet studies, stimulating European
research on these neglected topics is expected to lead
quickly to a better management of these conditions, to
the benefit of patients and the health care system.
Another major problem in the field of platelet disorders
is the gap between what is done in everyday clinical prac-
tice and what should be done. Many diseases are rare or
exceedingly rare, and awareness of these forms is not
widespread in the medical community. As a consequence,
affected patients often receive misdiagnoses and inappro-
priate treatments.208 Moreover, when the right diagnosis is
suspected, its confirmation requires tests that are avail-
able in only a few specialized laboratories.209
The resulting diagnostic delay due to logistic difficulties
can even put the lives of patients at risk because, as in
thrombotic microangiopathies, a very early therapeutic
intervention maximizes the chances of survival.210,211 Thus,
creating a network of centers for the diagnosis of specific
platelet disorders is expected to have a strong impact on
the quality of care for affected subjects. Moreover, central-
izing diagnosis may facilitate the creation of registries and
conduct of collaborative clinical trials, which are essential
for widening our knowledge and improving treatment of
rare diseases (Figure 5).
5.1. Congenital platelet disorders: number and function
Alessandro Pecci (Università degli Studi di Pavia, Pavia,
Italy), Remi Favier (Hôpital d'Enfants ‘A. Trousseau’, Paris,
France), Andrew Mumford (University of Bristol, Bristol,
United Kingdom), Hana Raslova (Université Paris Sud,
Villejuif, France), Barbara Zieger (Universitätsklinikum
Freiburg, Freiburg, Germany).
Introduction
Knowledge in the field of inherited thrombocytopenias
(ITs) and inherited platelet function disorders (IPFDs) has
greatly improved in the past 15 years. More than 20 new
genes responsible for ITs and IPFDs have been identified,
leading to the definition of novel nosographic entities and
better characterization of some disease phenotypes. This
has also provided novel information that widens our
understanding of human platelet production and function.
Despite impressive advances, many gaps still have to be
filled. In a considerable proportion of patients, a definite
diagnosis still cannot be made because their ITs and IPFDs
are still unknown. For example, nearly 50% of patients
with ITs are affected by disorders that have not yet been
identified. Moreover, the clinical features of some disor-
ders that have had their genetic defects identified remain
poorly characterized, as the information currently avail-
able comes from studies conducted in select single families
or small series, thus hampering a general representation of
clinical features of patients and preventing a data-driven
clinical management. Differential diagnosis of ITs and
IPFDs is currently based on pre-genetic laboratory assays
that are usually complex and only available in a few cen-
ters; in addition, the diagnostic significance of laboratory
findings is often uncertain. Therapy of ITs and IPFDs also
needs to be improved. For most patients, no evidence-
based protocols are available for treatment of bleeding or
management of the bleeding risk associated with hemo-
static challenges. Hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for a few, very severe
forms, and alternative treatments are needed for patients
with these forms for whom HSCT is not possible. Finally,
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validated alternative options to platelet transfusions for
the treatment of major bleedings or prophylaxis of hemo-
static challenges are needed.
European research contributions 
Researchers from Europe identified 15 novel genes
responsible for ITs and seven genes causing IPFDs.
Through the construction of patient databases,
European groups have provided a thorough definition of
the mutation spectrum, clinical features, and
genotype/phenotype correlations of some disorders,
including MYH9-related disease, Bernard-Soulier syn-
drome, Glanzmann thrombasthenia, Wiskott-Aldrich syn-
drome/X-linked thrombocytopenia, and thrombocytope-
nia 2. European researchers have provided effective tools
to standardize the diagnosis of both ITs and IPFDs;
European networks have developed methodologies that
combine phenotyping of IPFDs and application of next
generation sequencing (NGS) to unravel the genetic com-
plexity of these diseases.196,212,213 By using in vitro models of
megakaryopoiesis or animal models, European investiga-
tors identified the pathogenesis of several ITs and IPFDs,
including congenital amegakaryocytic thrombocytopenia,
disorders deriving from FLI1 or RUNX1 haploinsufficien-
cy, and thrombocytopenia 2.214,215 Groups from Europe
contributed to the improvement of HSCT in Wiskott-
Aldrich syndrome or congenital amegakaryocytic throm-
bocytopenia, performed the first clinical trials of gene ther-
apy for Wiskott-Aldrich syndrome, and successfully tested
a drug for increasing platelet production in one form of IT.
Proposed research for the Roadmap
Identify new genes responsible for ITs and IPFDs: the first step
toward this goal is the recruitment of large series of patients
with ITs and IPFDs of unknown genetic origin through
international co-operative efforts to collect biological sam-
ples and clinical data of patients. Application of NGS
approaches (whole-exome or -genome or RNA sequencing)
appears the most powerful tool for identifying candidate
genes. The demonstration of pathogenicity of genetic vari-
ations requires functional studies that preferably use in vitro
models of human platelet biogenesis or, alternatively, ani-
mal models (although these do not always reproduce the
phenotypes observed in IT/IPFD patients).
Establish national and international registries of patients
with known genetic defects: registries should be aimed at
two main objectives.
1. To define the clinical consequences of the mutations
responsible for ITs or IPFDs by the systematic investi-
gation of large series of consecutive patients. This con-
cerns not only the  disorders that will be defined by the
recognition of new causative genes, but also some ITs
and IPFDs with known molecular defects but a yet
poorly characterized clinical picture.
2. To define evidence-based protocols for the manage-
ment of bleeding risk. 
Optimize in vitro models of human platelet biogenesis
(megakaryopoiesis and platelet formation) and platelet
function for pathogenetic investigations and pre-clinical
studies of novel therapies. We have identified three prior-
ities.
1. To optimize in vitro models of platelet biogenesis obtained
by peripheral blood of IT and IPFD patients. Patient-
derived models are those that more closely reproduce
human diseases.  Because marrow sampling is often not
feasible for ethical reasons, improved in vitro models
obtained by circulating progenitors or using induced
pluripotent stem cells (iPSCs) derived  from peripheral
blood should be prioritized. The establishment of a
patient-derived European  bank of iPSCs would provide
an unlimited source of cells for pathogenetic studies.
2. To develop models of platelet biogenesis that reproduce
as close as possible the bone marrow microenviron-
ments: the endosteal niche that regulates megakary-
ocyte differentiation/maturation and the vascular niche
where platelets are released into flowing blood.
3. To improve models that reproduce the conditions of
human circulation to investigate platelet 
function defects.
Validate single-step sequencing approaches for diagnosis of
ITs and IPFDs: the single-step sequencing of all known
IT/IPFD genes (or whole-genome sequencing) as the first
diagnostic approach for patients with ITs or IPFDs may
prove more effective and cheaper than the complex and
time-consuming sequence of traditional assays currently
in use.
Identify and/or develop novel therapeutic options: these
include the following.
1. Defining the role of THPO mimetics and other drugs
that stimulate megakaryopoiesis with 
different mechanism in the treatment of ITs.
2. Promoting studies of gene therapy for the most severe
forms of IT and IPFD.
Anticipated impact of the research
Identifying new genes responsible for ITs and IPFDs
will increase the number of patients for whom it is pos-
sible to make a molecular diagnosis and will lead to the
identification of new key players in platelet production
and function. Validating single-step sequencing of all the
causative genes as the first-line diagnostic approach for
IT and IPFD patients will make it easier and more effec-
tive to reach a molecular diagnosis. The definition of the
clinical phenotypes deriving from the different mutations
is the basis for providing patients with a personalized,
genotype-driven prognostic assessment, and, therefore,
to set the appropriate follow up, choose the best treat-
ments, and offer correct genetic counseling. Optimizing
in vitro models of platelet biogenesis and function will
provide powerful tools to validate the pathogenicity of
the genetic variations identified by NGS, identify novel
therapeutic approaches, and test them in pre-clinical
studies.
5.2. Acquired non-immune thrombocytopenia and
acquired disorders of platelet function
Paolo Gresele (Università degli Studi di Perugia, Perugia,
Italy), Christel van Geet (KU Leuven, Leuven, Belgium),
Michael Makris (Royal Hallamshire Hospital, Sheffield,
United Kingdom), A Koneti Rao (Temple University
School of Medicine, Philadelphia, United States of
America), Rüdiger E. Scharf (Heinrich-Heine-Universität
Düsseldorf, Düsseldorf, Germany).
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Introduction
The understanding of the regulation of platelet function
and number has increased enormously during the past
decade. However, most of the advancements come from
the study of inherited platelet disorders or immune throm-
bocytopenia (ITP). In spite of this, qualitative and quanti-
tative APDs, different from ITP, are very common but rel-
atively little-studied. Several systemic disorders of large
epidemiological impact, such as chronic kidney and liver
disease, are associated with APD and a bleeding diathesis.
Despite the large epidemiological burden, the clinical rele-
vance of APD is still unclear, and no consensus is available
on its assessment and treatment. Moreover, many drugs
and foods transiently modify platelet function and may
provoke, especially when taken before surgery, increased
bleeding. Finally, nonimmune thrombocytopenia (NITP) is
very frequent in acutely ill patients, especially in associa-
tion with infection, but not well understood due to its
multifactorial pathogenesis, difficult differentiation from
ITP, heterogeneity of involved pathogens, comorbidities,
and the potential confounder represented by antimicrobial
drugs.216 Differentiation from ITP and other forms of
acquired thrombocytopenia is a crucial issue because
treatment is completely different.
European research contributions 
European researchers have strongly contributed to char-
acterizing APD in chronic liver and kidney disease.217-219
European investigators clarified, in particular, the role of
altered platelet formation versus platelet destruction in
thrombocytopenia and of in vivo platelet activation,
platelet “exhaustion”, altered nitric oxide signaling, and
enhanced nitric oxide formation in platelet dysfunction.
Similarly, the role of uremic toxins and enhanced genera-
tion of nitric oxide in uremic platelet dysfunction have
been shown by European investigators.218 The bleeding
risk associated with drug-induced platelet dysfunction in
patients undergoing surgery and its management has been
the object of position statements from European experts.219
Finally, several studies have documented the strong and
independent negative prognostic value of thrombocytope-
nia in critically ill patients.220 Mechanisms causing
pathogen-induced thrombocytopenias, including
decreased platelet production by megakaryocyte invasion
and/or enhanced platelet consumption by direct interac-
tion with platelet receptors or by antiplatelet antibodies or
immune complexes, have been described by European
researchers.220 European researchers have made an impor-
tant contribution towards identifying the role of platelet
toll-like receptors (TLRs) in the response to infection.220
TLR expression enables activated platelets to bind and kill
bacteria during sepsis and stimulate neutrophils to extrude
their DNA-forming neutrophil extracellular traps that cap-
ture bacteria and perpetuate platelet activation, promoting
thromboinflammatory processes or disseminated intravas-
cular coagulation.220
Proposed research for the Roadmap
Clarification of the clinical relevance of APD in chronic liver
and kidney disease: uncertainty remains about the clinical
relevance of APD in the hemostatic abnormalities of these
chronic conditions. A large international, collaborative,
prospective study on the prognostic value of a clinical
bleeding risk score, previously employed in congenital
hemostatic disorders and ITP, may clarify the clinical rele-
vance of the mild mucocutaneous bleeding diathesis typi-
cal of liver or kidney failure patients. Moreover, studies
employing new and sensitive techniques for the assess-
ment of platelet/vessel wall interactions and correlating
the results with clinical bleeding may conclusively unravel
the significance of APD in chronic liver and kidney dis-
ease. In addition, a rational diagnostic algorithm for the
identification of clinically relevant APD needs to be gener-
ated. Finally, the best management of impaired platelet
function and number needs to be established by prospec-
tive, European collaborative studies. Another issue to be
developed is the role of platelets in liver regeneration and
fibrosis.
Drug-induced platelet dysfunction in patients undergoing sur-
gery: clinical relevance and treatment. The relevance of
drug-induced platelet dysfunction in patients undergoing
surgery and of its management may initially be evaluated
by a large European retrospective survey assessing the rela-
tionship between pre-surgical drug intake and surgical
bleeding. Previous experience from the EHA-SWG shows
that surveys, although based retrospectively on clinical
records, may provide clinically relevant information when
the database obtained is sufficiently large. The survey will
analyze different drug treatments and various types of sur-
gery, classified as major or minor and by organs/systems.
Another subject of future research is the possibility of guid-
ing surgery and minimizing prophylactic platelet transfu-
sions by pre-operative platelet function testing with point-
of-care devices; appropriately designed, collaborative
prospective studies will clarify this important issue.
Infection-associated thrombocytopenia (IATP): mechanisms,
diagnosis, and treatment. Identification of the mechanism(s)
leading to IATP (decreased platelet production, enhanced
platelet consumption, or a combination of both), its diag-
nosis, and treatment are the crucial objectives of future
research. The questions to be addressed are whether the
dynamics of IATPs differ from other NITPs; whether
platelet count profiles differ depending on the invading
pathogen; if the immature platelet fraction is a reliable
index of thrombopoietic activity; what the bleeding risk is
depending on the degree of thrombocytopenia (using the
ISTH score); if THPO receptor agonists are safe and may
minimize prophylactic platelet transfusions in IATP; what
the frequency is of antiplatelet antibodies/immune com-
plexes in IATPs; what immune mediators are expressed by
platelets during infection (cytokines, CD40, CD154, TLR,
and P-selectin); what the expression profile is of platelet-,
monocyte-, and endothelial cell–derived microparticles
and their receptors; and what the platelet-induced inflam-
matory responses are that can be protective or detrimental
to the host. To answer these questions, an IATP registry
and prospective multicenter studies complemented by
murine sepsis models will have to be established.
The differentiation between ITP and NITP, clinical and labo-
ratory diagnosis: the rapid differentiation between ITP and
acquired NITP is a crucial task of future research as the
clinical management of the two conditions is very differ-
ent. Better and more rapid tests for the confirmation of
ITP are urgently required. In the area of pregnancy, a col-
laborative network for thrombocytopenia should be
established to better document the natural history in
mothers and fetuses.
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Anticipated impact of the research
The clarification of the clinical meaning of APD in dis-
orders of large epidemiological impact will improve clini-
cal knowledge in the complex hemostatic impairment of
these diseases and provide a guide to their diagnosis and
management. Moreover, understanding of the impact of
drug-induced platelet dysfunction on surgical bleeding and
its possible prediction by laboratory testing may greatly
reduce surgical and cardiovascular morbidity and mortali-
ty. In addition, the proposed research will provide further
insights into the mechanisms leading to thrombocytope-
nias associated with infections and improve their manage-
ment. Finally, the differentiation between ITP and NITP
will allow more appropriate and rapid treatment.
5.3. Primary and secondary immune thrombocytopenia
and fetal neonatal alloimmune thrombocytopenia
Thomas Kühne (Universitäts-Kinderspital Beider Basel,
Basel, Switzerland), Bertrand Godeau (Hôpitaux
Universitaires Henri Mondor, Créteil, France), Axel
Matzdorff (Caritasclinic Saarbrücken, Saarbruecken,
Germany), Irene Roberts (University of Oxford, Oxford,
United Kingdom), John Semple (St. Michael's Hospital,
Toronto, Canada).
Introduction
Primary immune thrombocytopenia (ITP) is a bleeding
disorder of unknown etiology characterized by low
platelet count, immune-mediated platelet destruction, and
reduced platelet production. As with many other autoim-
mune disorders, it is thought that environmental and
genetic factors may incite the autoimmune response
against some platelet and megakaryocyte membrane gly-
coproteins. Immune dysregulation manifests with a com-
plex pathophysiological mechanism, including peculiar
features of antigen-presenting cells and B and T cells. ITP
occurs in all age groups, with half of patients older than 60
years of age and 20% older than 75. Data for estimation of
frequency of this disorder are primarily from Europe and
include an incidence of 1.9 to 6.4 per 100,000 children per
year and 3.3 per 100,000 adults per year. In children, a
minority of patients has severe bleeding and persistence of
symptomatic thrombocytopenia, which is not predictable
at an early stage of the disease. In adults, comorbidity and
co-medication affect the bleeding phenotype, and there is
an increasing number of patients (currently approx. 20%)
with secondary forms of ITP, which have still not been
well studied. Severe hemorrhages and fatal outcome
increase with age and may become a cause of death in
approximately 5%-10% of refractory cases. It has been
realized that primary ITP is not a clinical-pathological enti-
ty, but rather has a heterogeneous background. Secondary
ITP occurs in patients with malignancy, systemic autoim-
mune disease, chronic viral infection, primary immune
deficiency, or drugs.
Fetal and neonatal alloimmune thrombocytopenia
(FNAIT) due to fetomaternal alloimmunization to paternal
human platelet antigens (HPAs) is a rare disorder (inci-
dence one in 1000 live births), but causes severe thrombo-
cytopenia and a high bleeding risk in fetuses and neonates.
Intracranial hemorrhage occurs in approximately one per
10,000 fetuses and neonates. Screening of all pregnant
women for HPA alloimmunization has been suggested,
because the risk of complications is very high and effective
intervention is available. The rarity of the disorder, and
the fact that alloantibodies are not identified in many
cases, makes FNAIT difficult to study except through large
transnational collaborative groups.
European research contributions 
For both ITP and FNAIT, European researchers are
playing a key role in epidemiology and clinical research.
There has been a significant increase in knowledge of the
natural history of ITP based on registries. It has been rec-
ognized that research activity should be co-ordinated for
an effective use of resources. These international collab-
orative activities have resulted in the development of
practice guidelines; standardizing of definitions, termi-
nology, and outcome criteria; therapeutic outcome meas-
ures, such as assessing bleeding; and co-ordination of
research activities.221 New innovative therapies have
been successfully introduced and have questioned cur-
rent therapeutic strategies and stimulated expert discus-
sions.222,223
Despite the relative rarity of FNAIT, several important
advances have been made in the past ten years. Firstly,
new diagnostic methods, including fetal genotyping on
maternal blood samples and antibody detection using
aptamers or recombinant peptides, have been developed
and are gradually being introduced into clinical practice.
Secondly, improvements in the management of pregnant
women with a positive history of FNAIT have resulted
from systematic studies of the use of antenatal
immunomodulation with IVIG in place of invasive treat-
ment (in utero platelet transfusion).224,225 Finally, large
screening studies have shown the potential benefit of test-
ing in combination with planned delivery and prophylac-
tic perinatal platelet transfusion.
Proposed research for the Roadmap
The pathophysiological mechanisms of ITP and FNAIT
are still not well understood and need to be studied in
more detail in order to precisely diagnose the disease at an
early stage, identify predictors of severe bleeding, and find
novel treatments. In both ITP and FNAIT, the functional
effects of putative or known auto- and alloantibodies on
megakaryopoiesis and thrombopoiesis should be studied,
as having a better understanding of this may help guide
new treatment protocols with existing drugs as well as
develop novel therapies.
Pathophysiology of ITP: new findings of immune respons-
es in autoimmune disorders include the identification of
the role of antigen-presenting cells, T and B cells, and their
interactions. Regulatory T cells maintaining self-tolerance
are involved in modulating ITP pathogenesis. Study of the
increased platelet mass due to various therapies, and its
role in presenting platelet autoantigens to T cells and
potential effects on activating and suppressing regulatory
T cells, may elucidate novel pathomechanisms. Improving
the knowledge of the pathogenesis of ITP is an essential
starting point for identifying effective diagnostic tests for
this form of thrombocytopenia, a very important goal that
has not yet been reached.
Pathophysiology and management of FNAIT: the assess-
ment of platelet function in thrombocytopenic individuals
is challenging and may be important for predicting bleed-
ing risk. Thus, the development of functional assays for
EHA Roadmap for European Hematology Research
haematologica | 2016; 101(2) 163
diagnostic and management applications is needed. The
application of high-throughput genomics to the identifica-
tion of causal antibodies and/or antigens should be
investigated. Effective therapies for antenatal and post-
natal management should be developed and assessed.
Some promising avenues include the development of
modified HPA-1a recombinant antibodies and mono-
clonal antibodies to induce neonatal Fc receptor block-
ade. Studies in animal models and clinical trials are a pri-
ority for further development and testing of these strate-
gies.
Clinical proposals in children and adults with ITP: a diagnos-
tic algorithm in children and adults with chronic primary
ITP should be developed to adequately diagnose patients
at acceptable costs. Clinical research activity in all age
groups is required to assess treatment end point alterna-
tives or additional to the platelet count, such as bleeding
and health-related quality of life (QoL), and to develop
innovative treatments. Criteria for defining both the
bleeding and the thrombotic risk, which seems to be
increased in some cases, are required to develop personal-
ized treatment strategies in all age groups of patients, par-
ticularly in elderly patients.
New treatments of patients with ITP: the introduction of
innovative treatments, such as THPO receptor agonists,
may change current therapeutic strategies, reducing the
rate of splenectomies and reserving this intervention to
the few patients who do not achieve a good QoL with
medical treatments. The occasional observation that
THPO receptor agonists may induce durable responses in
a small subgroup of adult patients that have been
weaned from therapy may reflect a tolerance-like activi-
ty of these drugs and should be studied in animal models.
New curative approaches of ITP based on restoring the
immune dysregulation are required. Outcomes of new
therapeutic interventions should be rooted in bleeding
assessment and QoL more than on platelet count meas-
urements.
Anticipated impact of the research
The systematic study of immune response mechanisms
in health, autoimmune (ITP), and alloimmune (FNAIT)
disorders will provide more insights into a highly complex
system and may identify, not only new diagnostic tools
with the potential to define patient prognosis (mild and
moderate disease or more severe forms with life-threaten-
ing bleedings), but also better and more personalized ther-
apeutic approaches.
5.4. Heparin-induced thrombocytopenia and other
drug-dependent immune thrombocytopenias
Andreas Greinacher (Universitätsmedizin Greifswald,
Greifswald, Germany), Tamam Bakchoul (Universitäts -
medizin Greifswald, Greifswald, Germany), Tadeja Dovcˇ
Drnovšek  (Zavod RS za transfuzijsko medicino, Ljubljana,
Slovenia), Yves Gruel (Hôpital Trousseau, Tours, France),
Volker Kiefel (Universitätsmedizin Rostock, Rostock,
Germany).
Introduction
Drug-induced immune thrombocytopenias (DITPs)
result from drug-dependent antibodies destroying
platelets in the presence of drugs. DITPs are a major safe-
ty concern for patients and also for approval of new
drugs. DITPs are: 1) life-threatening and require rapid
recognition to allow appropriate measures to be taken to
avoid harm for the patient; 2) iatrogenic adverse effects,
with medico-legal implications; 3) relevant for drug
approval, with a major economic impact on the develop-
ment of new compounds. As drug-induced immune reac-
tions are infrequent, they are typically recognized at a late
stage of clinical development, or even only after approval.
When they then cause the drug to be withdrawn from the
market, several hundreds of millions of euros have often
already been spent; and 4) DITPs are models to under-
stand mechanisms causing the human immune system to
attack self-proteins.
DITPs are based on different mechanisms: 1) the drug
may alter the immune system that produces autoantibod-
ies against several tissues; or 2) the drug or its metabolite(s)
binds to platelets and thereby induces the formation of
antibodies that cause platelet destruction. The most fre-
quent DITP is heparin-induced thrombocytopenia (HIT).226
HIT is currently the underlying cause of more than 95% of
all confirmed DITPs. Whereas most DITPs increase the risk
for bleeding, HIT is prothrombotic and affects 0.5% of
intensive care patients and approximately 1%-3% of car-
diac surgery patients. By conservative assumption, the inci-
dence of HIT is 1:10,000 in-hospital patients, making DITP
a substantial health issue in Europe.
Diagnosis of DITPs is based on clinical criteria followed
by laboratory confirmation of drug-dependent antibod-
ies.
Clinical criteria for non-HIT DITPs: clinical criteria for
non-HIT DITPs are the exposure to the candidate drug
started approximately 1-2 weeks before the onset of
thrombocytopenia and recovery from thrombocytopenia
after discontinuing the candidate drug.
Clinical criteria for HIT (e.g. 4Ts score): clinical criteria for
HIT include: 1) decrease in platelet count by more than
50% from the highest platelet count; 2) decrease in
platelet count between days 5 and 10 after start of
heparin; 3) often associated with new thromboembolic
complications; and 4) no other obvious cause of thrombo-
cytopenia.
These clinical criteria for DITPs are not very specific,
and diagnosis requires confirmation of drug-dependent
antibodies by laboratory tests. The currently available
tests, however, have major limitations.
Laboratory tests for non-HIT DITPs: laboratory tests for
non-HIT DITPs show low sensitivity (but high specifici-
ty), are restricted to specialized laboratories, and are poor-
ly standardized.227 In contrast, the widely available HIT
laboratory tests228 are easy to perform, show high sensi-
tivity but a low predictive value, and have unsatisfactory
specificity, whereas the much more specific functional
assays are technically demanding and not widely avail-
able.
Open issues include the following.
1. There is a strong need for sensitive but also specific
screening tests.
2. Access to appropriate testing is needed throughout
Europe.
A. Engert et al.
164 haematologica | 2016; 101(2)
3. A better understanding of the pathogenesis to develop
preventive measures is needed.
4. Current treatments of HIT and its clinical sequelae are
a major cost burden for hospitals.
European research contributions 
Several European groups made major contributions to
the pathogenesis of DITPs229 and developed test systems
and treatment recommendations. Access of physicians
and patients to appropriate laboratory testing is well
developed in some European countries (e.g. France,
Germany, Austria, Switzerland, the Netherlands, and the
UK).
Proposed research for the Roadmap
A better understanding of the pathogenesis of DITPs: under-
standing the pathogenesis of DITPs is important not only
for drug development but also for gaining new insights
into pathological states of the immune system.
1. With regard to drug development, it is of major rele-
vance that several polyanionic drugs, including
DNA/RNA-based230 and polysaccharide-based drugs,
can induce a HIT-like syndrome. In vitro assays able to
predict potential immunogenicity of polyanionic com-
pounds based on their interaction pattern with PF4 are
needed for the development of polyanion-based
drugs, such as RNA aptamers and antisense drugs, and
the rapidly developing field of carbohydrate engineer-
ing, which allows screening of new drugs for their
immunogenicity during pre-clinical development.
2. The immune response to PF4/polyanion complexes is
so frequent that this immune reaction can be studied
systematically in humans. This may be instrumental
to better understanding which factors lead the
immune system to develop antibodies against endoge-
nous proteins other than PF4.
3. Recent data make it highly likely that PF4 is a protein
involved in pathogen host defense. It acts as a danger
signal for the immune system. Further understanding
of these mechanisms could optimize antibacterial and
antiviral treatments and even identify new strategies
for anti-tumor treatment.
4. For the other drug-dependent thrombocytopenias,
first evidence suggests that the immune reaction is
caused by binding of the drug to the hypervariable
region of a pre-formed IgG antibody, which thereby
gains high affinity to an endogenous protein. A better
understanding of this mechanism may become very
important for understanding other autoimmune disor-
ders.
Improvement in diagnostic methods of DITPs: widely appli-
cable assays for drug-dependent antibodies are needed.
Especially for HIT, an easy-to-apply assay with a high
positive predictive value is one of the main needs in most
laboratories. Establishing networks in Europe providing
rapid access to diagnostic assays for DITPs with locally
available screening tests and a rapid turnaround time, fol-
lowed by confirmatory tests with high specificity, will be
a solution for a currently unmet need.
Anticipated impact of the research
Adverse immune reactions are the biggest threat for the
development of new biotherapeutic drugs. Understanding
the underlying mechanisms will not only improve patient
safety but will also strengthen the European biopharma-
ceutical industry. All DITPs are caused by antibodies react-
ing with endogenous (self) cells. Identifying the underlying
mechanisms at the molecular level will help to understand
mechanisms of autoimmunity.
5.5. Thrombotic thrombocytopenic purpura and other
thrombotic microangiopathies
Marie Scully (University College London Hospitals,
London, United Kingdom), Paul Coppo (Hôpital Saint-
Antoine, Paris, France), Johanna Kremer Hovinga
(Universität Bern, Bern, Switzerland).
Introduction
Thrombotic thrombocytopenic purpura (TTP) is a form
of thrombotic microangiopathy (TMA) characterized by
microangiopathic hemolytic anemia (HA), thrombocy-
topenia, and organ failure of variable severity generated by
microvascular aggregation of platelets causing ischemia in
the brain, heart, kidneys, and other organs. TTP is distinct
from other TMAs such as the hemolytic uremic syndrome
(HUS), in which renal involvement due to fibrin-rich
thrombi is the prominent feature, or the HELLP syndrome
in pregnant women. TMAs are very rare: the incidence of
TTP is between 6 and 10 per million of the population, and
for atypical HUS (aHUS), approximately 0.5 per million of
the population.
Thrombotic thrombocytopenic purpura is usually idio-
pathic, although it can also occur in association with HIV
infection, connective tissue disease, pregnancy, or cancer.
TTP is most frequently an acquired disorder, but rarely it
derives from inherited defects in ADAMTS13, which may
manifest itself not only in childhood but also in adult life,
sometimes in association with pregnancy.
Early recognition and treatment of TMAs is essential,
because they are most often fatal when left untreated.
Moreover, an early differentiation among the different
TMAs is crucial given the availability of targeted therapies
for each form.
European research contributions 
In the past 15 years, advances have delineated the molec-
ular mechanisms of most of the TMA syndromes, including
TTP, aHUS, and the HELLP syndrome, providing evidence
that they are caused by distinct molecular defects.231 In par-
ticular, complement dysfunction and immune-mediated
ADAMTS13 deficiency are responsible for aHUS and TTP,
respectively. The novel concepts and disease mechanisms
identified in the laboratory were rapidly and successfully
transferred into the clinic for the benefit of patients, and
recent studies reporting on the use of monoclonal antibodies
in the management of TTP and HUS provided convincing
examples of translational medicine. Indeed, the B-cell deplet-
ing monoclonal antibody rituximab successfully treated
refractory or relapsing acquired TTP.232 The results of two
international studies involving multiple European teams
clearly indicated that the complement blocker eculizumab
represents a breakthrough in the management of aHUS by
preventing the evolution to end-stage renal disease and
allowing dialyzed patients to have a successful kidney trans-
plant.233 Therefore, the rapid distinction between TTP and
aHUS at the time of diagnosis is now mandatory.
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From the research point of view, TTP represents a rel-
evant model to better understand the interrelations
between microbes, other environmental influences, the
immune system, and the endothelium within a still
uncharted specific genetic background. In this regard,
three European groups reported independently that
HLAs DRB1*11 and DQB1*03 were both susceptibility
alleles for acquired TTP and confirmed the protective
role of DRB1*04.234 Future large-scale studies should lead
to the identification of additional genetic risk factors
associated with acquired idiopathic TTP and in other
forms of TMA.
The ability to increase our knowledge and experience
in the field of TMAs was challenged in the past by the
low incidence of these diseases and their clinical hetero-
geneity. Several national groups have recently set up large
registries that include hundreds of patients with various
forms of TTP, however, and these reports have shed light
on the epidemiology, clinical presentation, prognosis, and
long-term outcome of the disease.235 This provides evi-
dence that collaborations at the national and international
level remain key to the continued advancement of the
knowledge and treatment of rare diseases. Collaborative
works have progressively led to the proposal of consensu-
al treatment modalities and the definitions of treatment
responses based on large series of patients. Though arbi-
trary and based only on clinical experience, these defini-
tions are progressively and advantageously shared by dif-
ferent groups and may foster a common language that can
allow fruitful meta-analyses in the future.
Proposed research for the Roadmap
1. Raise awareness of TMAs through multidisciplinary
educational programs for general medicine physicians,
emergency department physicians, and all other spe-
cialists possibly involved in the management of TTP.
Create a network of laboratories to facilitate patients'
access to specific tests (ADAMTS13 measurement and
genetics and complement genetics) to prove the
nature of their diseases and personalize treatment.
2. Identify tools for quickly distinguishing TTP from
HUS and other TMAs in order to use early targeted
therapies for each form of TMA.
3. Develop an international registry for TTP to identify: 
a) the genetic risk factors that, interacting with envi-
ronmental factors, are responsible for the onset of
TTP; 
b) relevant early prognostic factors to adapt treatment
to the severity of the disease; 
c) parameters that identify patients at risk of relapse
(e.g. decreasing ADAMTS13 levels in remission).
4. Organize international clinical trials to: 
a) identify the efficacy of early introduction of target-
ed therapies (e.g. B-cell depleting therapies for TTP
and complement blockers for HUS); 
b) test the effect of innovative, promising compounds
(e.g. recombinant ADAMTS13 and blockers of the
von Willebrand factor-glycoprotein Ib/IX pathway); 
c) verify the efficacy of B-cell depleting therapies in
the prevention of TTP relapses.
Anticipated impact of the research
The improvement of knowledge of TTP and other
TMAs at a multidisciplinary level will increase their diag-
nosis in emergency situations, and undoubtedly improve
patients’ prognosis. The development of clinical trials at
the international level (mandatory to achieve significant
patient numbers given the rareness of TTP) will allow
rapid evaluation of new strategies in the early manage-
ment of TTP, and for the prevention of relapses. The
understanding of genetic factors involved in the occur-
rence of autoimmune TTP, as well as the interaction
between genetic and environmental factors will increase
our knowledge about the initiation of the disease and,
again, better prevention of its occurrence.
The proposed initiatives are needed to improve the
knowledge of clinicians about this disease and related
TMAs that require a diagnosis and an adapted treatment
in emergency situations. Moreover, through collaboration
with industry, Europe’s role in the improvement of
knowledge of TTP and its management will become
more important, at a time when the field of rare diseases
is becoming a major goal.
The EHA Roadmap for European Hematology
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Thrombotic and bleeding disorders are a global disease
burden with considerable morbidity and a high mortality.
Estimates for the European Union (EU) arrived at a death
toll of 500,000 venous thrombosis (VT)-related deaths per
year.236 About one in 300 people is affected by an inherited
bleeding disorder. Uncontrolled bleeding is a major cause
of death not only among these patients but also among
those with an acquired bleeding disorder, including liver
disease and severe trauma.
Europe has a long-standing tradition in basic, translation-
al, and clinical science in practically all areas of blood coag-
ulation and hemostatic disorders.237 The identification of
coagulation factors, their interplay within the clotting sys-
tem, and the role of platelets in hemostasis are all seminal
discoveries made in Europe.238-242 Owing to the dedication
and scientific curiosity of physicians in many European
countries, the clinical aspects and pathophysiological fea-
tures of genetic and acquired coagulation disorders have
been described for the first time. Based on this knowledge,
coagulation assays were developed and the foundation for
standardized nomenclature in thrombosis and hemostasis
was laid. Drugs that saved or improved the lives of millions
of people worldwide, such as antithrombotics or procoagu-
lants, have been developed by researchers based in Europe.
Notably, these research activities are not clustered in certain
parts of the continent but are ongoing across the whole of
Europe, from the far north to the south, from east to west.
In the past decades, Europe has experienced exciting
developments and dramatic breakthroughs that offer a myr-
iad of possibilities to continue along the road of enlighten-
ment in order to unravel still hidden secrets of thrombosis
and hemostasis, thereby further improving the manage-
ment of the diseases. Moreover, we saw changes and will
see even more so in the upcoming years throughout the
continent due to an expanding EU, an aging population,
increasingly self-determined patients, intra- and interconti-
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nental migration, and a globalization that facilitates collab-
oration with research institutions also outside Europe.
These developments pose substantial challenges to
researchers, physicians, and health authorities alike, but at
the same time pave the way for exploring novel tools and
approaches in research and treatment options. Increasing
demands of regulatory authorities and decreasing financial
resources also weigh heavy on the shoulders of the academ-
ic research community in particular.243 The burden can be
alleviated at least to some extent by defining needs and
major goals, focusing on main research questions, stream-
lining resources, combining efforts, and intensifying collab-
orations.
Scientists and physicians working in the field of blood
coagulation and hemostatic disorders are privileged by the
fact that bleeding and thrombotic disorders are of utmost
relevance in almost all medical disciplines, which per se
fosters collaboration and provides a fruitful and inspiring
atmosphere for research.
The following chapters give an overview of the develop-
ments and multi-disciplinary aspects of hemostasis and
thrombosis. Although hematologists concern themselves
with clinical, consultative, and research aspects of arterial
thrombosis, including acute coronary syndromes and cere-
bral infarction, we will focus here on venous thromboem-
bolic diseases and bleeding disorders. We describe major
needs and cutting-edge questions in basic and clinical
research, and provide a view not only of the future but
also beyond.
6.1. Genomics in hemostasis
Pieter Reitsma (Leids Universitair Medisch Centrum,
Leiden, the Netherlands), Anne Goodeve (University of
Sheffield, Sheffield, United Kingdom), Christine
Mannhalter (Medizinische Universität Wien, Vienna,
Austria), Pierre-Emmanuel Morange (Aix-Marseille
Université, Marseille, France), Johannes Oldenburg
(Universitätsklinikum Bonn, Bonn, Germany), José
Manuel Soria (Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain).
Introduction
Inherited disorders of the hemostatic system can be
divided into those that increase the risk of bleeding and
those that increase the risk of thrombosis. Common inher-
ited bleeding disorders include the hemophilias and von
Willebrand disease, but a multitude of rare inherited
bleeding disorders involving blood coagulation factors or
platelets also amount to a significant disease burden.
Today, we have good evidence that the severity of the
bleeding phenotype can be modified by multiple common
genetic variations, such as the ABO blood group and the
activation status of platelets, as well as other confounders.
Severe inherited disorders that lead to thrombosis are
quite rare and mostly limited to homozygosity or com-
pound heterozygosity for loss of function mutations in
genes encoding natural anticoagulants. Lifetime risk of
thrombosis is influenced by inherited risk factors, such as
factor V Leiden; PT20210A; genetic variations in platelet
glycoproteins, such as P-selectin; and also the ABO blood
group.
European research contributions 
The field of human genetics in Europe has a proud his-
tory of leadership in the study of inherited hemostatic dis-
orders. Technological breakthroughs were always quickly
incorporated into European laboratories and clinics. For
example, in the early days of recombinant DNA technolo-
gy, restriction fragment length polymorphism–based diag-
nosis was immediately implemented for genetic diagnosis
and counseling in hemophilia A and B.244 Common risk
factors for VT were among the first risk factors for com-
plex diseases to be characterized in detail and applied for
risk stratification, and most of the research is this area was
led by European research groups.245
Proposed research for the Roadmap
Bleeding: in hemophilia A, genetic imprinting studies and
sequencing of the entire F8 gene have shown that, in rare
cases, mutations in intronic regions of the F8 gene can
cause a severe hemophilia phenotype. Furthermore, there
are preliminary data to suggest that the severity of hemo-
philia is influenced by the number of circulating activated
platelets present in the circulation. An answer to this
important question can be obtained only if many hemo-
philia centers collaborate more actively. In addition, new
knowledge has been obtained regarding the epigenetic
modification and imprinting of the F8 gene in females.
However, it is currently unclear whether certain mutations
(e.g. the intron 22 inversion) are associated with skewed
imprinting. To clarify this, large numbers of patients with
and without the mutation will have to be tested again,
underlining the need for collaboration.
The diagnosis and study of rare bleeding disorders,
including those involving blood platelets, will greatly ben-
efit from the introduction of next generation sequencing
(NGS) technology.246 To take full advantage of this, a stable
and sustainable database of genetic variation in hemostat-
ic genes is required. There is also a need for standardiza-
tion of clinical reporting of genetic test results for hemo-
static disorders to have long-term stability of reference
sequences to avoid confusion about “versioning” of DNA
sequences, and the locus reference genomic sequences aim
to achieve this.
VT: high-throughput genotyping technologies in the
framework of genome-wide association studies have led
to the identification of at least eight new loci associated
with the risk of first VT.247 However, the currently known
genetic factors explain only approximately 5% of VT her-
itability.248 An important question is how to discover the
missing heritability. The following research strategies can
be used to achieve this.
1. Increase sample sizes by pooling large collections of
comparable data. Importantly, the number of variants
discovered is strongly correlated with sample size.
Thus, increasing the sample size will increase the num-
ber of discovered variants.
2. Risk factors for first and recurrent VT may not be iden-
tical. Identifying genetic risk factors specific for recur-
rence is important as it could influence treatment deci-
sion, in particular duration of anticoagulant treatment
after a first VT event. To date, no genome-wide asso-
ciation study has been published on recurrent VT and
there is a need for a collaborative effort to reach a suf-
ficient sample size to approach this question.
3. Missing heritability for VT can be attributed to rare
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variants (minor allele frequency less than 0.5%). Such
variants are not sufficiently captured by current
genome-wide association genotyping arrays. The best
method for the detection of rare single nucleotide
polymorphisms is sequencing (ideally whole-genome
or alternatively exome) using NGS technology. These
approaches should be scaled up both in families with a
strong history of VT and in unselected individuals.
4. Missing heritability is not necessarily explained by
simple Mendelian genetics. Epigenetic processes that
influence gene expression may be highly important.
Investigating these processes might provide new
insights into the molecular mechanisms underlying
VT, as recently suggested for other human diseases.
For this purpose, specific high-throughput technolo-
gies are becoming available to quantify non-coding
RNA expression and methylation profiles from cells,
tissues, and blood.
The second goal for VT is to translate the genetic discov-
eries into useful clinical applications that lower the burden
of thrombotic disease. This process should primarily focus
on the prevention of secondary thrombosis after a first
event. Clinical trials need to be designed that stratify
patients with a first event based on genetic and non-genet-
ic risk factors. Patients with a high risk should be treated
differently from patients with a low or intermediate risk,
and the effect of such triaging on the number of thrombot-
ic and bleeding events should be recorded. This precision
medicine approach should lead to guidelines for thrombo-
sis prevention that are tailored to the individual character-
istics of the patient. Research groups in Europe have a
strong track record and the infrastructure to carry out such
trials.
Anticipated impact of the research
With the advent of genome-wide association studies and
NGS technologies, the introduction of genomic analysis in
the clinical care of patients with inherited bleeding and
thrombotic disorders is rapidly progressing, and there is a
need to achieve the safe and appropriate introduction of
this technology in clinical care delivery. In parallel, stan-
dardized and harmonized tools to collect clinical data
should be developed, adopting an ontological approach, in
order to attribute the right clinical significance to the spe-
cific genetic abnormality. This should lead to a lower dis-
ease burden and improved public health.
The discovery of the missing heritability in VT may
point to genes that operate outside the canonical coagu-
lation system. This may yield drug candidates that
decrease thrombotic risk without increasing bleeding
risk, which would revolutionize treatment and preven-
tion.
6.2. Novel mechanisms for coagulation activation
Wolfram Ruf (Johannes Gutenberg-Universität Mainz,
Mainz, Germany)
Introduction
Activation of the plasmatic coagulation cascade gener-
ates the key enzyme thrombin that is pivotal for convert-
ing the soluble plasma protein fibrinogen to fibrin and
the activation of blood platelets. Together, these form
hemostatic plugs to seal sites of vascular injury.
Thrombin is essential not only for hemostasis (the pre-
vention of bleeding) but also for thrombosis (the forma-
tion of blood clots in vessels). Since the first description
of the waterfall model of co-factor-amplified, consecu-
tive proteolytic activation of coagulant protease zymo-
gens 50 years ago, a wealth of biochemical data has
delineated the details of blood clotting in vitro.
Coagulation initiates through the cellular enzyme-co-fac-
tor complex of coagulation factor VIIa and tissue factor
or factor XIIa that is activated in the context of contact
with exogenous or endogenous polyanions, including
DNA, RNA, and polyphosphates (Figure 6). The main
routes of coagulation initiation have been refined by
description of amplification loops connecting these path-
ways (e.g. the direct activation of the anti-hemophilic
factor IX by tissue factor–factor VIIa or the feedback acti-
vation of factor XI by thrombin). Thrombin generation is
tightly controlled by plasma serine protease inhibitors
that prevent intravascular clotting, and thus thrombosis.
Important information on the physiological regulation of
coagulation initiation has been further uncovered in
patients with thrombophilia and validated by in vivo
studies in model organisms. Key roles are played by the
vascular antithrombotic mechanisms provided by the
anticoagulant thrombomodulin-protein C-protein S
pathway and plasma- or platelet-derived tissue factor
pathway inhibitor. Although the principles of initiation
and regulation of coagulation are well laid out, much
remains to be learned about the fine-tuning of these
responses to vascular injury and the implications for nor-
mal hemostasis and pathological thrombosis.
European research contributions 
European scientists were major contributors to recent
conceptual advances in our understanding of molecular
connections between innate host defense mechanisms
and coagulation, and the relevance of these interactions to
thromboembolic disease. The factor XII–dependent con-
tact pathway has experienced a flurry of research activities
after the realization that factor XII and factor IX deficien-
cies, while causing minimal hemostatic impairments, con-
fer resistance to vascular thrombosis in a variety of animal
models.249 Complementary research has identified patho-
physiologically relevant activators of this pathway, includ-
ing DNA and RNA released in the context of cell damage
and polyphosphates derived from platelets and microbial
pathogens.250 Initial clinical proof-of-concept studies
emphasize the feasibility of therapeutic intervention in
the contact pathway for antithrombotic benefit without
impairment of hemostasis during surgery.
In recent years, complex interactions of the coagulation
cascade have been uncovered, not only with platelets but
also with multiple intra- and extravascular cell types.
These studies led to the realization that coagulation
enzymes and their cognate receptors mediate crucial cell
signaling events in angiogenesis, inflammation, and
immunity.251 Conversely, effector mechanisms of innate
immunity couple coagulation with inflammation.
Activation of immune cells by injury signals are known to
trigger a variety of acute and chronic inflammatory dis-
eases, but the same cellular signaling mechanisms are
increasingly recognized as directly responsible for the gen-
eration of procoagulant tissue factor–bearing thromboin-
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flammatory microparticles. In addition, the complement
system serving host defense is connected through multiple
reciprocal effects with the coagulation cascade.
Complement activation not only enhances coagulation by
perturbing membrane integrity, exposure of negatively
charged phospholipids, and direct activation of coagula-
tion factors, but also through thiol-disulfide exchange–
dependent and protein disulfide isomerase–dependent
activation of tissue factor on monocytic cells.252 These
redox and innate immune reactions are emerging as
important regulators of both coagulation and platelet acti-
vation, and should remain a priority for future studies.
A key function of the coagulation system is to generate
fibrin that serves as a transitional barrier at sites of injury.
Fibrin formation also serves to wall off and protect the
organism from invading pathogens. Novel surveillance
functions of leukocytes have been defined that promote
similar protective functions within the vascular bed. In
these processes, termed immuno-thrombosis,253 neu-
trophil-derived proteases degrade tissue factor pathway
inhibitor leading to localized tissue factor–dependent
coagulation and fibrin formation. Alternatively, neu-
trophils can respond under certain conditions with co-
ordinated chromatin remodeling and expulsion of nuclear
DNA that entrap intravascular micro-organisms. The
formed neutrophil extracellular traps also serve as a matrix
for platelet deposition and both extrinsic and intrinsic
coagulation activation. These primarily host-protective
mechanisms are now recognized as crucial contributors to
the development of thrombosis, in particular in the
venous system. Important research into the multicellular
interactions in low- and high-flow vascular beds remains
to be pursued to understand the unique causes of coagula-
tion initiation in the venous and arterial system.
Proposed research for the Roadmap
Coagulation research has evolved novel technologies
and in vivo and translational approaches to move from sim-
ple test-tube research to a detailed understanding of coag-
ulation initiation in specific vascular and extravascular
locations. This productive path should be continued with
a special focus on understanding the common and dis-
criminating regulatory mechanisms of coagulation activa-
tion in thrombosis versus hemostasis. The specific research
areas with a high likelihood of return in resolving these
fundamentally important questions are as follows.
1. Triggers, modulators, and regulators of intrinsic and
extrinsic coagulation activation in the venous and arte-
rial circulation.
2. Contributions of the coagulation system to the com-
plex multicellular interactions of the blood and the vas-
cular endothelium under physiological and pathologi-
cal conditions, including cancer.
3. Thromboinflammatory circuits contributing to vascu-
lar dysfunction, thrombosis, or hematologic and
immunological disorders.
4. Environmental, metabolic, age, and gender effects on
the reciprocal interactions of the hematopoietic and
the coagulation systems.
Anticipated impact of the research
These areas of research are highly significant for the rap-
idly evolving landscape of antithrombotic therapy. The
availability of diverse target selective anticoagulants has
already changed the practice of hematology, and future
advances in anticoagulant therapy are on the horizon. The
proposed research areas will have an impact on these
developments by defining new interactions and pathogen-
ic roles of the coagulation system in hemato-oncological
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Figure 6. Synergistic activation of coagulation by contact and
tissue factor pathways.
diseases and vascular medicine. New insights into coagu-
lation-supported pathomechanisms can be used to tailor
and individualize antithrombotic therapy with new anti-
coagulants and may indicate additional areas for therapeu-
tic interventions with antithrombotic drugs in more com-
plex thromboinflammatory diseases.
6.3. Venous thromboembolism
Paul Kyrle (Medizinische Universität Wien, Vienna,
Austria).
Introduction
Venous thromboembolism (VTE), a syndrome consist-
ing of deep vein thrombosis and/or pulmonary embolism
(PE), occurs in one to 2 per thousand people per year. VTE
is one of the leading causes of death in Europe. It is esti-
mated that in France, Germany, Italy, Spain, Sweden, and
the UK together, VTE occurs in more than 750,000 people
per year and that VTE-related death affects more than
370,000 individuals annually in these countries.236 Millions
of VTE events or deaths per annum are expected in the
European Union. Most importantly, VTE is one of the best
examples of a preventable disease as antithrombotic treat-
ment is highly effective in both primary and secondary
prophylaxis. It is therefore of major importance to
improve the diagnostic and therapeutic strategies in order
to reduce the number of people affected by this frequent
and potentially fatal disease.
European research contributions 
European scientists were responsible for many impor-
tant breakthroughs in both basic and clinical thrombosis
research. This subsection addresses only a few of them.
The recognition of important pathomechanisms leading
to VT or PE has an essentially European origin. The German
pathologist Rudolf Virchow the etiology of VTE was
already clarified back in 1865, postulating that thrombi
occurring within the veins, particular in those of the
extremities, become dislodged and migrate to the pul-
monary vasculature. A few years later, the French internist
Armand Trousseau described for the first time the associa-
tion between cancer and vessel wall inflammation due to
blood clots, which are recurrent and appear in different
locations over time. In modern thrombosis research,
European scientists have greatly capitalized on advances in
genetics to identify important determinants of VT, such as
the factor V Leiden mutation and the G20210A mutation in
the prothrombin gene,254-256 which represent the two most
frequent congenital risk factors of VT known today.
A tremendous amount of pioneering work in the field of
antithrombotic treatment has been carried out in Europe.
Sir John Vane discovered the mechanism by which acetyl-
salicylic acid (aspirin) inhibits platelet function, thereby
paving the way for large clinical trials that the effective-
ness of aspirin in reducing the incidence of both arterial
and venous thrombosis on firm ground. As for the treat-
ment of acute PE, the first (and for ethical reasons last)
placebo-controlled trial was carried out in England to
show that patients greatly benefit from anticoagulant
treatment with heparin in terms of both morbidity and
mortality. Only recently, European researchers were the
masterminds behind the development of the novel antico-
agulant drugs rivaroxaban and dabigatran, which selec-
tively inhibit distinct coagulation factors (factor Xa or
thrombin), thereby protecting patients with VTE from
recurrence to the same extent as the vitamin K antagonists
but at a lower risk of (major) bleeding and without the
need of regular coagulation monitoring.
Proposed research for the Roadmap
Venous thromboembolism is a multicausal disease, and
its development can be explained by the interaction of var-
ious genetic and environmental risk factors. It is the main
task of future thrombosis research to find strategies for
identifying individuals/patients at risk for a first/recurrent
thrombotic event on the basis of their risk factor profile, to
delineate methods of prevention and prove that such a
personalized medicine approach is beneficial. To accom-
plish this ambitious task, large clinical studies are required
that enable differentiation between individuals at a high
or low risk for thrombosis. In these studies, clinical and
biochemical characteristics have to be complemented
with genetic determinates of VTE. It is important to recog-
nize that the development of VTE is to a great extent
genetically determined. It is very doubtful that the pres-
ence or absence of a few, so far unknown, strong risk fac-
tors determines the thrombosis risk. It is much more likely
that, according to the common variant–common disease
hypothesis, VTE development is driven by common vari-
ants in many genes, which occur with a high frequency in
the general population, with each variant at each gene
exerting a small additive or multiplicative effect on the dis-
ease phenotype.257
Specifically, future research on VTE should do the fol-
lowing.
1. Explore the incidence of VTE in well-defined popula-
tions of patients or so far unaffected individuals by the
use of prospective observational studies with large
numbers of individuals included.
2. Identify single genes, networks of genes, and signaling
pathways responsible for VTE development using
genome-wide linkage association studies.
3. Investigate the relationship between VTE occurrence
and hemostatic system activity by measuring (molecu-
lar) markers of platelet and coagulation activation.
4. Enable the construction of prediction tools that are
capable of differentiating between high- and low-risk
individuals on the basis of clinical, genetic, and molec-
ular evidence. This should be achieved in all groups of
patients with VTE including those with VTE provoked
by surgery, pregnancy or trauma and also in patients
with cancer.
5. Improve our knowledge on the association between
hematologic malignant and non-malignant diseases
and the risk of VTE.
Upon completion of these studies, findings have to be
validated in separate studies, and eventually management
studies will be required to prove that such a personalized
risk stratification strategy is helpful.
Anticipated impact of the research
The large number of people suffering from VTE is a seri-
ous challenge to European health care systems now and
will continue to be so in the years to come. The research
proposed in this document will provide indications for
A. Engert et al.
170 haematologica | 2016; 101(2)
prevention in patients as well as in those up till now
healthy individuals. It is a step-by-step plan that firstly
consists of the definition of populations that might bene-
fit, and subsequently of the estimation of risk based on
clinical, molecular, and genetic features, eventually allow-
ing a personalized prevention and treatment strategy.
Only a concerted action that brings together basic scien-
tists and clinically orientated researchers will eventually
be successful at achieving such an ambitious goal.
6.4. Venous thrombosis in aging populations
John-Bjarne Hansen (Universitetet i Tromsø, Tromsø,
Norway), Sigrid Brækkan (Universitetet i Tromsø,
Tromsø, Norway), Ellen Brodin (Universitetssykehuset
Nord-Norge, Tromsø, Norway), Frits Rosendaal (Leids
Universitair Medisch Centrum, Leiden, the Netherlands).
Introduction
Advancing age is associated with a shift of the hemosta-
tic balance in a prothrombotic direction. The incidence of
VT [e.g. deep vein thrombosis and pulmonary embolism
(PE)] increases sharply with age. The overall incidence of
first symptomatic VT is one to 2 per 1000 person-years in
the general population, increasing from one per 10,000
person-years in the age group 25 to 30 years to 5-8 per
1000 person-years in those above 75 years of age258 (Figure
7). Therefore, the risk of VT is 50- to 80-fold higher in the
older population, leading to a high attributable risk for
age-related factors. In the Scandinavian Thrombosis and
Cancer study, a merged cohort including individual data
from three large population-based cohorts in Scandinavia
(the Tromsø Study, the HUNT Study, and the Danish
Diet, Cancer and Health study), approximately 45% out
of a total of 2444 subjects with a first VT were over 70
years of age. Based on these results, age accounted for
78% of the VT events occurring in this age group (attrib-
utable risk), whereas previous estimations of the popula-
tion attributable risk were approximately 90%, indicating
that 90% of total incidence of VTE could be explained by
age-related factors.259
European research contributions 
Despite a striking increase in the incidence of VT with
age, few studies have addressed etiology and prevention
strategies in the elderly. Some studies have reported age-
related changes of the hemostatic system, such as
increased plasma concentrations of procoagulant coagula-
tion factors (fibrinogen, factor V, factor VII, factor VIII, fac-
tor IX, and von Willebrand factor) and inhibitors of the fib-
rinolytic system (PAI-1 and TAFI),260 but none have inves-
tigated the interactive effect between age and these hemo-
static factors on VT risk. A major proportion of the VT
events (45%-60%) occur during or shortly after hospital-
izations. However, the thrombotic risk associated with
hospitalization has not been studied in the elderly.
Because the incidence of hospitalization doubles with age,
the population attributable risk is expected to be highest
in the elderly (10% in the young and approximately 40%
in the elderly).259 Short-term bed rest in subjects over 65
years of age was associated with a 6-fold higher VT risk
than in subjects without bed rest,261 suggesting that a strat-
egy to either avoid bed rest or offer prophylaxis will sub-
stantially affect the VT incidence in elderly. The overall
risk of VT in cancer patients is 5- to 7-fold higher than in
individuals without cancer, and cancer-related VTs
account for 20%-25% of all VTs in the general population.
Due to the high incidence of cancer in the elderly, it has
been estimated that the population attributable risk for VT
in cancer patients is 15% in the young and 35% in the eld-
erly. Recently, Blix et al. calculated age-specific population
attributable risks of VT due to cancer based on incidences
of cancer and VT in the Tromsø Study and found a smaller
actual difference than postulated between the young (<50
years, population attributable risk 14%) and the elderly
(>70 years, population attributable risk 18%).262 These
findings show that malignancy does not explain a substan-
tial proportion of the VT events in the elderly, and, most
importantly, that studies focusing on risk factors in the
elderly are urgently needed, because extrapolations do not
suffice. A limited number of studies have investigated the
impact of age-specific risk factor on VT risk, and prelimi-
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Figure 7. Venous thrombosis (VT) incidence increases with
age. Incidence rates per 100,000 person-years with 95%
confidence intervals. Data are derived from the Tromsø Study
(1994–2012), in which 26,853 individuals were followed for
a median of 17.7 years, and a total of 710 first VTs occurred.
nary data have shown that thickening of the venous
valves occurs with age, which may contribute to the high
incidence of thrombosis in the elderly.
Proposed research for the Roadmap
The key question is: why does the incidence of VT
increase with age? We believe that the answer is multifac-
eted and involves at least three fundamental aspects: 1)
aging may be associated with an increased prevalence of
conventional risk factors (e.g. immobility, malignancy,
comorbidity, hemostatic factors, and genetic factors); 2)
VT risk may be conferred by age-specific risk factors (e.g.
reduced muscle strength, endothelial dysfunction, venous
insufficiency, and frailty); 3) synergistic effects with age
may occur for established risk factors, meaning that the
impact of a risk factor on VT may differ between young,
middle-aged, and elderly individuals.
The following issues need to be addressed.
1. Investigate the prevalence of established risk factors
(e.g. immobility, malignancy, comorbidity, surgery,
hemostatic factors, and genetic factors) in the elderly
and their effect on the thrombotic risk in different age
groups.
2. Identify novel risk factors of VT in the elderly by
applying state-of-the-art technologies in imaging, bio-
chemistry, genomics, genome-wide methylation pat-
terns, and proteomics.
3. Investigate joint effects between age and thrombotic
risk factors on VT risk.
4. Develop risk prediction models for VT in high-risk sit-
uations (e.g. malignancy, hospitalizations for acute
medical conditions, and surgery) specifically for the
elderly.
5. Identify age-specific risk factors (e.g. muscle strength,
endothelial dysfunction, venous insufficiency, and
hemodynamic changes) and elucidate underlying
mechanisms for VT risk.
These issues should be addressed in observational stud-
ies with validated information on exposures, effect modi-
fiers, and end points, and with no upper age limit. Risk
prediction models should be developed and validated in
prospective cohort studies.
Anticipated impact of the research
The total suffering and economic burden caused by VT
is tremendous, particularly among the elderly. VT is asso-
ciated with short- and long-term complications, such as
fatal or non-fatal recurrence (affecting 30% of the
patients within 10 years), post-thrombotic syndrome
(affecting 25%-50% of VT patients), and pulmonary
hypertension, all of which severely impair mobility and
quality of life (QoL). Extrapolated data from six EU coun-
tries estimated that a total of 680,000 deep vein throm-
bosis events, 430,000 PE events, 610,000 post-thrombotic
events, and 540,000 VT-related deaths occur in the EU
each year.
As the European population is becoming older, the
incidence of VT is expected to increase. Therefore,
efforts are urgently needed to identify inherited and
acquired risk factors and age-specific factors, and reveal
their interactions with advanced age, on risk of VT.
Targeted prevention strategies are needed to reduce the
incidence of VT in the elderly in order to reduce personal
suffering and the health burden in Europe, and promote
healthy aging.
6.5. Bleeding disorders
Flora Peyvandi (Università degli Studi di Milano, Milan,
Italy), Isabella Garagiola (Università degli Studi di Milano,
Milan, Italy), Michael Makris (University of Sheffield,
Sheffield, United Kingdom), Brian O’Mahony (European
Haemophilia Consortium, Brussels, Belgium), Johannes
Oldenburg (Universitätsklinikum Bonn, Bonn, Germany).
Introduction
Inherited abnormalities of coagulation factors or
platelets lead to lifelong bleeding. Hemophilia A and B due
to deficiency or dysfunction of factor VIII and factor IX
account for the majority of the severe disorders. Von
Willebrand disease is mostly a milder but much more
prevalent disorder of primary hemostasis. The remaining
defects, such as factor II, V, VII, X, XI, and XIII, are very
rare, with a prevalence of around one in 1 million. There
are 106,000 people with an inherited bleeding disorder in
Europe according to the World Federation of Hemophilia
Survey of November 2014. Mild deficiencies may be
asymptomatic until suitable challenges, such as surgery or
trauma, and may go undiagnosed until adult life.
Due to their low prevalence, current knowledge of the
genetic, laboratory, and clinical characteristics of these dis-
orders remains limited, making their diagnosis and man-
agement difficult. Their treatment involves replacement of
the missing factor with plasma-derived or recombinant
concentrates. Their management has recently improved
with the development of new extended half-life drugs.
Gene therapy is also emerging as a possible future treat-
ment with recent reports of success in hemophilia B. The
development of antibodies against the replaced factor
(inhibitors) is a major issue, affecting up to 30% of
patients with severe hemophilia.
The rare coagulation disorders present significant diffi-
culties in management. Affected individuals suffer
increased morbidity and mortality as a result of recurrent,
often spontaneous, bleeding, and there are wide variations
in the availability and quality of specialized health care
delivery in Europe.263-267
European research contributions 
In the past decade, European researchers have made
major contributions to the field, with some large collabo-
rative projects funded by the European Commission. The
PedNet registry of European pediatricians has contributed
to studies on severe hemophilia in terms of genotype, phe-
notype, role of prophylaxis, and risk of inhibitor develop-
ment by endogenous and exogenous factors. Large collab-
orative efforts of UK and French researchers have also
investigated inhibitor development. The Malmö
International Brother Study identified genetic determi-
nants of inhibitor development. The European
Haemophilia Network project established the hemophilia
center standards required for delivery of care, and the
European Haemophilia Safety Surveillance project
prospectively monitors the safety of hemophilia treat-
ments across Europe.
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The European Network of Rare Bleeding Disorders iden-
tified the critical levels in clotting factor deficiency leading
to clinical problems and has established prospective studies
to determine the natural history of the disorders. The mul-
ticenter European study Molecular and Clinical Markers for
the Diagnosis and Management of Type 1 von Willebrand
Disease documented that von Willebrand factor mutations
in type 1 disease are common and established the use of
bleeding scores in the diagnosis of the disease.
Proposed research for the Roadmap
We propose the following topics for future research in
the area.
1. The use of new technologies, such as next generation
DNA sequencing, to clarify the genetic determinants
involved in the complex multifactorial process of
inhibitor development in hemophilia.
2. The harmonization of standards for collecting and
sharing data on the development of inhibitors in
patients previously untreated and previously treated in
Europe for both standard and novel engineered prod-
ucts (e.g. the longer-acting factor concentrates).
3. The establishment of an optimal data collection sys-
tem through a European network to obtain more accu-
rate data on safety and efficacy of novel bioengineered
coagulation factors in the post-marketing investigation
period.
4. The monitoring of the safety and efficacy of gene ther-
apy clinical trials and ensuring collaboration in the con-
sistent long-term collection and sharing of these data at
a European level.
5. The collection of data on the prevalence and manage-
ment of the most frequent age-related hemophilic
comorbidities, in particular cardiovascular disease.
6. The prospective collection of data on the natural histo-
ry of the very rare bleeding disorders, which can only
be carried out by multinational, worldwide collabora-
tion.
7. The investigation of the ascertainment, diagnosis, clin-
ical implications, and natural history of mild bleeding
disorders.
8. The improvement of bleeding risk prediction in sub-
groups such as fragile and elderly patients.
9. The collaboration between diagnostic manufacturers
and clinical services to improve the quality, sensitivity,
and economic value of laboratory assays.
Anticipated impact of the research
Developing appropriate European networks based on
real collaboration and appropriate data sharing and agreed
methodologies will significantly enhance the power of the
data collected, minimize bias, and prevent wastage of
resources due to the current models of individual working.
The aim is to improve the health and quality of lives of
European citizens with these rare inherited bleeding disor-
ders through improved awareness, diagnosis, and knowl-
edge of the clinical manifestations and sequelae of these
disorders.
6.6. Women, hemostasis, and thrombosis
Rezan Kadir (The Royal Free Hospital, London, United
Kingdom), Hannah Cohen (University College London,
London, United Kingdom), Jacqueline Conard (Hôpital
Hôtel-Dieu, Paris, France), Chris Gardiner (University of
Oxford, Oxford, United Kingdom), Debra Pollard (The
Royal Free Hospital, London, United Kingdom).
Introduction
Inherited bleeding disorders are lifelong conditions that
remain largely undiagnosed in women and result in signif-
icant morbidity and impaired quality of life (QoL). A
World Federation of Hemophilia global survey in 2013
showed that the majority of patients with von Willebrand
disease, the most common bleeding disorder reported by
107 countries, are women in their reproductive years.268
Affected women suffer significant reproductive health
problems, with heavy bleeding during menstruation, ovu-
lation, and postpartum. There is an increased risk of preg-
nancy loss in women with severe deficiency of certain
coagulation factors. Affected newborns are at an increased
risk of intracranial hemorrhage during birth. The incidence
of intracranial hemorrhage is unknown, however, without
consensus on the optimal mode of delivery.
Venous thromboembolism (VTE) is rare in women of
childbearing age, but pulmonary embolism (PE) is a lead-
ing cause of maternal mortality. The optimal diagnostic
approach for PE during pregnancy and postpartum has not
been established, and lung imaging carries risks, including
those of radiation exposure for both the mother and baby.
Low molecular weight heparin is the standard treatment
of VTE in pregnancy and postpartum, although the evi-
dence for dosing regimens is limited. Thrombophilias,
both acquired and heritable, increase the risk of VTE in
relation to pregnancy and hormonal intake; increase the
risk of recurrent pregnancy loss and placenta-mediated
complications, such as pre-eclampsia, placental abruption,
and fetal growth restriction, and may be associated with
recurrent implantation failure in assisted conception.
European research contributions 
Research has highlighted increased menstrual and gyne-
cological morbidity in women with bleeding disorders.
Heavy menstrual bleeding is now recognized as a predic-
tor for bleeding disorders in women. A systematic review
of literature showed a 13% prevalence of von Willebrand
disease in women with menorrhagia, with a higher preva-
lence of 18% in the European population.269
Analysis of cell-free fetal DNA in maternal plasma has
been established as a non-invasive prenatal diagnosis
method for assessment of fetal sex in pregnant carriers of
hemophilia and can be used to detect fetal genotypes for
hemophilia mutations in male fetuses.270 The role of mul-
tidisciplinary management of pregnancy has also been
established for safe delivery, with regional block for pain
relief and anesthesia during labor and reduced risk of post-
partum hemorrhage. Postpartum hemorrhage remains a
leading cause of maternal mortality and morbidity in
Europe. Hypofibrinogenemia has been shown to be a
good marker for progression to severe postpartum hemor-
rhage.271 However, how to assess the fibrinogen level and
when to administer fibrinogen remains controversial.
The risks of thrombosis and pregnancy morbidity asso-
ciated with heritable thrombophilias have been estab-
lished. VTE risk assessment scores have been proposed to
guide VTE thromboprophylaxis and for exclusion of PE
during pregnancy and postpartum. Low-dose aspirin plus
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heparin have been demonstrated to lead to a significant
increase in live births in women with antiphospholipid
syndrome-related recurrent miscarriage. The TIPPS trial
did not show benefit with antenatal low molecular weight
heparin in women with heritable thrombophilia; howev-
er, the power calculations were based on an aggregate of
adverse outcomes rather than individual obstetric compli-
cations.272 The role of heparin in women undergoing
assisted conception is unclear.
Proposed research for the Roadmap
Bleeding disorders
1. Studies in women with heavy menstrual bleeding on
assessing underlying bleeding disorders, the predictive
value for the menstrual pictorial blood assessment
chart and bleeding assessment tool, and to validate the
benefits of incorporating these tools into routine clini-
cal practice.
2. Studies to assess gynecological problems and treat-
ment options in women with bleeding disorders;
development and validation of a disease-specific QoL
tool, to develop optimal care services.
3. Assessment of the role of local hemostatic mecha-
nisms within the endometrium as an underlying cause
for gynecological pathologies, such as heavy menstrual
bleeding and endometriosis, and also in implantation
and early placental development, in particular in
women with recurrent early pregnancy loss and recur-
rent implantation failure following in vitro fertilization.
4. Refinement of non-invasive prenatal diagnostic tech-
niques for the prenatal diagnosis of severe and com-
mon mutations, such as intron 22 inversion; qualitative
research to explore feelings that influences decision
making about reproductive choices.
5. Pooling of European prospective data to establish the
risk of intracranial hemorrhage with various modes of
delivery, and the impact of neonatal intracranial hem-
orrhage on neurocognitive development.
6. For women with rare bleeding disorders, multicenter
studies and/or a web-based international registry to
provide more evidence for management.
7. Assessment of real-time hemostatic monitoring by
point-of-care testing in postpartum hemorrhage, to
guide a tailored approach to management of coagu-
lopathy and administration of blood components/
products.
Thrombotic disorders
1. Prospective studies to establish the optimal strategies
for management of VTE (stratification of risk factors
and clinical prediction rules for suspected VTE, the
potential use of higher D-dimer cut-off values, and
appropriate low molecular weight heparin dosing) in
pregnancy and postpartum.
2. Prospective studies to investigate the pathogenesis,
diagnostic validity, management implications, and
long-term outcome in women with thrombotic and
obstetric complications, associated with antiphospho-
lipid antibodies.
3. Research to define the optimal management of preg-
nancy in women with heritable thrombophilia and
other thrombotic states, including hemoglo-
binopathies, MPNs, and thrombotic microan-
giopathies.
4. Assessment of combining cardiovascular measure-
ments with circulating biomarkers for early prediction
of pre-eclampsia; development of diagnostic algo-
rithms; definition of mechanisms for improved out-
come with aspirin or other agents; definition of the
role of complement.
5. Prospective studies on the effects of heparin in assisted
conception.
Anticipated impact of the research
Research will enable improved diagnosis and an evi-
dence-based approach for minimizing obstetric and gyne-
cological morbidity. This will improve quality of life (QoL)
and, in turn, educational achievement and productivity at
work.
Definition of the diagnosis of mild bleeding disorders
will enable assessment as to whether this improves repro-
ductive health outcome and/or has a health economic
benefit. Development of non-invasive prenatal diagnosis
for hemophilia and information on the risk of intracranial
hemorrhage during birth improve obstetric management,
avoiding unnecessary intervention and medicalization of
delivery. Development of strategies for the prevention and
diagnosis of VTE and obstetric morbidity will reduce
maternal and fetal/neonatal morbidity and mortality. A
further understanding of the pathogenesis of pregnancy
morbidity associated with thrombotic states and predic-
tive biomarkers will inform optimal management.
Appropriate management of obstetric antiphospholipid
syndrome, as well as other obstetric morbidity associated
with thrombotic states, will reduce long-term disability in
the offspring, along with its health care and economic
implications. Improvements in the understanding of
mechanisms responsible for pre-eclampsia will achieve
the long-term goal of curing this condition.
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Transfusion therapy started a century ago with the aim
of rescuing soldiers with large blood loss. Since then,
transfusions reduced maternal mortality and enabled
major surgery, leukemia treatment, and transplantation.
Despite a lack of studies on when and how much a patient
needs, transfusions became increasingly used. Recent
studies lowering transfusion thresholds, conducted in sur-
gical and intensive care patients, mostly favor a restrictive
policy.273 However, for most indications, the balance
between benefit and harm of transfusion is still
unknown.274,275 Although in rich countries transfusions are
safe, alertness for emerging infections remains, and for
under-resourced countries and immunocompromised
patients transfusion-transmitted infections still pose a con-
siderable risk. Besides transfusion-transmitted infections,
harm caused by transfusion results from transfusion-
induced alloimmunization and transfusion-related
immunomodulation, causing (transient) immune suppres-
sion.276
Transfusion represents a huge (economic) market, albeit
with a wide range of use in Europe. Reported by 32 of 47
Section 7. Transfusion medicine
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(70%) member states, on average 37 units of red blood
cells (RBCs) are transfused per 1000 inhabitants (range 8–
126 units), identifying three countries with a possibly
insufficient blood supply (<20 units/1000). One-third of
platelet transfusions are supplied by apheresis, and 8.5 L
plasma/1000 inhabitants (range 0-49 L) is fractionated into
medicinal products. In about half of the countries, all RBC
and platelet transfusions are leukocyte-reduced. All coun-
tries have legally binding national regulations and 90%
have a hemovigilance registry.277 Future blood supply
needs are expected to reflect an increase in patients need-
ing blood components because of age-related morbidity
coinciding with less accrual of young donors and donors
from ethnic minorities.
Although for approximately half of the patients transfu-
sion is a single lifetime event, patients with hereditary
anemias from Europe’s former colonies and residents in
Mediterranean and eastern Europe need lifelong RBC sup-
port, leading to iron overload.
Overarching research proposals include the following
(Figure 8).
1. Evidence-based indications of virtually all (individual,
pooled/cellular, or plasma-derived) blood components
demand new research methodology for clinical trials,
as well as (bio)markers for indication and monitoring
of effects.278,279 Improved disease-specific IVIG products
require human research on the mechanisms of
immunomodulation and optimal dose and timing of
administration. Hemovigilance would include surveil-
lance of thrombotic complications of blood products.
2. Technology is available to match donors and recipients
for almost any antigen avoiding alloimmunization, but
scarcity of matched donors makes this impossible for
all transfusions.280,281 An immunovigilance registry of
allo-(RBC, HLA, and HPA) immunized patients will
assist selection of eligible patients (patient groups) for
pre-emptive matching.282 Such a registry can also stim-
ulate collaborative studies that aim to reverse antibody
production283 and explore new treatment for severe
complications of incompatible transfusions, trans-
plants, or unborn children.284
3. For (emerging) transfusion-transmitted infections, the
best future solution must be sought. Additional tests
for immune-compromised patients and pathogen-
reduction methods that optimally preserve intended
(also red) cell functions should be compared. In the
long term, ex vivo culture of transfusion-transmitted
infection-safe (and antigens defined) blood cells lie
ahead.285 These three approaches need triage for feasi-
bility, costs, and patient selection.
4. Good donor management, not solely considering them
as resource material, must safeguard donors of blood,
cells, tissues, and organs.286 Achievements of transfu-
sion medicine (non-remunerated donors, good manu-
facturing practice, traceability, and hemovigilance) can
support quality management of new cellular products
for immunotherapy and repair treatment.287
7.1. Conventional blood products: indications and usage
Simon Stanworth (John Radcliffe Hospital, Oxford,
United Kingdom), Shubha Allard (Barts Health NHS Trust
& NHS Blood and Transplant, London, United Kingdom),
Milos Bohonek (Central Military Hospital, Prague, Czech
Republic), Enrico Lopriore (Leiden University Medical
Centre, Leiden, the Netherlands), Miguel Lozano
(Universitat de Barcelona, Barcelona, Spain), Cynthia So-
Osman (Sanquin Research, Amsterdam, the Netherlands).
Introduction
The most commonly transfused blood component
remains red blood cells (RBCs), followed by platelets and
plasma. Granulocyte transfusions are still considered an
experimental product. Bleeding with shock and anemia is
an undisputed indication for RBC transfusion. However,
RBCs are commonly used to correct anemia in patients
without bleeding to improve the oxygen-carrying capaci-
ty, for instance in critically unwell patients and bone mar-
row failure (BMF) disorders. Although the evidence base
for RBC transfusion practice is incomplete, randomized
studies in surgery and intensive care settings consistently
support a more restrictive use of RBCs, with no evidence
of benefit (and arguably harm by increasing post-operative
infections and organ failure) for maintaining patients at
higher Hb thresholds (liberal strategy).288 The past ten
years have also seen an increasing scrutiny of RBC usage
in medical patients (accounting in the UK for approx. two-
thirds of all RBC transfusions) compared with surgical
indications. The degree to which the optimal Hb transfu-
sion “trigger” should be modified for patients with specific
risk factors (e.g. coronary disease, radiotherapy, and
chemotherapy) remains unclear, and clinical dilemmas are
clearly shown when considering the appropriate RBC
transfusion threshold in the extremes: elderly, and prema-
ture neonates.
The evidence for a prophylactic platelet transfusion
threshold of 10x109 /L instead of higher triggers has come
from randomized controlled trials in hematology patients
with chemotherapy-associated thrombocytopenia.289
More recent studies even questioned the effectiveness of
prophylactic platelet transfusions in all patients with
(onco) hematologic diseases. There is a lack of evidence to
guide use of platelet transfusions to cover invasive/surgical
procedures in patients with platelet dysfunction and/or
thrombocytopenia, and guidelines for these indications
outside hematologic settings remain largely based only on
expert opinion.
Fresh frozen plasma contains pro- and anticoagulant fac-
tors and other proteins. Most guidelines describe the use of
laboratory coagulation tests to guide administration of plas-
ma, but there are uncertainties about the value of standard
coagulation tests in predicting clinical bleeding risk and a
lack of evidence of benefit for the prophylactic administra-
tion of fresh frozen plasma in non-bleeding patients.
European research contributions 
Major steps toward questioning the evidence base for
use of blood were established in Europe, beginning with
descriptive data by the Sanguis Study Group, which in
1994 reported large differences between hospitals and
clinical teams in the use of RBC transfusions (and other
blood products) for the same surgical procedures with no
clear clinical explanation. Many subsequent activities (e.g.
the European Society of Anaesthesiology Clinical Trial
Network, established in 2010) have facilitated clinical
research in anesthesia and intensive care. An ongoing
study termed the European Transfusion Practice and
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Outcome Survey has collected transfusion and outcome
data from large numbers of patient transfusion episodes
from many centers across Europe. According to reports
from the European Blood Alliance, although average RBC
use per 1000 inhabitants in Europe is substantially lower
than in the US, large variations in usage rates are still
reported between European countries, and audits indicate
greater than 15% inappropriate use.
Several leading clinical trials have been conducted in
Europe for platelets, red cells, and granulocyte and fresh
frozen plasma transfusions,289-292 but given the broad ranges
of clinical setting where transfusions occur, many research
gaps remain.
Proposed research for the Roadmap
Clinical studies on appropriate use/linking to ongoing studies and
patient input: the aforementioned European Transfusion
Practice and Outcome Survey on blood usage for surgical
interventions in Europe still has no counterpart for (onco)
hematologic diseases. There is an opportunity to explore
current hospital databases to characterize blood use in
(onco) hematology and hemoglobinopathy, to generate key
base-line information on blood usage practice. Incorporation
of data collection for transfusion usage and bleeding out-
come in hemato-oncology trials should be encouraged.
Policies to enhance patient engagement, for instance in
transfusion-dependent myelodysplasia, are required. This
could be achieved by introduction of patient-reported out-
comes related to physical activity, well-being, and quality of
life (QoL) as part of post-transfusion follow up.
Research is warranted to identify (predictive) risk factors
for severe thrombocytopenic bleeding. A European reg-
istry is required that reports bleeding after commonly
applied interventions in hematology (e.g. lumbar puncture
and organ biopsies), in relation to platelet count, coagula-
tion profile, and use of platelet transfusions and/or plas-
ma/coagulation factors. Studies on transfusion manage-
ment for pre-term infants and elderly patients undergoing
cancer treatment are essentially lacking. Emphasis should
also be given to medical and economic considerations of
different approaches to transfusion or alternatives, includ-
ing hematopoiesis-stimulating agents, iron, and prohemo-
static drugs. Indications and patterns of use of granulocyte
transfusions are unknown.
Better biomarkers identifying transfusion needs and results:
the hemoglobin (Hb) concentration is still used to define
the need for red cell transfusions, calculate the dose of
RBCs required, and monitor the response to transfusion or
alternative treatment. However, Hb is a surrogate marker,
and research should address better-targeted measures of
oxygen requirements that can identify specific patient
needs. Similarly, to identify patients with a high bleeding
risk requiring prophylactic platelet or plasma transfusions,
the safety of alternatives (near-patient point-of-care tests)
and the value of biomarkers for endothelial damage pre-
ceding bleeding should be explored.
Physician behavior and education: many interventions are
undertaken to change transfusion practice based on suspect-
ed wrong practice or guidelines, but there are uncertainties
about their effectiveness and durability. There is a need to
define the determinants of transfusion behavior to deliver
optimal transfusion practice. Electronic blood ordering and
better information technology support for prescribers may be
of value. Prevention of hospital-acquired anemia is one key
tenet of patient blood management, defined as a patient-cen-
tered, evidence-based approach of good clinical transfusion
practice. Patients may lose significant volumes of blood for
laboratory evaluation. In pre-term infants, this is even the
major cause of transfusions. Non-invasive assays or micro-
testing would help minimize the need for transfusions.
Anticipated impact of the research
Blood components are biological products and a costly
resource. The uptake of patient blood management,
which includes consideration of transfusion alternatives,
remains highly variable. Studies in surgical and intensive
care patients generally support a restrictive use of blood
components. There are hardly any studies in (onco) hema-
tologic diseases. The proposed research will contribute to
patient blood management for hematologic patients.
7.2. Plasma-derived and recombinant human plasma
proteins
Srini Kaveri (Institut National de la Santé et de la
Recherche Médicale, Paris, France), Sébastien Lacroix-
Desmazes (Institut National de la Santé et de la Recherche
Médicale, Paris, France), Stephan von Gunten (Universität
Bern, Bern, Switzerland), Jagadeesh Bayry (Institut National
de la Santé et de la Recherche Médicale, Paris, France).
Introduction
Plasma products are produced by (non-profit) blood
establishments or by the pharmaceutical industry. Plasma is
recovered from whole blood donations or collected by
(sometimes remunerated) plasmapheresis. Plasma is used as
single-donor fresh frozen plasma units (quarantine, methyl-
ene-blue-treated) or as pooled plasma products requiring a
pathogen-reduction treatment. Pooled plasma and fraction-
ated plasma products (e.g. factor VIII, albumin, prothrom-
bin concentrate, immunoglobulins, von Willebrand factor,
and fibrinogen). as well as factors produced by recombinant
techniques (e.g. factor VIIa, factor VIII, and factor IX), are
pharmaceutical products. The huge variation in usage of
various plasma-derived and recombinant products per 1000
inhabitants in the European member states is not explained
by differences in plasma-product-dependent diseases.
According to a 2010 report by the International Plasma
Fractionation Association 2010, high-dose IVIG usage in
European member states is, on average, 36.5 g per 1000
inhabitants (range 1.2–97 g), compared with an average of
120 g per 1000 US inhabitants.
Indications for recombinant and plasma-derived coagu-
lation factors comprise substitution in massive bleeding
and prevention of bleeding in patients with congenital or
acquired coagulation factor deficiencies. Patients with pri-
mary or acquired hypogammaglobulinemia are substitut-
ed with immunoglobulins. Anti-RhD immunoglobulin is
applied for immunoprophylaxis of hemolytic disease of
the newborn. IVIG is used for many (auto-)immune-
mediated disorders and to neutralize alloantibodies. IVIG
exerts multiple immunoregulatory mechanisms, such as
anti-idiotypic activity, inhibition of activation of B cells
and antigen-presenting cells such as dendritic cells and
macrophages, enhancement of IgG catabolism, and recip-
rocal regulation of regulatory T cells and pathogenic Th17
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and Th1 cells. The precise mechanisms underlying its
beneficial effects in various diseases are still largely
unknown. Many indications for IVIG are not evidence-
based, and off-label use is frequent.
European research contributions 
The past decades have seen enormous progress in the
development of therapeutic coagulation factors, greatly
improving the treatment of bleeding disorders.
Improvement in the very nature of the recombinant
products has been constant, starting, in the case of proco-
agulant factor VIII, from albumin-stabilized products to
3rd-generation products that are devoid of contact with
mammal proteins in both the production and purification
phases. Recent efforts aspire to generating products with
longer half-lives, to improve patients’ quality of life (QoL),
or to fully human products to ensure normal glycosylation
and sulfation, aiming to reduce alloimmunization and
neutralizing antibodies.
It was a European discovery by Imbach in 1981 that
high-dose IVIG increased the platelet count in an autoim-
mune thrombocytopenia patient, and since then a large
number of immune-mediated diseases are treated with
IVIG. European researchers and physicians have made a
considerable contribution toward understanding the
mechanisms of action of IVIG and conducted randomized
clinical trials with IVIG contributing to the evidence base
for (new) indications.
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Figure 8. Activation of the adaptive antigen-specific immune response. Potential targets for interventions to reduce Ab production or mitigate destruction. Potential
interventions include high-dose IVIG and PDN (prednisolone).
Proposed research for the Roadmap
Immunogenicity of coagulation factors and gene therapy:
replacement therapy with procoagulant products is com-
plicated by the occurrence of neutralizing antidrug anti-
bodies. Particularly in patients with hemophilia A, the
prevalence of these antibodies may reach 30% and pose
a major clinical concern. Several strategies are being
investigated to reduce the immunogenicity of therapeutic
factor VIII. These include alteration of factor VIII moieties
implicated in its processing/recognition by immune effec-
tors, control of the inflammatory status of the patients at
the time of replacement therapy and induction of active
immune tolerance, for example, upon oral or transplacen-
tal transfer of factor VIII,293 or using cell therapy for toler-
ance induction.
Pre-clinical studies with recombinant adeno-associated
viral vectors encoding variant human factor VIII294 are
encouraging and may lead to a successful gene therapy
strategy for hemophilia A similar to that achieved with
hemophilia B.
Prediction and treatment of massive bleeding: evidence-
based assays to predict bleeding severity and monitor
optimal substitution (bedside point-of-care and coagula-
tion factor levels) are required. European consortia should
continue to investigate the optimal mix of coagulation
factor suppletion and drug treatment in massive bleeding
of various origins (e.g. military and civil casualties, major
surgery, postpartum hemorrhage, and congenital or
acquired bleeding disorders) (see Section 6). Addressing
these questions should proceed independently and free of
any influence from producers.
Thrombotic complications: for both antifibrinolytic treat-
ment and coagulation factor substitution, the window of
opportunity may be small, depending on the underlying
condition, and late treatment may enhance thrombotic
complications. Also, possible contamination of coagula-
tion factors in IVIG products carries a risk of thrombotic
events. A step has recently been made to remove coagu-
lation factor impurities in IVIG. Besides hyperviscosity,
thrombogenic activity of some products may play an
additional role. Thrombotic complications should be
monitored in plasma product surveillance systems, prefer-
ably European-wide. National hemovigilance registra-
tions, which are in place in many European member
states, can possibly facilitate this.
Innovation of IVIG products and identification of biomarkers:
the same IVIG products are used for substitution of
immunodeficiency conditions and for immunomodula-
tion in immune-mediated diseases. For substitution,
research should aim for the conception of highly concen-
trated immunoglobulin products to reduce the volume of
injection by subcutaneous route. For immunomodulation
studies, identification of biomarkers to predict IVIG
responders and appropriate dose are warranted. Although
controversies regarding dependence of Fc-sialylation
toward anti-inflammatory functions of IVIG exist,295 the
necessity of CD209 for the IVIG-mediated expansion of
regulatory T cells is established in both humans and
mice.296,297 Sialylation-mediated structural modifications
can be mimicked by specific amino acid modifications at
position 241 (F→A) of the CH2 domain.297 This variant
IgG Fc molecule demonstrated anti-inflammatory effects
similar to IVIG. Therefore, sialylation is not mandatory
for anti-inflammatory effects of IVIG. The eventual clini-
cal application of these innovative IVIG products needs to
be further explored.
Anticipated impact of the research
In well-resourced countries with access to products to
combat bleeding after trauma, delivery, or surgery, vali-
dated assays to predict bleeding risk and monitor treat-
ment can improve survival. Despite its complex clinical
environment, European groups treating these patients and
adjustments to (inter)national reporting systems will help
to arrive at more evidence-based use of available treat-
ments. Reducing the incidence of immune response to
coagulant factors, such as anti–factor VIII, would reduce
the cost associated with patients’ management.
As IVIG is the driving force for plasma collection and
represents a huge budget, appropriate dosage, treatment
window, cellular and molecular mechanisms, and ran-
domized clinical trials to confirm off-label usage may ulti-
mately save costs. Similarly, clinical and basic research
can ultimately lead to the conception of IVIG similars or
IVIG-derived therapeutic molecules for treating specific
pathological conditions.
7.3. Hemapheresis
Hans Vrielink (Sanquin Research, Amsterdam, the
Netherlands), Olivier Garraud (Université Jean Monnet,
Saint-Etienne, France), Jörg Halter (Universitätsspital
Basel, Basel, Switzerland), Luca Pierelli (Università degli
Studi di Roma ‘La Sapienza’, Rome, Italy), Bernd
Stegmayr (Umeå Universitet, Umeå, Sweden).
Introduction
Hemapheresis encompasses a method of obtaining one
or more blood components by using a special blood sep-
aration device processing whole blood, removing the
component of interest, and returning the residual compo-
nents of the blood to the donor/patient during or at the
end of the process. Apheresis can be divided into aphere-
sis to collect blood components from donors/patients and
therapeutic apheresis. Component apheresis involves col-
lection of plasma, red blood cells (RBCs), and platelets
from blood donors for the purpose of direct cellular ther-
apy or further modification. Both patients and donors
donate peripheral hematopoietic stem cells (HSCs) and
other mononuclear cells. Therapeutic apheresis is per-
formed to remove large numbers of cells or plasma from
patients for specific disease treatment and is applied for
more than 75 different, mostly immune-mediated, rare
diseases, varying from macular degeneration to sickle cell
crisis.298
In 2007, the American Society for Apheresis started an
initiative to classify the applied indications for therapeu-
tic hemapheresis according to evidence base, and these
recommendations are regularly up-dated. The latest
update of 2013298 recommends hemapheresis for 25 dis-
eases either as a first-line lifesaving treatment or a valid
adjuvant to other therapies. Still, there are more than 50
benefit-of-doubt indications. Hemapheresis serves a mul-
titude of medical disciplines (neurology, nephrology, der-
matology, ophthalmology, dermatology, cardiology, and
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hematology), requiring joint studies and multidisciplinary
recommendations. Besides the most pivotal plasma-
exchange indication (TTP), for hematology, the collection
of cells for autologous and allogeneic use play an increas-
ing dominant role. Of the more than 20,000 hematopoiet-
ic stem cell transplants (HSCTs) performed worldwide
each year, more than 70% are obtained by blood stem cell
apheresis.
European research contributions 
The European Society for Hemapheresis collaborates
with the national apheresis societies to establish stan-
dardized education and certification programs for special-
ized nurses for apheresis. There is also co-operation in
contributing to evidence-based medicine indications (e.g.
systemic lupus erythematosus, as well apheresis treat-
ment in inflammatory bowel disease). The evolving use
of blood stem cell, lymphocyte, and monocyte/dendritic
cell collections resulted in dedicated working parties
within the European Group for Blood and Marrow
Transplantation (EBMT) and the International Society for
Hematotherapy and Graft Engineering. Two Italian scien-
tific societies for hematology and hemapheresis (SIDEM
and GITMO) produced best practice recommendations
for stem cell mobilization in children and adults.299
Extracorporeal photopheresis is a treatment in which
blood mononuclear cells collected by apheresis are incu-
bated with methoxsalen and exposed to UV light, and
subsequently reinfused to the patient. Extracorporeal
photopheresis is by UK and Italian scientific/clinical con-
sensus groups recommended as 2nd-line treatment for
graft-versus-host disease (GvHD) after allogeneic stem cell
transplantation and for scleroderma and other autoim-
mune diseases.300 Because of the high costs, however,
many patients cannot be treated with extracorporeal pho-
topheresis.
Stem cell donations by healthy donors pose special
medico-ethical problems. Surveys in Europe and the US
reveal that the care for the family donor differs from the
strict guidelines from the World Marrow Donor
Association aiming at optimal donor safety for unrelated
donors. Collections of mononuclear cells and subsequent-
ly ex vivo preparation of the collected leukocytes for cellu-
lar therapies is currently being explored as a novel potent
anticancer treatment or antiviral vaccination therapy.
This requires a further commitment and poses a burden
for the volunteer donor.
Proposed research for the Roadmap
Therapeutic apheresis: there remains an ongoing need to
contribute to evidence base indications for therapeutic
apheresis. Given the orphan character of diseases this
requires broad collaboration with all involved institutes in
Europe and the establishment of European databases in
conjunction with the scientific societies of various med-
ical disciplines.
Stem cell donation by autologous, related, and unrelated
donors: for stem cell donation, the establishment of a glob-
al standardized system for related donor care comparable
to unrelated volunteer donors is in progress. This initia-
tive is a joint effort of the World Marrow Donor
Association and EBMT, resulting from the establishment
of an EBMT board committee on donor follow up (2012)
with one of the goals to set up a donor follow-up registry
for all EBMT related and unrelated stem cell donors and
to provide the possibility for systematically collecting
adverse events and longer follow up for family donors.
The safety of new stem cell mobilization drugs (e.g.
biosimilars and CXCR4 agonists) requires European col-
laboration and uniform medico-ethical procedures.301
Plasma and platelet donation from unrelated donors: a donor-
related aspect is whether the repeated exposure to citrate
(binding calcium) and protein removal is harmful and
poses risks for osteoporosis and hypogammaglobuline-
mia in the long term, an important issue for recommen-
dation on plasma- or apheresis-derived platelet prod-
ucts.302
Anticipated impact of the research
Hemapheresis represents a unique medical (supportive)
specialty for patient treatment and depends highly on
industry-driven technology and drug development to
obtain optimal efficacy. Moreover, a huge part of the
worldwide allogeneic hematopoietic transplants, as well
as the European blood supply of plasma and platelet
products, depends on apheresis. Although short-term
adverse effects of patient as well as donor apheresis are
minimal, long-term effects of many procedures applied in
healthy (volunteer, non-remunerated) donors are less well
studied. The proposed research subjects can provide the
European community with information about the risk
and safety issues for donors, and promote convenient
devices and drugs for their voluntary donations.
7.4. Immunological transfusion complications:
alloimmunization/transfusion-related immunomodula-
tion/ hemovigilance
Andreas Greinacher (Ernst-Moritz-Arndt-Universität,
Greifswald, Germany), Anneke Brand (Leids Universitair
Medisch Centrum, Leiden, the Netherlands), Frans Claas
(Leids Universitair Medisch Centrum, Leiden, the
Netherlands), France Noizat-Pirenne (Etablissement
Français du Sang, Créteil, France), Martin Olsson (Lunds
Universitet, Lund, Sweden), Sacha Zeerleder (Sanquin
Research, Amsterdam, the Netherlands).
Introduction
Currently, donor counseling, sensitive laboratory tests,
good manufacturing practice, and hemovigilance have
substantially increased transfusion safety with respect to
transfusion-transmitted infections. However, blood trans-
fusions also bear immunological risks, yet lack a surveil-
lance system. Although alloantibodies can result from
pregnancy, most are induced by transfusions. Red blood
cell (RBC) antibodies can cause (sub)acute hemolytic
transfusion reactions and hemolytic disease of the
fetus/newborn. Leukocyte/HLA antibodies can cause
transfusion-related acute lung injury and limit the chance
of finding a compatible (organ/stem cell) graft. HLA and
platelet antibodies destroy transfused blood platelets
needed for leukemia treatment and stem cell transplanta-
tion. Many European countries apply universal leukore-
duced transfusions, which reduces HLA immunization,
but HLA antibodies still hamper optimal platelet transfu-
sion and transplantation treatment. Except (Rh-K) match-
ing of RBC transfusions for (pre)fertile women and for
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patients with hemoglobinopathies, applied by some
European countries, measures to avoid antibody forma-
tion are not yet possible. Although some countries have a
national registry for RBC/HPA-immunized pregnant
women, the overall prevalence of alloimmunization
across Europe is unknown. However, immunization has a
huge economic impact in the need to provide safety nets
for immunized patients needing blood or transplants, or
who are pregnant.
Besides antigen-specific immunization, clinical studies
suggest transfusion-related immunomodulation, an ill-
defined complication also affecting the innate (not anti-
gen-specific) recipient immune system, transiently
impairs resistance against infections, enhancing organ
damage and resulting in unknown consequences for can-
cer immunosurveillance.
Research on the mechanism of alloimmunity has most-
ly focused on animal models, even though pregnancies
and blood transfusions in humans provide unique models
for systematic studies of in vivo reactions of the human
immune system.
European research contributions 
In the past decade, European research groups have
advanced our knowledge of the genetics, polymorphism,
expression, function, and pathophysiology of the many
blood groups expressed on RBCs, leukocytes, and
platelets. Molecular genotyping of most antigens is now
possible for donors and patients, and even fetal polymor-
phic antigens can be determined in maternal blood during
pregnancy. Demonstration of the absence of (fetal)
RhDpos DNA in Rh-Dneg gravidas avoids unnecessary
immunoprophylaxis with human anti-D immunoglobulin
and saves money.303 A European platform performed
preparations for implementation of “RBC bloodmatch on
a chip.”304 For stem cell and organ transplantation and
donor selection for platelet transfusions, provided elec-
tronic matching programs can select HLA-compatible
donors from large international registries. HLA-net aims
at networking researchers in bone marrow transplanta-
tion (BMT), epidemiology, and population genetics to
improve the molecular characterization of genetic HLA
diversity of human populations with an impact on both
public health and fundamental research (Allele Frequency
Net Database). A European subgroup of the Allele
Frequency Net Database (EUROSTAM/HLA-net) is set-
ting up an HLA allele frequency database to enable renal
transplantation in highly sensitized patients on the basis
of acceptable HLA mismatches.305 The European platelet
immunology working party contributed insight in fetal
alloimmune thrombocytopenia.306 Unraveling the minor
histocompatibility antigens aims at dissecting the T-cell
immunity causing graft-versus-host disease (GvHD) and
graft-versus-tumor effect (see Section 9).
Proposed research for the Roadmap
Four broad research goals are proposed.
Epidemiology: the current EU hemovigilance registries
could be extended with immunovigilance. Registration of
alloantibodies is important to define which phenotypes
we should focus on for blood and stem cell donor recruit-
ment (e.g. ethnic minorities), for composition of high-
throughput RBC, HLA, and HPA typing platforms of
donors, recipients, pregnant females, and fetuses.
Immunovigilance would also serve as post-marketing sur-
veillance of pathogen-reduced products to exclude
immunogenic neoantigen formation. A registry of trans-
fusion-dependent RBC diseases in Europe can identify the
incidence and stimulate collaborative treatment studies
for hyperhemolysis, a life-threatening transfusion compli-
cation.
Prevention: prevention of alloimmunization requires bet-
ter matching and the detection of potentially dangerous
memory responses. Currently, about 300 RBC antigens
are genetically and/or molecularly defined.
Approximately 40 more residual (orphan) groups need to
be unraveled, while new RBC groups are still discovered
through unexpected antibodies. It is important to know
their genetic backgrounds for inclusion in platforms for
high-throughput donor and patient typing. The polymor-
phism of the HLA system with more than 10,000 identi-
fied alleles complicates relevant clinical matching. Every
HLA allele poses a unique combination of antigenic epi-
topes, but many epitopes are shared with other HLA alle-
les.307 Consequently, the immune response to a foreign
HLA antigen can be explained by a restricted number of
epitopes. New strategies should focus on matching for
the relevant immunogenic epitopes between donor and
recipient rather than matching for the HLA alleles. The
complex pathophysiology of high and low responder
individuals to alloantigens needs studies of genetic and
environmental factors for T- and B-cell activation, memo-
ry, and antibody persistence. Instead of studies in mice,
pregnancy and transfusions in humans can enhance
insight.
Reversal of immunity: alloimmunization cannot be com-
pletely abolished. To reverse antibody production and
memory immune cells is extremely complex. For this pur-
pose, the effect of selected drugs/immune cells shall be
explored on the behavior of B/plasma cells, regulatory
mechanisms at the T-cell level, antibody affinity develop-
ment, and the role of (post-pregnancy) chimerism.
Mitigating severe alloimmune complications: antibodies can
cause severe (lethal) complications, such as hyperhemol-
ysis after transfusion, severe bleeding and lack of compat-
ible platelet donors, graft rejection, and fetal morbidity
and mortality. New drugs mitigating complement activa-
tion and other sequels (cytokine storm) of antigen-anti-
body reactions may save lives and safeguard transplanted
organs.
To reach these goals, translational research programs
including bioinformatics analyzing big-data output304-307
should be combined with basic studies using the unique
situation of the highly ethical exchange of alloantigens by
blood transfusions.
Anticipated impact of the research
For patients suffering from a wide range of (onco)
hematologic diseases, transfusions, stem cell transplanta-
tion, and immunotherapy can be indispensable.
Alloimmu nization hampers optimal access and increases
costs related to these treatments. The proposed research
will result in the reduction of immunization and of dam-
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age caused by immune incompatibility, and can reduce
the current high cost of care for alloimmunized patients.
7.5. Blood-borne infections and hematologic patients:
lines of research
Hans Zaaijer (Sanquin Research, Amsterdam, the
Netherlands), Dragoslav Domanovic´ (European Center
for Disease Prevention and Control, Stockholm, Sweden).
Introduction
The donation of organs, tissues, and cells as well as the
pooling of large numbers of donor plasma units for pro-
tein fractionating bears the risk of transmission of
pathogens to recipients. For hepatitis B, hepatitis C, HIV,
and variant Creutzfeldt-Jakob disease, donor counseling,
testing, product processing, and traceability of donors and
recipients are successfully applied to limit the risk of
transmission by transfusion and transplantation.
However, the increase in global travel, intensive animal
farming, and climate change may cause a quick spread of
emerging bacterial, viral (e.g. West Nile virus, chikungun-
ya virus, and dengue virus), and parasitic infections.
European research contributions 
Safeguarding blood products and other substances of
human origin (SoHO), intended for human treatment, is
regulated in the European Union by several directives,
launched from 2004 to 206 (2004/23/EC, 2006/17/EC, and
2006/86/EC). The European Commission leads the regu-
latory activities, co-ordinates the work of national com-
petent authorities for SoHO, and runs Rapid Alert plat-
forms monitoring serious adverse reactions and events
caused by SoHO therapies and traceability from donor to
patient and vice versa. The European Network of
Competent Authorities for Tissues and Cells participates
in the vigilance and surveillance of SoHO. For the blood
supply, the European Blood Alliance emerging infectious
disease monitoring group ensured quick monthly infor-
mation with recommendations for donor/donation exclu-
sion, in particular related to traveling.
In 2005, the European Centre for Disease Prevention
and Control was established in Stockholm. Its mission is
to identify, assess, and divulge information about the cur-
rent and emerging threats to human health posed by
infectious diseases. The center communicates with Co-
ordinating Competent Bodies in each member state to
strengthen and develop continent-wide disease surveil-
lance and early warning systems. In the field of SoHO
safety, the center provides member states and the
European Commission with the best advice available
concerning infectious risks of donations and human use
of SoHO. The center also develops risk assessments and
tools related to infectious safety of SoHO and provides
weekly maps of areas affected by West Nile virus infec-
tion, to support blood banks and pharmaceutical produc-
tion plants to take preventive measures and help with val-
idation of infectious disease tests.
Proposed research for the Roadmap
In the Western world, the risk that blood transfusions
and blood-derived products transmit blood-borne infec-
tions to patients is very small. For example, the introduc-
tion of sensitive nucleic acid amplification testing for
HIV1/2, hepatitis B virus, and hepatitis C virus reduced
transmission of these agents to one residual infection in 1-
10 million transfusions. Nevertheless this risk is not zero,
and for hematologic patients the risk is higher than for
many other categories of recipients. Besides prolonged
immune impairment in transplant recipients, it has been
shown that patients treated with chemotherapy for
hematologic cancer may also lose pre-existing immuni-
ty.308 It is obvious that the ongoing research in pathogen
inactivation and pathogen removal is of great importance
for blood recipients that are especially vulnerable to
blood-transmitted infections (see Subsection 7.6;
pathogen inactivation and removal). An important topic,
especially relevant for blood disorders, is the question of
whether blood and blood-derived products for immuno-
suppressed hematologic patients should be safer than for
other categories of patients. At least three elements of this
question are candidates for applied research.
1. Does severe (iatrogenic) immunodeficiency warrant
additional safety measures for blood transfusions and 
blood-derived products [e.g. pooled plasma and
hematopoietic stem cells (HSCs)] in hematologic
patients, and if so, which agents and which safety
measures must be considered and what are the trig-
gers for their implementation? At the same time, it
seems desirable to apply this question on a more prac-
tical level to at least two specific infectious agents.
2. In parts of the Western world, currently there is a high
incidence of silent hepatitis E virus genotype 3 infec-
tion among blood donors. Transmission via blood and
blood-derived products has been demonstrated.
Hepatitis E virus is a non-enveloped virus and is not
sufficiently inactivated by the current solvent-deter-
gent procedures used for pathogen reduction (PR) of
pooled plasma products, which are in large quantities
administered to patients with thrombotic thrombocy-
topenic purpura (TTP). In immunosuppressed
patients, hepatitis E virus genotype 3 may cause silent,
chronic infection that rapidly leads to cirrhosis.309
Chronic hepatitis E is often interpreted as a drug-
induced liver injury or a sign of graft-versus-host dis-
ease (GvHD), which may lead to an increase in
immunosuppressive treatment and thus may worsen
the viral infection. From a technical point of view,
donor screening for hepatitis E virus genotype 3 RNA
is possible, but so far it has not been implemented.
3. Parvovirus B19 (B19V) infection has a seasonal and
cyclic nature: each year in springtime blood donors
may harbor acute, asymptomatic B19V infection. In
addition, every four years, there is a marked increase
of B19V infections. In immunosuppressed patients,
exposure to B19V may cause severe and chronic ane-
mia, which can be controlled only by repeated blood
transfusions or monthly administration of IVIG. To
prevent B19V infection of vulnerable patients, some
blood transfusion services (e.g. in the Netherlands)
provide “B19V-safe” blood for specific categories of
recipients. It is desirable to evaluate this policy in the
EU member states.
Anticipated impact of the research
With the implementation of serological and molecular
testing, at least in high-income countries, transfusion-
transmitted infections of a limited number of specific
pathogens (HIV, hepatitis B virus, hepatitis C virus, and
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human T-cell leukemia virus) have become extremely
rare. Full control of infectious disease transmission has
not yet been achieved because many pathogens are not
included in test protocols and new agents continue to
emerge. The immune status of recipients has a consider-
able impact on the outcome of transfusion-transmitted
infections. This particularly affects hematologic patients
who received anti-lymphocytic agents or underwent
stem cell transplantation. The results of the proposed
research can be used to better assess patient risks,
enhance the cost-effectiveness of treatments, and increase
the safety of blood and blood-derived products for hema-
to-oncology patients across Europe.
7.6. Pathogen reduction of blood components
Lello Zolla (University of Tuscia, Viterbo, Italy), Paolo
Rebulla (Ospedale Maggiore, Milan, Italy), Sara Rinalducci
(University of Tuscia, Viterbo, Italy), Peter Schlenke
(Medical University Graz, Graz, Austria), Jean Daniel
Tissot (University of Lausanne, Lausanne, Suisse).
Introduction
Nowadays, thanks to the measures adopted to increase
the safety of transfusions (including optimized donor
selection programs and mandatory screening tests), the
residual risk of suffering a transfusion-related pathogen
infection is extremely low, especially with regard to viral
infections. Transfusion medicine research has, therefore,
moved toward the development of methods intended to
reduce the risks posed by bacterial contamination, partic-
ularly in platelet components. Transfusion of bacteria-con-
taminated platelets can cause a septic reaction in the recip-
ients (1:20,000 to 1:50,000). The fatality rate is expected to
be around 10%; however, transfusion-associated bacterial
infections may be underestimated due to the fact that
platelet transfusions are frequently administered to
patients suffering from hemato-oncology diseases where
the use of antibiotics-based therapies may mask the
symptoms of a septic transfusion reaction. To prevent
platelet transfusion-related bacterial sepsis, several coun-
tries have implemented bacterial detection, but unfortu-
nately, available bacterial screening methods (even the
more sensitive ones) are not able to completely eliminate
the cases of this infectious complication of transfusion.
Moreover, one should not forget the issue of novel emerg-
ing pathogens, including not only undiscovered strains of
bacteria, but also viruses with genomic mutations suscep-
tible to immune escape mechanisms or known
parasites/viruses that are continuously on the rise in non-
endemic regions in view of globalization and climate
changes (e.g. Plasmodium spp., Babesia spp., Trypanosoma
cruzi and HIV, as well as dengue, West Nile, and chikun-
gunya viruses).310,311 The arduous search for the zero-risk
strategy to reach a completely safe blood transfusion will
probably never end, although a complicated and intense
debate about the implementation of pathogen reduction
(PR) technologies continues. This is due to the paradox
that innovation directly related to the safety of blood
products is most frequently associated with impairment of
a product’s intrinsic quality. Thus, scientists have to find
the equilibrium between safety and clinical efficiency.
This observation means that we urgently need basic as
well as clinical research. Although in some European
countries PR technologies for plasma and platelets fulfill
the overall criteria of acceptability, there are currently no
acceptable PR methodologies for whole blood and red
blood cells (RBCs).
European research contributions 
The variety of emerging pathogens and the costs of
development of new counseling and detection assays
were (besides more ideological purposes for under-
resourced countries) driving forces to develop techniques
for PR of cellular blood components, often in close collab-
oration between research centers and pharmaceutical
companies. For platelets, three PR techniques have been
developed and approved in Europe.311 One is based on the
addition of amotosalen and illumination with UVA light; a
second combines the addition of riboflavin (vitamin B2)
and illumination with 265 to 370 nm UV light; and the
third applies only UVC (below 280 nm) under loose strong
agitation. However, in France only A-L (Intercept) has
been approved (by the National Agency for the Safety of
Medicines and Health Products, in 2003). The first two
methodologies are approved for clinical application or in
phase III studies, while Theraflex UV is currently in phase
I-II.311 In Europe, there is a wide range of use of PR-treated
platelets for routine transfusion. Published hemovigilance
data predominantly concern the A-L (Intercept) method
with all reports confirming both the safety and efficacy of
A-L–treated platelets in a huge number of platelet transfu-
sions.312 If on the one hand, PR technologies are designed
to irreversibly disrupt nucleic acids of pathogens, on the
other, they also cause collateral reactive oxidation-related
damage to platelet proteins, thus enhancing the platelet
storage lesion. Comparison of such damage by different
PR techniques has been shown by a consortium represent-
ed by four (Switzerland, Italy, France, Germany) European
research groups, along with a Canadian group.313 Studying
platelet proteome changes revealed that each PR tech-
nique affects different protein pathways relevant for
essential platelet functions.313 A great challenge is posed by
PR of RBCs for which UV light cannot be applied.
Currently, the S-303–based technology (Cerus
Corporation, Concord, USA) is the pre-eminent system
for PR of whole blood and RBCs.314
Proposed research for the Roadmap
The following are important issues to be examined: 1) to
what extent PR of platelets affect the potential to
prevent/treat bleeding; 2) immunogenicity of PR-treated
cellular blood products; 3) clinical comparison of blood
products treated by different PR techniques; 4) PR of RBCs;
and 5) assessment of cost-effectiveness of PR interventions.
Anticipated impact of the research
The proposed research will contribute to improving the
quality of established commercial technologies for PR in
platelets and plasma through the co-operation of academic
expert centers in proteomic analysis and cellular biology.
Moreover, experience gained in the studies performed in
platelets will facilitate the development of novel technolo-
gies for PR in RBCs and whole blood. The achievement of
a unique procedure carried out on whole blood will con-
tribute to reducing the high costs of current PR proce-
dures. Besides this important economical benefit, the
development of a global PR reduction technology for
whole blood will significantly reduce the frequency and
severity of pathogen transmission with blood transfu-
sions.
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7.7. Toward large-scale production of blood cells for
transfusion purposes
Luc Douay (Université Pierre et Marie Curie, Paris,
France), Emile van den Akker (Sanquin Research,
Amsterdam, the Netherlands), David Anstee (NHSBT
Blood Centre, Filton, United Kingdom), Dominique
Baruch (Université Paris Descartes, Paris, France ), Johan
Flygare (University of Lund, Lund, Sweden), Marieke von
Lindern (Sanquin Research, Amsterdam, the
Netherlands), Anna Rita Migliaccio (Mount Sinai
Hospital, New York, United States of America), Kenichi
Miharada (University of Lund, Lund, Sweden), Wassim el
Nemer (INSERM UMR S1134, Paris, France), Ash Toye
(University of Bristol, Clifton, United Kingdom).
Introduction
Blood transfusions in Europe depend on the recurrent,
non-remunerated contribution of blood by donors. Part of
the donor population is genetically typed. In addition,
banks store typed erythrocyte units in liquid nitrogen,
available for patients with alloantibodies having no other
option. It is, however, logistically impossible to provide
all patients that require regular blood transfusions with
matched blood products.
A solution to this problem would be the availability of
cultured red blood cells (cRBCs) and cultured platelets
(cPLTs) that are perfectly matched for all blood groups.
When successful, this will be a major clinical break-
through providing transfusion-dependent patients with
a non-immunizing safe transfusion product, likely
diminishing iron overload in transfusion-dependent
patients. 315-319
European research contributions 
Over the past decades, several major steps towards cul-
tured human blood cells were established in Europe,
paving the way to major advances in our understanding of
the mechanisms that regulate erythropoiesis/megakary-
opoiesis. The first key development for the ex vivo produc-
tion of erythroid cells was made at the end of the last cen-
tury when liquid culture systems replaced semisolid cul-
ture, allowing the expansion and differentiation of pure
erythroid cultures in distinct medium conditions. This
enabled large-scale culture of cRBC from hematopoietic
stem cells (HSCs) of adult or umbilical cord blood origin,
which was achieved with different cocktails of cytokines
and additives. Improved culture conditions yielded high
numbers of fully mature cRBCs and cPLTs, and the
prospect of culturing blood cells for transfusion purposes
became closer to a reality. Industrial production of both
cRBCs/cPLTs has been tackled by simplification of proto-
cols. Procedures without stroma or xenogenic components,
using pharmaceutical-grade reagents, have been devel-
oped, allowing the production of cRBCs/cPLTs for transfu-
sion from various stem cell sources. The first proof of con-
cept (autologous mini-transfusion with cRBC from adult
CD34+ cells) in a healthy volunteer was performed in Paris.
Erythropoiesis and megakaryopoiesis should ideally be
initiated from an unlimited source, such as induced
pluripotent stem cells (iPSCs). The big advantage of iPSCs
is that they can be selected for their phenotype of interest,
or manipulated to generate specific phenotypes. Several
EU teams can now produce cRBCs/cPLTs from various
sources (HSCs, human ESCs, iPSCs), but not yet at suffi-
cient numbers or quality. An alternative may reside in
immortalized cell lines, for which a Japanese team provid-
ed proof of concept by production of cRBCs and cPLTs.
The major remaining challenge for in vitro blood pro-
duction is the affordable cost. The development of biore-
actor conditions for cost-effective production at a thera-
peutic scale, however, is still at an early phase. The pro-
duction of cRBCs/cPLTs is optimized in standard liquid
bioreactors under good manufacturing practice conditions
to generate enough cells for mini-transfusions for further
clinical trials. In addition, 3-D bioengineered scaffolds are
being tested for more efficient stem cell expansion and
cost reduction. This has brought our EU consortium to a
lab-to-market stage. For cPLTs in particular, 3-D culture is
required, which requires the development of flow devices
that are based on microfluidics and engineered biomateri-
als mimicking the bone marrow environment, such as silk
and hydrogels.
Proposed research for the Roadmap
The next step is to optimize the production of
cRBCs/cPLTs at the required scale for safe patient transfu-
sion. EU blood supply centers and scientists must co-
operate to: 1) fulfill regulatory compliance of
cRBCs/cPLTs as new advanced therapy medicinal prod-
ucts (ATMPs), to define the release criteria and set func-
tional standards for cRBCs/cPLTs; 2) prepare cRBCs/cPLTs
for clinical studies; and 3) optimize culture conditions to
reduce costs for the large scale required for clinical use.
The key objectives for the next few years can be summa-
rized in three steps.
1. Achieving regulatory compliance: the objective is to
define standards for quality and safety regulations and
release criteria that comply with the good manufac-
turing practice requirements for the production of
ATMPs. These standards should be used by regulatory
committees throughout Europe that have to decide on
the use of cRBCs/cPLTs in clinical trials. European
teams need to organize consensus approach and
progress meetings with stakeholders that include
experts in transfusion technology, immunohematol-
ogy, clinical transfusion science, hematologists, repre-
sentatives of patient organizations, and representa-
tives of donor councils throughout the European
research area.
2. Establishing proof of principle by large-scale transfusion of
cRBCs/cPLTs: proof of principle by large-scale transfu-
sion of cRBCs/cPLTs should be established by transfu-
sion studies in healthy volunteers, giving insight into:
1) the stability and functionality of cRBCs/cPLTs after
administration; and 2) the risk of immunization
against neoantigens. The aim of the clinical trials will
be to validate the release criteria set in vitro for their
suitability to predict cellular function in vivo.
3. Therapeutic-scale production at reasonable cost: the aim is
to generate cRBCs/cPLTs more efficiently without
compromising the functional parameters and thresh-
olds that define a safe cRBC/cPLT product. Modified
culture conditions should result in a more efficient,
automated, and economical process. There is a need
to devise optimal bioreactor conditions to culture cells
at high density in a low-cost medium. Immortalized
EHA Roadmap for European Hematology Research
haematologica | 2016; 101(2) 183
cells derived from universal donors that generate suit-
able, high-quality transfusion units for (almost) all
patients, without adverse transfusion reactions, have
to be designed. Efficient expansion and maturation of
these cells may be supported by small molecular com-
pounds. Chemical libraries can be tested to find sub-
stances that control or enhance expansion and matu-
ration of erythroid/megakaryocytic cells, and to deter-
mine expression of appropriate types of Hbs for
cRBCs.
Anticipated impact of the research
cRBCs and cPLTs derived in vitro with rare or near uni-
versal phenotypes would revolutionize blood transfusion
practices for future safe blood transfusions.
Development of culture conditions to produce pharma-
ceutical quantities of blood involves a considerable
amount of knowledge, innovation, and technology gener-
ation. To this end, EU teams should collaborate closely
with industrial partners. In addition to the transfusion
market, RBCs may be manipulated for drug delivery,
promising a further revolution in blood transfusion prac-
tices.
The EHA Roadmap for European Hematology
Research
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Parallel to great progress made in the treatment of
hematologic malignancies in the past 20 years, the
research carried out by the hematology community has
led to equally valuable progress in the incidence, causes,
presentation, and mortality of infectious complications.
These changes have usually been poorly anticipated, and
sometimes not identified before several trials have
assessed a new drug. Since tyrosine kinase inhibitors
(TKIs) have been made available for chronic myeloid
leukemia (CML), the indication for allogeneic hematopoi-
etic stem cell transplantation (HSCT) has decreased con-
siderably in this disease, and although TKIs impact on
immunity, infection is now extremely rare in this setting
before acute transformation of the disease. On the other
hand, new monoclonal antibodies such as rituximab,
which is highly efficient in many CD20-positive lym-
phoid malignant disorders, have created a risk of pro-
longed B-cell deficiency, increasing a natural risk of infec-
tion due to encapsulated pathogens and impairing the
response to vaccines. In general, few new therapeutic
approaches have been devoid of adverse infectious risks:
the older age of HSCT candidates increases the risk of
many infections after transplant; alemtuzumab treatment
increases the risk for cytomegalovirus (CMV) infection
and disease; eculizumab, a humanized anti-C5 mono-
clonal antibody used for treatment of paroxysmal noctur-
nal hemoglobinuria (PNH), results in susceptibility to
meningococcal infection, requiring vaccination. However,
many unmet needs remain and will continue to remain as
long as new therapies are being developed.
Understanding the mechanism of predisposition to cer-
tain pathogens is of crucial importance to develop strate-
gies, as are exhaustive epidemiological data each time a
new treatment or strategy is assessed in hematology. This
should be done not only in the classical high-risk patient
populations such as neutropenic patients or HSCT recipi-
ents, but also in patients with lympho- or myeloprolifer-
ative chronic disorders who are increasingly being man-
aged as outpatients and deserve specific considerations in
terms of control of infection.
Europe has been highly active in the field. The
Infectious Diseases Group of the European Organisation
for Research and Treatment of Cancer has been one of
the very first in the world to prospectively study febrile
neutropenia.320 Twenty-five years ago, the European
Group for Blood and Marrow Transplantation (EBMT)
created a dedicated working party for infectious compli-
cations after HSCT. The EBMT was able to show that
death from infections significantly declined over time
since the very early times of transplant, although it
remains a major concern.321 The European Conference on
Infections in Leukemia was initiated ten years ago to
share practices and expert opinions, elaborate guidelines
for the management of infectious complications in hema-
tology patients, and define new areas of research. More
recently, the European Society of Clinical Microbiology
and Infectious Diseases created a group for immunocom-
promised patient populations. Pharmaceutical companies
have also been very active in developing new anti-infec-
tive drugs for high-risk patients. However, the evolution
of bacterial resistance worldwide, more aggressive thera-
pies for some conditions, and an older age limit for per-
forming HSCT mean these advances are associated with
a greater risk of patients dying from infection, often
before benefiting from the treatment of their underlying
disease. This is especially the case in acute leukemia or
high-risk lymphoma patients, allogeneic HSCT recipi-
ents, and primary immunodeficient children. Several
issues concern all of these populations, and targeted stud-
ies should be encouraged.
1. We need to better anticipate the infectious risk and
adopt a more preventative approach on an individual
basis. This implies good epidemiological data in
hematology patients, better identification of specific
infectious risks, and the development of scoring sys-
tems322 to better target prophylaxis, which, for many
reasons, including toxicity, resistance, and cost, can-
not be universal.
2. We need new classes of antibacterials to overcome the
inevitable increase of multi-drug resistance, which is a
worldwide phenomenon and may soon constrain us
to give up curative treatment in hematologic diseases.
In parallel, we should explore how to limit the admin-
istration of the available antimicrobials as far as possi-
ble each time they are needed. To reach this goal,
antimicrobial stewardship in the hematology ward is
crucial, and yet more difficult than with other patient
populations.323 This requires studies and resources.
3. In order to challenge the empirical anti-infectious
approach widely used in many hematology patients,
we need to develop sensitive, direct or indirect mark-
ers of bacterial, fungal, and viral infection and assess
their clinical value in prospective trials. The main goal
should be to restrict the administration of anti-infec-
tives as much as possible, on the basis of infection
markers.
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4. Faced with the real lack of new antibacterials, we
need to develop alternative strategies to prevent and
treat 
infection. To this end, vaccination, monoclonal anti-
bodies, and targeted cellular therapy should be prop-
erly assessed in well-designed prospective and con-
trolled trials. Except after HSCT, where it has been
possible to produce evidenced-based guidelines, vacci-
nation has been poorly explored in hematology
patients so that clinical practice is heterogeneous.
Prospective trials on vaccination in specific diseases
should be encouraged, taking into account the timing
of the therapeutic program of the underlying dis-
ease.324
Although the role of the pharmaceutical industry is of
the utmost importance to produce new tests and new
drugs and support large, well-designed trials, more aca-
demic involvement is essential for translational research,
epidemiology, and prospective randomized trials within
the field.
The unmet needs of infectious complications in hema-
tology patients are mainly observed in four different set-
tings.
1. HSCT recipients.
2. Neutropenic patients. 
3. Non-neutropenic patients with acquired immune defi-
ciencies. 
4. Primary immune deficiencies.
We also think that exploring genetic predisposition to
infections in these patients will greatly help anticipate
and manage the risks.
8.1. Infections in HSCT recipients
Per Ljungman (Karolinska Institutet, Stockholm,
Sweden), Simone Cesaro (Policlinico GB Rossi, Verona,
Italy).
Introduction
Infections have been major obstacles to the success of
allogeneic stem cell transplantation from the beginning,
more than 40 years ago. The immunosuppression needed
for successful transplantation, including the conditioning
regimen, prevention of, and treatment of graft-versus-
host disease (GvHD), all contribute to these risks.
Transplant strategies are continuously evolving with the
introduction of new conditioning regimens, an increased
utilization of alternative donors (e.g. haploidentical
donors), and single and double cord blood grafts. Many of
these new techniques will affect the speed and degree of
immune reconstitution and be related to the risk of infec-
tions. Haploidentical transplantation is performed in an
increasing number of patients. However, the strategies
used to perform allogeneic transplantations vary between
centers. Strategies are likely to affect the immune recon-
stitution in different ways, and knowledge of the risks of
specific infection in short, intermediate, and long-term
perspectives are still limited.
Patient populations are changing, especially with more
elderly patients undergoing allogeneic transplantation.
Elderly patients are more vulnerable to infections such as
pneumococci and influenza, and are also likely to have
comorbidities that influence the risk for infections.
Viral infections have been recognized as important for
outcome, especially in allogeneic stem cell transplant
recipients. Despite many advances in the field, these
infections are still associated with morbidity and mortal-
ity. Several new antiviral drugs, as well as
cytomegalovirus (CMV) vaccines are in late clinical devel-
opment. Techniques allowing monitoring of CMV-specif-
ic immune responses in the individual patient are also
being developed and might be valuable in the manage-
ment algorithm. A challenge for the next few years will
be to implement these new agents and techniques in the
clinical management of stem cell transplant recipients,
taking into consideration efficacy, toxicity, and cost
aspects. New drugs are likely to be more expensive than
the currently available agents, but might have significant
advantages in terms of toxicity. In addition, vaccines and
specific T-cell therapies are under development, and
strategies for their implementation need to be developed
addressing efficacy, safety, and costs.325
The importance of human herpesvirus 6 has been dis-
cussed for at least two decades, but the diagnostics and
management of these infections have been controversial.
Recent studies suggest that human herpesvirus 6 is an
important pathogen mainly causing complications in the
central nervous system in patients with poor or delayed
T-cell reconstitution, such as cord blood transplant recip-
ients.326 For the moment, the available antiviral drugs are
not very effective in controlling this virus.
A changing epidemiology of viral infections poses new
challenges. Respiratory viruses such as respiratory syncy-
tial virus and influenza are well recognized as important
pathogens especially after allogeneic stem cell transplan-
tation. During the past decade, at least 10 new respiratory
viruses have been described, of which several have the
potential to become relevant pathogens.
Previously known viruses can change their epidemio-
logical pattern and appear as important pathogens. This is
illustrated by the recent emergence of severe infections
caused by enterovirus D68 in outbreaks in both North
America and Europe.327 Recent experience also includes
the emergence of the West Nile virus, outbreaks of
chikungunya virus, and the expanding areas of the world
where patients are at risk of dengue virus infections. A
recently recognized potentially important pathogen is the
hepatitis E virus that has been associated with chronic
hepatitis and possibly the rapid development of cirrhosis
in small patient series.328 Several of these viruses can also
be transmitted from stem cell donors, possibly requiring
testing for new viruses.
Vaccines are important for preventing infections in the
general population. There are major gaps in our knowl-
edge of how best to utilize vaccines in stem cell trans-
plant.329
European research contributions 
European centers and collaborative groups, such as the
Infectious Diseases Working Party of the European Group
for Blood and Marrow Transplantation (EBMT) and the
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European Organisation for Research and Treatment of
Cancer working groups, have been active in the field of
infectious diseases in transplant recipients. Topics of par-
ticular interest for European investigators include the
management of viral infections due to CMV, Epstein-Barr
virus (EBV), respiratory syncytial virus, and polyomavirus
(BK). Other topics include the development of vaccina-
tion strategies for HSCT recipients, randomized studies
of antibacterial agents, and diagnosis and management of
fungal infections. Many of these studies have changed
practice, not only in Europe.
Proposed research for the Roadmap
1. Immune reconstitution and infections with special
emphasis on new transplant strategies.
a) studies are needed in patients undergoing hap-
loidentical transplantation;
b) studies addressing the specific needs of elderly
patients must also be developed.
2. Herpesviruses.
a) CMV: strategies are needed for introduction of new
prophylactic, monitoring, and therapeutic strategies in
patient management;
b) Human herpesvirus 6: new strategies must be
developed through proper controlled clinical trials.
3. Respiratory viruses - new viruses.
a) Careful surveillance and rapid recognition of respi-
ratory viruses by sensitive and specific diagnostic
techniques are necessary for the development of
infection control and management strategies. New
antiviral drugs against respiratory syncytial virus,
parainfluenza viruses, and influenza are undergoing
clinical tests, and well-designed studies in the HSCT
patient population are important.
4. T-cell therapy for infections.
a) Approaches aiming to improve the immune recon-
stitution with a minimal risk of uncontrollable GvHD,
such as the use of suicide gene-expressing T cells,
should be encouraged;
b) Multi-specific T cells with activity against several
infections are interesting options, especially for pre-
vention of viral infections;
c) T cells against aspergillosis might become impor-
tant, because the development of new antifungals
remains limited;
d) CMV-specific T cells are commercially available
and need to be tested in larger trials.
5. Vaccines.
The following topics need to be addressed:
a) whether different vaccine schedules should be used
in patients having undergone different transplant pro-
cedures needs to be examined;
b) new vaccines, such as inactivated varicella-zoster
vaccines, CMV vaccines, and vaccines against human
papillomaviruses, should be evaluated in well-
designed studies.
Anticipated impact of the research
In past decades, major improvements have been
achieved in infectious disease management in allogeneic
HSCT recipients. Despite these advances, infections
remain important causes of non-relapse mortality. New
infections can quickly become severe threats, as shown
by the 2009 influenza pandemic. Therefore, the impact of
the proposed projects will be in two areas: to further
reduce the morbidity and mortality of infections, and to
develop management strategies that quickly meet new
challenges.
8.2. Infections in neutropenic patients
Georg Maschmeyer (Ernst von Bergmann Klinikum,
Potsdam, Germany), Peter Donnelly (Radboud Universitair
Medisch Centrum, Nijmegen, the Netherlands), Inge
Gyssens (Universiteit Hasselt, Hasselt, Belgium), Hans
Hirsch (Universität Basel, Basel, Switzerland), Marie von
Lilienfeld-Toal (Universitätsklinikum Jena, Jena, Germany).
Introduction
Infections are the leading cause of death in patients
with hematologic malignancies undergoing myelosup-
pressive chemotherapy. The majority of infections are
caused by bacteria, but invasive fungal or viral infections
also occur frequently.
European research contributions 
A variety of European scientific associations and
groups have played a leading role in advancing the diag-
nosis, prevention, and treatment of infectious diseases in
patients with hematologic malignancies. In particular,
Europeans have pioneered research in the field of inva-
sive fungal diseases. Most of the diagnostic tools (e.g.
galactomannan antigen and the detection of Aspergillus
nucleic acid by PCR) have been developed and validated
in Europe, leading to the globally adapted definitions of
invasive fungal diseases by the European Organisation
for Research and Treatment of Cancer–Mycoses Study
Group in 2008 (www.eortc.org) and the European
Aspergillus PCR Initiative (www.eapcri.eu) has developed
a standard for detecting Aspergillus nucleic acid.
Moreover, European clinical trials of antifungal treatment
and prophylaxis have resulted in an overall survival ben-
efit. Beyond this, European groups have led the field in
clinical studies on antibiotic treatment and thus paved
the way for internationally recognized clinical guidelines
on antimicrobial strategies in patients with hematologic
malignancies.
Proposed research for the Roadmap
Despite this progress, there are medical and scientific
needs that remain unmet in the field of infections in neu-
tropenic patients. The most pressing topics include: 1)
the need for antimicrobial stewardship in the face of
emerging multi-drug-resistant bacteria given the lack of
new antimicrobial agents; 2) the challenge of communi-
ty-acquired respiratory viruses; 3) improvements in con-
trol of infection; and 4) establishing the role of the micro-
biome.
Proposed research topics:
Antimicrobial stewardship in prophylaxis and therapy: the
current standard of care for neutropenic patients is a pre-
defined form of antimicrobial prophylaxis and empiric
antimicrobial therapy as soon as fever occurs. This has
been a lifesaving approach for many years, but several
issues remain: 1) improving the initial response to antimi-
crobial therapy; 2) establishing the minimum duration of
systemic antimicrobial therapy after defervescence, as
current approaches often result in unnecessarily pro-
longed use of antibiotics; and 3) in the era of multidrug-
resistant pathogens,330 the current recommendations for
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antimicrobial prophylaxis and treatment, even after
establishing an etiology, need to be reevaluated. Thus, we
propose research regarding the following topics.
1. Use of therapeutic drug monitoring to personalize
dosing and improve response to prophylaxis and ini-
tial empirical therapy.
2. Prospective comparison of the duration of antibiotic
treatment, including in de-escalation (step-down)
strategies, with or without guidance by inflammatory
markers such as C-reactive protein, procalcitonin,
interleukin-6, and markers of gut function (e.g. cit-
rulline).
3. Prospective evaluation of different antimicrobial pro-
phylaxis regimens utilizing commonly used fluoro-
quinolones, as well as "older" drugs such as cotrimox-
azole, with prospective monitoring of inflammatory
markers and citrulline.
4. Prospective evaluation of a systematic approach based
on clinical and laboratory findings to guide pre-emp-
tive compared with empiric antimicrobial therapy
including antifungal therapy.
5. Clinical trials of novel antibacterial agents with new
targets and mechanisms of action in neutropenic
patients.
Community respiratory viruses (CRV): a series of outbreaks
have brought CRVs to the attention of clinicians and sci-
entists.331 CRVs are regarded as an uncommon cause of
fever during neutropenia, because they tend to occur sea-
sonally and are difficult to diagnose, but they have not
yet been studied systematically. However, the increasing
number of reports of fatal CRV infections has illustrated
the need for a better understanding of CRV epidemiology.
Further research is warranted, and we suggest the follow-
ing topics for clinical studies.
1. Studies on epidemiology, seasonality, and clinical rel-
evance of CRVs in neutropenic patients using modern
diagnostic methods.
2. Prospective evaluation of infection control measures,
especially in asymptomatic patients shedding the
virus.
3. Clinical development of novel antiviral agents with
activity against relevant CRVs.
Efficacy of infection control measures: infection control
measures are adopted routinely to reduce the risk of hos-
pital-acquired infections. These measures include protec-
tive isolation, use of gloves and gowns, rigorous disinfec-
tion measures, reduction of inhaled potentially infective
particles by air filtration and masks worn by patients
leaving their rooms or wards, and low-microbial hospital
diets. However, there is no evidence of benefit from these
measures in terms of reducing infection-related morbidity
and mortality.332 In the light of an increasing threat from
multi-drug-resistant bacteria and fungi among hemato-
logic patients, a comprehensive review is long overdue.
What is needed is a series of prospective, randomized
clinical studies focused on the use of the following.
1. Low-microbial hospital diet.
2. High-effiency air particle filtration.
3. Disposable gowns, gloves, and masks for caregivers
and visitors.
4. Well-fitting masks for patients outside their treatment
rooms.
Microbiome: in recent years, a rapidly evolving insight
into the essential role of the intestinal and skin microbio-
me for the quality of immune responses in normal and
immunocompromised individuals has been attained. This
has been shown to have a significant impact on the clinical
course of allogeneic stem cell transplant recipients, but
potentially also on the general interaction between host
and tumor cells.333,334 There is a need to better understand
the pathogenesis and background of fever and infections
in patients undergoing myelosuppressive chemotherapy,
for distinguishing febrile immune reactions from infec-
tions due to microbial pathogens, and for designing more
specific (“targeted”) antimicrobial or anti-inflammatory
treatment in this severely immunocompromised patient
cohort. Clinical and translational studies are needed in
neutropenic patients to explore the role of the microbiome
in the following.
1. The intestinal tract.
2. The oral cavity and teeth.
3. The respiratory system.
4. The skin.
Anticipated impact of the research
These projects will result in the following.
1. A significant improvement of survival rates of neu-
tropenic patients.
2. An improvement of the quality of life of neutropenic
patients through better prophylaxis of infectious
events, deletion of unnecessary procedures, shortening
of antimicrobial therapy duration, and subsequent
reduction of collateral damages of antibacterials.
3. Reduction of unnecessary antimicrobial prophylaxis
and therapy leading to reduced pathogen and com-
mensal resistance rates.
4. Evidence-based update of the guidelines on the ration-
al use of infection control measures for severely
immunocompromised patients.
5. A fundamental revision of the current approach to
fever and infections in neutropenic patients.
8.3. Infections in non-neutropenic patients other than
hematopoietic stem cell transplantation recipients
Claudio Viscoli (Università degli Studi di Genova,
Genova, Italy), Malgorzata Mikulska (Università degli
Studi di Genova, Genova, Italy).
Introduction
There is a growing population of patients with hemato-
logic malignancies who receive chemotherapeutic agents
that do not cause neutropenia but result in other types of
severe immunodeficiencies, such as T-cell defects and
hypogammaglobulinemia. These patients are at risk of
developing potentially life-threatening infections, which are
different from those commonly seen during neutropenia,
due to differences in the underlying immunodeficiency.
There is little reliable and systematic information on infec-
tions in non-neutropenic hematologic patients, even though
they significantly outnumber those with neutropenia.335
Studies on infectious complications in patients with
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hematologic malignancies are paramount for determining
the efficacy of chemotherapeutic agents. Indeed, even a
drug with a 100% curative effect of the underlying hema-
tologic disease cannot be used if it results in a 90% rate of
severe infections, which cannot be prevented or treated.
Thus, the lack of advances in infectious diseases (e.g. the
shortage of efficacious antibiotics against multidrug-resis-
tant gram-negative bacteria) may result in unacceptably
high mortality, hampering advances in chemotherapy.336
Most of the infections developing in subjects undergoing
different chemotherapeutic treatments are not unexpected,
and they could be predicted and prevented if timely studies
on the infectious complications were to be carried out. The
monoclonal antibody eculizumab is a good example; it pre-
disposes patients to meningococcal infection, and this
could be foreseen based purely on the knowledge of its
mechanism of action. Eculizumab mimics the C5 comple-
ment deficit, which can occur as an inherited immunodefi-
ciency, and it is associated with repeated or relapsing
meningococcal infections. Secondly, if registration trials
were properly designed, the true rate of specific infections
could have been established before the drug was marketed
and proper preventive measures could be designed.
Another example is alemtuzumab: here, no regular moni-
toring of cytomegalovirus (CMV) reactivation was per-
formed in the first efficacy studies. Dedicated studies and
appropriate recommendations on CMV management in
this setting could only be made several years later. Last but
not least, post-marketing monitoring of infectious compli-
cations would benefit from a standardized and dedicated
approach so that real-life incidence of infectious complica-
tions can be properly assessed.
Preventing infectious complications has always been the
most appealing approach, yet the benefit of prophylaxis
must be carefully weighed against its short- and long-term
side effects, such as drug toxicity and a change in epidemi-
ology or resistance patterns. The latter is of particular
importance in our era of multidrug-resistant bacteria, yet it
has rarely been evaluated in trials aimed at short-term ben-
efits.337 Antibiotics are the only drugs in which improper
use does not reflect on the patient being treated, but rather
on other patients and generations of future patients.
In addition, there is a global understanding that hospital
stay is associated with several risks and substantial costs,
such as colonization and infection with nosocomial
pathogens, including resistant bacteria or Clostridium diffi-
cile. Along with a reduced risk of health care–associated
infections, the undeniable benefits of outpatient therapy
are better quality of life (QoL) for patients and reduced
costs.338 Although some neutropenic patients are also cared
for in their home environment, outpatient management is
particularly suitable for non-neutropenic populations. In
order to perform secure treatment in outpatient settings, all
management procedures, such as diagnostic methods,
infection control measures, and treatment, should be
adapted to the outpatient condition. Therefore, rapid diag-
nosis, possibly based on a point-of-care approach, should
be developed; oral or once-daily intravenous therapy
should be preferred.
European research contributions 
Multidisciplinary efforts, including efforts from infec-
tious disease specialists, hematologists, microbiologists,
and infection control specialists, are needed in the field of
infectious complications in hematology patients, and sev-
eral studies have been successfully carried out in Europe
for more than 40 years.339 Scientific organizations and soci-
eties, such as the Infectious Diseases Group of the
European Organisation for Research and Treatment of
Cancer, the European Conference on Infections in
Leukemia, the European Group for Blood and Marrow
Transplantation (EBMT), the Immunocompromised Host
Society, the European Conference on Infections in
Leukemia and the European Society of Clinical
Microbiology and Infectious Diseases, have significantly
contributed with studies and guidelines on the manage-
ment of infectious diseases in patients with hematologic
malignancies.
Proposed research for the Roadmap
Several initiatives at different levels, ranging from basic
science to large epidemiological studies, should be under-
taken to comprehensively address the problem of infec-
tions in non-neutropenic populations. Major areas of
interest requiring research resources and efforts include
the following.
1. Background and basic science studies aiming at under-
standing the intimate mechanism of action and the
potential proinfectious effect of novel molecules or
biological agents, with certain infectious problems
possibly anticipated even before clinical trials.
2. Inclusion in clinical trials of new agents of an ad hoc
section for the detection of infectious complications,
designed and reviewed by experts in the field of infec-
tious diseases.
3. Setting up pre- and post-marketing registers of infec-
tious complications in patients receiving chemothera-
py, in order to establish long-term safety of new prod-
ucts and to react immediately when unexpected prob-
lems arise, which would also allow full assessment of
the risk profile of novel therapies.
4. Studies on the need for prophylaxis of bacterial, viral
(including hepatitis B), and fungal (including
Pneumocystosis pneumonia) infections, its efficacy, cost-
effectiveness, and short- and long-term benefits and
risks.
5. Studies on the role of vaccination for preventable dis-
eases (e.g. influenza and pneumococcus), and imple-
mentation of new efforts for new approaches.
6. Tuned-up revaccination strategies.
7. Studies in the non-neutropenic population on the per-
formance of diagnostic assays based on antigen or
DNA detection for bacterial and fungal diseases, and
further development of immunological diagnosis by
means of monitoring cellular immune responses to
specific pathogens (e.g. ELISPOT).
8. Novel rapid diagnostic methods, to be used especially
in the outpatient setting (e.g, point-of-care tests and
molecular diagnostics).
9. Studies on effective and convenient outpatient thera-
py of infections, including oral antibiotics and antibi-
otics with prolonged half-lives.
Anticipated impact of the research
Implementing the studies and initiatives described
above, we should be able to obtain a more complete and
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thorough approach to infectious complications in non-
neutropenic patients. Thus, mortality and morbidity can
be reduced, providing full benefit of novel therapies by
minimizing the drawback of unexpected or uncontrolled
infections. The individualization of the management of
infectious risk and the development of outpatient infec-
tion control protocols and tools for diagnosis and treat-
ment of infections should result in better quality of life
and reduced cost.
8.4. Infections in primary immune deficiencies
Andrew Cant (Great North Children’s Hospital,
Newcastle upon Tyne, United Kingdom), Marieke Emonts
(Great North Children’s Hospital, Newcastle upon Tyne,
United Kingdom), Charlene Rodrigues (Great North
Children’s Hospital, Newcastle upon Tyne, United
Kingdom).
Introduction
Although individually rare disorders, there are now
more than 200 genetic primary immunodeficiencies (PIDs)
described, with 1:2500 people having one PID or another.
The lifetime burden of infection in this group is high and
infections can be unusual and difficult to treat. The risk is
increased by immunosuppression associated with
hematopoietic stem cell transplantation (HSCT).
Early diagnostics and effective treatment for bacterial,
viral, and fungal infection is important, as is surveillance
within the bone marrow transplantation (BMT) unit set-
ting.
The research is relevant for various patient populations.
1. Severe combined immunodeficiencies, including condi-
tions such as X-linked severe combined immunodefi-
ciency, adenosine deaminase deficiency, and Omenn
syndrome.
2. Combined immunodeficiency syndromes, including
conditions such as Wiskott-Aldrich syndrome, T-cell
activation defects, MHC class II deficiency, and CD40
ligand deficiency.
3. Antibody deficiencies, including X-linked agammaglob-
ulinemia, common variable immunodeficiency, and
selective IgA/specific antibody deficiencies.
4. Diseases of immune dysregulation, including hemo-
phagocytic lymphohistiocytosis and X-linked lympho-
proliferative syndrome.
5. Congenital defects of phagocyte number, function, or
both, including disorders such as chronic granulomatous
disorder.
6. Defects in innate immunity, including conditions such
as NEMO deficiency and complement deficiencies.
European research contributions 
More than 200 PIDs have now been genetically defined
and infectious complications and prognosis are more pre-
dictable. Viral PCR tests enable much more rapid accurate
diagnosis. Furthermore, new antiviral and antifungal
drugs improve outcome. Clearer guidelines for the man-
agement of febrile neutropenia and research networks for
studying infections in the immunocompromised have
been developed through learned societies such as the
European Society for Paediatric Infectious Diseases and
the European Society of Clinical Microbiology and
Infectious Diseases.
Proposed research for the Roadmap
Viral infections: improved rapid methods for detection of
viruses are now in clinical use. PCR methodology allows
an accurate identification and quantification of viral load,
as well as better planning of treatment strategies and
monitoring of therapeutic effects; however, some caveats
remain.
1. There is a need for better treatments; current approaches
are associated with significant toxicities for the patient
(e.g. foscarnet and cidofovir) and potentially also for the
staff (e.g. nebulized ribavirin). The prolonged treatment
required confers a risk of emerging resistance. Little is
known about efficacy and toxicity of combination ther-
apy in these complex cases. Particular viral treatment
challenges include Epstein-Barr virus (EBV), adenovirus,
and cytomegalovirus (CMV), where cellular (virus-spe-
cific cytotoxic lymphocytes) and antibody (monoclonal
antibody, e.g. respiratory syncytial virus–specific
palivizumab) therapies seem to be of limited effective-
ness and not always easy to arrange and administer.
2. Improved prevention and treatment of respiratory infec-
tions are needed, especially for rhinovirus, respiratory
syncytial virus, parainfluenza, influenza, and aden-
ovirus.340
3. Human papillomaviruses cause severe massive skin
warts in specific immunodeficient patients, and better
therapeutic options are needed.
4. New live attenuated vaccines, such as the rotavirus vac-
cine, given prior to PID diagnosis, confer new chal-
lenges. Ideally, PIDs should be diagnosed prior to first
vaccinations.
Central line-associated bloodstream infections: this remains a
significant issue in oncology and chronic diseases. The mor-
bidity and mortality of central line–associated bloodstream
infections mean that all children with fevers and central
lines undergo blood culturing and empirical broad-spectrum
antibiotic treatment, affecting antimicrobial resistance in a
high-risk population.341
1. There remains a need for more timely diagnostics and
better prevention of central line-associated bloodstream
infections, including adjuncts or alternatives to antibiot-
ic use (e.g. biofilm inhibitors).
2. A better antimicrobial stewardship is required to pre-
serve antibiotics for now and the future in an era of
increased antimicrobial resistance.
Gastrointestinal infections: PID patients are affected by
many bacterial and viral gut pathogens with an ongoing
impact on nutrition and fluid management, a significant
cause of morbidity and mortality.
1. Improved diagnostics and treatments for Cryptosporidium
spp. are required.342
2. Improved treatment modalities for enteroviruses in the
context of X-linked agammaglobulinemia, where paral-
ysis and death can result from ongoing infection, are
required.
3. A better understanding of the human gut microbiome
and its impact on the immune system is needed.
4. Improved diagnostics to distinguish gut graft-versus-
host disease (GvHD) from infectious enteritis requiring
distinct management are needed.
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Nosocomial infections: PID patients who require pro-
longed or multiple hospital admissions are at a very high
risk of nosocomial infections. These potentially increase
the length of hospital stay, having not only clinical but
also economic implications on health services.
1. Better estimation of the prevalence of nosocomial
infections (e.g. norovirus and sapovirus) is needed.
The morbidity and mortality associated with these
infections require effective preventative strategies and
new therapeutic interventions.
2. For those patients requiring ventilation, ventilator-
associated pneumonia is an important cause of mor-
bidity. Better anti-infective and anti-inflammatory
treatments are needed here.
Infections associated with biologics: biological agents, par-
ticularly monoclonal antibodies to proinflammatory
cytokines, are being widely used, increasing the risk of
infections in a high-risk population:343
1. More information regarding specific infectious risks of
this family of agents would be useful to allow appro-
priate prophylaxis to be instituted.
2. More information regarding how this family of agents
affects immune response to vaccination is warranted.
While aiming to prevent vaccine strain infections,
whenever possible, appropriate protection with vacci-
nation is needed. Timing of vaccination is likely to be
important and should be considered prior to com-
mencing immune-modulating therapy.
Fungal diagnostic markers and treatment monitoring: mor-
bidity and mortality due to invasive fungal infections are
increasing in PID patients, especially those who are on
immunosuppression.344 Candida spp. and Aspergillus spp.
diagnostics are currently limited to culture and
histopathology, with serum markers such as galactoman-
nan showing limited reliability.
1. Surveillance throughout HSCT could be improved
with better rapid diagnostic tests to allow more timely
management and reduced mortality.
2. Call for standardized diagnostic tests to be established
to allow universal diagnostic criteria to be set and
commercial assays or protocols to set up services.
3. Large interindividual variabilities of antifungal drug
levels are observed in children. Pharmacokinetic/phar-
macodynamic data are limited in this group and are
warranted for prompt informed adjustment of dosing,
allowing optimal treatment with these potentially
lethal infections.
4. Optimal duration of antifungal treatment is ill defined,
as is subsequent secondary prophylaxis.
Surveillance of infections post HSCT: PID patients prepar-
ing for HSCT are screened for blood, respiratory, and gut
pathogens. Although reasonably controlled pre-HSCT,
these pathogens can cause significant problems as the
child progresses through HSCT with the conditioning
and immunosuppressive regimens. A further understand-
ing of control mechanisms and preventative strategies are
needed for CMV, EBV, adenovirus, and cryptosporidium
in the PID patient leading up to HSCT.
Anticipated impact of the research
The impact of these proposed research areas will have a
huge benefit on the management of PID patients. Their
vulnerability to both common and opportunistic
pathogens leaves them at a high risk even before they go
through the HSCT process. We have a limited repertoire
of prophylactic antimicrobials, immunoglobulins, and
treatment modalities for these patients. Even those who
are appropriate for and successfully transplanted are high-
ly susceptible at various points. Therefore, in order to min-
imize the impact of their underlying diseases and HSCT,
improved diagnostics, therapeutics, and monitoring are
desperately needed.
8.5. Genetic predisposition factors for infection
in hematology and hematopoietic stem cell 
transplantation patients
Pierre-Yves Bochud (Centre Hospitalier Universitaire
Vaudois/Université de Lausanne, Lausanne, Switzerland),
Agnieszka Wójtowicz (Centre Hospitalier Universitaire
Vaudois, Lausanne, Switzerland).
Introduction
Infectious complications represent a major challenge in
patients undergoing intensive chemotherapy for the treat-
ment of hemato-oncological diseases and/or hematopoietic
stem cell transplantation (HSCT). The most common
pathogens are gram-positive and gram-negative bacteria
(usually causing bloodstream infections during the course of
neutropenia); fungi such as Candida or Aspergillus species
(causing invasive infections during the course of neutrope-
nia or after HSCT); and viruses such as cytomegalovirus
(CMV) (that can be reactivated and/or cause disease after
HSCT). Although specific risk factors, such as patient age,
comorbid conditions, and type and duration of immuno-
suppression, have been identified, it is still difficult to accu-
rately predict which patient will develop which infection,
and at which time. Because most infections are severe, pro-
phylactic and empirical drugs are increasingly administered,
exposing patients to potentially unnecessary side effects
and the development of resistance.345 It is becoming clear
that an individualized risk assessment may dramatically
improve the appropriateness of antimicrobial use in such
immunocompromised patients.
Over the past 15 years, a number of studies have eval-
uated whether genetic factors influence susceptibility to
infections in hematologic patients. These studies have
been made possible through several concomitant events,
including the availability of the full human genome in the
early 2000s; the development of new, rapid, and inexpen-
sive genotyping techniques; and major discoveries in the
field of innate immunity. At the molecular level, the
detection of pathogens is mediated by pattern recognition
receptors located on the surface or within immune cells.
Pattern recognition receptors detect specific molecular
patterns from microorganisms and mediate immune
response and cytokine production. Therefore, polymor-
phisms in gene-encoding cytokines and pattern recogni-
tion receptors, such as TLRs and C-type lectin receptors
(e.g. CLEC7A), were extensively studied.
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However, such studies were often limited by several
factors, including problematic design, lack of precise def-
initions for infections, inappropriate control selection,
small sample size, increasing use of prophylactic regimen,
failure to account for important covariates, and/or lack of
correction for multiple testing.345 Another important limi-
tation has been the lack of a definite role for some of the
reported genes and/or their polymorphism(s) in the
immune response mechanisms against the offending
pathogen. So far, existing data have not supported the use
of such polymorphisms for individual risk stratification in
clinical practice. However, recent associations have been
reported that are more promising, because they have
been replicated in different studies and/or different popu-
lations at risk and/or are supported by strong functional
evidence.
European research contributions 
Most genetic association studies in hemato-oncological
patients focused on susceptibility to invasive fungal infec-
tions (n=30). Only a limited number of studies analyzed
the risk of developing bacterial (n=8) and viral infections
(n=4). Among studies reporting associations supported by
replication and/or convincing functional evidence, all
were performed on susceptibility to invasive fungal infec-
tions in relatively large cohorts of Caucasian patients
undergoing HSCT,346-348 mostly in European centers.347,348
In a study of 702 HSCT recipients (336 included in a
discovery and 366 in a replication cohort), rs4986790 and
rs4986791 single nucleotide polymorphisms in TLR4were
associated with an increased risk for the development of
invasive aspergillosis. The relevant polymorphisms were
found in the donor, not the recipient, a specific feature
that was observed in subsequent studies of HSCT
patients. Although TLR4 is a detector for O-linked man-
nan, an important component of the fungal cell wall, the
exact mechanism by which the polymorphisms influ-
enced fungal pathogenesis has remained controversial. In
another study of 205 HSCT patients, a stop codon poly-
morphism in CLEC7A (Y238X, found either in the donor
and/or the recipient) was associated with susceptibility to
invasive aspergillosis.347 CLEC7A is the detector of b-glu-
can, a key component of the fungal cell wall. The Y238X
polymorphism leads to CLEC7A deficiency and was also
associated with different forms of Candida infections.349
Although promising, associations with relatively infre-
quent polymorphisms, such as those in TLR4 (minor
allele frequency ~0.05) and CLEC7A (minor allele fre-
quency ~0.08), may be difficult to replicate and imple-
ment as risk predictors in clinical practice.
A more frequent polymorphism in donor pentraxin 3
(PTX3, rs3816527, minor allele frequency ~0.43) was
associated with susceptibility to invasive aspergillosis in a
study of 268 HSCT recipients. The investigators replicat-
ed the association in an independent cohort of 330 HSCT
patients. Furthermore, a similar association was observed
in a cohort of 1101 solid organ transplant recipients.350
PTX3 is a pattern recognition receptor that can directly
bind to Aspergillus conidia, thereby acting as an opsoniz-
ing factor for complement activation and phagocytosis, or
can interact with CLEC7A or TLR4 to enhance immune
recognition. PTX3 variants were associated with reduced
PTX3 production in neutrophils with defective phagocyt-
ic activities and reduced Aspergillus clearance. Altogether,
these features currently make PTX3 rs3816527 the most
promising marker for invasive fungal infections in hema-
to-oncological patients.345
Proposed research for the Roadmap
Implement prospective cohorts of hemato-oncological patients:
efficient exploration of host genetics in susceptibility to
infections among hemato-oncological patients needs data
from a much larger number of patients than most studies
have been able to collect so far. This could be obtained by
implementing a large multicenter cohort with efficient
structures for prospective data collection (e.g. electronic
case report forms, use of standard definitions for relevant
phenotypes, and systematic quality checking) and
biobanking (e.g. centralized storage and processing and
genotyping) in accordance with existing regulations.
Improving the quality of genetic association studies: there is
an urgent need to improve the quality and reliability of
genetic association studies. Future proposals need to fol-
low stringent criteria for cases and control enrollment
(e.g. standard definition of cases, controls exposed to the
same risk as cases, and period of observation and/or use
of time-dependent analyses), study design (e.g. complete
publication of polymorphisms tested, rationale for
gene/polymorphism selection, and replication for rele-
vant associations), genotyping (e.g. standardization and
quality controls), and statistics (e.g. power calculation,
multiple testing correction, and multivariate analyses
accounting for all factors influencing the phenotype).
Anticipated impact of the research
Well-conducted studies based on large, multicenter
cohorts are needed to further establish the role of host
genetics on susceptibility to infections in high-risk hema-
to-oncological patients. Such factors may contribute to
improved infectious risk stratification and individualized
prevention strategies.
The EHA Roadmap for European Hematology
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More than 35,000 hematopoietic stem cell transplanta-
tions (HSCTs) were performed in Europe in 2011. Of
these, 60% were autologous and 40% were allogeneic
transplants. It is worthy of note that allogeneic HSCT
remains the single potentially curative option for many
patients with hematologic malignancies, despite recent
progress with chemotherapeutic treatment modalities.
Allogeneic stem cell transplantation largely relies on the
principle that the immune system has the power to cure
hematologic tumors, provided that tolerance is achieved
for the immune cells that mediate these activities. With
the development of the reduced intensity conditioning
regimens aiming primarily at tolerance induction rather
than at eradicating disease, allogeneic stem cell transplan-
tation can now be applied in elderly patients and in
patients with significant comorbidities. Issues that remain
to be solved, and that require a better understanding,
Section 9. Hematopoietic stem cell transplantation 
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include graft-versus-host disease (GvHD), promotion of
immune reconstitution, and mechanisms underlying the
graft-versus-tumor effect. In particular, following reduced
intensity conditioning, the transplant procedure itself
may not be sufficient to eradicate disease. Therefore,
additional steps are required that include post-transplant
immunotherapy, such as donor lymphocyte infusions or
other forms of cellular immunotherapy. In this regard, sig-
nificant scientific progress has been made in the past few
years with the development of novel approaches in this
setting. These include the targeting of extracellular anti-
gens through chimeric antigen receptor (CAR) T cells, T-
cell therapy with gene-modified T-cell receptors, and
strategies aiming at amplification of in vivo immune
responses. Through these “checkpoint-blocking agents”,
potentially curative immune responses become apparent
by blocking inhibitory signals to immune cells. The iden-
tification of antigens underlying these responses will be
of crucial importance to further develop disease- or
patient-specific forms of immunotherapy. The disadvan-
tage of checkpoint blockers via inducing autoimmunity
underscores the need for further research into this prom-
ising new approach.
Expansion of hematopoietic stem and progenitor cells
may aim at solving the problem of hematopoietic and
immune reconstitution that is observed particularly fol-
lowing cord blood transplantation. A further understand-
ing of the hematopoietic niche in regulating HSC expan-
sion and differentiation is required to develop novel
expansion technologies. This will also be important for
the further development of genetically repaired
hematopoietic stem cells (HSCs) through the use of artifi-
cial nucleases. Through these novel technologies, it may
be possible to edit the genome of patients with congenital
hematologic abnormalities, thereby bypassing the need
for allogeneic stem cell transplantation (ASCT). A require-
ment to make this technology successful will be amplify-
ing the corrected HSCs to the numbers that are required
for functional engraftment. This will enable a novel form
of ASCT.
These new therapeutic strategies require substantial
manipulation of cells, including expansion, differentia-
tion, and gene transfer.
Cells that have undergone this more than “minimal
manipulation” are regarded as advanced therapy medici-
nal products (ATMPs) and are regulated as drugs. As such,
approval is required of a national regulatory and ethical
committee before clinical studies can be undertaken. In
addition, ATMPs have to be produced under good manu-
facturing practice conditions and require an
Investigational Medicinal Product Dossier and an
Investigator’s Brochure. There is a clear need to make the
regulatory procedure less complicated in order to allow
an easier and more rapid development of these novel
therapeutics.
9.1. Allogeneic stem cell transplantation
Andrea Bacigalupo (Ospedale San Martino, Genova,
Italy), Gerard Socie (Hôpital Saint Louis, Paris, France).
Introduction
Prevention and control of graft-versus-host disease (GvHD):
during the past decade, our understanding of the patho-
physiology of acute GvHD has greatly improved. Much
has been learned from pre-clinical models and less from
correlations with clinical observations or therapeutic
interventions. Little progress has been made since the mid
1980s, and GvHD still develops in approximately 40%-
60% of recipients. Thus, there is a deep need to develop
newer approaches to mitigate and effectively treat
GvHD, which may facilitate the wider use of allogeneic
hematopoietic stem cell transplantation (HSCT).
Promoting immune reconstitution without increasing
GvHD is still the main challenge, especially after umbili-
cal cord blood or T-cell depleted haploidentical HSCT,
which are associated with prolonged immunodeficiency.
While a slow T-cell reconstitution is regarded as prima-
rily responsible for deleterious infections, GvHD, and
relapse, the importance of innate immune cells for disease
and infection control is currently being re-evaluated.
Relapse following allogeneic HSCT has remained
unchanged throughout the past three decades, as recently
reviewed in the second workshop convened by the
National Institutes of Health.351
European research contributions 
Clinical trials mainly conducted in the European Union
(EU) demonstrated that intensifying GvHD prophylaxis
by T-cell depletion with antithymocyte globulin prevents
GvHD. Up to 60% of patients who develop GvHD will
have inadequate responses to corticosteroids, however,
portending a dismal prognosis. Trials conducted have
demonstrated that high doses are not more efficient than
standard dose steroids, and that adding any new drug to
steroids improves outcome.
Proposed research for the Roadmap
Considering the increased utilization of hematopoietic
cell transplantation, the morbidity and mortality associat-
ed with GvHD, and the limitations inherent to contempo-
rary therapies, novel approaches are urgently needed.
Two main priorities have been identified.
1. Developing translational research at the European
level on human GvHD to study pathophysiology and
develop biomarkers to assess disease severity.
2. Favoring the development of clinical trials with ancil-
lary studies based on strong biological background,
leading to rapid development to phase III trials
through “pick-the-winner” phase II trials.
A variety of approaches have been explored pre-clini-
cally and clinically, including cytokines, keratinocyte
growth factor, growth hormone, cytotoxic lymphocytes,
and mesenchymal stromal cells (MSC) or blockade of sex
hormones.
Dissecting GvHD from graft-versus-leukemia has been
the aim of several decades of unsuccessful pre-clinical
and clinical studies. A recent study352 suggests that the
combined use of regulatory and conventional T cells
prior to selected CD34+ cell transplants may result in a
surprisingly low rate of relapse, without increasing
GvHD. In other words, we now have several studies
suggesting that leukemia relapse can be diminished
either by pre-transplant, peri-transplant, or post-trans-
plant interventions. We also have new cellular tools.
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Prospective trials with a control arm are badly needed to
prove this is the case.
Strategies to prevent or treatment post-HSCT relapse351
include the following.
Prophylaxis pre-transplant: several agents can be given
before HSCT in the attempt of reducing relapse; pre-
HSCT azacytidine, other chemotherapy, and bispecific
antibodies have been used in phase II trials. In particular,
one study has reported interesting results in refractory or
relapsed patients with acute myeloid leukemia (AML): a
short course chemotherapy, given prior to the condition-
ing regimen, produced survival in excess of 50%, but
only if patients had received one to two courses of induc-
tion therapy.353 If patients had received more than two
courses of chemotherapy, results were very poor.353
Therefore, AML patients with primary induction failure
should proceed to transplant immediately after the sec-
ond course of failed chemotherapy, rather than attempt-
ing sequential intensive additional chemotherapy.
The role of pre-transplant azacytidine in patients with
refractory anemia with excess blasts is controversial;
unfortunately there has been no prospective randomized
trial, and a large retrospective study by the French trans-
plant group has failed to show any advantage of pre-
transplant azacytidine on post-transplant relapse or sur-
vival.354
Prospective randomized trials are necessary to assess
whether a short course of chemotherapy the week prior
to conditioning in AML or azacytidine in refractory ane-
mia with excess blast patients will reduce the risk of
post-transplant relapse.
Prophylaxis post transplant: prophylactic tyrosine kinase
inhibitors (TKIs) have been tested prospectively post
HSCT against controls and have been shown to reduce
the risk of relapse in patients with Ph+ acute lymphoblas-
tic leukemia (ALL). Recent data would suggest that pro-
phylactic post-transplant panobinostat or azacytidine
may be beneficial in patients with AML; these data war-
rant confirmation through controlled trials.
Preemptive treatment of molecular relapse: markers for
minimal residual disease (MRD) are required to imple-
ment pre-emptive treatment: in acute myeloblastic
leukemia, treatment driven by WT1-based MRD, with
donor lymphocyte infusions, has limited success. The
use of bispecific antibodies and cellular therapy with
CAR T cells355 may produce significantly better results
and should be tested prospectively.
Treatment of hematologic relapse: once hematologic
relapse has occurred, outcome depends on the pace of
the underlying disease; in chronic disorders, long-term
survival is still possible.351 In patients with acute
leukemia, the major predictor of outcome is the interval
between the first transplant and relapse:351 patients
relapsing within six months are at a very high risk of
early death, whereas delayed relapses can be successfully
treated in a proportion of cases with a second transplant
or chemotherapy and donor lymphocyte infusions.351
The use of bispecific antibodies and CAR T cells may
offer better results,355 and trials are under way to assess
optimal protocols.
Anticipated impact of the research
HSCT is increasingly performed in Europe (15,000 per
year). Recent progress now allows transplantation in older
patients (over 60 years of age). Prediction and improved
treatment of early immunological complications remain
an unmet medical need.
Progresses in managing infectious complications have
contributed to improved survival rates during the past ten
years. Further improvement should incorporate recent
knowledge about innate lymphoid cells and immune
response to cancer to improve long-term outcome.
9.2. Immune-based therapies for hematologic 
malignancies
Hermann Einsele (Universitätsklinikum Würzburg,
Würzburg, Germany), Marcel van den Brink (Memorial
Sloan Kettering Cancer Centre, New York, United States of
America), Fred Falkenburg (Leids Universitair Medisch
Centrum, Leiden, the Netherlands).
Introduction
Targeted therapy in patients with hematologic malignan-
cies aims at generating new agents, such as monoclonal
antibodies, that are less toxic than conventional chemo- or
radiotherapy. Monoclonal antibodies are effective in a num-
ber of hematologic malignancies. Most of the currently
identified targets for monoclonal antibodies are also
expressed on non-malignant cells. The ability to genetically
engineer structure and function of these antibodies has sig-
nificantly improved their effectiveness.
T lymphocytes recognize antigens through a unique anti-
gen-specific T-cell receptor (TCR), promoting the elimina-
tion of a given target and amplifying the attack through
recruitment of other components of the immune response.
T cells can target antigens derived from both intracellular
and extracellular proteins, including peptides encoded by
mutated genes. T lymphocytes can actively distribute
themselves within tissues and in the tumor environment
and have the potential for in vivo expansion and self-main-
tenance, as they can establish a memory compartment.
Donor lymphocyte infusion is used to treat relapsed or
residual tumor cells following allogeneic stem cell trans-
plantation. In addition, adoptive transfer of antigen-specific
cytotoxic T lymphocytes and CD4+ T-helper cells has been
used to treat viral or fungal infections.
Immunotherapy based on a personalized dendritic cell can-
cer vaccine represents an innovative approach for hematolog-
ic malignancies. In some cancer entities, dendritic cell/peptide
vaccines have demonstrated clinical benefit in phase III trials.
A clear shortcoming of cancer vaccines is the difficult stan-
dardization of the antigenic material. Therefore, most inves-
tigators favor mixing relevant immunogenic peptides to be
used directly as peptide vaccines or loaded onto dendritic
cells as professional antigen-presenting cells.
Checkpoint blockade is a form of releasing the brakes on
tumor-specific T cells, allowing them to persist and expand
to attack malignant cells. Cancers can develop in part as a
consequence of cancer-induced immunosuppression. In
many individuals, immunosuppression is mediated by
CTLA4 and PD-1, two immunomodulatory receptors
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expressed on T cells. Monoclonal antibody–based therapies
targeting CTLA4 or PD-1 have shown significant clinical
effects in patients with hematologic malignancies, such as
Hodgkin lymphoma (HL).
Recent advances have allowed genetic modifications of
T cells to provide robust, personalized lymphocytes that
target specific tumor-associated antigens. Gene transfer in
human T lymphocytes can be accomplished by several
means. Here, long-term culture is required, significantly
compromising their capacity to survive long term in vivo.
Gene delivery can also be achieved through retroviral vec-
tors. These vectors can be manufactured on a large-scale
producing stable integration into the genome of the T cell
and its progeny. Adverse consequences due to insertional
mutagenesis in T cells have not yet been reported.
Lentiviral vectors have also been used to engineer T cells.
These vectors are particularly attractive when less differen-
tiated T-lymphocyte subsets are targeted, as they have the
unique ability to infect T cells even upon minimal activa-
tion, a property lacking in retroviral vectors. Novel nonviral
systems (Sleeping Beauty and PiggyBac) allow larger frag-
ments of DNA to be inserted than viral vectors permit.
T cells redirected to specific surface antigens on malig-
nant cells by engineered CARs are also emerging as pow-
erful therapies for hematologic malignancies. More than
10 clinical trials using CAR T cells for treatment of hema-
tologic malignancies have been reported. Dramatic
responses were observed, especially in patients with B-lin-
eage ALL, even in high-risk patients. Similar to T-cell
engaging antibodies, clinical use of CAR T cells especially
in patients with advanced disease was associated with sig-
nificant but reversible toxicity.
European research contributions 
New bispecific antibodies also have the properties of
selective antigen specificity and T-cell activation. Very
high response rates and long-lasting remissions, especially
after the application of the CD3/CD19–directed bispecific
antibody blinatumomab, indicate that in some patients
either the tumor is eradicated during T-cell activation and
expansion or, more likely, a memory T-cell response
directed against the tumor cells was induced or expanded.
The development of bispecific antibodies for hematologic
malignancies was mainly done in Europe.356,357 Also new
targets for bispecific antibodies will be tested in pilot trials
in Europe, including multiple myeloma and AML.
Technologies of gene modification of T cells have been
intensively developed in Europe.358 However, Europe is
lacking behind the large number of clinical trials initiated
in the US. Currently, European patients are queuing up to
receive treatment with CAR T cells for hematologic malig-
nancies in US centers due to the lack of clinical trials in
Europe. European biotech companies are also moving to
the US for a much more rapid transfer of CAR T
approaches into the clinic. T-cell therapy has been devel-
oped for clinical use in Europe, as have novel strategies of
cell selection.359,360 TCR gene transfer has been developed
by groups in Europe, and pilot trials are ongoing.
Proposed research for the Roadmap
The following questions and research priorities have
been identified.
1. Which antigens expressed by both malignant and non-
malignant cells can be safely targeted?
2. Do all tumor cells express similar tumor-specific anti-
gen(s)?
3. Can the tumor be eradicated if only some tumor cells
are susceptible to immune-mediated targeting?
4. Are there tumor stem/initiating cell-specific antigens?
5. Can stroma-specific antigens be used to target the
tumor?
6. How are long-lasting remissions following treatment
with bispecific antibodies induced?
7. How can resistance be overcome, especially target loss
variants?
8. How can the neurotoxicity of the constructs be
explained?
9. How can the significant cytokine release syndrome
following treatment with bispecific antibodies be
reduced, especially in patients with more advanced
disease?
10. How can specificity by combinatorial approaches tar-
geting several tumor antigens on the tumor cell be
increased?
11. Are trispecific antibodies a better strategy?
Other topics include strategies to: reduce the side effects
of CAR T-cell therapy; improve long-term persistence of
CAR T cells; improve efficacy of CAR T cells by combina-
tion with other T-cell activation modifiers; overcome
resistance to CAR T cells, especially target antigen loss on
tumor cells; and develop combinatorial approaches to
improve. Efficacy and tolerability of CAR T-cell approach-
es tackling tumors other than the CD19+ B-cell malignan-
cies will have to be shown.
In addition, the best and most specific T-cell epitopes
and most suitable T-cell subsets for adoptive T-cell thera-
py must be identified, and strategies to improve in vivo
expansion must be developed. We also need to maximize
the surface expression of the introduced TCR, optimize
the translation of the introduced TCR a and b chain, iden-
tify high avidity T cells, and increase TCR affinity to pro-
mote in vivo persistence.
To optimize induction of tumor-specific T cells and
response to vaccination, we need better adjuvants to
improve the mode of antigen delivery. However, little is
known about the identity of tumor antigens that represent
the targets of activated T cells. Currently, genomic and
bioinformatic approaches are applied to identify tumor-
specific mutant proteins following anti-PD-1 and/or anti-
CTLA4 therapy. In addition, efficacy of checkpoint block-
ade is dependent on a sufficiently broad T-cell repertoire.
Therefore, strategies to enhance T-cell repertoire could
enhance strategies involving checkpoint blockade.
9.3. The hematopoietic stem cell niche: regulation of
hematopoietic stem cell function and significance for
hematopoietic stem cell expansion
Cristina Lo Celso (Imperial College London, London,
United Kingdom), Simón Méndez-Ferrer (University of
Cambridge, Cambridge, United Kingdom), Michael
Milsom (Deutsche Krebsforschungszentrum Im
Neuenheimer Feld, Heidelberg, Germany), Timm
Schroeder (ETH Zurich, Basel, Switzerland).
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Introduction
Europe has a long-lasting track record of research focus-
ing on the hematopoietic stem cell (HSC) niche. In fact, in
1978, Manchester-based Ray Schofield was the first to
postulate that HSC function critically depends on their
occupancy of specific niches located within the bone mar-
row. Since then, numerous cell types comprising the HSC
bone marrow niche have been identified, and some of the
molecular signals that they transmit to HSCs have been
discovered. These signals trigger the cell-intrinsic molecu-
lar mechanisms known to regulate HSC fate. Here we pro-
vide a short summary of these studies, and discuss the
new challenges and questions faced by the HSC niche
field. A better understanding of the HSC niche is critical to
develop both novel therapies for and preventative strate-
gies against hematologic disease. Furthermore, delineating
the molecular pathways by which the niche regulates
HSC fate decision may contribute to solving the unmet
clinical need for HSC ex vivo expansion and enhanced in
vivo reconstitution activity for regenerative therapies.
European research contributions 
Both functional studies and direct observation of HSCs
in vivo and ex vivo have been critical in developing our
knowledge of the HSC niche and have highlighted how
several stromal and hematopoietic cells must co-operate
to ensure that the necessary number of hematopoietic
cells are produced every day. European researchers have
both contributed to and led these studies since their earli-
est days. Osteoblastic cells were the first to be identified
as a component of the HSC niche and subsequently sever-
al perivascular mesenchymal cells, including nestin+ pro-
genitor cells, PDGFR/NG2/LepR-expressing cells,
Schwann cells, neuronal terminations, adipocytes, and,
within the hematopoietic lineages, macrophages, regula-
tory T cells, and megakaryocytes, have all been shown to
produce molecular signals directing HSC quiescence and
proliferation, self-renewal, and differentiation. These sig-
nals act through direct cell-cell interactions, such as Notch-
Delta and integrin signaling; short-range gradients, such as
Wnt, CXCL12, Ang1, and SCF; and long-range signals,
such as cytokines and hormones. More recently, the
chemical and physical composition of the bone marrow
microenvironment has begun to be studied, including fac-
tors such as oxygen levels and matrix stiffness.
Proposed research for the Roadmap
Given the complexity of the bone marrow microenvi-
ronment, the abundance of most niche components, and
the rarity of HSCs themselves, a central question within
the field is whether unique and rare combinations of niche
cells are required to ensure correct stem cell function or
whether the bone marrow space is, in fact, more fluid than
postulated and stem cells are free to migrate between mul-
tiple niches to undergo different fates. To this end, intrav-
ital microscopy has shown that infection-exposed, highly
engrafting HSCs are migratory and interact with larger
niches than stem cells at steady state.45 Although there is a
clear appreciation that bone marrow physiology alters
with age, most dramatically seen in the age-associated
accumulation of adipocytes, we are only just beginning to
understand how this affects the HSC-supporting function
of the niche.361,362
Clearly this is a phenomenon that is likely to contribute
to the decreased efficacy of bone marrow transplantation
(BMT) as a therapeutic modality in elderly individuals and
is, therefore, an area that requires further attention.
Interestingly, not only stem but also progenitor cell func-
tion is influenced by their microenvironment, and progen-
itor niches need to receive further attention as their
manipulation is likely to lead to better short- and long-
term recovery of BMT patients.
Moreover, the bone marrow microenvironment is
deeply affected by the development of hematologic malig-
nancies,47 and it is, therefore, critical to understand the
impact of both leukemia and chemotherapy on HSC nich-
es, and how to restore the bone marrow microenviron-
ment to improve outcome for therapeutic BMT. In addi-
tion, to prevent the development of hematologic malig-
nancies, it is critical to study and understand their initial
steps, when the niche conditions that support expansion
of specific, often mutant, clones of HSCs are established.
A better understanding of the relationship between
hematopoietic stem and progenitor cells and the bone
marrow microenvironment is needed not only to improve
current BMT-based therapies, but also to enable us to cul-
ture or even expand HSCs for therapeutic purposes.
Currently, as few as 5% of banked cord blood samples
contain a sufficient amount of stem cells to be deemed
usable for transplantation. Achieving efficient in vitro
expansion of HSCs has long been a Holy Grail of the
experimental hematology community, as this would both
increase the size of the stem cell pool transplanted into
each patient and, therefore, ensure more rapid recovery,
while dramatically expanding the pool of usable cord
bloods, increasing by orders of magnitude the number of
successful haplotype matches. In order to achieve this aim,
and potentially revolutionize HSCT by opening up novel
sources of donor cells, significant further research needs to
be performed in order to ascertain how HSC-supportive
signals provided by the niche can be provided artificially in
vitro.
Cytokines have so far been the main factors used to
improve HSC culture conditions. Co-culture systems,
including stroma and hematopoietic cells in two or three
dimensions, are currently being developed and will likely
provide much insight into what molecular, chemical, and
physical factors need to be combined to achieve efficient,
clinical-grade, feeder-free expansion of HSCs. When not
only freshly isolated but also genome-edited HSCs are
expanded and transplanted, the patient population that
will benefit from these studies will be even greater.
Anticipated impact of the research
The past 30 years have seen many exciting discoveries
highlighting the dazzling complexity of the HSC niche
and providing some clues to its plasticity in response to
stress, de-regulation when hematologic disease occurs,
and critical factors that may be combined to achieve HSC
expansion for therapeutic purposes. However, our knowl-
edge about the cellular and molecular components of the
hematopoietic niches and spatial organization and
dynamics remain extremely rudimentary, and strong
research efforts are required to enable potential future
therapeutic use. The clinical need for better niche regener-
ation and larger availability of HSCs remains critically
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unmet, and further in vivo and in vitro studies relying on
genetically engineered mouse strains, xenograft models,
clinical samples, and refined culture conditions are critical
to start making sense of the complexity of the HSC niches.
Prolonged observation of stem cells in vivo and ex vivo363
will allow an understanding of how self-renewal is
achieved at the single cell level and how pre-malignant
clones develop into full disease, so that not only improved
therapies but also effective preventive strategies will be
developed.
This research will affect all patients with hematologic
disease, as well as all of those requiring BMT for other rea-
sons, and ultimately the population as a whole by reduc-
ing the burden of these diseases and, most importantly,
their incidence.
9.4. Human pluripotent stem cells: source 
of hematopoietic stem cells and hematopoietic 
progenitor cells
Christine Mummery (Leids Universitair Medisch
Centrum, Leiden, the Netherlands), Frank Staal (Leids
Universitair Medisch Centrum, Leiden, the Netherlands).
Introduction
The present availability of human pluripotent stem cells
(PSCs) (see subsection 1.9) raises promise for a universal
resource for cell-based therapies in regenerative medicine.
Rapid progress has been made in generating human PSCs
amenable for clinical applications, culminating in repro-
gramming of adult somatic cells to autologous human
PSCs that can be indefinitely expanded in vitro. However,
how to differentiate human PSCs to specific lineages effi-
ciently and how to select for cells that will function nor-
mally upon transplantation in adults remain major chal-
lenges. The hematopoietic lineage has been particularly
refractory, and derivation of adult-type hematopoietic
stem cells (HSCs) has not yet been possible, even though
various other blood lineages can be obtained.364 If HSCs
could be generated from a patient's own human PSCs,
genetic engineering could easily be used to correct genetic
defects prior to differentiation into transplantable HSCs,
which would overcome some caveats of conventional
hematopoietic stem cell transplantation (HSCT) therapies.
Skin fibroblasts were the first human somatic cells to be
reprogrammed into human induced pluripotent stem cells
(iPSCs), but blood cells are increasingly used because of
the availability of banked (cord and peripheral) blood sam-
ples covering a range of diseases, ages, genders, and ethnic
backgrounds. Complementing human iPSC generation are
attempts at “direct reprogramming” using sets of lineage-
specific transfer factors (TFs) that act as master regulators
and convert cells to a new differentiation state without
intermediate pluripotency. Generating human iPSCs from
mature B cells requires silencing of lineage-specific factors,
such as PAX5, so that direct reprogramming into blood
cells where this would not be necessary may, therefore, be
quite feasible.365
The first steps in directed differentiation of human PSCs
are guided by morphogens (e.g. Wnt, TGF-b, activin, and
BMP) important in development. Human PSCs progress
through a primitive-streak–like stage before forming the
three germ layers, endoderm, ectoderm, and mesoderm,
which is the layer giving rise to (hemogenic) endothelial
cells and blood. While early embryonic stages are quite
faithfully mimicked in culture, patterning of the meso-
derm requires anatomical structure of the embryo, embry-
onic cell-to-cell interactions, expression of patterning
genes (Cdx/Hox), certain cell non-autonomous effects, and
exposure to physical stimuli (flow) that occur at specific
stages of development. Human PSC derivatives thus
remain immature, and to date, all human PSC–derived
HSCs have been deficient in their developmental potential
and ability to self-renew and engraft upon transplantation
in mice, even though animal studies have shown that this
is possible in the context of a developing embryo. PSCs do
have the innate ability to differentiate into fully function-
al, definitive HSCs. Normal HSC development during
embryogenesis occurs in several distinct temporal/spatial
waves, each characterized by its own set of HPCs. Only
those produced from the latter, or “definitive”, wave give
rise to mature, functional HSCs, but during in vitro differ-
entiation, it is believed that the HSC-like cells produced
are from the more primitive waves. These give rise to
HSC-like cells biased toward myeloid lineages at the
expense of lymphoid potential. These are unable to self-
renew in culture and lack long-term engraftment capacity.
The key to overcoming this HSC bottleneck will be under-
standing: 1) the ontogeny of human HSCs; 2) how they
progress at the molecular level to become mature, adult
HSCs; and 3) intrinsic and extrinsic factors that govern
HSC behavior and function.
European research contributions 
Several prominent European hematologists are using
genomic approaches (e.g. gene expression and microRNA
profiles and TF and histone ChIP data) to examine the
molecular mechanisms that regulate cell fate decisions
(e.g. self-renewal versus differentiation and quiescence ver-
sus proliferation and apoptosis) by HSCs or HPCs and
their more differentiated progenies. This focus on genetic
modification of stem cells especially using gamma-retrovi-
ral and lentiviral vectors has brought Europe to the global
forefront of genetically modified stem cell therapy for
treatment of various types of severe combined immunod-
eficiencies. This has been in part through EU FP7-funded
projects that included PERSIST, EuroStemCell, and NOV-
EXPAND, among others. This momentum is poised to
combine HSC expansion with gene editing approaches
that will move the field forward toward innovative thera-
pies in the coming decade.
Proposed research for the Roadmap
An exciting new development in the gene therapy field
is the use of designer nucleases, most recently
CRISPR/Cas9-based, that are proving exceptionally effi-
cient in engineering the genome.366 Recent work has estab-
lished the potential for site-specific gene editing to repair
disease mutations in the human genome by targeting the
integration of a corrective cDNA into the IL2RG locus of
HSCs from a severe combined immunodeficiency–X1
patient.367 For homologous recombination–based gene
editing approaches to be successful, HSCs need to prolif-
erate and template DNA harboring the corrective
sequences needs to be efficiently introduced into the tar-
get cells. This can be readily achieved in human iPSCs so
that these cells are prime targets for gene editing tech-
niques. As gene editing can also be done in primary HSCs,
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however, it is crucial to find conditions that allow HSCs to
proliferate without loss of phenotype. Therefore, expan-
sion protocols (see subsection 9.1) are directly relevant for
the gene repair described here. Niche signals, expansion,
directed differentiation toward induced HSCs, and genetic
modification of HSCs and their progenies are related
research topics that need an integrated approach for opti-
mal exploitation in the clinical context.
Anticipated impact of the research
A major bottleneck to curing genetic diseases originating
from mutations in HSCs is that even though efficient
methods for gene targeting are now available, HSCs from
neither adult nor human PSC sources can be expanded
sufficiently for this to become routine practice. The com-
bined projects in subsections 9.1 and 9.2 seek to address
this and bring safe gene therapy to the clinic via HSCs.
9.5. Advanced therapy medicinal products and other
cell therapies
Chiara Bonini (Ospedale San Raffaele, Milan, Italy), Jaap
Jan Zwaginga (Leids Universitair Medisch Centrum,
Leiden, the Netherlands), Willem Fibbe (Leids Universitair
Medisch Centrum, Leiden, the Netherlands). 
Introduction
Advanced therapy medicinal products (ATMPs) com-
prise somatic cell therapy medicines, gene therapy medi-
cines, and tissue-engineered medicines or combinations.
The first class of ATMPs includes mesenchymal stem cells
(MSCs). These are adult, fibroblast-like multipotent cells
characterized by their ability to differentiate into tissues of
mesodermal origin, including adipocytes, chondrocytes,
and osteocytes. MSCs have been initially isolated from
bone marrow, but can also be expanded from a variety of
other tissues including periosteum, muscle connective tis-
sue, adipose tissue, umbilical cord (blood), amniotic fluid,
and placenta. Isolation relies on their ability to adhere to
plastic surfaces and they are able to expand significantly
by consecutive passaging in vitro. The lack of uniform cri-
teria to define MSCs has prevented efforts to compare
results from different experimental and clinical studies,
and therefore the International Society for Cellular
Therapy formulated minimal criteria for defining MSCs.
Mesenchymal stem cells  have also been shown to pos-
sess broad immunoregulatory abilities, which can influ-
ence both adaptive and innate immune response in vitro
and in vivo. The mechanisms through which MSCs exert
these functions, either through cell-to-cell contact or by
secretion of soluble factors, are still not completely under-
stood. Recent findings indicate that MSCs are able to
actively interact with cells of the innate immune system
through which they may display both anti-inflammatory
and proinflammatory effects. This ability to adopt a differ-
ent phenotype in response to sensing an inflammatory
environment is not yet captured in assays that are current-
ly used to characterize these cells. The putative role of
stromal cells in maintaining tissue homeostasis serves as
the basis for their application in disorders resulting from
auto- or alloimmune responses, including graft-versus-host
disease (GvHD) and autoimmune disorders. These poten-
tial anti-inflammatory properties of MSCs are distinct
from their stem cell characteristics.
Cell-based gene therapy is an innovative therapeutic
approach based on the possibility of permanently intro-
ducing a gene of interest in the genome of human cells,
thus conferring a new function to the cells and their prog-
enies. The first clinical trials of gene therapy, performed in
the 1990s with gamma-retroviral vectors, have produced
promising clinical results. The recent introduction of inno-
vative gene transfer vectors, such as self-inactivating
lentiviral vectors, have further increased the efficacy and
safety profile of gene therapy. Recently, the introduction
of artificial nucleases, molecules able to mediate DNA
strand breaks in selected genomic regions, allow not only
a gene of interest to be added in human cells but also a cel-
lular gene and thus a cellular function to be precisely sub-
stituted, thus offering new hope for the cure of several dis-
eases. 368-372
European research contributions 
Whereas the development of cellular therapies in the US
is primarily driven by biotech, the role of academic devel-
opments in Europe is more prominent. A broad range of
phase I and II studies have been performed.
Following the first report on a pediatric patient suffering
from grade IV refractory acute GvHD of the liver who was
rescued by the infusion of bone marrow-derived MSCs,
the cells have been studied in the context of hematopoiet-
ic stem cell transplantation (HSCT), as well as
immunoregulating and regenerative therapies. These stud-
ies confirm the safety of MSC therapy and indicate signif-
icant response rates in steroid-resistant acute GvHD, solid
organ transplantation, Crohn disease (fistulas), and other
autoimmune disorders.
Cell-based gene therapy is currently being tested in clin-
ical trials for the cure of genetic and acquired diseases. In
recent years, patients affected by genetic diseases, such as
immunodefiencies, metabolic diseases, and thalassemias,
have been enrolled in phase I-II clinical trials based on the
infusion of autologous HSCs genetically modified with
viral vectors, to express the correct gene and restore cellu-
lar functions. Initial results have been highly promising.
Gene therapy has been also recently applied to treat
patients affected by hematologic malignancies. In this set-
ting, T lymphocytes have been modified by viral vectors
to express genes selected to increase the safety and effica-
cy of cancer immunotherapy. Suicide genes have been
successfully introduced in allogeneic lymphocytes, to pro-
mote anti-tumor responses and control side effects.
Molecules conferring cancer specificity, such as TCRs and
CARs, have been introduced in patients’ T cells, to medi-
ate tumor regression. In initial phase I-II clinical trials
with CAR-redirected T cells, striking complete remissions
have been observed in patients affected by B-cell malig-
nancies.
Proposed research for the Roadmap
The clinical efficacy for the treatment of allo- (e.g. acute
GvHD and solid organ transplantation) and autoimmune
(e.g. Crohn disease and multiple sclerosis) disorders is cur-
rently being studied in several randomized phase II and III
studies. In addition to demonstrating improved outcome,
it will be crucial to gain further insight into the biology of
response. Advanced immunological monitoring that will
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take into account the inflammatory status in the host at
the time of treatment in conjunction with extensive analy-
sis of the products will be crucial for the development of a
signature that is associated with outcome. This will be
crucial for the development of next generation MSC prod-
ucts with enhanced therapeutic efficacy.
Several hurdles need to be cleared before ATMP therapy
can be fully exploited in Europe. Multicenter phase III stud-
ies across Europe, required to validate promising approaches
tested in phase I-II studies, must be carried forward together
with many national regulatory agencies, some of which
interpret the European guidelines on ATMPs in different
ways. This complex scenario largely explains why and how
the successful clinical trials with CAR T cells have been per-
formed mainly in the US. The scientific and medical com-
munity, and most importantly, patients and patients’ associ-
ations, urgently need the use of cell-based gene therapy to
be promoted in Europe, and this can be achieved only
through harmonization, simplification of the procedures
required for trial approval, and dedicated funding.
Finally, the full exploitation of T-cell-based cancer gene
therapy to additional cancer types requires a co-ordinated
and multidisciplinary effort to speed up the generation of
new cancer-specific receptors, able to target a wide range
of cancer subtypes. This important aim, that can now be
reached, thanks to the most innovative technologies cur-
rently available, can be achieved only by multidisciplinary
teams and dedicated funding.
Anticipated impact of the research
The development of a biomarker signature will allow
the design of MSC products with enhanced therapeutic
efficacy that can be applied in a variety of auto- and
alloimmune disorders.
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